学术周报 · IF≥10 或专科旗舰刊

肿瘤领域文献阅读汇编

2026年第47周 (2026-11-20) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
收录论文
224
临床研究
44
基础研究
180
IF≥20
60
IF 10-20
164
子领域
10
期刊种类
69
数据日期
2026-11-20

★本周 Top 10 高影响力文献

#论文期刊IF
1Engineering signal transduction for closed-loop gene and cell therapies.Signal transduction and targeted therapyIF 81.2
2Drug delivery systems: current applications and future directions.Signal transduction and targeted therapyIF 81.2
3Reinvigorating immunotherapy: harnessing tumor microenvironment modulation for enhanced cancer treat...Signal transduction and targeted therapyIF 81.2
4Ferroptosis in cancer cells triggers PGE2 production for tumour immune escape.NatureIF 56.1
5Conservation of the tumour microenvironment across organs and species.NatureIF 56.1
6Antibiotics counteracting tumor-promoting dysbiosis in colorectal cancer.Cancer cellIF 56.1
7Targeting F.nucleatum with metronidazole plus tislelizumab and fruquintinib in MSS colorectal cancer...Cancer cellIF 56.1
8Transition metal-based nanocatalysts for bidirectional immunomodulation: from catalytic anti-inflamm...Chemical Society reviewsIF 48.3
9Label-free Raman spectroscopy for cancer therapy response: from methodological framework to clinical...Chemical Society reviewsIF 48.3
10Chemotherapy-induced mast-cell degranulation constrains tertiary lymphoid maturation in lung cancer ...Journal of hematology & oncologyIF 47.8

Ŧ期刊分布统计

期刊篇数IF
Biosensors & bioelectronics22IF 11.8
Cancer research21IF 22.6
Science advances13IF 13.9
Cancer letters12IF 11.8
Advanced healthcare materials9IF 11.0
Nucleic acids research8IF 15.0
Pharmacological research8IF 12.2
Biomarker research7IF 14.6
Neuro-oncology7IF 13.1
Journal for immunotherapy of cancer7IF 11.7

1肿瘤免疫/微环境 (76篇)

临床研究 (8篇)

Journal for immunotherapy of cancer IF 11.7 2026-11-18 PMID: 43051942
Programmed death-ligand 1 (PD-L1) expression incompletely captures the tumor and immune contexture in gastric cancer, and clinical benefit within PD-L1 expression strata is heterogeneous. To explore additional chemoimmunotherapy biomarkers, we leveraged spatially resolved transcriptome profiling in two advanced gastric cancer cohorts: 70 patients from a completed phase II chemoimmunotherapy trial and 137 patients from an independent real-world immunotherapy cohort. In total, 1,337 tumor and immune areas of illumination were profiled from 794 regions of interest. In the trial cohort, SPP1, CXCL8, and IL1B, genes previously linked to tumor-promoting macrophage programs and immunotherapy resistance, were significantly downregulated within the tumor compartment in patients with durable clinical benefit (DCB) relative to those with no clinical benefit (NCB). In parallel, higher tumor-compartment SPP1 expression was significantly associated with inferior overall survival in the real-world cohort. Notably, these associations were weaker or absent in the immune compartment. Plasma proteomics suggested lower circulating SPP1 levels in patients with DCB than in those with NCB in the trial cohort. Collectively, these findings build on our prior work and nominate SPP1 expression as a spatially resolved correlate of chemoimmunotherapy efficacy.
中文摘要:程序性死亡配体1(PD-L1)表达未能完全反映胃癌中的肿瘤和免疫微环境,且在PD-L1表达不同分层中临床获益存在异质性。为探索额外的化疗免疫治疗生物标志物,我们利用空间分辨转录组分析技术对两个晚期胃癌队列进行了研究:一个包含70名已完成II期化疗免疫治疗试验的患者,另一个包含137名来自独立真实世界免疫治疗队列的患者。共分析了来自794个感兴趣区域的1337个肿瘤和免疫区域。在试验队列中,与无临床获益(NCB)患者相比,具有持久临床获益(DCB)患者的肿瘤区室中SPP1、CXCL8和IL1B基因显著下调,这些基因此前被认为与促肿瘤巨噬细胞程序及免疫治疗耐药相关。同时,在真实世界队列中,较高的肿瘤区室SPP1表达与较差的总生存期显著相关。值得注意的是,这些关联在免疫区室中较弱或不存在。血浆蛋白质组学结果表明,试验队列中DCB患者的循环SPP1水平低于NCB患者。综上所述,这些发现基于我们之前的工作,并将SPP1表达确定为化疗免疫治疗疗效的空间分辨相关性标志物。
Journal of the American Academy of Dermatology IF 12.3 2026-11-18 PMID: 43051553
Viral vectors therapies have entered clinical dermatology through approved treatments for advanced melanoma and dystrophic epidermolysis bullosa (DEB). However, many dermatologists remain unfamiliar with patient selection, referral pathways, and the expanding role of these therapies in cutaneous disease. To provide a practical review of currently available and emerging viral vector therapies relevant to dermatologic practice. This paper includes a narrative review of clinical trials, regulatory approvals, and emerging evidence involving oncolytic virotherapy, topical gene therapy, and selected vaccine-based immune modulation strategies. Oncolytic herpes simplex virus (HSV)-based therapies have demonstrated meaningful clinical activity in advanced melanoma, including patients with disease progression after immune checkpoint inhibition. Emerging data and trials suggest benefit in selected nonmelanoma skin cancers. In DEB, topical beremagene geperpavec-svdt (B-VEC) has established viral vector-mediated gene therapy as an effective treatment capable of promoting durable wound closure and improving quality of life. Additional applications, including vaccine-mediated immune modulation and in vivo cellular therapies, remain investigational. Many emerging applications are supported right now by only early-phase clinical or preclinical studies. Viral vector therapeutics are becoming increasingly relevant to dermatology. Familiarity with currently approved therapies, appropriate referral candidates, and evolving clinical applications will help dermatologists integrate these advances into patient care.
中文摘要:病毒载体疗法已通过针对晚期黑色素瘤和营养不良型大疱性表皮松解症(DEB)的获批治疗进入临床皮肤科领域。然而,许多皮肤科医生对患者选择、转诊途径以及这些疗法在皮肤疾病中日益扩大的作用仍不熟悉。本文旨在对目前可用及新兴的与皮肤科实践相关的病毒载体疗法进行实用综述。文章通过叙述性综述了涉及溶瘤病毒疗法、局部基因治疗和选定疫苗介导免疫调节策略的临床试验、监管批准及新兴证据。基于溶瘤单纯疱疹病毒(HSV)的疗法在晚期黑色素瘤中显示出有意义的临床活性,包括在免疫检查点抑制剂治疗后疾病进展的患者中。新兴数据和试验表明,在某些非黑色素瘤皮肤癌中也存在获益。在DEB治疗中,局部使用的贝瑞马根基因珀普韦克(beremagene geperpavec-svdt)已确立病毒载体介导的基因疗法作为一种有效治疗手段,能够促进持久的伤口愈合并提高生活质量。其他应用包括疫苗介导的免疫调节和体内细胞疗法,目前仍处于研究阶段。许多新兴应用目前仅得到早期临床试验或临床前研究的支持。病毒载体治疗药物在皮肤科领域正变得日益重要。熟悉目前获批的疗法、合适的转诊候选者以及不断发展的临床应用,将有助于皮肤科医生将这些进展整合到患者护理中。
Journal for immunotherapy of cancer IF 11.7 2026-11-17 PMID: 43045480
Only ~50% of patients with metastatic Merkel cell carcinoma (MCC) respond to immune checkpoint inhibitor (ICI) therapy, necessitating alternative salvage options. Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus approved by the US Food and Drug Administration for metastatic melanoma, but data on its use in MCC remain limited. We retrospectively evaluated eight patients with MCC who progressed on prior systemic therapy and were subsequently treated with T-VEC between 2017 and 2024. Response was assessed by investigator-interpreted Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and adverse events were recorded for all patients. Two patients received multiple T-VEC courses. Paired pretreatment and post-treatment biopsies were analyzed in two patients. Of the eight patients treated with T-VEC, seven were evaluable for response. Four of seven patients (57%) achieved objective response (OR) in injected lesions—one complete response (CR) and three partial responses—with a median time to OR of 9 months (range, 1.2–14.2). Two of those four responders did not have any non-injected lesions and, therefore, were classified as having an OR across all assessable lesions (median time to OR: 11 months; range, 7.8–14.2), with lasting responses after therapy completion at the last follow-up (range, 0.9–5.1 years). The remaining two responders possessed non-injected disease that remained stable or progressed, with no lesions regressing without additional intervention of concurrent systemic and radiation therapy (RT), indicating a lack of clinically evident abscopal effect. Additionally, one of these patients developed additional distant metastases over their T-VEC treatment course. Two patients who achieved initial CR received repeat T-VEC courses, with one progressing on the final course. Grade 3 adverse events occurred in two of eight patients. Pathologic analysis of paired pretreatment and post-treatment biopsies from two patients showed that the patient who achieved CR (also received simultaneous neutron RT) had greater tumor viability and mitotic activity prior to T-VEC and RT and then developed more prominent lymphohistiocytic inflammation in the treated area compared with the patient who did not respond. T-VEC is a minimally toxic salvage option that provided meaningful clinical benefit in four of eight evaluable patients with ICI-refractory MCC.
中文摘要:仅约百分之五十的转移性默克尔细胞癌患者对免疫检查点抑制剂治疗产生反应,因此需要替代的挽救治疗方案。T-VEC是一种溶瘤单纯疱疹病毒,已获美国食品药品监督管理局批准用于转移性黑色素瘤,但其在默克尔细胞癌中的应用数据仍然有限。我们回顾性评估了八名在既往全身治疗后进展并于二零一七年至二零二四年间接受T-VEC治疗的默克尔细胞癌患者。通过研究者解读的实体瘤疗效评价标准评估反应,并记录所有患者的不良事件。两名患者接受了多次T-VEC疗程。对两名患者的配对治疗前和治疗后活检进行了分析。在八名接受T-VEC治疗的患者中,七名可评估反应。七名患者中有四名(百分之五十七)在注射病灶中达到客观缓解,其中一例完全缓解,三例部分缓解,客观缓解的中位时间为九个月(范围一点二至十四点二)。这四位响应者中的两位没有非注射病灶,因此被归类为所有可评估病灶均达到客观缓解(中位时间十一个月;范围七点八至十四点二),且在最后一次随访时治疗结束后反应持续存在(范围零点九至五点一年)。其余两名响应者拥有非注射疾病,这些疾病保持稳定或进展,在没有联合全身治疗和放射治疗的额外干预下没有病灶消退,表明缺乏临床上明显的远隔效应。此外,其中一名患者在T-VEC治疗过程中出现了额外的远处转移。八名患者中有两名出现三级不良事件。对两名患者的配对治疗前和治疗后活检进行的病理分析显示,达到完全缓解的患者(同时接受了中子放射治疗)在T-VEC和放疗前具有更高的肿瘤活力和有丝分裂活性,随后在治疗区域表现出比未响应者更明显的淋巴组织细胞炎症。T-VEC是一种毒性最小的挽救方案,为八名可评估患者中的四名免疫检查点抑制剂难治性默克尔细胞癌患者提供了有意义的临床获益。
European urology IF 29.1 2026-11-16 PMID: 43039767
To quantify heterogeneity in the treatment effects of first-line immuno-oncology (IO)-based combination regimens among patients with metastatic clear-cell renal cell carcinoma (RCC) according to prognosis and potential effect modifiers and to assess which patients benefit most. Meta-analysis (preregistered in PROSPERO: CRD42023483638) including randomised trials underpinning first-line IO-based regimens recommended in the European Society for Medical Oncology 2024 guidelines using sunitinib as control, with mature overall survival (OS) data available as of November 2023. Individual patient data (IPD) were obtained for two trials and aggregate data for two others. Prognostic stratification was performed by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model and, for IPD trials, by the Clinical Prognostic Index in the Checkpoint Inhibitor era (CPI2) model. Effect modification by sex and programmed death-ligand 1 (PD-L1) expression was assessed. OS benefit was summarised as a hazard ratio (HR) and, in IPD, as the difference in restricted mean survival time (dRMST), and was pooled across trials using fixed-effects inverse-variance-weighted models. CheckMate-214, CheckMate-9ER, KEYNOTE-426 and CLEAR were included, totalling 3320 patients (IPD for CheckMate-214 and CheckMate-9ER; n = 1747). Among IPD studies, 42%, 32%, and 26% of patients had CPI2 favourable, intermediate, and poor prognosis, respectively. The respective pooled subgroup dRMSTs were 1.21 (95% CI = -0.82 to 3.25), 3.15 (0.50 to 5.81), and 7.36 (4.56 to 10.17) mo. Using all four studies, the pooled HRs for IMDC favourable, intermediate, and poor subgroups were 0.98 (0.81 to 1.19), 0.78 (0.68 to 0.89), and 0.51 (0.40 to 0.65), respectively. PD-L1 expression at 5% significantly modified the treatment effect. IO-based regimens showed highly divergent OS efficacy across prognostic subgroups, with no significant benefit among patients with a favourable prognosis and the strongest benefit in patients with a poor prognosis.
中文摘要:本研究旨在量化转移性透明细胞肾细胞癌(RCC)患者在接受一线免疫肿瘤(IO)联合治疗方案时,根据预后及潜在效应修饰因素产生的治疗异质性,并评估哪些患者获益最大。这是一项在PROSPERO注册的荟萃分析(注册号:CRD42023483638),纳入了支持欧洲肿瘤内科学会2024年指南推荐的一线IO联合方案随机试验,以舒尼替尼作为对照,且截至2023年11月拥有成熟的总生存期(OS)数据。两项试验获取了个体患者数据(IPD),另外两项获取了汇总数据。预后分层采用国际转移性肾细胞癌数据库联盟(IMDC)模型进行,对于IPD试验还采用了检查点抑制剂时代临床预后指数(CPI2)模型。评估了性别和程序性死亡配体1(PD-L1)表达作为效应修饰因素的作用。OS获益以风险比(HR)表示,在IPD中则以限制性平均生存时间差值(dRMST)表示,并使用固定效应逆方差加权模型对试验进行汇总。纳入CheckMate-214、CheckMate-9ER、KEYNOTE-426和CLEAR四项研究,共3320名患者(其中CheckMate-214和CheckMate-9ER为IPD数据,n=1747)。在IPD研究中,CPI2预后良好、中度和差的患者比例分别为42%、32%和26%。相应的汇总亚组dRMST分别为1.21(95% CI = -0.82至3.25)、3.15(0.50至5.81)和7.36(4.56至10.17)个月。利用全部四项研究,IMDC预后良好、中度和差亚组的汇总HR分别为0.98(0.81至1.19)、0.78(0.68至0.89)和0.51(0.40至0.65)。PD-L1表达在5%时显著修饰了治疗效果。基于IO的方案在不同预后亚组中显示出高度分化的OS疗效,预后良好患者无显著获益,而预后差患者获益最强。
Journal for immunotherapy of cancer IF 11.7 2026-11-16 PMID: 43039403
Immune checkpoint inhibitors show limited efficacy in previously treated recurrent or metastatic cervical cancer (rmCC). BVAC-C is an autologous B cell-based and monocyte-based therapeutic vaccine targeting human papillomavirus (HPV)16/18 E6 and E7 oncoproteins. We report a phase II trial—representing the first clinical evaluation of a B cell– and monocyte-based therapeutic HPV vaccine combined with a programmed death-ligand 1 (PD-L1) inhibitor—evaluating BVAC-C combined with durvalumab in patients with HPV16/18-positive rmCC who had progressed after platinum-based chemotherapy. This single-arm, open-label, two-part phase II trial was registered prospectively at ClinicalTrials.gov (NCT04800978) on 15 March 2021, before enrollment of the first participant. 30 patients received treatment; 29 were evaluable for efficacy. The objective response rate (ORR) was 37.9% (six complete responses and five partial responses), and the disease control rate was 62.1%. The 6-month progression-free survival (PFS) rate was 51.7% and median PFS was 8.7 months (95% CI 4.0 to 24.3 months). Patients with a treatment-free interval >6 months achieved a significantly higher ORR (52.9% vs 16.7%; p=0.047). Notably, the median duration of response was 20 months and complete responders showed sustained remission beyond 18 months, raising the possibility of functional cure in a subset of patients. Antigen-specific T-cell responses and cytokine activation were robust and PD-L1-independent. BVAC-C plus durvalumab showed encouraging antitumor activity with a manageable safety profile, supporting further evaluation in HPV-positive rmCC. NCT04800978.
中文摘要:免疫检查点抑制剂在治疗既往接受过治疗的复发或转移性宫颈癌(rmCC)中疗效有限。BVAC-C是一种自体B细胞和单细胞治疗疫苗,靶向人乳头瘤病毒(HPV)16/18 E6和E7癌蛋白。我们报告了一项II期试验,这是首次对B细胞和单细胞治疗HPV疫苗联合程序性死亡配体1(PD-L1)抑制剂进行临床评估,旨在评价BVAC-C联合度伐利尤单抗在铂类化疗后进展的HPV16/18阳性rmCC患者中的疗效。这项单臂、开放标签的两部分II期试验于2021年3月15日首次参与者入组前在ClinicalTrials.gov上前瞻性注册(NCT04800978)。30名患者接受了治疗;29名患者的疗效可评估。客观缓解率(ORR)为37.9%(6例完全缓解,5例部分缓解),疾病控制率为62.1%。6个月无进展生存(PFS)率为51.7%,中位PFS为8.7个月(95% CI 4.0至24.3个月)。治疗间隔大于6个月的患者ORR显著更高(52.9% vs 16.7%; p=0.047)。值得注意的是,中位缓解持续时间为20个月,完全缓解者显示出超过18个月的持续缓解,这在一部分患者中引发了功能性治愈的可能性。抗原特异性T细胞反应和细胞因子激活强劲且独立于PD-L1。BVAC-C联合度伐利尤单抗显示出令人鼓舞的抗肿瘤活性和可控的安全性特征,支持在HPV阳性rmCC中进一步评估。NCT04800978。
Nature cancer IF 28.0 2026-11-13 PMID: 43026320
Spatial proteomics enables high-resolution mapping of protein expression within the tumor microenvironment, but its routine clinical application remains limited by cost, technical complexity and restricted tissue coverage. Here we present Hist2Prot, a deep learning framework that generates single-cell spatial proteomic profiles from routine hematoxylin and eosin histology. Trained on approximately 51 million paired cells from a same-section G4X spatial proteomics dataset, Hist2Prot was evaluated in internal test cohorts, independent same-platform G4X cohorts and external cross-platform datasets comprising approximately 72 million additional cells, showing concordance with measured protein profiles and outperforming established baselines. Hist2Prot-derived virtual proteins preserved immune, stromal and tumor cell phenotypes and recapitulated clinically relevant tumor microenvironment organization. Across seven independent patient cohorts comprising 1,774 patients, virtual spatial proteomics improved molecular biomarker, prognostic and immunotherapy response prediction beyond hematoxylin and eosin morphology alone. Hist2Prot enables scalable single-cell computational spatial proteomics from routine histology for precision oncology.
中文摘要:空间蛋白质组学能够实现对肿瘤微环境中蛋白质表达的高分辨率映射,但其常规临床应用仍受限于成本、技术复杂性及组织覆盖范围。本研究提出Hist2Prot深度学习框架,该框架利用常规苏木精-伊红(H&E)组织病理学图像生成单细胞空间蛋白质组学谱系。基于来自同一切片G4X空间蛋白质组学数据集的约5100万个配对细胞进行训练后,我们在内部测试队列、独立的同平台G4X队列以及包含约7200万额外细胞的跨平台外部数据集中对Hist2Prot进行了评估,结果显示其与实测蛋白质谱系具有高度一致性,且优于既定基线方法。Hist2Prot生成的虚拟蛋白质保留了免疫、基质和肿瘤细胞表型,并重现了具有临床意义的肿瘤微环境组织结构。在包含1774名患者的七个独立患者队列中,相较于仅依靠H&E形态学,基于虚拟空间蛋白质组学的分析在分子生物标志物、预后及免疫治疗反应预测方面表现出更优性能。Hist2Prot实现了从常规组织病理学出发的可扩展单细胞计算空间蛋白质组学,为精准肿瘤学提供了技术支持。
Pharmacology & therapeutics IF 13.5 2026-11-13 PMID: 43025815
Human epidermal growth factor receptor 2 (HER2) is a key therapeutic target in gastroesophageal adenocarcinoma (GEA) and its targeting agents form the backbone of treatment for HER2-positive disease. Therapeutic options have expanded from the HER2-targeting antibody trastuzumab to antibody-drug conjugates (ADC). HER2-directed small-molecule inhibitors and bispecific HER2-directed compounds are under evaluation in treatment-naive and previously treated patients across different stages of disease. Beyond combinations with chemotherapy, combinations with immune checkpoint inhibitors (ICI) are of particular interest due to potential synergistic mechanisms, including antigen release, immune-cell recruitment, and antibody-dependent cellular cytotoxicity resulting in enhanced antitumor immunity. The current standard of care for HER2- and PD-L1-positive metastatic GEA (mGEA) combines chemotherapy with the HER2-targeting antibody trastuzumab and the PD-1-targeting ICI pembrolizumab. In the second-line setting, the ADC trastuzumab deruxtecan has further improved outcomes for these patients. Despite these advances and the emergence of new therapeutic options, several challenges remain, including optimal patient and drug selection, treatment sequencing, and the management of acquired resistance. Advances in liquid biopsy approaches, including the analysis of circulating tumor DNA, may facilitate longitudinal disease monitoring and guide personalized treatment strategies. This review summarizes the current and evolving role of HER2-targeted therapies in GEA, examines the growing integration of immunotherapy, and discusses future directions.
中文摘要:人表皮生长因子受体2(HER2)是胃食管腺癌(GEA)的关键治疗靶点,其靶向药物构成了HER2阳性疾病治疗的基石。治疗选择已从HER2靶向抗体曲妥珠单抗扩展至抗体偶联药物(ADC)。在初治和既往治疗过的不同分期患者中,正在评估HER2导向的小分子抑制剂和双特异性HER2导向化合物。除了与化疗联合外,与免疫检查点抑制剂(ICI)的联合因潜在协同机制而备受关注,包括抗原释放、免疫细胞招募以及抗体依赖性细胞介导的细胞毒性作用从而增强抗肿瘤免疫力。对于HER2和PD-L1阳性的转移性GEA(mGEA),当前标准治疗方案将化疗与HER2靶向抗体曲妥珠单抗及PD-1靶向ICI帕博利珠单抗相结合。在二线治疗中,ADC药物曲妥珠单抗德鲁替康进一步改善了这些患者的预后。尽管取得了这些进展并出现了新的治疗选择,但仍面临若干挑战,包括最佳患者和药物选择、治疗顺序以及获得性耐药的管理。液体活检技术的进步,包括循环肿瘤DNA分析,可能促进纵向疾病监测并指导个性化治疗策略。本综述总结了HER2靶向疗法在GEA中的当前及演变作用,考察了免疫治疗日益增强的整合情况,并讨论了未来方向。
Cancer cell IF 56.1 2026-11-13 PMID: 43025423
Antibiotics usually sabotage immune checkpoint blockade. In this issue of Cancer Cell, Jiang et al. report that pulsed, anaerobe-directed metronidazole added to an anti-PD-1 antibody and a VEGF receptor inhibitor achieved encouraging progression-free survival in Fusobacterium nucleatum-positive microsatellite-stable metastatic colorectal cancer, selectively dismantling a pathobiont network without inducing global dysbiosis.
中文摘要:抗生素通常会破坏免疫检查点阻断疗法的效果。在本期《癌症细胞》杂志中,Jiang等人报道,在抗PD-1抗体和VEGF受体抑制剂的基础上加入脉冲式厌氧菌靶向甲硝唑,在核梭杆菌阳性的微卫星稳定型转移性结直肠癌患者中取得了令人鼓舞的无进展生存期,该方案选择性地破坏了病原共生网络而未引发全身性菌群失调。

基础研究 (68篇)

Science advances IF 13.9 2026-11-20 PMID: 43050537
Bioorthogonal prodrug activation offers a promising approach for site-specific drug release, significantly reducing the systemic toxicity associated with conventional chemotherapy. However, challenges remain in precisely controlling prodrug activation at the target site while maintaining optimal selectivity, reactivity, and potency. Here, we report a dual-targeting peptide, TzFFYpHH, that integrates on-membrane enzyme-instructed self-assembly (EISA) with bioorthogonal chemistry to enable selective chemotherapy. Exploiting the overexpression of alkaline phosphatase (ALP) and programmed death-ligand 1 (PD-L1) on cancer cells, TzFFYpHH selectively anchors and self-assembles on the cancer cell membrane, enriching tetrazine (Tz) handles that act as bioorthogonal reactors to activate a trans-cyclooctene (TCO)-caged prodrug (TCO-Dox) for precise drug release. Upon topical administration, TzFFYpHH forms a hydrogel at subcutaneous tumor sites, enabling in situ prodrug activation for effective tumor inhibition. Notably, this localized chemotherapy elicits a potent antitumor immune response, which, when combined with anti-programmed death-1 antibody (αPD-1), synergistically potentiates therapeutic outcomes. By coupling supramolecular self-assembly with bioorthogonal reactivity on the cell membrane, this work establishes a chemically programmable platform for spatiotemporally controlled prodrug activation and provides a general strategy for integrating localized chemotherapy with immunotherapy.
中文摘要:生物正交前药激活为特异性药物释放提供了一种有前景的方法,显著降低了传统化疗相关的全身毒性。然而,在靶点精确控制前药激活的同时保持最佳的选择性、反应性和效力仍面临挑战。本研究报道了一种双重靶向肽TzFFYpHH,该肽整合了膜上酶指导的自组装(EISA)与生物正交化学,以实现选择性化疗。利用癌细胞上碱性磷酸酶(ALP)和程序性死亡配体1(PD-L1)的过表达,TzFFYpHH选择性地锚定并自组装在癌细胞膜上,富集作为生物正交反应器的四嗪(Tz)手柄,从而激活反式环辛烯(TCO)笼状前药(TCO-Dox)以实现精确的药物释放。局部给药后,TzFFYpHH在皮下肿瘤部位形成水凝胶,实现原位前药激活以有效抑制肿瘤。值得注意的是,这种局部化疗引发了强大的抗肿瘤免疫反应,当与抗程序性死亡1抗体(αPD-1)联合使用时,协同增强了治疗效果。通过将超分子自组装与细胞膜上的生物正交反应性相结合,本研究建立了一个化学可编程平台用于时空控制前药激活,并为将局部化疗与免疫治疗相结合提供了一种通用策略。
Science advances IF 13.9 2026-11-20 PMID: 43050536
Long noncoding RNAs (lncRNAs) have been shown as critical components in cancer genomics, yet their functionality and regulation remain elusive. Here, we present an integrative lncRNA atlas covering more than 370,000 cells from 18 cancer types. In addition to multiple lineage- and cellular state transition-associated lncRNAs, we identify a set of lncRNAs that are embedded within cell type-specific regulons, suggesting associations between lncRNA expression and cell type-enriched transcriptional programs. By integrating CRISPR-based functional genomic screens and clinical data, we further prioritize not only CRISPR-supported candidate lncRNAs linked to tumor cell fitness and immune cell state features but also specific lncRNA signatures correlated with patient survival and immunotherapy response.
中文摘要:长链非编码RNA(lncRNAs)已被证明是癌症基因组学中的关键组成部分,但其功能性和调控机制仍不明确。在此,我们构建了一个整合性的lncRNA图谱,涵盖来自18种癌种的超过37万个细胞。除了多种谱系特异性及细胞状态转换相关的lncRNAs外,我们还鉴定出一组嵌入细胞类型特异性调控子中的lncRNAs,提示lncRNA表达与细胞类型富集的转录程序之间存在关联。通过整合基于CRISPR的功能基因组筛选和临床数据,我们进一步优先确定了不仅与肿瘤细胞适应性及免疫细胞状态特征相关且经CRISPR支持的候选lncRNAs,还确定了与患者生存及免疫治疗反应相关的特定lncRNA特征。
Science advances IF 13.9 2026-11-20 PMID: 43050532
The hypoxic characteristics of the tumor microenvironment and endogenous antioxidant defenses compromise the efficacy of oxygen-consuming oxidative therapy, positioning oxygen-free reductive stress as a new paradigm in tumor treatment. Nevertheless, the immunosuppressive characteristics of hypoxia and reductive stress pose significant challenges for advancing reductive stress-induced immunotherapy. Here, we constructed a hydrogen radical (H•) generator synergistically activated by near-infrared light and thiols, and first elucidated that photocatalytic H•-mediated reductive stress can elicit a robust antitumor immune response via the H•-featured mechanism. Nanoplatform HA@UFTL was engineered using lactate oxidase as an ideal H• partner, with the synergistic contribution enabling cross-amplified antitumor immunotherapy. The H•-participating spatiotemporal sequential strategy highlights a triple spatiotemporal sequential cascade, including dual sequential hypoxia exacerbation, sequential oxidative-reductive stress, and sequential organelle damage. By aggravating rather than alleviating hypoxia, HA@UFTL overcomes immunosuppression induced by hypoxia and reductive stress with H• as a universal building block, providing new insights for hypoxia-based immunotherapy.
中文摘要:肿瘤微环境的缺氧特征和内源性抗氧化防御机制削弱了耗氧氧化疗法的疗效,使无氧还原应激成为肿瘤治疗的新范式。然而,缺氧和还原应激的免疫抑制特性为推进还原应激诱导的免疫治疗带来了重大挑战。本研究构建了一种由近红外光和硫醇协同激活的氢自由基(H•)发生器,并首次阐明光催化H•介导的还原应激可通过H•特征机制引发强大的抗肿瘤免疫反应。纳米平台HA@UFTL以乳酸氧化酶作为理想的H•伴侣进行工程化设计,其协同作用实现了交叉放大的抗肿瘤免疫治疗。H•参与的时空序贯策略凸显了三重时空序级联效应,包括双重序贯缺氧恶化、序贯氧化还原应激以及序贯细胞器损伤。HA@UFTL通过加剧而非缓解缺氧,以H•作为通用构建模块克服了由缺氧和还原应激诱导的免疫抑制,为基于缺氧的免疫治疗提供了新见解。
Advanced healthcare materials IF 11.0 2026-11-19 PMID: 43059289
The effective absorption of oral chemotherapy drugs in the intestines is of vital importance for enhancing their therapeutic effects. Natural plant-derived compounds, in specific, their diversities in type, structure, and function, might offer opportunities to modulate gut microbiota metabolites for enhancing colorectal cancer therapy. Guided by this thinking, synergistic self-assembly of natural products, namely Xyl-CA/Sin nanoparticles (NPs), was engineered by integrating the prebiotic xylan (Xyl) with chlorogenic acid (CA) and sinomenine (Sin). Xyl protects the formulation during gastric transit and promotes targeted accumulation in colorectal tumors. Upon exposure to the acidic tumor microenvironment (TME), the NPs release CA and Sin, enabling their therapeutic actions. In colorectal cancer (CRC) models, CA triggers tumor cell pyroptosis, while Sin reshapes macrophage polarization and elevates the microbial tryptophan metabolite indole-3-acetic acid (3-IAA). Acting synergistically, 3-IAA and CA suppress glutathione peroxidase 3 (GPx3) and glutathione peroxidase 7 (GPx7), leading to reactive oxygen species (ROS) accumulation and autophagy inhibition. This cascade restrains tumor growth, induces immunogenic cell death (ICD), and stimulates antitumor immunity. Overall, this study presents a microbiota metabolite-driven strategy through the application of natural plant-derived bioactive compounds to potentiate chemotherapy and establishes a concise, multimodal framework for antitumor therapy based on natural products.
中文摘要:口服化疗药物在肠道内的有效吸收对于增强其治疗效果至关重要。天然植物来源的化合物,特别是其在类型、结构和功能上的多样性,可能为调节肠道菌群代谢物以增强结直肠癌治疗提供机会。基于这一思路,通过将益生元木聚糖(Xyl)与绿原酸(CA)和青藤碱(Sin)整合,构建了天然产物的协同自组装体系,即Xyl-CA/Sin纳米颗粒(NPs)。Xyl保护制剂在胃部通过时的稳定性,并促进其在结直肠肿瘤中的靶向积累。在酸性肿瘤微环境(TME)暴露下,NPs释放CA和Sin,从而发挥治疗作用。在结直肠癌(CRC)模型中,CA触发肿瘤细胞焦亡,而Sin重塑巨噬细胞极化并提高微生物色氨酸代谢物吲哚-3-乙酸(3-IAA)的水平。3-IAA和CA协同作用抑制谷胱甘肽过氧化物酶3(GPx3)和谷胱甘肽过氧化物酶7(GPx7),导致活性氧(ROS)积累和自噬抑制。这一级联反应限制肿瘤生长,诱导免疫原性细胞死亡(ICD),并刺激抗肿瘤免疫。总体而言,本研究提出了一种通过应用天然植物来源的生物活性化合物来增强化疗的菌群代谢物驱动策略,并建立了基于天然产物的简洁多模态抗肿瘤治疗框架。
Advanced healthcare materials IF 11.0 2026-11-19 PMID: 43059127
The convergence of coordination chemistry and nanomedicine has unlocked new frontiers in disease treatment. While metal ions act as essential physiological regulators, their dysregulation is intrinsically linked to pathologies such as cancer and infection. Harnessing the therapeutic versatility of metal ions, metal ion-mediated co-assembly has risen as a transformative strategy to construct carrier-free nanodrugs. Unlike traditional formulations, this paradigm exploits coordination interactions to co-assemble drugs and metal ions into all-in-one nanostructures, delivering synergistic therapeutic efficacy, exceptional drug loading capacity, and controllable biodegradation while eliminating carrier-related toxicity. This review comprehensively summarizes the state-of-the-art design strategies, assembly kinetics, and key performance metrics of metal ion-based nanomedicines. Special attention is dedicated to their applications in multimodal treatments, spanning chemotherapy, phototherapy, chemodynamic therapy, and immunotherapy, which highlights their capability to tackle complex biological challenges. Furthermore, we critically discuss the challenges impeding clinical translation and propose future directions for this rapidly evolving field. Collectively, these coordination-driven innovations provide a framework for next-generation precision nanomedicine, but their clinical translation will depend on rigorous translational validation, scalable manufacturing, predictable in vivo fate, and data-driven optimization.
中文摘要:配位化学与纳米医学的融合为疾病治疗开辟了新的前沿。尽管金属离子作为重要的生理调节因子,其失调与癌症和感染等病理过程密切相关,但利用金属离子的治疗多功能性,金属离子介导的共组装已成为构建无载体纳米药物的变革性策略。与传统制剂不同,该范式利用配位相互作用将药物与金属离子共组装为一体化纳米结构,在消除载体相关毒性的同时,提供协同治疗效果、卓越的载药量和可控的生物降解性。本综述全面总结了基于金属离子的纳米医学的最新设计策略、组装动力学和关键性能指标。特别关注其在多模态治疗中的应用,涵盖化疗、光疗、化学动力学治疗和免疫治疗,突显了其应对复杂生物学挑战的能力。此外,我们批判性地讨论了阻碍临床转化的挑战,并提出了该快速发展的领域的未来方向。总体而言,这些由配位驱动的创新为下一代精准纳米医学提供了框架,但其临床转化将取决于严格的转化验证、可扩展的制造、可预测的体内命运以及数据驱动的优化。
Cancer letters IF 11.8 2026-11-19 PMID: 43057412
Pancreatic ductal adenocarcinoma (PDAC) is one of the most devastating malignancies, with its incidence and mortality rates remaining particularly discouraging. Elucidating the molecular mechanisms driving PDAC progression and identifying potential therapeutic targets are critical to improve the clinical prognosis of PDAC patients. Accumulating evidence has highlighted the pivotal functions of centromere proteins (CENPs) in tumor progression. Accordingly, this study aimed to screen and identify key CENP family members implicated in PDAC pathogenesis. Through systematic analysis of CENP family proteins in PDAC, we identified CENPT as a critical regulator involved in disease progression. We further validated that CENPT promoted the proliferation and metastasis of PDAC cells via activating the RAF/MEK/ERK signaling pathway through a series of in vitro and in vivo experiments. In addition, CENPT was also found to be implicated in tumor microenvironment remodeling. Single-cell and bulk transcriptomic analyses demonstrated that CENPT expression was positively correlated with Treg cell abundance and an immunosuppressive tumor microenvironment. Further experiments suggested that CENPT upregulated the synthesis and secretion of MIF in PDAC cells, which acted on naive CD4+ T cells to promote the differentiation into Treg cells. This process ultimately induced the formation of an immunosuppressive tumor microenvironment and facilitated PDAC progression, whereas blockade of MIF enhanced the efficacy of immune checkpoint blockade for PDAC. In conclusion, this study revealed the crucial role of CENPT in PDAC progression, and targeting CENPT may serve as one of the potential therapeutic strategies for PDAC.
中文摘要:胰腺导管腺癌(PDAC)是最具破坏性的恶性肿瘤之一,其发病率和死亡率持续低迷。阐明驱动PDAC进展的分子机制并识别潜在治疗靶点对于改善患者临床预后至关重要。越来越多的证据强调了着丝粒蛋白(CENPs)在肿瘤进展中的关键作用。因此,本研究旨在筛选和鉴定参与PDAC发病的关键CENP家族成员。通过对PDAC中CENP家族蛋白的系统分析,我们确定CENPT是参与疾病进展的关键调节因子。通过一系列体外和体内实验,我们进一步验证了CENPT通过激活RAF/MEK/ERK信号通路促进PDAC细胞的增殖和转移。此外,研究发现CENPT还参与肿瘤微环境的重塑。单细胞和批量转录组分析表明,CENPT表达与Treg细胞丰度及免疫抑制性肿瘤微环境呈正相关。进一步实验表明,CENPT上调了PDAC细胞中MIF的合成和分泌,MIF作用于初始CD4+ T细胞促进其向Treg细胞分化。这一过程最终诱导了免疫抑制性肿瘤微环境的形成并促进了PDAC进展,而阻断MIF则增强了免疫检查点阻断疗法对PDAC的疗效。综上所述,本研究揭示了CENPT在PDAC进展中的关键作用,靶向CENPT可能成为PDAC的一种潜在治疗策略。
Molecular cell IF 16.0 2026-11-19 PMID: 43057208
In this issue of Molecular Cell, Bai et al.1 describe a read-orchestrate-write mechanism that maintains m6A homeostasis by linking m6A levels to METTL3 activity and reveal its implications for cancer treatment. In this negative feedback loop, IGF2BP proteins recruit PARP1 to m6A-modified RNAs, triggering METTL3 ADP-ribosylation and limiting m6A deposition.
中文摘要:本期《分子细胞》杂志中,Bai等人描述了一种读-编排-写机制,该机制通过将m6A水平与METTL3活性相关联来维持m6A稳态,并揭示了其对癌症治疗的启示。在该负反馈环路中,IGF2BP蛋白将PARP1招募至m6A修饰的RNA上,触发METTL3的ADP核糖基化并限制m6A沉积。
Chemical Society reviews IF 48.3 2026-11-19 PMID: 43056229
Immune homeostasis is crucial for health, yet its hyperactivation or suppression poses significant therapeutic challenges. Nanocatalysts, especially transition metal-based nanocatalysts, are powerful chemical tools for immunomodulation. They work by precisely regulating chemical species in pathological microenvironments. These nanocatalysts serve two therapeutic purposes. First, antioxidative nanocatalysts scavenge excess ROS. This "cools down" hyperactivated immunity in inflammatory diseases, such as cardiovascular disorders, neuroinflammation, and bone diseases. Second, pro-oxidative nanocatalysts generate ROS. This "heats up" suppressed immunity in cancer and infections, mainly by inducing immunogenic cell death. This tutorial review elucidates the chemical basis of nanocatalytic bidirectional immunomodulation, discussing related catalytic and therapeutic mechanisms based on typical paradigms. Rational design of nanocatalysts determines which chemical reactions occur. These reactions lead to different immunoregulatory outcomes. Nanocatalytic bidirectional immunomodulation provides a richer set of chemical tools to meet the requirements of immune activation or suppression during disease treatments. Most existing reviews have focused on unidirectional nanocatalytic therapy. This tutorial review is the first work to systematically unify nanocatalytic anti-inflammation and nanocatalytic immunotherapy from the perspective of "bidirectional immunomodulation".
中文摘要:免疫稳态对健康至关重要,但其过度激活或抑制带来重大治疗挑战。纳米催化剂尤其是过渡金属基纳米催化剂是强大的免疫调节化学工具,通过精确调控病理微环境中的化学物种发挥作用。这些纳米催化剂具有两种治疗目的:首先,抗氧化纳米催化剂清除过量活性氧(ROS),从而「冷却」心血管疾病、神经炎症和骨病等炎症性疾病中过度激活的免疫反应;其次,促氧化纳米催化剂产生ROS,主要通过诱导免疫原性细胞死亡来「加热」癌症和感染中受抑制的免疫反应。本教程综述阐明了纳米催化双向免疫调节的化学基础,基于典型范式讨论了相关的催化和治疗机制。纳米催化剂的合理设计决定了发生的化学反应,进而导致不同的免疫调节结果。纳米催化双向免疫调节提供了更丰富的化学工具,以满足疾病治疗过程中免疫激活或抑制的需求。现有综述多聚焦于单向纳米催化治疗,本教程综述首次从「双向免疫调节」的角度系统统一了纳米催化抗炎与纳米催化免疫治疗。
Cancer research IF 22.6 2026-11-19 PMID: 43055341
Resistance to PD-1-based immunotherapy remains a major challenge in cancer treatment, especially in immunologically "cold" tumors characterized by T-cell exclusion and impaired T-cell effector function. Mechanical processes impact T-cell activity, and mechanical perturbations may represent a distinct mode of immune suppression. Here, we identified CD209, a myeloid-expressed C-type lectin receptor, as a mechanosuppressive regulator of antitumor T-cell immunity. CD209 was selectively enriched in tumor-infiltrating M2-like macrophages and monocytes, and elevated CD209 expression was associated with poor clinical response to PD-1 blockade and immune dysfunction and exclusion across multiple cancer types. Mechanistically, CD209 directly engaged ICAM-2 on T cells and activated ROCK1-ERM signaling. This interaction increased T-cell cortical stiffness, destabilized T cell-antigen presenting cell interactions, and attenuated T-cell receptor signaling. Blocking the CD209-ICAM-2-ERM pathway restored T-cell activation and promoted CD8+ T-cell infiltration and effector function in both in vivo mouse models and ex vivo human tumor systems. Importantly, CD209 blockade enhanced the response to PD-1 inhibition and overcame resistance to PD-1-based immunotherapy in refractory and immunologically "cold" tumor models. Together, these findings define a myeloid-derived mechanical immune checkpoint and reveal T-cell mechanosuppression as a targetable mechanism of tumor immune evasion and immunotherapy resistance.
中文摘要:对PD-1免疫疗法的耐药性仍是癌症治疗的主要挑战,尤其在以T细胞排斥和效应功能受损为特征的免疫冷肿瘤中。机械过程影响T细胞活性,机械扰动可能代表一种独特的免疫抑制模式。本研究鉴定出CD209,一种髓系表达的C型凝集素受体,作为抗肿瘤T细胞免疫的机械抑制调节因子。CD209选择性富集于肿瘤浸润的M2样巨噬细胞和单核细胞中,且CD209表达升高与多种癌种中对PD-1阻断的临床反应差、免疫功能障碍及排斥相关。机制上,CD209直接与T细胞上的ICAM-2结合并激活ROCK1-ERM信号通路。这种相互作用增加了T细胞皮层刚度,破坏了T细胞与抗原呈递细胞的相互作用,并减弱了T细胞受体信号。阻断CD209-ICAM-2-ERM通路恢复了T细胞活化,并在体内小鼠模型和体外人肿瘤系统中促进了CD8+ T细胞的浸润和效应功能。重要的是,CD209阻断增强了难治性和免疫冷肿瘤模型中对PD-1抑制的反应并克服了对PD-1基础免疫疗法的耐药性。综上所述,这些发现定义了一种髓系来源的机械免疫检查点,并揭示T细胞机械抑制是肿瘤免疫逃逸和免疫治疗耐药的可靶向机制。
Journal of the American Chemical Society IF 16.6 2026-11-18 PMID: 43053362
"One-for-all" phototheranostics with the second near-infrared window (NIR-II) emission have garnered great enthusiasm for seamlessly integrating superb imaging and high-efficiency therapy into a single formula. However, it is still a nontrivial conundrum to achieve balanced excited-state energy dissipation to guarantee high NIR-II brightness, photothermal conversion, and reactive oxygen species (ROS) generation. As a powerful tool for balancing radiative and nonradiative decays, aggregation-induced emission luminogens (AIEgens) are emerging as a promising frontier in developing "one-for-all" phototheranostic agents, while their phototheranostic performance needs to be further improved. In this contribution, we designed and synthesized two positional isomers, 5BT-PBPT and 6BT-PBPT, by attaching donors at the 5- and 6-positions of the benzo[b]thiophene (BT) segment, respectively, to investigate the effect of positional isomerism on the phototheranostic performance of NIR-II AIEgens. Interestingly, both experimental and computational results demonstrate that the isomerization affords great strength in tuning energy levels, structural conformations, aggregation behaviors, and excited-state energy dissipation. Consequently, a sweet spot for fully utilizing excitation energy was achieved in 5BT-PBPT nanoparticles (NPs), which exhibited not only strong NIR absorption but also high NIR-II fluorescence brightness, strong ROS production, and excellent photothermal conversion efficiency (η). Benefiting from this, 5BT-PBPT NPs afforded superior performance in the "one-for-all" phototheranostics for orthotopic breast tumor treatment. This study fully demonstrates the effectiveness of the isomeric engineering strategy in comprehensively improving the phototheranostic capabilities of NIR-II AIEgens and thereby provides an effective approach for the construction of high-performance NIR-II "one-for-all" phototheranostic agents.
中文摘要:具有第二近红外窗口发射的一体化光热诊疗技术因能将卓越成像与高效治疗无缝整合于单一配方中而备受瞩目。然而,实现平衡的激发态能量耗散以确保高近红外荧光亮度、光热转换及活性氧生成仍是一个棘手难题。作为平衡辐射与非辐射衰减的有力工具,聚集诱导发光分子正成为开发一体化光热诊疗试剂的前沿领域,但其诊疗性能仍有待提升。本研究设计并合成了两种位置异构体5BT-PBPT和6BT-PBPT,分别在苯并[b]噻吩片段的5位和6位连接供体,以探究位置异构对近红外聚集诱导发光分子光热诊疗性能的影响。实验与计算结果均表明,异构化在调节能级、结构构象、聚集行为及激发态能量耗散方面具有显著优势。因此,5BT-PBPT纳米颗粒实现了激发能利用的最佳平衡点,表现出强近红外吸收、高近红外荧光亮度、强活性氧产生及优异的光热转换效率。得益于这一特性,5BT-PBPT纳米颗粒在原位乳腺癌治疗的一体化光热诊疗中展现出卓越性能。本研究充分证明了异构工程策略在全面提升近红外聚集诱导发光分子光热诊疗能力方面的有效性,为构建高性能的近红外一体化光热诊疗试剂提供了有效途径。
Biomarker research IF 14.6 2026-11-18 PMID: 43053248
Although immune checkpoint inhibitors (ICIs) have transformed breast cancer treatment, predicting durable clinical benefit remains challenging. Current biomarkers, primarily derived from tumor tissue or peripheral blood, do not directly capture the adaptive immune response at its site of initiation. Tumor-draining lymph nodes (TDLNs) are not passive conduits for metastasis but dynamic immunological hubs where anti-tumor T cell priming and immune evasion converge. In this review, we critically examine the nascent intersection of TDLN immunobiology, high-resolution multi-omics, and artificial intelligence (AI) to evaluate TDLN-derived features as candidate next-generation biomarkers for immunotherapy. We synthesize the complex cellular and molecular architecture of the breast cancer TDLN, including T cell exhaustion, B cell-mediated immunity, and stromal crosstalk, before evaluating the state-of-the-art single-cell and spatial technologies capable of decoding this microenvironment. We assess the application of AI and foundation models in this domain, identifying a major methodological gap: while AI frameworks are increasingly mature for primary tumors, their application to TDLNs remains unvalidated and limited by a severe scarcity of annotated multi-omics datasets. Furthermore, we address pivotal translational considerations, including the immunological implications of axillary surgery in the ICI era. We emphasize that no TDLN-derived biomarker has yet undergone prospective validation as a predictive biomarker for immunotherapy in breast cancer, and that retrospective analyses of trial specimens must account for the timing of tissue acquisition relative to systemic therapy. Finally, we chart immediate research priorities, including establishing TDLN reference atlases and developing clinically feasible specimen collection pathways for biomarker validation. This review provides a conceptual framework and translational roadmap to assess whether TDLN-derived features can complement existing tumor-centric metrics in guiding immunotherapy decisions.
中文摘要:尽管免疫检查点抑制剂已改变乳腺癌治疗格局,但预测持久临床获益仍具挑战。当前生物标志物主要源自肿瘤组织或外周血,未能直接捕捉适应性免疫反应在起始部位的情况。肿瘤引流淋巴结并非被动的转移通道,而是动态的免疫枢纽,在此处抗肿瘤T细胞启动与免疫逃逸相互交汇。本综述批判性地审视了肿瘤引流淋巴结免疫生物学、高分辨率多组学与人工智能的交叉领域,以评估源自肿瘤引流淋巴结的特征作为下一代免疫治疗生物标志物的潜力。我们综合阐述了乳腺癌肿瘤引流淋巴结复杂的细胞和分子结构,包括T细胞耗竭、B细胞介导的免疫及基质串扰,并评估了能够解码该微环境的最先进单细胞和空间技术。我们评估了人工智能和基础模型在该领域的应用,指出了一个主要的方法学差距:虽然针对原发肿瘤的人工智能框架日益成熟,但其在肿瘤引流淋巴结中的应用仍未得到验证,且受限于注释多组学数据集的严重匮乏。此外,我们讨论了关键的转化考量,包括在免疫检查点抑制剂时代腋窝手术的免疫学意义。我们强调,目前尚无源自肿瘤引流淋巴结的生物标志物经过前瞻性验证作为乳腺癌免疫治疗的预测性生物标志物,且对试验标本的回顾性分析必须考虑组织采集时间相对于全身治疗的时间关系。最后,我们规划了紧迫的研究优先事项,包括建立肿瘤引流淋巴结参考图谱以及开发用于生物标志物验证的临床可行标本采集路径。本综述提供了概念框架和转化路线图,以评估源自肿瘤引流淋巴结的特征能否补充现有的以肿瘤为中心的指标,从而指导免疫治疗决策。
Journal of hematology & oncology IF 47.8 2026-11-18 PMID: 43053209
Tertiary lymphoid structures (TLSs) support local adaptive immunity and are associated with favorable antitumor responses across multiple cancers. However, how anticancer treatment reshapes TLS maturation, particularly in lung cancer brain metastasis (LCBM), remains poorly understood. We integrated clinicopathological profiling of LCBM cohorts with bulk and single-cell RNA sequencing, spatial profiling, immune-repertoire analysis, histological validation, and murine intracranial tumor models. Associations between prior treatment and TLS maturation were evaluated using multivariable analyses. Mechanistic studies examined chemotherapy-associated IL-33 release, mast-cell activation, and the effects of PGD2 on antigen-specific T-cell cytotoxicity and B-cell differentiation. Pharmacological inhibition of H-PGDS and mast-cell stabilization were further evaluated in vivo. Mature TLSs were associated with favorable survival in patients with LCBM, whereas preoperative chemotherapy was independently associated with impaired TLS maturation after adjustment for measured clinical and treatment covariates. Consistent with this observation, chemotherapy-treated tumors exhibited increased IL-33 levels, mast-cell accumulation, and enhanced mast-cell degranulation, with spatial analyses placing activated mast cells within TLS-associated immune niches. Mechanistically, IL-33 activated ST2-expressing mast cells, induced NF-κB-associated transcriptional programs. Functionally, mast cell-derived PGD2 suppressed antigen-specific CD8⁺ T-cell cytotoxicity and impaired plasma-cell differentiation, providing a potential link between chemotherapy and weakened local adaptive immunity. In vivo, pharmacological inhibition of H-PGDS enhanced chemotherapy efficacy, while mast-cell stabilization with cromolyn sodium reduced chemotherapy-associated degranulation, increased local adaptive immune-cell infiltration, improved intracranial tumor control, and prolonged survival when combined with chemotherapy. Our findings support a model in which chemotherapy-associated tissue stress activates an IL-33-responsive mast-cell program and restrains TLS-associated adaptive immunity in LCBM. Although this pathway is unlikely to operate as an exclusively linear or mast-cell-specific mechanism, targeting mast-cell-associated inflammatory signaling may provide a strategy to preserve antitumor immunity and improve the therapeutic efficacy of chemotherapy in brain metastasis.
中文摘要:三级淋巴结构(TLSs)支持局部适应性免疫,并与多种癌症中良好的抗肿瘤反应相关。然而,抗癌治疗如何重塑 TLS 成熟,特别是在肺癌脑转移(LCBM)中,目前尚不清楚。我们整合了 LCBM 队列的临床病理特征、bulk 和单细胞 RNA 测序、空间分析、免疫库分析、组织学验证以及小鼠颅内肿瘤模型。通过多变量分析评估了既往治疗与 TLS 成熟之间的关联。机制研究考察了化疗相关的 IL-33 释放、肥大细胞激活以及 PGD2 对抗原特异性 T 细胞细胞毒性和 B 细胞分化的影响。在体内进一步评估了 H-PGDS 的药理学抑制和肥大细胞稳定作用。成熟的 TLSs 与 LCBM 患者的良好生存期相关,而术前化疗在调整临床和治疗协变量后,独立地与 TLS 成熟受损相关。与此观察结果一致,接受化疗的肿瘤表现出 IL-33 水平升高、肥大细胞积聚以及肥大细胞脱颗粒增强,空间分析显示活化的肥大细胞位于 TLS 相关的免疫生态位中。机制上,IL-33 激活表达 ST2 的肥大细胞,诱导 NF-kB 相关的转录程序。功能上,肥大细胞来源的 PGD2 抑制抗原特异性 CD8+ T 细胞的细胞毒性并损害浆细胞分化,为化疗与局部适应性免疫减弱之间的联系提供了潜在依据。在体内实验中,H-PGDS 的药理学抑制增强了化疗疗效,而使用色甘酸钠稳定肥大细胞减少了化疗相关的脱颗粒,增加了局部适应性免疫细胞的浸润,改善了颅内肿瘤控制,并在与化疗联合使用时延长了生存期。我们的研究结果支持一种模型,即化疗相关的组织应激激活了 IL-33 响应的肥大细胞程序,并限制了 LCBM 中 TLS 相关的适应性免疫。尽管该通路不太可能作为唯一线性或仅肥大细胞特异性的机制发挥作用,但靶向肥大细胞相关的炎症信号可能为保留抗肿瘤免疫和提高脑转移化疗疗效提供策略。
Nature IF 56.1 2026-11-18 PMID: 43052431
Current understanding of the host tissue response to solid tumours is largely based on investigations of tumour types in isolation1. Given the breadth and diversity of human tumour pathology and contributions of tumour microenvironment (TME) cells to disease progression, pan-cancer analysis is needed to bridge major themes of stromal and immune cell evolution. To date, however, efforts to compare the TME response across cancers have been limited in scope2,3. Here we conduct a comprehensive pan-cancer analysis by algorithmically screening thousands of publicly available single-cell transcriptomic datasets for stromal and immune signatures across species and tissue types. We demonstrate conserved hallmarks of host cell transcriptional programming in response to malignancy across 42 cancer types in more than 2,000 human and mouse tumour samples. These findings are codified as an interactive web atlas ( tmeatlas.stanford.edu ) and software package (scTME) that will serve as practical resources for the systematic interrogation of the TME in tumours.
中文摘要:当前对实体瘤宿主组织反应的理解主要基于孤立研究的肿瘤类型。鉴于人类肿瘤病理的广泛多样性以及肿瘤微环境细胞对疾病进展的贡献,需要进行泛癌分析以桥接基质和免疫细胞演化的主要主题。然而迄今为止,跨癌症比较肿瘤微环境反应的尝试范围有限。本研究通过算法筛选数千个公开的单细胞转录组数据集,跨物种和组织类型分析基质和免疫特征,进行了全面的泛癌分析。我们在超过两千个人类和小鼠肿瘤样本中证明了针对恶性病变的宿主细胞转录编程保守标志物跨越四十二种癌症类型。这些发现被编码为交互式网络图谱及软件包,将作为系统探究肿瘤微环境的实用资源。
Journal for immunotherapy of cancer IF 11.7 2026-11-18 PMID: 43051941
Although chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in hematological malignancies, its efficacy against solid tumors remains limited due to the immunosuppressive tumor microenvironment (TME). In triple-negative breast cancer (TNBC), interleukin 4 (IL-4) is markedly enriched and serves as a critical driver of CAR-T cell exhaustion and resistance to immune checkpoint inhibition. However, merely blocking IL-4 signaling provides limited benefit because it fails to actively reinforce T-cell fitness. To overcome this limitation, we engineered an IL-4/IL-9 inverted cytokine receptor (4/9ICR) that introduces IL-9 receptor (IL-9R) signaling in response to IL-4, and evaluated its capacity to enhance CAR-T cell efficacy in TNBC. The 4/9ICR construct was generated by fusing the extracellular domain of IL-4 receptor α with the transmembrane and intracellular domains of IL-9R α. Signal conversion was confirmed by phospho-STAT (pSTAT) profiling in murine and human B7-H3-targeted CAR-4/9ICR-T cells. CAR-T cell phenotype and functional properties were characterized in vitro under IL-4 exposure. Antitumor efficacy was assessed in vivo using a syngeneic 4T1 TNBC model and an NCG mouse human xenograft model. The 4/9ICR successfully introduced IL-9R-mediated activation, as evidenced by robust phosphorylation of STAT1, STAT3, STAT4, and STAT5 on IL-4 stimulation. In vitro, both murine and human CAR-4/9ICR-T cells stimulated with IL-4 exhibited increased effector cytokine production and enhanced expression of stemness-associated markers. In vivo, CAR-4/9ICR-T cells exerted enhanced tumor control, maintained cytotoxicity, and reduced exhaustion compared with conventional CAR-T cells. Moreover, 4/9ICR reprogrammed the TME by repolarizing tumor-associated macrophages from an immunosuppressive M2-like to a proinflammatory M1-like phenotype. The 4/9ICR platform effectively rescues IL-4-driven CAR-T cell exhaustion and reinforces multipotent effector function and stemness. IL-4/IL-9 signal reprogramming represents a clinically applicable strategy to enhance CAR-T efficacy in TNBC and other IL-4-enriched solid tumors.
中文摘要:尽管嵌合抗原受体T细胞疗法在血液恶性肿瘤中取得了显著成功,但由于免疫抑制性肿瘤微环境的存在,其在实体瘤中的疗效仍然有限。在三阴性乳腺癌中,白细胞介素4被显著富集,是驱动T细胞耗竭和抵抗免疫检查点抑制剂的关键因素。然而,仅阻断白细胞介素4信号提供的益处有限,因为它未能主动增强T细胞的功能状态。为了克服这一局限性,我们设计了一种白细胞介素4/9倒置细胞因子受体,该受体在响应白细胞介素4时引入白细胞介素9受体信号,并评估了其增强三阴性乳腺癌中CAR-T细胞疗效的能力。通过融合白细胞介素4受体α的胞外域与白细胞介素9受体α的跨膜和胞内域构建了该结构。通过在小鼠和人B7-H3靶向CAR-4/9ICR-T细胞中进行磷酸化STAT谱分析,证实了信号转换。在体外暴露于白细胞介素4的条件下,表征了CAR-T细胞的表型和功能特性。在小鼠同基因4T1三阴性乳腺癌模型和NCG小鼠人异种移植模型中评估了体内抗肿瘤疗效。结果表明,该结构成功引入了白细胞介素9受体介导的激活,证据是在白细胞介素4刺激下STAT1、STAT3、STAT4和STAT5出现强磷酸化。在体外实验中,经白细胞介素4刺激的小鼠和人CAR-4/9ICR-T细胞表现出效应细胞因子产生增加以及干性相关标志物表达增强。在体内实验中,与传统CAR-T细胞相比,CAR-4/9ICR-T细胞实现了更强的肿瘤控制,维持了细胞毒性并减少了耗竭。此外,该结构通过将肿瘤相关巨噬细胞从免疫抑制性的M2样表型重极化为促炎性的M1样表型,重塑了肿瘤微环境。该平台有效挽救了白细胞介素4驱动的CAR-T细胞耗竭,并增强了多能效应功能和干性。白细胞介素4/9信号重编程代表了增强三阴性乳腺癌及其他白细胞介素4富集实体瘤中CAR-T疗效的临床适用策略。
Kidney international IF 21.8 2026-11-18 PMID: 43051538
Clear cell renal cell carcinoma (ccRCC), the most common subtype of RCC, is characterized by constitutive activation of hypoxia-inducible factors (HIF-1α and HIF-2α), with HIF-2α promoting peroxisome turnover. Although peroxisomes play key roles in lipid metabolism and reactive oxygen species homeostasis, they remain relatively understudied in cancer research, and their contribution to ccRCC is poorly understood. Notably, peroxisome abundance is more frequently reduced in low-grade than in high-grade tumors, suggesting a potential role in tumorigenesis. Peroxisome depletion was induced by impairing peroxisome biogenesis and by inducing pexophagy. Tumor growth was evaluated in subcutaneous xenograft models. Multi-omics analyses, including transcriptomics, proteomics, metabolomics, and lipid profiling, were performed on tumor tissues. Cellular metabolism was assessed using Seahorse extracellular flux analysis in spheroids cultured in human plasma-like medium. Changes in the tumor microenvironment (TME) were evaluated by histological analysis. Peroxisome depletion significantly suppressed ccRCC progression by reducing tumor cell proliferation. It impaired mitochondrial fitness, particularly oxidative phosphorylation, the tricarboxylic acid cycle, and mitochondrial translation. These changes were accompanied by reductions in both glycolytic and mitochondrial flux, resulting in decreased metabolic flexibility and a shift toward a quiescent bioenergetic state that limits tumor growth. Peroxisome-depleted tumors also exhibited oxylipin accumulation. Moreover, peroxisome loss reshaped the TME, as evidenced by increased collagen deposition, enhanced stromal cell infiltration, and a shift in fibroblast populations toward SERPINH1-positive (Serpin Family H Member 1) phenotypes. Consistently, low peroxisome abundance was associated with increased fibrosis in human ccRCC samples. Peroxisome loss constrains ccRCC progression through coordinated metabolic and microenvironmental alterations. These findings highlight a previously underappreciated role of peroxisomes in regulating metabolic fitness and the TME in ccRCC, and suggest potential therapeutic strategies aimed at targeting peroxisome homeostasis in kidney malignancies.
中文摘要:透明细胞肾细胞癌(ccRCC)是肾细胞癌最常见的亚型,其特征为缺氧诱导因子(HIF-1α和HIF-2α)的组成性激活,其中HIF-2α促进过氧化物酶体周转。尽管过氧化物酶体在脂质代谢和活性氧稳态中发挥关键作用,但其在癌症研究中的作用相对被忽视,且其对ccRCC的贡献尚不清楚。值得注意的是,低级别肿瘤中过氧化物酶体丰度减少的频率高于高级别肿瘤,提示其在肿瘤发生中具有潜在作用。本研究通过损害过氧化物酶体生物合成和诱导自噬性过氧化物酶体降解来诱导过氧化物酶体耗竭。在皮下异种移植模型中评估了肿瘤生长情况。对肿瘤组织进行了多组学分析,包括转录组学、蛋白质组学、代谢组学和脂质谱分析。在人血浆样培养基中培养的球状体中,使用Seahorse细胞外通量分析评估了细胞代谢变化。通过组织学分析评估了肿瘤微环境(TME)的变化。过氧化物酶体耗竭通过减少肿瘤细胞增殖显著抑制了ccRCC进展。它损害了线粒体适应性,特别是氧化磷酸化、三羧酸循环和线粒体翻译。这些变化伴随着糖酵解通量和线粒体通量的减少,导致代谢灵活性降低,并转向限制肿瘤生长的静止生物能状态。过氧化物酶体耗竭的肿瘤还表现出氧脂蛋白积累。此外,过氧化物酶体丢失重塑了TME,表现为胶原沉积增加、基质细胞浸润增强以及成纤维细胞群向SERPINH1阳性表型转变。一致的是,低过氧化物酶体丰度与人类ccRCC样本中纤维化增加相关。过氧化物酶体缺失通过协调代谢和微环境改变限制ccRCC进展。这些发现强调了过氧化物酶体在调节ccRCC代谢适应性和TME中以前未被充分重视的作用,并提示针对肾脏恶性肿瘤过氧化物酶体稳态的潜在治疗策略。
Science translational medicine IF 15.6 2026-11-18 PMID: 43050504
Loss of major histocompatibility complex class I (MHC-I) antigen presentation in tumor cells drives immune evasion and resistance to immune checkpoint blockade (ICB) in colorectal cancer (CRC). To identify therapeutic targets reversing this, we conducted fluorescence-activated cell sorting-based CRISPR activation screens using a druggable genome library and identified folate receptor α (FOLR1) as a top negative regulator. FOLR1 was heterogeneously expressed in CRC tumors but undetectable in adjacent normal tissues. High expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes. Functional assays showed that FOLR1 promoted CRC stemness-associated properties and fostered an immunosuppressive tumor microenvironment (TME) with impaired CD8+ T cell infiltration and cytotoxicity, thereby driving tumor progression. Proteomic analyses revealed that FOLR1 stabilized the lactyltransferase AARS1 (alanyl-tRNA synthetase 1), which lactylated signal transducer and activator of transcription 1 (STAT1) at lysine-193 (K193), facilitating its interaction with TCPTP (T cell protein-tyrosine phosphatase) and inducing STAT1 dephosphorylation at tyrosine-701. Consequently, impaired STAT1 signaling down-regulated MHC-I and up-regulated MYC proto-oncogene protein (c-MYC), facilitating evasion of T cell surveillance and enhancing cancer stemness. The anti-FOLR1 antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) exhibited potent activity against FOLR1-positive CRC cells, reprogramming the TME to an immune-active status. Combining IMGN853 with anti-PD-1 (programmed cell death protein-1) therapy boosted antitumor immunity, sensitized tumors to immunotherapy, and induced robust tumor regression in vivo. Our findings support anti-FOLR1 ADC as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in CRC.
中文摘要:肿瘤细胞主要组织相容性复合体I类(MHC-I)抗原提呈的缺失驱动了结直肠癌(CRC)中的免疫逃逸及对免疫检查点阻断(ICB)的耐药。为寻找逆转这一现象的治疗靶点,我们利用可成药基因组文库进行了基于荧光激活细胞分选的CRISPR激活筛选,鉴定出叶酸受体α(FOLR1)为关键的负调控因子。FOLR1在CRC肿瘤中异质性表达,但在邻近正常组织中检测不到。高表达FOLR1预测了较差的ICB反应、增强的癌症干性及不良的患者预后。功能实验表明,FOLR1促进了CRC干细胞相关特性,并通过损害CD8+ T细胞的浸润和细胞毒性营造了免疫抑制性肿瘤微环境(TME),从而驱动肿瘤进展。蛋白质组学分析显示,FOLR1稳定了乳酸转移酶AARS1(丙氨酰-tRNA合成酶1),后者在赖氨酸-193(K193)位点对信号转导和转录激活因子1(STAT1)进行乳酸化修饰,促进其与T细胞蛋白酪氨酸磷酸酶(TCPTP)的相互作用并诱导STAT1在酪氨酸-701位点的去磷酸化。结果导致STAT1信号受损,下调MHC-I并上调MYC原癌基因蛋白(c-MYC),从而促进T细胞监视逃逸并增强癌症干性。抗FOLR1抗体偶联药物(ADC)mirvetuximab soravtansine(IMGN853)对FOLR1阳性CRC细胞表现出强效活性,将TME重编程为免疫活跃状态。联合使用IMGN853与抗PD-1疗法增强了抗肿瘤免疫,使肿瘤对免疫治疗敏感,并在体内诱导了显著的肿瘤消退。我们的研究结果支持抗FOLR1 ADC作为克服免疫逃逸并释放CRC免疫治疗疗效的临床可行策略。
Molecular biomedicine IF 13.0 2026-11-18 PMID: 43050068
The liver combines continuous exposure to gut-derived antigens and metabolites with immune surveillance and tissue repair. Its immune niche is organized by interactions among sinusoidal endothelial cells, Kupffer cells, recruited leukocytes, and parenchymal and stromal cells. At homeostasis, these interactions support antigen clearance and restrained immune activation. Persistent injury changes antigen presentation, metabolite availability, leukocyte recruitment, and extracellular matrix composition, allowing local immune responses to contribute to continued tissue damage. In chronic viral, steatotic, alcohol-associated, cholestatic, and autoimmune liver diseases, distinct patterns of myeloid activation, lymphocyte dysfunction, cytotoxicity, and fibrogenesis emerge at parenchymal, biliary, and vascular interfaces. Hepatocellular carcinoma (HCC) adds tumor-derived signals that suppress antitumor immunity within a heterogeneous hepatic environment. In liver transplantation, perioperative injury intersects with donor-specific cellular and humoral immunity, with outcomes ranging from controlled donor reactivity to distinct, sometimes overlapping forms of rejection and chronic remodeling. Xenotransplantation further exposes the graft to interspecies antibody, complement, endothelial, and coagulation incompatibilities. In inflammatory liver disease and transplantation, blocking local signals that support pathogenic lymphocyte survival or myeloid activation may reduce continued tissue injury. In HCC, limiting tumor-derived metabolic signals that suppress immune-cell function may instead help restore antitumor responses. Continued recruitment from the circulation may replenish pathogenic populations despite suppression of cells already within the liver, making cellular recruitment an additional potential target. Effective treatment must therefore interrupt the processes sustaining injury while preserving antimicrobial defense, antitumor surveillance, graft regulation, and tissue repair.
中文摘要:肝脏结合了来自肠道的抗原和代谢物的持续暴露与免疫监视及组织修复功能。其免疫微环境由窦内皮细胞、库普弗细胞、招募的白细胞以及实质性和间质细胞之间的相互作用所组织。在稳态下,这些相互作用支持抗原清除并限制免疫激活。持续性损伤改变了抗原呈递、代谢物可用性、白细胞招募和细胞外基质组成,使得局部免疫反应有助于持续的组织的损伤。在慢性病毒性、脂肪变性、酒精性、胆汁淤积性和自身免疫性肝病中,实质、胆管和血管界面出现了独特的髓系细胞活化、淋巴细胞功能障碍、细胞毒性和纤维生成模式。肝细胞癌增加了肿瘤来源的信号,这些信号在一个异质性的肝脏环境中抑制抗肿瘤免疫。在肝移植中,围手术期损伤与供体特异性的细胞和体液免疫相互交织,结果从受控的供体反应到不同且有时重叠形式的排斥反应和慢性重塑不等。异种移植进一步使移植物暴露于种间抗体、补体、内皮和凝血不相容性之中。在炎症性肝病和移植中,阻断支持致病性淋巴细胞存活或髓系细胞激活的局部信号可能减少持续的损伤。在肝细胞癌中,限制抑制免疫细胞功能的肿瘤来源代谢信号可能有助于恢复抗肿瘤反应。尽管抑制了肝脏内的细胞,但来自循环系统的持续招募可能会补充致病性群体,使得细胞招募成为另一个潜在靶点。因此,有效的治疗必须中断维持损伤的过程,同时保留抗菌防御、抗肿瘤监视、移植物调节和组织修复。
Advanced healthcare materials IF 11.0 2026-11-17 PMID: 43046126
Development of a nanovaccine (NV) that can simultaneously manipulate multiple immune cell types to activate both adaptive and innate immunity still remains a great challenge. In this study, we employed a phosphorus dendrimer (termed AK38, generation 0) with intrinsic NK cell-proliferative activity as a carrier to complex model antigen ovalbumin (OVA) and load agonist imiquimod (R837), followed by cancer cell membrane coating. The resulting AK38-OVA/R837@CM NV exhibits spherical morphology, stimuli-responsive release, excellent colloidal stability, and cytocompatibility. It promotes dendritic cell (DC) maturation and enhances antigen cross-presentation by integrating cancer cell membrane antigens, OVA, and adjuvant. Meanwhile, the NV polarizes tumor-associated macrophages (TAMs) toward the antitumor M1 phenotype, reversing immunosuppression. Importantly, the phosphorus dendrimer enables NK cell proliferation to induce tumor apoptosis. The NV synergistically activates DCs, TAMs, and NK cells, eliciting cytotoxic T lymphocyte-mediated adaptive immunity while enhancing TAM- and NK-dominated innate responses. This was validated in a murine melanoma model, where the NV effectively inhibited tumor growth and recurrence. With its simple composition and multi-cell immune cascade modulation, this phosphorus dendrimer-based NV offers a versatile tumor immunotherapy strategy, showing great promise for broad cancer treatment applications by mimicking biological systems to induce robust immune responses.
中文摘要:开发能同时操控多种免疫细胞以激活适应性和固有免疫的纳米疫苗仍面临巨大挑战。本研究采用具有内在NK细胞增殖活性的磷树枝状聚合物(AK38,零代)作为载体,与模型抗原卵清蛋白(OVA)复合并负载激动剂咪喹莫特(R837),随后进行癌细胞膜包被。所得AK38-OVA/R837@CM纳米疫苗呈球形形态,具有刺激响应性释放、优异的胶体稳定性和细胞相容性。通过整合癌细胞膜抗原、OVA和佐剂,该疫苗促进树突状细胞成熟并增强抗原交叉提呈。同时,该疫苗将肿瘤相关巨噬细胞极化为抗肿瘤M1表型,逆转免疫抑制状态。重要的是,磷树枝状聚合物能诱导NK细胞增殖从而引发肿瘤凋亡。该纳米疫苗协同激活DC、TAM和NK细胞,在引发CTL介导的适应性免疫的同时增强以TAM和NK为主导的固有免疫反应。这一效果在小鼠黑色素瘤模型中得到验证,该纳米疫苗有效抑制了肿瘤生长和复发。凭借其简单的组成和多细胞免疫级联调节能力,这种基于磷树枝状聚合物的纳米疫苗提供了一种通用的肿瘤免疫治疗策略,通过模拟生物系统诱导强大的免疫反应,在广泛癌症治疗应用中展现出巨大潜力。
Trends in microbiology IF 18.7 2026-11-17 PMID: 43045551
Epstein-Barr virus (EBV) infects more than 95% of the global population and contributes to multiple human cancers and autoimmune diseases. Co-infection with pathogens including Helicobacter pylori, human immunodeficiency virus, human papillomavirus, and Plasmodium falciparum can reshape host immunity and the EBV latency-lytic balance and, in some settings, promote reactivation. Collectively, these interactions may exacerbate chronic inflammation, immunosuppression, and epigenetic dysregulation to accelerate disease progression and tumor formation. Existing clinical treatments control only the active pathogens but fail to target latent EBV. Emerging strategies such as clustered regularly interspaced short palindromic repeats (CRISPR) gene editing and EBV-targeted immunotherapy aim to eliminate latent viral reservoirs. This review outlines the synergistic mechanisms of EBV co-infection in oncogenesis, highlighting that further research on pathogen interactions is vital for developing better prevention and treatment options.
中文摘要:EB病毒(EBV)感染全球超过95%的人口,并导致多种人类癌症和自身免疫性疾病。与幽门螺杆菌、人类免疫缺陷病毒、人乳头瘤病毒和恶性疟原虫等病原体的共感染可以重塑宿主免疫力和EBV潜伏-裂解平衡,并在某些情况下促进再激活。这些相互作用可能加剧慢性炎症、免疫抑制和表观遗传失调,从而加速疾病进展和肿瘤形成。现有的临床治疗仅能控制活跃病原体,但无法靶向潜伏的EBV。新兴策略如CRISPR基因编辑和EBV靶向免疫疗法旨在消除潜伏的病毒库。本综述概述了EBV共感染在致癌中的协同机制,强调进一步研究病原体相互作用对于开发更好的预防和治疗方案至关重要。
Seminars in cancer biology IF 20.3 2026-11-17 PMID: 43045023
Deficiency of DNA mismatch repair (dMMR), whether acquired sporadically or in the context of Lynch Syndrome (LS), is a potent driver of mutagenesis in cancer. Continuous accumulation of insertion-deletion mutations (indels) at highly repetitive DNA regions, called microsatellites, leads to the molecular phenotype of microsatellite instability (MSI). MSI generates an exceptionally high mutational burden and a dynamic neoantigen landscape, placing tumors with MSI under strong immune surveillance. MSI tumors typically display a high degree of heterogeneity, however, converge on recurring evolutionary outcomes with stereotyped driver pathway mutations and shared immune evasion strategies. From an evolutionary perspective, MSI leads to rapid adaptive evolution at the cost of increased deleterious mutations. We highlight key differences in carcinogenesis in sporadic and hereditary MSI cancers, and their impact on tumor evolution and intratumoral heterogeneity (ITH). We discuss an evolutionary framework where clonal evolution in MSI cancers is shaped by the interplay between ongoing mutagenesis, immune-mediated selection, as well as multiple other intrinsic and extrinsic constraints that influence MSI carcinogenesis. Further, we examine immune evasion as a clonal or subclonal adaptation, including alterations in antigen presentation, interferon signaling, and immune checkpoint regulation. Therapeutic pressure, particularly through immune checkpoint blockade, adds an additional evolutionary layer that can reshape clonal composition and promote the emergence of immune-resistant clones. In summary, MSI cancers illustrate how intrinsically and extrinsically constrained evolutionary processes jointly determine tumor heterogeneity. Understanding constraints in MSI cancer evolution has important implications in pathogenesis and should inform further strategies for clinical management in therapy and prevention.
中文摘要:DNA错配修复缺陷无论是散发性获得还是林奇综合征背景下,都是癌症中强大的致突变驱动因素。高度重复DNA区域即微卫星中插入缺失突变的持续积累导致微卫星不稳定的分子表型。微卫星不稳定产生极高的突变负荷和动态的新抗原景观,使具有微卫星不稳定的肿瘤处于强烈的免疫监视之下。尽管微卫星不稳定肿瘤通常表现出高度的异质性,但它们会收敛于具有刻板驱动通路突变和共享免疫逃逸策略的重复性进化结果。从进化角度看,微卫星不稳定以增加有害突变为代价导致快速的适应性进化。我们强调了散发性和遗传性微卫星不稳定癌症在致癌作用上的关键差异及其对肿瘤进化和肿瘤内异质性的影响。我们讨论了一个进化框架,其中微卫星不稳定癌症中的克隆进化由持续的致突变、免疫介导的选择以及影响微卫星不稳定致癌作用的其他多种内在和外在约束之间的相互作用所塑造。此外,我们考察了作为克隆或亚克隆适应的免疫逃逸,包括抗原呈递改变、干扰素信号传导改变和免疫检查点调节的改变。治疗压力特别是通过免疫检查点阻断增加了额外的进化层,可以重塑克隆组成并促进免疫抵抗克隆的出现。总之,微卫星不稳定癌症说明了内在和外在约束的进化过程如何共同决定肿瘤异质性。理解微卫星不稳定癌症进化中的约束对发病机制具有重要意义,并应为治疗和预防的临床管理策略提供指导。
Acta biomaterialia IF 10.4 2026-11-17 PMID: 43044702
The clinical treatment of osteosarcoma (OS) faces the great challenges of inefficient tumor progression control and extreme lung metastases. To conquer the bottleneck, this study develops a self-assembled carrier-free, dual-organelle-targeted nanomedicine (IR-DOX NPs) by conjugating photosensitizer IR780 and chemotherapeutic doxorubicin (DOX) via a pH-responsive hydrazone bond. Remodeling of the immunosuppressive tumor microenvironment was achieved by synergistic induction of potent immunogenic cell death (ICD) via DOX/ phototherapy and activation of the cGAS-STING innate immune pathway through mtDNA release upon mitochondrial photodamage. The activation of systemic immunity was first demonstrated in a bilateral OS mouse model. Finally, in challenging orthotopic OS models with lung metastasis, IR-DOX NPs plus laser irradiation further combined with anti-PD-L1 antibody amplified primary tumor eradication and anti-metastatic efficacy, and preserved bone integrity by inhibiting osteoclast activity. Biosafety evaluations confirmed the nanomedicine's favorable in vivo biocompatibility. In conclusion, this translatable nanomedicine approach offers an innovative strategy to achieve immunity strengthened primary tumor ablation and metastatic control. STATEMENT OF SIGNIFICANCE: Osteosarcoma (OS) remains one of the most lethal adolescent cancers owing to ineffective control of primary tumors and an exceptionally high incidence of lung metastasis. To address these challenges, we designed a translational, carrier-free nanomedicine for immunity strengthened metastatic osteosarcoma therapy. Precise molecular engineering was implemented to fabricate the nanomedicine, enabling carrier-free molecular self-assembly, tumor microenvironment specific drug release and dual mitochondria/nuclei targeting. The nanomedicine synergistically activates potent immunogenic cell death (ICD) and cGAS-STING pathway, coupling innate and adaptive immunity, to remodel immunosuppressive "cold" tumors into immunogenic "hot" microenvironments. This strategy overcomes limitations of current OS treatments, offering a multiple-combination paradigm merging localized ablation with systemic immunity for metastatic control.
中文摘要:骨肉瘤的临床治疗面临肿瘤进展控制效率低下和肺转移严重的挑战。为突破这一瓶颈,本研究开发了一种自组装无载体双细胞器靶向纳米药物(IR-DOX NPs),通过pH响应性腙键将光敏剂IR780与化疗药物阿霉素(DOX)偶联。通过阿霉素/光疗协同诱导强效免疫原性细胞死亡,并在线粒体光损伤后通过释放mtDNA激活cGAS-STING先天免疫通路,实现了免疫抑制性肿瘤微环境的重塑。在双侧骨肉瘤小鼠模型中首次证实了系统免疫的激活。最终,在伴有肺转移的难治性原位骨肉瘤模型中,IR-DOX NPs联合激光照射及抗PD-L1抗体进一步增强了原发肿瘤的清除和抗转移效果,并通过抑制破骨细胞活性保留了骨骼完整性。生物安全性评估证实该纳米药物具有良好的体内生物相容性。综上所述,这种可转化的纳米药物策略为实现增强免疫的原发肿瘤消融和转移控制提供了创新方案。骨肉瘤仍是最致命的青少年癌症之一,原因在于原发肿瘤控制无效且肺转移发生率极高。为解决这些挑战,我们设计了一种用于增强免疫的转移性骨肉瘤治疗的转化型无载体纳米药物。通过精确的分子工程制造该纳米药物,实现了无载体分子自组装、肿瘤微环境特异性药物释放及双线粒体/细胞核靶向。该纳米药物协同激活强效免疫原性细胞死亡和cGAS-STING通路,耦合先天与适应性免疫,将免疫抑制性冷肿瘤重塑为免疫原性热微环境。该策略克服了当前骨肉瘤治疗的局限性,提供了一种结合局部消融与系统免疫以控制转移的多重联合范式。
Acta biomaterialia IF 10.4 2026-11-17 PMID: 43044701
Triple-negative breast cancer (TNBC) remains a therapeutic challenge due to its immunosuppressive tumor microenvironment (TME), orchestrated by multiple immune checkpoint mechanisms, including Programmed Cell Death Ligand 1 (PD-L1) upregulation and dysregulated tryptophan metabolism. To concurrently target these pathways, we engineered a tumor-targeted nanoformulation, Biotin@NPs, consisting of a mitoxantrone (MTO)-derived metal-organic framework co-loaded with the tryptophan catabolism inhibitor 1-methyl-tryptophan (1-MT). Mechanistically, upon laser irradiation, MTO mediated localized photothermal conversion, inducing tumor cell damage and apoptosis. Meanwhile, this platform induced comprehensive mitochondrial damage, leading to cytosolic mitochondrial DNA (mtDNA) release and activation of the dormant cGAS-STING pathway. Importantly, the resultant metabolic stress potently downregulated the expression of the canonical immune checkpoint PD-L1 on cancer cells. This effect was synergized by 1-MT, which blocked the alternative, metabolic immune checkpoint mediated by the indoleamine-2, 3-dioxygenase (IDO)/kynurenine axis. This dual-checkpoint inhibition effectively reversed the immunosuppressive TME, enhancing tumor infiltration and cytotoxicity of T cells. Consequently, Biotin@NPs not only sensitized TNBC to chemotherapy but also ignited a robust systemic anti-tumor immune response, achieving potent tumor suppression in preclinical models. Our work demonstrates that co-targeting structural (PD-L1) and metabolic (IDO) immune checkpoints via a single nanoplatform provides a powerful strategy to overcome treatment resistance in TNBC. STATEMENT OF SIGNIFICANCE: Triple-negative breast cancer (TNBC) remains the most aggressive and immunologically "cold" subtype, with limited responses to immune checkpoint blockade due to redundant and non-overlapping suppressive axes within the tumor microenvironment. Here, we move beyond single-agent immunotherapy by co-targeting two mechanistically distinct checkpoints-the canonical PD-L1 axis and the metabolic IDO-kynurenine pathway-using a tumor-targeted Biotin@NPs platform. This nanoplatform couples mitochondrial-directed chemotherapy with local inhibition of tryptophan catabolism, triggering cytosolic mtDNA release and cGAS-STING activation while suppressing PD-L1 expression and IDO-mediated immunosuppression. This dual-hitting strategy not only relieves T-cell exhaustion but also converts the tumor microenvironment from an immunosuppressive barrier into a fire-break for systemic antitumor immunity. By integrating clinically approved mitoxantrone with the well-tolerated metabolic modulator 1-MT in a targeted delivery system, our approach offers a readily translatable blueprint for overcoming resistance to chemotherapy and checkpoint inhibitors in TNBC and other hard-to-treat malignancies.
中文摘要:三阴性乳腺癌因由程序性死亡配体1上调和色氨酸代谢失调等多种免疫检查点机制共同塑造的免疫抑制性肿瘤微环境,仍面临治疗挑战。为同时靶向这些通路,我们设计了一种肿瘤靶向纳米制剂Biotin@NPs,该制剂由米托蒽醌衍生的金属有机框架组成,并共负载色氨酸分解代谢抑制剂1-甲基色氨酸。机制上,激光照射后米托蒽醌介导局部光热转换,诱导肿瘤细胞损伤和凋亡。同时,该平台诱导全面的线粒体损伤,导致胞质线粒体DNA释放并激活休眠的cGAS-STING通路。重要的是,由此产生的代谢应激有效下调了癌细胞上经典免疫检查点PD-L1的表达。这一效应与1-MT的作用协同,后者阻断了由吲哚胺2,3-双加氧酶/犬尿氨酸轴介导的替代性代谢免疫检查点。这种双重检查点抑制有效逆转了免疫抑制性肿瘤微环境,增强了T细胞的肿瘤浸润和细胞毒性。因此,Biotin@NPs不仅使三阴性乳腺癌对化疗敏感,还激发了强大的全身抗肿瘤免疫反应,在临床前模型中实现了有效的肿瘤抑制。我们的研究表明,通过单一纳米平台同时靶向结构性和代谢性免疫检查点,为克服三阴性乳腺癌的治疗耐药提供了有力策略。三阴性乳腺癌是最具侵袭性且免疫学上呈冷表型的亚型,由于肿瘤微环境中存在冗余且非重叠的抑制轴,对免疫检查点阻断的反应有限。本研究通过肿瘤靶向Biotin@NPs平台共同靶向两个机制不同的检查点——经典PD-L1轴和代谢性IDO-犬尿氨酸通路,超越了单药免疫治疗。该纳米平台将线粒体导向化疗与色氨酸分解代谢的局部抑制相结合,触发胞质mtDNA释放和cGAS-STING激活,同时抑制PD-L1表达和IDO介导的免疫抑制。这种双重打击策略不仅缓解了T细胞耗竭,还将肿瘤微环境从免疫抑制屏障转化为全身抗肿瘤免疫的火线。通过将临床批准的米托蒽醌与耐受性良好的代谢调节剂1-MT整合到靶向递送系统中,我们的方法为克服三阴性乳腺癌及其他难治性恶性肿瘤对化疗和检查点抑制剂的耐药提供了易于转化的蓝图。
Cancer discovery IF 29.5 2026-11-17 PMID: 43043388
Cutaneous melanoma exhibits strong responses to immunotherapy, yet the system-level mechanisms linking mutational burden, genomic alterations, antigen landscapes, post-transcriptional and post-translational regulation, and immune outcomes remain incompletely defined. We profiled 183 cutaneous melanomas using 13 omic layers, including immunopeptidomics, metabolomics, protein ubiquitylation and glycosylation, to construct a holistic view of tumor immunogenicity. Mass spectrometry-based HLA-I immunopeptidomics revealed correlation between tumor antigens and CD8+ T-cell infiltration. Metabolomics revealed distinct ether-linked lipids and mitochondrial metabolic profiles between primary and metastatic tumors. Ubiquitylomics uncovered a subset of tumors associated with worse survival, characterized by high ubiquitylation of the IFN signaling pathway and ubiquitylation-dependent activation of AKT1. Glycoproteomic analyses identified GPNMB glycosylation as a key feature associated with sex-specific survival, linking this signal to a lysosome-associated program and suggesting potential sex-dependent differences in immunotherapy response. This multi-omic atlas of cutaneous melanoma illuminates mechanisms of immune evasion, informing treatment-relevant patient stratification in melanoma care.
中文摘要:皮肤黑色素瘤对免疫治疗表现出强烈的反应,但连接突变负荷、基因组改变、抗原景观、转录后和翻译后调控以及免疫结局的系统水平机制仍未完全明确。我们利用包括免疫肽组学、代谢组学、蛋白质泛素化和糖基化在内的13个组学层面对183例皮肤黑色素瘤进行了分析,以构建肿瘤免疫原性的整体视图。基于质谱的HLA-I免疫肽组学揭示了肿瘤抗原与CD8+ T细胞浸润之间的相关性。代谢组学揭示了原发性肿瘤和转移性肿瘤之间独特的醚键脂质和线粒体代谢特征。泛素组学发现了一组与较差生存率相关的肿瘤亚群,其特征是IFN信号通路的泛素化水平高以及AKT1的泛素化依赖性激活。糖蛋白组学分析确定GPNMB糖基化是与性别特异性生存相关的关键特征,将该信号与溶酶体相关程序联系起来,并提示免疫治疗反应可能存在性别差异。这一皮肤黑色素瘤的多组学图谱阐明了免疫逃逸机制,为黑色素瘤治疗相关的患者分层提供了信息。
ACS nano IF 17.3 2026-11-17 PMID: 43043225
Bladder cancer is a type of prevalent malignant tumor of the urinary system, for which transurethral endoscopic resection serves as the first-line clinical treatment, followed by adjuvant intravesical chemotherapy or BCG immunotherapy. Current clinical regimens suffer largely from surgical trauma, procedural risks, long treatment cycles, severe systemic side effects, and high recurrence rates; conventional tumor cell-killing modalities relying on highly toxic chemotherapeutics and vaccines will inevitably damage normal tissues and induce less-tolerable adverse reactions in patients. By overturning this conventional therapeutic philosophy, we previously proposed a globally pioneering bladder cancer disaggregation therapy: calcium chelation disrupts intercellular cadherin-mediated adhesion, triggering exfoliation and detachment of tumor cells, which are subsequently excreted from the body via urine. Taking advantage of the unique anatomical and physiological characteristics of the bladder, this strategy achieves noninvasive tumor elimination through spontaneous urinary expulsion. To further enhance the disaggregation efficiency, the present work advances this concept by incorporating collagenase to realize the dual disruption of both cadherin and collagen proteins. To this end, we constructed a layered double hydroxide (LDH) nanoplatform coloaded with collagenase and EDTA. The nanosystem efficiently degrades key extracellular matrix components, thereby relieving steric hindrance and exposing cellular surfaces, which significantly promotes the subsequent disruption of intercellular junctions via enhanced EDTA accessibility for calcium deprivation from E-cadherin. This work establishes an efficient, noncell-killing modality for the physical clearance of bladder tumors, offering a promising alternative clinical strategy to suppress tumor recurrence and reduce systemic toxic side effects.
中文摘要:膀胱癌是泌尿系统常见的恶性肿瘤,经尿道内镜切除术是一线临床治疗手段,随后辅以膀胱内化疗或BCG免疫治疗。现有临床方案存在手术创伤大、操作风险高、疗程长、全身副作用严重及复发率高等问题;依赖高毒性化疗药物和疫苗的常规肿瘤细胞杀伤模式不可避免地损伤正常组织并引发患者难以耐受的不良反应。通过颠覆这一传统治疗理念,我们此前提出了一种全球首创的膀胱癌解聚疗法:钙螯合破坏细胞间钙黏蛋白介导的黏附,触发肿瘤细胞脱落并从尿液中排出体外。利用膀胱独特的解剖和生理特征,该策略通过自发性尿液排出实现无创肿瘤清除。为进一步提高解聚效率,本研究推进了这一概念,引入胶原酶以实现对钙黏蛋白和胶原蛋白的双重破坏。为此,我们构建了负载胶原酶和EDTA的层状双氢氧化物纳米平台。该系统有效降解关键细胞外基质成分,从而缓解空间位阻并暴露细胞表面,显著促进后续通过增强EDTA获取E-钙黏蛋白中钙离子以实现钙剥夺而破坏细胞间连接的过程。本研究建立了一种高效的非杀伤性物理清除膀胱肿瘤模式,为抑制肿瘤复发和减少全身毒性副作用提供了一种有前景的替代临床策略。
ACS nano IF 17.3 2026-11-17 PMID: 43043202
Adenoviral vectors have been widely validated as effective vaccine platforms for both infectious diseases and cancer due to their strong immunostimulatory properties. However, their application to personalized cancer vaccines and other time-sensitive antigens is limited by the prolonged production time required for conventional vector generation. Here, we developed an adenovirus-derived virus-like particle (Ad5VLP) platform that enables modular incorporation of antigen cargo without reconstruction of a complete antigen-encoding adenoviral genome. Ad5VLPs successfully packaged and delivered foreign mRNA, although mRNA-derived antigen expression remained insufficient to induce robust antigen-specific immunity in vivo. In contrast, direct encapsulation of protein or peptide antigens substantially improved intracellular antigen delivery and major histocompatibility complex (MHC) class I antigen presentation. Following subcutaneous prime-boost immunization in mice, antigen-loaded Ad5VLPs induced robust antigen-specific interferon-γ (IFN-γ) responses, with functional activity preferentially enriched within CD44hi CD8+ T cells and accompanied by effector-associated CD8+ T-cell differentiation. Importantly, robust cellular immune responses were also observed using an E0771 tumor neoantigen, demonstrating that the platform extends beyond the model ovalbumin (OVA) antigen. Protein-loaded Ad5VLPs also elicited antigen-specific and antivector humoral responses. Vaccination was well tolerated over the 14 day study period, with no substantial changes in body weight, clinical observations, serum markers of hepatic or renal injury and systemic inflammation, or broad splenic inflammatory transcriptional signatures. Together, these findings demonstrate that Ad5VLPs enable modular delivery of protein and peptide antigens and induce robust cellular immune responses, supporting further investigation for personalized cancer vaccination and other time-sensitive vaccine applications.
中文摘要:腺病毒载体因其强免疫刺激特性,已被广泛验证为针对传染病和癌症的有效疫苗平台。然而,传统载体生成所需的长时间生产限制了其在个性化癌症疫苗及其他时间敏感抗原中的应用。本研究开发了一种腺病毒来源的病毒样颗粒(Ad5VLP)平台,该平台无需重建完整的抗原编码腺病毒基因组即可实现抗原载荷的模块化整合。Ad5VLP成功包装并递送了外源mRNA,但由mRNA衍生的抗原表达不足以在体内诱导强烈的抗原特异性免疫反应。相比之下,直接封装蛋白质或多肽抗原显著提高了细胞内抗原递送效率及主要组织相容性复合体(MHC)I类抗原呈递。在小鼠皮下初免加强免疫后,负载抗原的Ad5VLP诱导了强烈的抗原特异性干扰素-γ(IFN-γ)反应,功能性活性优先富集于CD44hi CD8+ T细胞中,并伴随效应相关的CD8+ T细胞分化。重要的是,使用E0771肿瘤新抗原也观察到了强大的细胞免疫反应,证明该平台不仅适用于模型卵清蛋白(OVA)抗原。负载蛋白的Ad5VLP还引发了抗原特异性和抗载体体液反应。在为期14天的研究期间,疫苗接种耐受性良好,体重、临床观察指标、肝肾功能损伤血清标志物、全身炎症或广泛的脾脏炎症转录特征均无显著变化。综上所述,这些发现表明Ad5VLP能够实现蛋白质和多肽抗原的模块化递送并诱导强大的细胞免疫反应,支持其在个性化癌症疫苗及其他时间敏感疫苗应用中的进一步研究。
Clinical and molecular hepatology IF 21.7 2026-11-17 PMID: 43041057
Despite the rising global incidence of metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma (MASLD-HCC), immunotherapy offers limited survival benefits in this non-viral etiology, positioning lenvatinib as a critical treatment that necessitates novel strategies to enhance its efficacy. This study aimed to identify MASLD-HCC signature genes and to explore a novel agent to overcome lenvatinib resistance. Single-cell RNA sequencing identified signature genes, validated by immunohistochemistry, qPCR, Western blot, and spatial transcriptomics in human and murine specimens. Virtual screening identified a natural compound targeting hub genes. Direct binding was confirmed using molecular dynamics simulations, cellular thermal shift assays, and surface plasmon resonance. Therapeutic efficacy and underlying mechanisms were comprehensively evaluated in vitro under lipotoxic stress conditions and in vivo using diet-induced orthotopic MASLD-HCC mouse models. A 170-gene signature was established, with ABAT and ALDH2 prioritized as hub genes. Podocarpusflavone A (PCFA) emerged as a dual-targeting agent that robustly reverses acquired lenvatinib resistance. Instead of increasing protein abundance, PCFA directly binds these targets, which is accompanied by markedly enhanced cellular ABAT and ALDH activities. This diminishes the protective GABA shield and disrupts the mitochondrial NAD⁺ balance, precipitating a lethal mitochondrial superoxide burst and inhibiting key oncogenic pathways. In vivo, the PCFA and lenvatinib combination profoundly suppressed orthotopic tumor progression and was associated with short-term improvements in hepatic steatosis and fibrosis-related histological findings, with no evident toxicity under the conditions tested. PCFA combined with lenvatinib represents a promising strategy for MASLD-HCC and provides mechanistic insights into its antitumor activity.
中文摘要:尽管代谢功能障碍相关脂肪性肝病相关肝细胞癌(MASLD-HCC)的全球发病率不断上升,但免疫治疗在此类非病毒性病因中提供的生存获益有限,这使得仑伐替尼成为关键的治疗手段,亟需新策略以提高其疗效。本研究旨在鉴定MASLD-HCC的特征基因并探索一种克服仑伐替尼耐药性的新型药物。通过单细胞RNA测序识别特征基因,并在人和小鼠标本中利用免疫组化、qPCR、Western blot和空间转录组学进行验证。虚拟筛选确定了靶向核心基因的天然化合物。利用分子动力学模拟、细胞热位移测定和表面等离子共振证实了直接结合。在脂毒性应激条件下的体外实验以及饮食诱导的原位MASLD-HCC小鼠模型体内实验中,全面评估了其治疗功效和潜在机制。建立了包含170个基因的签名,并将ABAT和ALDH2确定为核心基因。Podocarpusflavone A(PCFA)作为一种双重靶向药物,能有效逆转获得性仑伐替尼耐药性。PCFA并非通过增加蛋白质丰度发挥作用,而是直接结合这些靶点,伴随细胞内ABAT和ALDH活性的显著增强。这削弱了保护性的GABA屏障并破坏了线粒体NAD⁺平衡,引发致命的线粒体超氧化物爆发并抑制关键致癌通路。在体内实验中,PCFA与仑伐替尼联合使用显著抑制了原位肿瘤进展,并与肝脏脂肪变性和纤维化相关组织学发现的短期改善有关,且在测试条件下未见明显毒性。PCFA联合仑伐替尼代表了MASLD-HCC的一种有前景的策略,并为其抗肿瘤活性提供了机制见解。
Medicinal research reviews IF 13.6 2026-11-16 PMID: 43041013
Lactate is now recognized as an active immunometabolic regulator in the tumor microenvironment (TME), not simply as a glycolytic byproduct. Its immunological effects arise through several related but distinct routes. Extracellular acidosis, glucose competition, and impaired monocarboxylate transporter-dependent flux can impair CD8+ T cells, natural killer cells, and dendritic cells. Lactate- and proton-sensing receptors can also favor suppressive myeloid and regulatory-cell programs. Histone and non-histone lactylation add another layer by linking lactate availability to chromatin regulation and protein function. During sustained or repeated metabolic stress, these processes may support regulatory T-cell fitness, suppressive programs in tumor-associated macrophages and myeloid-derived suppressor cells, checkpoint expression, and resistance to immunotherapy. Lactylation is a plausible mediator through which sustained metabolic stress may be converted into persistent immune reprogramming; however, post-withdrawal persistence and cellular memory remain to be demonstrated in cancer. We distinguish lactate-dependent regulation from acidosis and evaluate the links to immune dysfunction and treatment resistance by their temporal, causal, and clinical support. This framework defines tests of post-exposure persistence and connects mechanistic evidence and pharmacological specificity to biomarker development and mechanism-matched trial design.
中文摘要:乳酸现被认定为肿瘤微环境中的活性免疫代谢调节因子,而非单纯的糖酵解副产物。其免疫效应通过多种相关但不同的途径产生。细胞外酸中毒、葡萄糖竞争以及单羧酸转运蛋白依赖性通量受损可损害CD8+ T细胞、自然杀伤细胞和树突状细胞。乳酸及质子感应受体也可促进抑制性髓系细胞和调节性细胞程序。组蛋白和非组蛋白乳酸化通过连接乳酸可用性与染色质调控及蛋白质功能增加了另一层复杂性。在持续或重复的代谢应激期间,这些过程可能支持调节性T细胞的适应性、肿瘤相关巨噬细胞和髓系来源抑制性细胞的抑制性程序、检查点表达以及免疫治疗耐药性。乳酸化可能是将持续代谢应激转化为持久免疫重编程的合理介质;然而,撤除后的持久性和细胞记忆在癌症中仍有待证明。我们区分了乳酸依赖性调节与酸中毒,并通过时间、因果和临床支持评估其与免疫功能障碍和治疗耐药的关联。该框架定义了暴露后持久性的测试,并将机制证据和药理学特异性连接到生物标志物开发和机制匹配的试验设计。
Nature biotechnology IF 44.5 2026-11-16 PMID: 43040071
Adeno-associated virus (AAV) vectors have been applied for precise genome engineering in human T cells but poor tropism restricts their efficiency and translational potential. Here, through directed evolution of the AAV6 capsid in primary human T cells, we identified a family of variants containing an APR motif at residues 455-457. The lead candidate, AAV.APR31, enabled robust transduction of primary T and NK cells at nearly 100-1,000-fold lower doses than AAV6 and outperformed the human T cell-tropic capsid AAV-hT7. CRISPR screening identified CD7 as a lineage-specific entry enhancer alongside the canonical AAVR pathway and structural analysis suggested that the APR motif facilitates CD7 engagement. Unlike existing delivery systems confined to one engineering mode, AAV.APR31 enabled transient transgene delivery, site-specific knock-in and transposon integration in human T and NK cells, generating CAR-T cells functionally equivalent to lentiviral vector-manufactured products. Systemic administration of AAV.APR31-generated CAR-T cells in vivo resulted in potent tumor control in hematologic and solid tumor mouse models.
中文摘要:腺相关病毒载体已应用于人类T细胞的精准基因组工程,但其较差的嗜性限制了效率和转化潜力。本研究通过对原代人T细胞中AAV6衣壳进行定向进化,鉴定出一个在455至457位残基含有APR基序的变异体家族。先导候选物AAV.APR31以比AAV6低100至1,000倍近乎一致的剂量实现了原代T细胞和NK细胞的强效转导,并优于人T细胞嗜性衣壳AAV-hT7。CRISPR筛选鉴定CD7为与经典AAVR通路并列的谱系特异性进入增强因子,结构分析表明APR基序促进CD7结合。不同于局限于单一工程模式的现有递送系统,AAV.APR31实现了人T细胞和NK细胞的瞬时转基因递送、位点特异性敲入及转座子整合,生成的CAR-T细胞在功能上等同于慢病毒载体制造的产品。体内系统性施用AAV.APR31生成的CAR-T细胞在血液瘤和实体瘤小鼠模型中均产生了强效的肿瘤控制效果。
Archives of toxicology IF 10.9 2026-11-16 PMID: 43039993
Oral squamous cell carcinoma (OSCC) is a global health burden, particularly in South and Southeast Asia, where betel quid (BQ) chewing remains highly prevalent. As epidemiological evidence consistently identifies BQ as an independent risk factor for OSCC, recent high-throughput sequencing analyses and experimental mutagenesis studies have substantially advanced our understanding of the biological mechanisms underlying BQ-related oral tumorigenesis. This review provides an updated overview of the molecular and cellular alterations associated with chronic BQ exposure during OSCC development, with particular emphasis on genotoxicity, epigenetic and noncoding RNA-mediated remodeling, and immune dysregulation. BQ and its related constituents induce diverse forms of genomic instability in oral tissues, including chromosomal abnormalities, impaired DNA repair, characteristic mutational spectra/signatures, copy-number alterations, and loss of heterozygosity. Concurrently, chronic BQ exposure promotes widespread epigenetic dysregulation through altered DNA methylation, histone modification, and noncoding RNA-mediated pathways, resulting in silencing of tumor suppressor genes and activation of oncogenic signaling. Emerging evidence also suggests that BQ exposure may reshape the immune microenvironment of OSCC into a permissive niche for tumor progression and therapeutic resistance, highlighted by increased infiltration of tumor-associated macrophages, altered immunoregulatory dendritic cell programs, and activation of immune checkpoint pathways such as PD-L1/PD-1 and CD155/TIGIT. Collectively, these findings suggest that BQ-related OSCC may represent an etiologically defined subgroup of oral cancer with partially distinct genomic, epigenetic, and immunologic features, although further validation across anatomical sites, exposure patterns, and population backgrounds is required. A better understanding of these alterations may facilitate the development of novel prognostic biomarkers and precision therapeutic strategies for BQ-related oral cancer.
中文摘要:口腔鳞状细胞癌是全球健康负担,尤其在南亚和东南亚地区,嚼槟榔行为依然普遍。流行病学证据一致表明槟榔是口腔鳞状细胞癌的独立危险因素,近期的高通量测序分析和实验性致突变研究显著推进了我们对槟榔相关口腔肿瘤发生生物学机制的理解。本综述提供了慢性槟榔暴露与口腔鳞状细胞癌发展相关的分子和细胞改变的更新概述,特别强调致突变性、表观遗传和非编码RNA介导的重塑以及免疫失调。槟榔及其相关成分诱导口腔组织多种形式的基因组不稳定性,包括染色体异常、DNA修复受损、特征性突变谱/签名、拷贝数变异和杂合性缺失。同时,慢性槟榔暴露通过改变DNA甲基化、组蛋白修饰和非编码RNA介导的途径促进广泛的表观遗传失调,导致抑癌基因沉默和致癌信号激活。新证据还表明槟榔暴露可能重塑口腔鳞状细胞癌的免疫微环境,使其成为有利于肿瘤进展和治疗抵抗的许可生态位,表现为肿瘤相关巨噬细胞浸润增加、免疫调节树突状细胞程序改变以及PD-L1/PD-1和CD155/TIGIT等免疫检查点通路的激活。总之,这些发现表明槟榔相关口腔鳞状细胞癌可能代表一个病因明确的口腔癌亚组,具有部分独特的基因组、表观遗传和免疫特征,尽管需要在不同解剖部位、暴露模式和人群背景中进行进一步验证。对这些改变的更好理解可能有助于开发槟榔相关口腔癌的新型预后生物标志物和精准治疗策略。
Acta pharmacologica Sinica IF 10.4 2026-11-16 PMID: 43039967
The emergence of multi-omics technologies has enabled the integration of genomic, transcriptomic, epigenomic, proteomic, and metabolomic data to characterize the molecular complexity of cancer. Single-cell and spatial profiling further resolve intratumoral heterogeneity, cell-cell interactions, and the microenvironmental determinants of therapeutic responses. In parallel, artificial intelligence (AI) provides computational approaches for integrating these heterogeneous data types across target identification, drug response prediction, toxicity assessment, and drug-combination modeling. Across these domains, the available evidence indicates that multi-omics integration is most beneficial when the included layers provide complementary biological information; that single-cell and spatial omics analyses reveal treatment-resistant populations and niches but remain largely research-grade and thus not ready for routine clinical deployment; and that although foundation models support some representation-learning tasks, their advantages in perturbation-response prediction require confirmation via stringent evaluation. By distinguishing externally validated advances from retrospective proof-of-concept studies, we provide a practical framework for evaluating the translational readiness of AI-driven multi-omics tools in precision oncology.
中文摘要:多组学技术的出现使得整合基因组、转录组、表观基因组、蛋白质组和代谢组数据成为可能,从而表征癌症的分子复杂性。单细胞和空间谱系分析进一步揭示了肿瘤内异质性、细胞间相互作用以及治疗反应的微环境决定因素。与此同时,人工智能为跨靶点识别、药物反应预测、毒性评估和药物组合建模等过程整合这些异构数据类型提供了计算方法。现有证据表明,当纳入的各层数据提供互补的生物学信息时,多组学整合最为有益;单细胞和空间组学分析虽能揭示治疗耐药人群和生态位,但主要仍属于研究级水平,尚未准备好用于常规临床部署;尽管基础模型支持部分表示学习任务,但其在扰动反应预测方面的优势仍需通过严格评估予以确认。通过区分经外部验证的进展与回顾性概念验证研究,我们提供了一个实用框架,用于评估人工智能驱动的多组学工具在精准肿瘤学中的转化成熟度。
Journal for immunotherapy of cancer IF 11.7 2026-11-16 PMID: 43039404
Upper tract urothelial carcinoma (UTUC) exhibits poor outcomes and modest immunotherapy response. While tertiary lymphoid structures (TLSs) orchestrate anti-tumor immunity, their spatial functional heterogeneity and interaction with neoplastic epithelium in UTUC remain poorly characterized. We integrated single-cell RNA sequencing (n=4) with Xenium-based spatial transcriptomics (n=20) to delineate TLS functional states. A 17-gene, four-module TLS functional signature trained in The Cancer Genome Atlas–Bladder Urothelial Carcinoma (TCGA-BLCA) was combined with a four-gene basal-squamous signature to construct a dual-dimensional risk framework, validated in IMvigor210 (n=348) with GSE32894 (n=224) as a cross-platform sensitivity cohort. We identified a functional maturation continuum across TLS zones (core, edge, peri-TLS), with enhanced antigen presentation and cytotoxic activity in TLS-positive microenvironments. Spatial analysis revealed that basal-squamous epithelial cells co-localized with TLS but established immunosuppressive niches via SPP1/FN1-mediated fibrosis and checkpoint upregulation. The dual-dimensional model significantly stratified survival in both TCGA-BLCA and IMvigor210 cohorts (log-rank p<0.05) and was associated with immunotherapy response in IMvigor210. Notably, patients with TLS-positive/basal-high tumors (Q3) exhibited paradoxically poor outcomes comparable to immune-desert phenotypes, suggesting basal-squamous features compromise TLS-mediated immunity. This study establishes a spatially resolved functional taxonomy of TLS in UTUC, revealing antagonistic interplay between TLS-mediated immunity and basal-squamous epithelial immune evasion. The dual-dimensional framework provides a biologically grounded tool with modest prognostic discrimination in urothelial carcinoma.
中文摘要:上尿路尿路上皮癌(UTUC)预后较差且免疫治疗反应有限。虽然三级淋巴结构(TLSs)调控抗肿瘤免疫,但其在UTUC中的空间功能异质性及与肿瘤上皮细胞的相互作用尚不明确。我们整合了单细胞RNA测序(n=4)与基于Xenium的空间转录组学(n=20)以描绘TLS的功能状态。利用在泛癌数据集The Cancer Genome Atlas–Bladder Urothelial Carcinoma(TCGA-BLCA)中训练的17基因四模块TLS功能特征,结合四基因基底鳞状特征构建双维度风险框架,并在IMvigor210队列(n=348)中进行验证,以GSE32894(n=224)作为跨平台敏感性队列。我们识别出TLS各区域(核心、边缘、周围)的功能成熟连续体,发现TLS阳性微环境中抗原提呈和细胞毒性活性增强。空间分析显示基底鳞状上皮细胞与TLS共定位,但通过SPP1/FN1介导的纤维化和检查点上调建立免疫抑制生态位。该双维度模型在TCGA-BLCA和IMvigor210队列中显著分层了生存期(log-rank p<0.05),并与IMvigor210中的免疫治疗反应相关。值得注意的是,TLS阳性/基底高表达肿瘤患者(Q3)表现出与免疫荒漠表型相当的矛盾性不良预后,提示基底鳞状特征削弱了TLS介导的免疫反应。本研究建立了UTUC中TLS的空间分辨功能分类,揭示了TLS介导的免疫与基底鳞状上皮免疫逃逸之间的拮抗相互作用。该双维度框架为尿路上皮癌提供了一种具有生物学基础的、具备有限预后判别能力的工具。
Acta biomaterialia IF 10.4 2026-11-16 PMID: 43039208
Immune checkpoint blockade has substantially improved outcomes in non-small cell lung cancer (NSCLC), although durable responses remain limited in a large fraction of patients. Increasing evidence links this resistance to epithelial-mesenchymal transition (EMT), a cellular program that not only enhances invasiveness but also restricts T-cell access within the tumor microenvironment. By integrating transcriptomic profiles from immunotherapy-resistant lung cancer organoids with The Cancer Genome Atlas Lung Adenocarcinoma cohort (TCGA-LUAD) and independent immunotherapy datasets, we identified twist family bHLH transcription factor 1 (TWIST1) as a central epithelial-mesenchymal transition (EMT)-associated factor linked to poor immunotherapeutic response. Tumors with high TWIST1 expression displayed reduced CD8⁺ T-cell infiltration, attenuated cytotoxic immune signatures, and unfavorable clinical outcomes. To interfere with this EMT-associated immune resistance, we developed oxidized hyaluronic acid/oxidized dextran-thioketal nanogels (OO-TK NGs) for the localized delivery of small interfering RNA targeting TWIST1 (siTWIST1), termed siTWIST1@OO-TK NGs. The nanogel was constructed from oxidized hyaluronic acid and oxidized dextran, crosslinked through a thioketal-containing bis-hydrazide linker that undergoes degradation under acidic and reactive oxygen species (ROS)-rich tumor-mimic conditions. This design enabled controlled intracellular release of siTWIST1 in tumor cells. TWIST1 silencing restored E-cadherin expression while reducing Vimentin and matrix metalloproteinase-9 (MMP9) levels, accompanied by diminished proliferation, and migration. Therapeutic efficacy was evaluated in Lewis lung carcinoma (LLC) tumor-bearing mice. Administration of siTWIST1@OO-TK NGs suppressed intratumoral TWIST1 expression, delayed tumor progression, and extended survival. The effect became more pronounced when combined with programmed cell death protein 1 (PD-1) blockade treatment, which increased CD8+ T-cell infiltration and enhanced IFN-γ-related effector activity within tumors. In a lung metastasis model, combination therapy markedly reduced metastatic burden and MMP9 expression, consistent with partial reversal of the EMT-associated markers. These findings support the potential of combining microenvironment-responsive TWIST1-targeted siRNA delivery with PD-1 blockade to concurrently modulate tumor plasticity and antitumor immunity. STATEMENT OF SIGNIFICANCE: Immune checkpoint blockade has reshaped the treatment landscape of non-small cell lung cancer (NSCLC), yet resistance remains a major clinical obstacle. Increasing evidence suggests that epithelial-mesenchymal transition (EMT) contributes to this resistance by establishing an immune-excluded tumor microenvironment that limits cytotoxic T-cell infiltration and function. In this study, through integrated analyses of immunotherapy-resistant organoid transcriptomes and clinical datasets, we identify TWIST1 as a key regulator linking EMT activation to impaired antitumor immunity and poor response to PD-1 blockade. Based on these findings, we developed a dual-responsive hydrogel nanogel system for tumor-selective delivery of siTWIST1. The nanogel undergoes degradation under acidic and reactive oxygen species-rich conditions characteristic of the tumor microenvironment, enabling controlled intracellular release of siRNA. TWIST1 silencing reversed EMT-associated phenotypes, suppressed tumor invasion and metastasis, and substantially enhanced the therapeutic efficacy of anti-PD-1 treatment in vivo through increased CD8⁺ T-cell infiltration and restoration of IFN-γ-associated immune activity.
中文摘要:免疫检查点阻断显著改善了非小细胞肺癌(NSCLC)患者的预后,但大部分患者仍存在持久应答有限的耐药问题。越来越多的证据表明这种耐药性与上皮间质转化(EMT)有关,该细胞程序不仅增强侵袭性,还限制肿瘤微环境中T细胞的浸润。通过整合免疫治疗耐药肺癌类器官的转录组特征、癌症基因组图谱肺腺癌队列(TCGA-LUAD)及独立的免疫治疗数据集,我们确定twist家族bHLH转录因子1(TWIST1)是关键的EMT相关因素,与不良免疫治疗反应相关。高表达TWIST1的肿瘤表现出CD8+ T细胞浸润减少、细胞毒性免疫特征减弱及临床预后不良。为干预这种EMT相关的免疫耐药,我们开发了氧化透明质酸/氧化葡聚糖二硫键纳米凝胶(OO-TK NGs)用于局部递送靶向TWIST1的小干扰RNA(siTWIST1),命名为siTWIST1@OO-TK NGs。该纳米凝胶由氧化透明质酸和氧化葡聚糖构成,通过含二硫键的双酰肼交联剂连接,在酸性及富含活性氧(ROS)的肿瘤模拟条件下发生降解,从而实现siTWIST1在肿瘤细胞内的可控释放。沉默TWIST1恢复了E-cadherin表达并降低Vimentin和基质金属蛋白酶9(MMP9)水平,伴随增殖和迁移能力减弱。在Lewis肺癌(LLC)荷瘤小鼠模型中评估了治疗效果。给予siTWIST1@OO-TK NGs抑制了肿瘤内TWIST1表达,延缓肿瘤进展并延长生存期。当与程序性死亡蛋白1(PD-1)阻断治疗联合使用时,效果更为显著,增加了CD8+ T细胞浸润并增强了肿瘤内IFN-γ相关的效应活性。在肺转移模型中,联合疗法显著降低了转移负荷和MMP9表达,这与EMT相关标志物的部分逆转一致。这些发现支持将微环境响应的TWIST1靶向siRNA递送与PD-1阻断相结合,以同时调节肿瘤可塑性和抗肿瘤免疫的潜力。研究意义:免疫检查点阻断重塑了NSCLC的治疗格局,但耐药仍是主要临床障碍。越来越多的证据表明EMT通过建立限制细胞毒性T细胞浸润和功能的免疫排斥型肿瘤微环境导致这种耐药。本研究通过分析免疫治疗耐药的类器官转录组和临床数据集,确定TWIST1是连接EMT激活与抗肿瘤免疫受损及PD-1阻断反应不良的关键调节因子。基于这些发现,我们开发了双重响应水凝胶纳米凝胶系统用于肿瘤选择性递送siTWIST1。该纳米凝胶在肿瘤微环境特有的酸性和富含ROS条件下发生降解,实现siRNA的可控细胞内释放。沉默TWIST1逆转了EMT相关表型,抑制肿瘤侵袭和转移,并通过增加CD8+ T细胞浸润和恢复IFN-γ相关的免疫活性,显著增强了体内抗PD-1治疗的疗效。
Cancer letters IF 11.8 2026-11-16 PMID: 43039102
Chemotherapy resistance remains a major obstacle in the clinical management of gastric cancer (GC), driven largely by cancer-associated fibroblasts (CAFs). CAFs activate the JAK/STAT signaling pathway in GC cells, promoting proliferation, migration, and resistance to 5-fluorouracil (5-FU). Fibroblast activation protein (FAP), highly expressed on CAFs but minimally in normal tissues, is an attractive target for molecular imaging. Here, we developed FAPtp-ICG, a near-infrared fluorescent probe comprising an FAP-targeting peptide conjugated to indocyanine green (ICG), for noninvasive visualization of FAP expression. We established CAFs-conditioned GC models with graded chemoresistance, in which FAP-associated fluorescence and FAP expression were positively associated with the degree of CAFs-mediated 5-FU resistance in the experimental models. FAPtp-ICG enabled noninvasive fluorescence imaging of FAP-associated stromal changes, allowing longitudinal assessment of treatment-associated changes related to CAFs-mediated drug resistance. Mechanistically, combination therapy with 5-FU and ruxolitinib (RUX) suppressed JAK/STAT signaling, alleviated chemoresistance, inhibited tumor growth, and restored drug sensitivity. Multi-omics profiling further revealed that RUX treatment was associated with transcriptomic and proteomic alterations in the tumor microenvironment, attenuating inflammatory signaling, immune cell recruitment, and extracellular matrix remodeling. By integrating a FAP-targeted optical probe with therapeutic JAK/STAT inhibition, this work demonstrates a theranostic strategy for assessing and overcoming CAFs-mediated chemoresistance in GC, supporting the potential utility of FAP-targeted imaging for longitudinal assessment of treatment-associated stromal changes.
中文摘要:化疗耐药仍是胃癌临床管理的主要障碍,主要由癌症相关成纤维细胞(CAFs)驱动。CAFs激活胃癌细胞中的JAK/STAT信号通路,促进增殖、迁移及对5-氟尿嘧啶(5-FU)的耐药性。成纤维细胞活化蛋白(FAP)在CAFs上高表达而在正常组织中极少表达,是分子成像的理想靶点。本研究开发了FAPtp-ICG,这是一种近红外荧光探针,由与吲哚菁绿(ICG)偶联的FAP靶向肽组成,用于无创可视化FAP表达。我们建立了具有分级化疗耐药的CAFs条件化胃癌模型,其中实验模型中FAP相关荧光强度与FAP表达水平呈正相关,且与CAFs介导的5-FU耐药程度密切相关。FAPtp-ICG实现了FAP相关基质变化的无创荧光成像,允许纵向评估与CAFs介导的药物耐药性相关的治疗相关变化。在机制上,5-FU与鲁索替尼(RUX)联合治疗抑制了JAK/STAT信号通路,缓解了化疗耐药,抑制了肿瘤生长并恢复了药物敏感性。多组学分析进一步揭示,RUX治疗与肿瘤微环境中的转录组和蛋白质组改变相关,减轻了炎症信号、免疫细胞募集及细胞外基质重塑。通过将FAP靶向光学探针与治疗性JAK/STAT抑制相结合,本研究展示了一种评估和克服胃癌中CAFs介导化疗耐药的诊疗一体化策略,支持了FAP靶向成像在纵向评估治疗相关基质变化中的潜在应用价值。
Cancer letters IF 11.8 2026-11-16 PMID: 43039100
CD8 T cells can make a decisive contribution to anticancer immune responses. While the glycoprotein CD101 is present on effector CD8 T cells, the signaling pathways driving CD101 expression and the outcome of CD101 engagement on CD8 T cells are elusive. Here, we show that the activation of TGF-β signaling induces CD101 on mouse and human CD8 T cells. CD101 expression on CD8 T cells was dependent on TCR signaling and TGF-β-induced Smad3. In multiple cancers, we found that mouse and human CD8(+) CD101(+) tumor infiltrating lymphocytes exhibited a resident memory phenotype, as illustrated by co-expression of CD69 and CD103. Accordingly, CD101-deficient mice featured accelerated tumor growth and were unable to respond to anti-PD-1 therapy. Altogether, these results suggest that CD101 expression on CD8 T cells has functional relevance and can be therapeutically exploited for anticancer therapy.
中文摘要:CD8 T细胞对抗肿瘤免疫反应具有决定性贡献。尽管糖蛋白CD101存在于效应CD8 T细胞上,但驱动CD101表达的信号通路以及CD101在CD8 T细胞上结合后的结果尚不明确。本研究显示,TGF-β信号通路的激活诱导小鼠和人CD8 T细胞表达CD101。CD8 T细胞上的CD101表达依赖于TCR信号和TGF-β诱导的Smad3。在多种癌症中,我们发现小鼠和人的CD8(+) CD101(+)肿瘤浸润淋巴细胞表现出驻留记忆表型,这通过CD69和CD103的共同表达得以证实。因此,CD101缺陷小鼠表现为肿瘤生长加速且无法对抗PD-1治疗产生反应。综上所述,这些结果表明CD8 T细胞上的CD101表达具有功能相关性,并可作为抗肿瘤治疗的潜在靶点加以利用。
Cancer letters IF 11.8 2026-11-16 PMID: 43039099
The highly immunosuppressive tumor microenvironment (TME) of glioblastoma (GBM) is particularly prominent in tumors exhibiting mesenchymal-like (MES-like) transcriptional programs and represents a major barrier to immune checkpoint blockade (ICB). Integrating single-cell and spatial transcriptomics, we identified TAGLN2 as an immune-regulatory molecule preferentially enriched in MES-like tumor-cell states. High TAGLN2 expression correlated with increased tumor-associated macrophage infiltration and poor prognosis. Mechanistically, TAGLN2 drives immune evasion via dual pathways. Intracellularly, TAGLN2 directly interacts with HSPA8 and promotes p65 phosphorylation and NF-κB activation, with HSPA8 functioning as a downstream mediator. Intercellularly, TAGLN2 promotes ANXA2 stability and its enrichment in tumor-derived exosomes. Donor-cell ANXA2 loss-of-function experiments further showed that ANXA2 knockdown substantially attenuated the macrophage-remodeling activity, while recipient-cell analyses positioned STAT3 downstream of ANXA2, together supporting a TAGLN2-vesicular ANXA2-STAT3 signaling pathway. Direct exosomes intervention and donor-cell ANXA2 rescue in immunocompetent orthotopic glioma models further supported the functional involvement of this pathway in tumor progression and macrophage-associated remodeling. In an immunocompetent orthotopic glioma model, genetic TAGLN2 knockdown enhanced CD8-associated effector-marker signals and improved responsiveness to anti-PD-1 treatment. Through virtual drug screening, we identified Givinostat hydrochloride monohydrate, a histone deacetylase inhibitor prioritized by in silico prediction of central nervous system accessibility, as a candidate pharmacological modulator that directly binds TAGLN2 and modulates the TAGLN2-associated signaling network. Together, these findings support TAGLN2 as an important regulator of GBM immune remodeling and suggest a candidate combination strategy for enhancing responsiveness to PD-1 blockade.
中文摘要:胶质母细胞瘤(GBM)具有高度免疫抑制的肿瘤微环境,在呈现间质样转录程序的肿瘤中尤为显著,是免疫检查点阻断的主要障碍。整合单细胞与空间转录组学数据,我们发现TAGLN2是一种优先富集于间质样肿瘤细胞状态的免疫调节分子。高表达TAGLN2与肿瘤相关巨噬细胞浸润增加及不良预后相关。机制上,TAGLN2通过双重途径驱动免疫逃逸:细胞内,TAGLN2直接与HSPA8相互作用并促进p65磷酸化及NF-κB激活,其中HSPA8作为下游介质;细胞间,TAGLN2促进ANXA2稳定性及其在肿瘤来源外泌体中的富集。供体细胞ANXA2功能缺失实验显示,ANXA2敲低显著削弱巨噬细胞重塑活性,而受体细胞分析将STAT3定位在ANXA2下游,共同支持TAGLN2-囊泡ANXA2-STAT3信号通路。免疫健全原位胶质瘤模型中的直接外泌体干预及供体细胞ANXA2挽救进一步证实该通路在肿瘤进展和巨噬细胞相关重塑中的功能作用。在该模型中,遗传性TAGLN2敲低增强了CD8相关效应因子信号并改善了对抗PD-1治疗的反应性。通过虚拟药物筛选,我们鉴定出Givinostat盐酸一水合物(一种组蛋白去乙酰化酶抑制剂,基于中枢神经系统可及性的计算机预测被优先考虑)为候选药理学调节剂,其直接结合TAGLN2并调节相关信号网络。这些发现支持TAGLN2作为GBM免疫重塑的重要调节因子,并提出增强PD-1阻断反应性的候选联合策略。
Ageing research reviews IF 15.5 2026-11-16 PMID: 43039084
Cancer and its treatments may induce biological changes overlapping with the hallmarks of ageing, potentially contributing to cognitive and physical vulnerability in older adults. This narrative review examines the potential links between cancer- and treatment-associated ageing-related changes and cognitive frailty from a geroscience perspective. Cellular senescence, inflammatory signalling, mitochondrial dysfunction, and metabolic dysregulation may contribute to neural and muscular vulnerability, while physiological reserve and resilience may influence individual trajectories. However, current evidence derives largely from indirect clinical observations, non-cancer populations, and preclinical studies. Direct longitudinal evidence linking accelerated systemic biological ageing to cognitive frailty in older adults with cancer remains limited. Geriatric assessment provides an established framework for identifying multidimensional vulnerability, whereas biological ageing biomarkers and digital phenotyping require further validation for risk stratification. Integrating these measures may inform future precision geriatric oncology approaches, although their incremental clinical value remains uncertain. Exercise, nutritional support, and symptom management may improve selected functional outcomes, but their effects on biological ageing and cognitive frailty prevention remain unproven. Prospective longitudinal studies incorporating pretreatment assessments, repeated biological and functional measurements, and appropriate comparison groups are needed to clarify causal relationships and guide personalised interventions.
中文摘要:癌症及其治疗可能诱发与衰老特征重叠的生物学改变,从而增加老年患者的认知和身体脆弱性。本叙述性综述从老年科学视角探讨了癌症及治疗相关的衰老变化与认知脆弱性之间的潜在联系。细胞衰老、炎症信号传导、线粒体功能障碍和代谢失调可能导致神经和肌肉脆弱,而生理储备和韧性可能影响个体的发展轨迹。然而,现有证据主要来源于间接临床观察、非癌症人群和临床前研究。将加速的系统性生物学衰老与老年癌症患者的认知脆弱性直接联系起来的纵向证据仍然有限。老年综合评估为识别多维脆弱性提供了既定框架,而生物学衰老生物标志物和数字表型分析仍需进一步验证以进行风险分层。整合这些措施可能为未来的精准老年肿瘤学方法提供信息,尽管其额外的临床价值仍不确定。运动、营养支持和症状管理可能改善特定的功能结局,但其对预防生物学衰老和认知脆弱性的作用尚未得到证实。需要开展前瞻性纵向研究,纳入治疗前评估、重复的生物学和功能测量以及适当的对照组,以阐明因果关系并指导个性化干预。
Chemical Society reviews IF 48.3 2026-11-16 PMID: 42949705
The early detection of therapy-induced biomolecular changes and the prediction of therapeutic response remain major challenges in oncology. Current clinical methods often assess treatment response through macroscopic or morphological endpoints, whereas molecular alterations associated with sensitivity, resistance, or recurrence may arise earlier and remain undetected. Raman spectroscopy offers a label-free and non-destructive approach to probe the intrinsic biochemical composition of cells, tissues, and biofluids, providing spectral and spatial information that can support therapy response prediction and longitudinal monitoring. This review discusses Raman-based technologies for cancer therapy assessment, from preclinical models to emerging clinical applications. We first outline the clinical need for rapid, non-destructive, and molecularly informative tools, considering tumor heterogeneity, therapy resistance, the tumor microenvironment, and current standards for response evaluation. We then provide a methodological framework for selecting Raman modalities, including spontaneous Raman (SR) spectroscopy, surface-enhanced Raman spectroscopy (SERS), stimulated Raman spectroscopy (SRS), and coherent anti-Stokes Raman spectroscopy (CARS), together with key considerations on acquisition strategies, multimodal integration, experimental design, preprocessing, feature analysis, and machine learning. We summarize Raman spectral biomarkers associated with therapy-induced changes in nucleic acids, proteins, lipids, metabolites, extracellular matrix components, and anticancer drugs, and critically examine studies using Raman spectroscopy to predict or monitor responses to major therapeutic approaches. Finally, we discuss barriers to clinical translation, including acquisition speed, inter-instrument reproducibility, preclinical model limitations, regulatory requirements, workflow integration, clinical trials, and prospective validation. Overall, Raman spectroscopy emerges as a promising platform for molecular phenotyping in precision oncology, provided that future studies progress toward standardized, clinically validated, and actionable workflows.
中文摘要:治疗诱导的生物分子变化的早期检测和疗效预测仍是肿瘤学面临的主要挑战。当前临床方法通常通过宏观或形态学终点评估治疗反应,而与敏感性、耐药性或复发相关的分子改变可能更早发生且难以被检测到。拉曼光谱提供了一种无标记且非破坏性的方法来探测细胞、组织和生物流体固有的生化成分,提供的光谱和空间信息可支持疗效预测和纵向监测。本综述讨论了用于癌症治疗评估的基于拉曼的技术,涵盖从临床前模型到新兴临床应用的全过程。我们首先概述了快速、非破坏性且具有分子信息量的工具的临床需求,考虑了肿瘤异质性、治疗耐药性、肿瘤微环境以及当前的疗效评估标准。随后提供了选择拉曼模态的方法学框架,包括自发拉曼光谱、表面增强拉曼光谱、受激拉曼光谱和相干反斯托克斯拉曼光谱,并讨论了采集策略、多模态整合、实验设计、预处理、特征分析和机器学习等关键考量因素。我们总结了与核酸、蛋白质、脂质、代谢物、细胞外基质成分及抗癌药物在治疗诱导变化相关的拉曼光谱生物标志物,并批判性地审查了利用拉曼光谱预测或监测主要治疗方法反应的现有研究。最后,我们讨论了临床转化面临的障碍,包括采集速度、仪器间重现性、临床前模型局限性、监管要求、工作流程整合、临床试验及前瞻性验证。总体而言,在推进标准化、经临床验证且可操作的流程的前提下,拉曼光谱有望成为精准肿瘤学中分子表型分析的有前景平台。
Cancer research IF 22.6 2026-11-16 PMID: 42836774
Immune checkpoint blockade (ICB) has shown limited efficacy in metastatic breast cancer. Resistance mechanisms involve suppressive myeloid and stromal populations in the tumor microenvironment (TME). In this issue of Cancer Research, Gonzalez and colleagues integrate single-cell transcriptomics, spatial proteomics, functional immunology, and mathematical modeling to dissect how combined treatment with the histone deacetylase (HDAC) inhibitor entinostat and anti-PD-1/anti-CTLA-4 blockade (EPC) sensitizes these refractory tumors. Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression (via ICAM-1 and IFNγ signaling) along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation. Some of these findings are further validated in biospecimens from patients on a phase Ib trial treated with the EPC combination treatment. Mathematical modeling formalizes this insight, demonstrating that simultaneous modulation of T-cell activation and myeloid suppression, rather than either alone, is required to drive tumor eradication in silico. This work highlights the increasingly accepted idea that the answer to how current treatments modify and shape tumors is multifactorial. Thus, diversified strategies that include comprehensive analysis of the TME, mathematical modeling tools, and validation in human specimens are required to optimize treatment efficacy. See related article by Gonzalez et al., p. 5667.
中文摘要:免疫检查点阻断在转移性乳腺癌中疗效有限,其耐药机制涉及肿瘤微环境中的抑制性髓系和基质细胞群。本期《癌症研究》中,Gonzalez及其同事整合单细胞转录组学、空间蛋白质组学、功能免疫学和数学建模,解析了联合使用组蛋白去乙酰化酶抑制剂恩替诺司与抗PD-1/抗CTLA-4阻断治疗如何使这些难治性肿瘤对免疫治疗敏感。利用转移性小鼠模型的研究表明,抗肿瘤反应是多因素的,包括下调髓系介导的CD8+ T细胞抑制(通过ICAM-1和IFNγ信号通路),以及增加B细胞和浆细胞活化、抗体产生和三级淋巴结构成熟。这些发现部分在参与Ib期临床试验接受EPC联合治疗患者的生物样本中得到进一步验证。数学建模形式化了这一见解,证明同时调节T细胞活化和髓系抑制(而非单独调节)是在计算机模拟中驱动肿瘤根除所必需的。这项工作强调了日益被接受的观念,即当前治疗如何改变和塑造肿瘤的答案是多因素的。因此,需要包括对肿瘤微环境的综合分析、数学建模工具以及在人类样本中的验证在内的多样化策略,以优化治疗效果。参见Gonzalez等人第5667页的相关文章。
Cancer research IF 22.6 2026-11-16 PMID: 42743210
The aged tumor microenvironment can impair antitumor T-cell function, but the molecular regulators that become limiting in this setting remain poorly defined. In a recent issue of Cell, Chen and colleagues harness in vivo CRISPR screening to compare the effects of genetic perturbations in tumor-reactive CD8+ T cells across young and aged hosts. The screen reveals that increased T-cell persistence or an effector-like transcriptional state does not necessarily translate into improved tumor control and identifies Dusp5 and Zfp219 as distinct functional regulators. DUSP5 broadly restrains ERK-dependent proliferation, and its loss improves tumor control in both young and aged mice. ZFP219, by contrast, preferentially limits cytotoxicity in aged hosts; its deletion increases granzyme expression and improves tumor control specifically in the aged setting. Human tumor datasets show that ZNF219 expression in intratumoral CD8+ T cells increases with age and is associated with poorer clinical outcomes. Moreover, Zfp219 loss enhances the response to PD-1 blockade in aged mice, producing complete tumor clearance in a subset of animals and durable protection after rechallenge. Together, these findings show that host age can reshape the functional consequences of T-cell perturbations and reveal age-dependent genetic vulnerabilities with potential therapeutic relevance.
中文摘要:衰老的肿瘤微环境可损害抗肿瘤T细胞功能,但在此背景下成为限制因素的分子调节因子仍不明确。Chen等人在最新一期Cell杂志中利用体内CRISPR筛选技术,比较了年轻和衰老宿主中肿瘤反应性CD8+ T细胞遗传扰动的影响。筛选结果显示,增加的T细胞持久性或效应样转录状态并不一定转化为改善的肿瘤控制,并鉴定出Dusp5和Zfp219为不同的功能调节因子。DUSP5广泛限制ERK依赖性增殖,其缺失在年轻和衰老小鼠中均改善了肿瘤控制。相比之下,ZFP219优先限制衰老宿主中的细胞毒性;其缺失增加了颗粒酶表达并仅在衰老背景下改善肿瘤控制。人类肿瘤数据集显示,肿瘤内CD8+ T细胞中ZNF219的表达随年龄增长而增加,并与较差的临床结果相关。此外,在衰老小鼠中,Zfp219缺失增强了PD-1阻断治疗的反应,在部分动物中实现了完全肿瘤清除并在再挑战后产生持久保护。综上所述,这些发现表明宿主年龄可以重塑T细胞扰动的功能后果,并揭示具有潜在治疗相关性的年龄依赖性遗传脆弱性。
Cancer research IF 22.6 2026-11-16 PMID: 42734483
Human papillomavirus (HPV) plays a pivotal role in various malignancies, including cervical, anogenital, head, and neck cancers. Despite the availability of highly effective prophylactic vaccines, many individuals remain susceptible to HPV-driven cancers because of barriers such as limited vaccine access, lack of awareness, or personal preferences. Current treatments primarily target lesions without eradicating persistent HPV infections, leading to an increased risk of subsequent HPV-associated cancers. This scenario underscores an urgent need for innovative treatment modalities aimed at eliminating persistent HPV infections. In this study, we developed NTX250, a messenger RNA (mRNA)-based therapeutic platform engineered to deliver HPV type 16 (HPV16) E6 and E7 antigens, in conjunction with the immunomodulators interleukin (IL) 12 and LIGHT. A lipid and ionizable peptoid nanoparticle system facilitated precise intralesional delivery of NTX250. Localized NTX250 administration in HPV16-transformed tumor-bearing models led to complete tumor regression and established durable, antigen-specific immune memory. Replacing the HPV antigens with a construct comprising colorectal cancer cell-specific neoepitopes enabled stimulated antitumor immunity and suppressed tumor growth, supporting the generalizability of the approach. Overall, NTX250 represents a promising nonsurgical immunotherapy platform that is capable of eliciting robust and targeted antitumor immune responses across diverse malignancies. This adaptable mRNA nanoparticle approach enables the codelivery of tumor-specific antigens and immunomodulators, with the potential to target tumor-associated antigens beyond HPV. NTX250 is an mRNA-based therapeutic platform that offers a noninvasive approach to eradicate persistent HPV infections and induce strong antitumor immune responses, fulfilling a critical need in HPV-related cancer treatment.
中文摘要:人乳头瘤病毒(HPV)在多种恶性肿瘤包括宫颈癌、生殖道肿瘤以及头颈部癌症中发挥关键作用。尽管已有高效预防性疫苗,但由于疫苗获取受限、缺乏意识或个人偏好等障碍,许多个体仍易患HPV相关癌症。当前治疗主要针对病灶,无法根除持续性HPV感染,导致后续HPV相关癌症风险增加。这一现状凸显了对旨在消除持续性HPV感染的创新治疗模式的迫切需求。本研究开发了NTX250,这是一种基于mRNA的治疗平台,旨在递送HPV16型E6和E7抗原,并联合免疫调节剂白细胞介素(IL)12和LIGHT。脂质及可离子化肽纳米颗粒系统促进了NTX250的病灶内精准递送。在HPV16转化肿瘤模型中局部给药NTX250导致肿瘤完全消退并建立了持久且抗原特异性的免疫记忆。将HPV抗原替换为结直肠癌细胞特异性新抗原构建体,能够刺激抗肿瘤免疫并抑制肿瘤生长,支持该方法的普适性。总体而言,NTX250代表了一种有前景的非手术免疫治疗平台,能够在多种恶性肿瘤中引发强大且靶向的抗肿瘤免疫反应。这种可适应的mRNA纳米颗粒方法实现了肿瘤特异性抗原与免疫调节剂的共递送,具有针对HPV以外肿瘤相关抗原的潜力。NTX250作为一种基于mRNA的治疗平台,提供了一种无创方法来根除持续性HPV感染并诱导强效抗肿瘤免疫反应,满足了HPV相关癌症治疗中的关键需求。
Cancer research IF 22.6 2026-11-16 PMID: 42696459
Current immunotherapies often fail in immunologically "cold," macrophage-rich tumor microenvironments (TME). Multitargeting approaches that modulate innate-adaptive immune activation represent a promising frontier in cancer immunotherapy. In this study, we developed phagocytic synapse enhancers (PSE), a class of modular immune engagers comprising a high-affinity PD-L1 binder coupled to a macrophage-stimulating peptide, tuftsin. PSEs strengthened effector-target cell interactions and enhanced tumor phagocytosis by bridging tumor PD-L1 to macrophage neuropilin-1, bypassing the classic FcγR-dependent pathways. The PSEs also acted in cis on PD-L1+ macrophages, accelerating the endocytosis and lysosomal compartmentalization of surface PD-L1 and therefore stripping the immunosuppressive checkpoint from the local microenvironment. Beyond physical clearance, the PSEs reprogrammed macrophage phenotype and triggered a robust proinflammatory cytokine and chemokine response. The lead molecule, longPSE, and its half-life-extended variant fused to the albumin-binding domain, ABD-longPSE, showcased superior efficacy than the macrophage enhancer magrolimab in a syngeneic tumor model of colorectal cancer and an orthotopic model of pancreatic cancer. PSE treatment remodeled the TME by inducing phenotypic changes in the lymphoid and myeloid compartments, together with a reduction of tumor-associated macrophages and regulatory T cells. These findings establish PSEs as bifunctional molecules that complement innate and adaptive immune modulation. The bifunctional design offers a versatile approach for next-generation immunotherapies and provides a blueprint for a plug-and-play platform of immune engagers targeting diverse cancer-associated pathways. Bifunctional immune modulators that simultaneously boost phagocytosis and block immune checkpoints offer a versatile strategy to reprogram the tumor microenvironment and advance next-generation cancer immunotherapy.
中文摘要:当前免疫疗法在免疫学「冷」且富含巨噬细胞肿瘤微环境中常告失败。调节先天与适应性免疫激活的多靶点策略是癌症免疫治疗的前沿领域。本研究开发了吞噬突触增强剂,这是一类模块化免疫连接分子,由高亲和力PD-L1结合蛋白与巨噬细胞刺激肽tuftsin组成。通过桥接肿瘤PD-L1与巨噬细胞neuropilin-1,该分子绕过了经典的FcγR依赖途径,强化了效应细胞与靶细胞的相互作用并增强了肿瘤吞噬作用。此外,该分子在顺式作用下作用于PD-L1阳性巨噬细胞,加速表面PD-L1的内吞及溶酶体区室化,从而清除局部微环境中的免疫抑制检查点。除物理清除外,该分子重编程了巨噬细胞表型并触发了强烈的促炎细胞因子和趋化因子反应。先导分子longPSE及其与白蛋白结合域融合的半衰期延长变体ABD-longPSE在小鼠同系结直肠癌模型及原位胰腺癌模型中展现出优于巨噬细胞增强剂magrolimab的疗效。治疗通过诱导淋巴和髓系区室的表型变化,并减少肿瘤相关巨噬细胞和调节性T细胞,重塑了肿瘤微环境。这些发现确立了该分子作为同时补充先天与适应性免疫调节的双功能分子的地位。这种双功能设计为下一代免疫疗法提供了通用策略,并为针对多种癌症相关通路的即插即用免疫连接平台提供了蓝图。
Cancer research IF 22.6 2026-11-16 PMID: 42627859
Immune checkpoint blockade (ICB) has revolutionized cancer treatment, yet its efficacy in gastrointestinal malignancies is often limited by an immunosuppressive tumor microenvironment. In this study, we identified phospholipase C beta 1 (PLCβ1) as a central driver of pathogenesis and ICB resistance in gastrointestinal cancer. Unlike classical oncogenes, PLCβ1 promoted tumor progression by fostering immune evasion rather than directly enhancing intrinsic tumor cell survival. Mechanistically, PLCβ1 interacted with ERC1, promoting its ubiquitin-proteasomal degradation. ERC1 destabilization suppressed NF-κB-dependent transcriptional activation of MHC-I, thereby impairing antigen presentation. Upstream, the YAP1 complex served as a direct transcriptional activator of PLCβ1, and pharmacologic disruption of this pathway using the YAP inhibitor effectively restored MHC-I expression. Expression of PLCβ1 was associated with reduced responsiveness to immunotherapy in patients, and combining the YAP inhibitor with anti-PD-1 therapy elicited synergistic antitumor responses in both syngeneic mice and patient-derived xenografts. Collectively, these findings uncover the YAP1-PLCβ1-MHC-I axis as a critical mechanism of immune escape and propose combinatorial YAP inhibition as a promising strategy to sensitize gastrointestinal tumors to immunotherapy. PLCβ1 is a critical determinant of tumor immunogenicity in gastrointestinal malignancies by suppressing MHC-I expression and antigen presentation, providing rationale for targeting this axis to overcome immunotherapy resistance.
中文摘要:免疫检查点阻断(ICB)彻底改变了癌症治疗,但其在胃肠道恶性肿瘤中的疗效常受限于免疫抑制性肿瘤微环境。本研究鉴定出磷脂酶Cβ1(PLCβ1)是胃肠道癌发病机制和ICB耐药的关键驱动因素。与经典癌基因不同,PLCβ1通过促进免疫逃逸而非直接增强肿瘤细胞内在存活来推动肿瘤进展。在机制上,PLCβ1与ERC1相互作用,促进其泛素-蛋白酶体降解。ERC1的不稳定抑制了NF-κB依赖性的MHC-I转录激活,从而损害抗原呈递。在上游,YAP1复合作为PLCβ1的直接转录激活因子发挥作用,使用YAP抑制剂药理学破坏该通路可有效恢复MHC-I表达。患者中PLCβ1的表达与对免疫治疗的反应性降低相关,而在同系小鼠和患者来源的异种移植物模型中,将YAP抑制剂与抗PD-1疗法联合应用可产生协同抗肿瘤反应。综上所述,这些发现揭示了YAP1-PLCβ1-MHC-I轴作为免疫逃逸的关键机制,并提出联合YAP抑制作为使胃肠道肿瘤对免疫治疗敏感的有效策略。PLCβ1通过抑制MHC-I表达和抗原呈递,成为决定胃肠道恶性肿瘤肿瘤免疫原性的关键因素,为靶向该轴以克服免疫治疗耐药提供了依据。
Cancer research IF 22.6 2026-11-16 PMID: 42578817
High levels of immune suppression are a common intrinsic mechanism of resistance in metastatic breast cancer that calls for developing immunotherapeutic combinations to broaden treatment responses. Histone deacetylase (HDAC) inhibitors can sensitize tumors to dual checkpoint inhibition in patients. Here, we investigated the tumor microenvironment (TME) of breast metastases by combining experimental and clinical data with theory to elucidate the mechanism of response to treatment with the HDAC inhibitor entinostat combined with anti-PD-1 and anti-CTLA-4. Knowledge-guided subclustering of single-cell RNA-sequencing (scRNA-seq) data and cell circuit analyses from murine breast-to-lung metastases identified 39 cell states and salient interactions, of which myeloid, T-cell, and B-cell subpopulations were most affected. Analyses of patient biopsy specimens and blood via spatial proteomics and flow cytometry corroborated the preclinical findings, showing increased T- and B-cell activation, mature tertiary lymphoid structures, and increased CD8+ T cell-macrophage distances in responders to entinostat + nivolumab + ipilimumab. Combination treatment increased immunoglobulin production in patients and mice, and murine studies demonstrated increased tumor-targeting IgG and implicated B cells as necessary for treatment response. Inhibition of the intercellular adhesion molecule 1 and IFNγ pathways in myeloid cells partially recapitulated treatment effects on CD8+ T cells observed via scRNA-seq. Mathematical modeling of tumor-immune dynamics implicated simultaneous modulation of multiple TME interactions as required for response to the combination treatment. Overall, this study identifies lymphoid and myeloid cell contributions to response to treatment with HDAC inhibitors and immune checkpoint blockade, providing a framework for discovering interactions driving responses in complex TMEs. Integrative data analysis and mathematical modeling reveal immune interactions that sensitize the metastatic tumor microenvironment to checkpoint inhibition, validating the potential of cancer systems immunology approaches to uncover mechanisms of immunotherapeutic response. See related commentary by Senent and Manguso, p. 5603.
中文摘要:高水平的免疫抑制是转移性乳腺癌常见的内在耐药机制,亟需开发免疫治疗联合方案以拓宽治疗反应。组蛋白去乙酰化酶(HDAC)抑制剂可使肿瘤对双重检查点阻断产生敏感性。本研究结合实验与临床数据及理论,探究了乳腺转移灶的肿瘤微环境(TME),旨在阐明HDAC抑制剂恩替诺司特联合抗PD-1和抗CTLA-4的治疗反应机制。通过对小鼠乳腺至肺转移模型的单细胞RNA测序(scRNA-seq)数据进行知识引导的子聚类及细胞回路分析,鉴定出39种细胞状态及显著相互作用,其中髓系、T细胞和B细胞亚群受影响最大。通过空间蛋白质组学和流式细胞术对患者活检标本及血液的分析证实了临床前发现,显示对恩替诺司特联合纳武利尤单抗和伊匹木单抗产生反应的患者中T细胞和B细胞活化增加、成熟三级淋巴结构出现以及CD8+ T细胞与巨噬细胞距离增加。联合治疗增加了患者和小鼠体内的免疫球蛋白产生,小鼠研究证实肿瘤靶向IgG增加并将B细胞确定为治疗反应所必需。髓系细胞中细胞间粘附分子1和IFNγ通路的抑制部分重现了通过scRNA-seq观察到的CD8+ T细胞治疗效应。对肿瘤-免疫动力学的数学模型表明,同时对多种TME相互作用进行调节是产生联合治疗反应所必需的。总体而言,本研究确定了淋巴和髓系细胞对HDAC抑制剂和免疫检查点阻断治疗反应的贡献,为发现驱动复杂TME中反应的相互作用提供了框架。整合数据分析与数学模型揭示了使转移性肿瘤微环境对检查点抑制敏感的免疫相互作用,验证了癌症系统免疫学方法揭示免疫治疗反应机制的潜力。
Cancer research IF 22.6 2026-11-16 PMID: 42561142
Induction of ferroptosis is a potential strategy for treating cancer and improving the efficacy of immunotherapy. Ferroptosis is driven by excessive peroxidation of polyunsaturated fatty acid-containing phospholipids, suggesting that microenvironmental lipid metabolites may regulate ferroptotic sensitivity. By integrating single-cell and bulk transcriptomics from immunotherapy cohorts, we identified the prostaglandin (PG) pathway as closely associated with tumor ferroptosis and therapeutic efficacy. Further screening revealed PGF2α as a potent endogenous ferroptosis sensitizer. Mechanistically, microenvironmental PGF2α bound to ferroptosis suppressor protein 1 (FSP1) at alanine 295 (A295) and inhibited its enzymatic activity, leading to lipid peroxidation accumulation upon ferroptotic stimuli. Preclinically, PGF2α supplementation or FSP1 ablation enhanced tumoral ferroptosis, potentiated CD8+ T cell-mediated immunity, and suppressed tumor progression in immunocompetent mice. Moreover, PGF2α improved immunotherapy efficacy across multiple mouse models, including subcutaneous allograft, Braf/Pten-driven spontaneous melanoma, and humanized mouse models. Clinically, a high PGF2α activity-related transcriptomic signature correlated with elevated ferroptosis and improved patient survival. Collectively, these findings establish PGF2α as a proferroptotic metabolite and propose that targeting the PGF2α/FSP1 axis may offer an effective cancer immunotherapeutic strategy. PGF2α promotes ferroptosis by directly binding and inhibiting FSP1 to enhance lipid peroxidation, which potentiates CD8+ T cell-mediated antitumor immunity and offers an approach for improving cancer immunotherapy.
中文摘要:诱导铁死亡是治疗癌症及提高免疫疗法疗效的潜在策略。铁死亡由含多不饱和脂肪酸的磷脂过度过氧化驱动,提示微环境脂质代谢物可能调控铁死亡敏感性。通过整合来自免疫治疗队列的单细胞与批量转录组数据,我们发现前列腺素通路紧密关联于肿瘤铁死亡与治疗疗效。进一步筛选揭示PGF2α是一种强效的内源性铁死亡增敏剂。机制上,微环境中的PGF2α在丙氨酸295位点结合并抑制铁死亡抑制蛋白1的酶活性,导致铁死亡刺激下脂质过氧化物积累。临床前研究中,补充PGF2α或敲除FSP1增强了免疫健全小鼠体内的肿瘤铁死亡,强化了CD8+ T细胞介导的免疫反应并抑制肿瘤进展。此外,在皮下异种移植、Braf/Pten驱动的自发性黑色素瘤及人源化小鼠模型中,PGF2α均提高了免疫疗法疗效。临床数据显示,高PGF2α活性相关转录组特征与铁死亡水平升高及患者生存改善相关。综上,这些发现确立PGF2α为促铁死亡代谢物,并提出靶向PGF2α/FSP1轴可能提供有效的癌症免疫治疗策略。PGF2α通过直接结合并抑制FSP1促进脂质过氧化,从而增强CD8+ T细胞介导的抗肿瘤免疫,为改善癌症免疫疗法提供了途径。
Cancer research IF 22.6 2026-11-16 PMID: 42554434
Cancer-associated fibroblasts (CAF) drive key aspects of tumor malignancy. However, the profound heterogeneity in cytokine secretion and cell-cell communication orchestrated by CAFs renders therapeutic strategies targeting these molecules largely ineffective against cancer. In contrast, exploring the metabolic reprogramming mechanisms of CAFs could be conducive to therapeutic intervention in colorectal cancer. In this study, we conducted metabolomic and single-cell RNA sequencing analyses that uncovered increased glycolysis, intracellular lactate, and histone lactylation in CAFs compared with normal fibroblasts. Elevated histone 3 lysine 18 lactylation (H3K18la) in CAFs promoted the transition of CAFs to myofibroblastic CAFs, increased collagen deposition, and enhanced organoid growth. Furthermore, fibroblast-specific conditional lactic dehydrogenase A knockout in a mouse model mitigated colorectal cancer tumorigenesis and progression in vivo. Cancer cell-derived TGFβ accelerated metabolic reprogramming and histone lactylation in CAFs. Nucleophosmin 1, a histone chaperone functioning as a cofactor of P300, enhanced the H3K18la level of the rho-associated, coiled-coil-containing protein kinase 1 (ROCK1) promoter and activated ROCK1 transcription. The RhoA/ROCK1/myosin light chain 2/myocardin-related transcription factor-A pathway and extracellular matrix (ECM) remodeling were indispensable for the tumor-promoting effect of CAF histone lactylation in colorectal cancer. Additionally, CAF histone lactylation limited CD8+ T-cell infiltration and aggravated CD8+ T-cell exhaustion via ECM remodeling. Stiripentol, a clinical drug that targets lactylation, potentiated the efficacy of immunotherapy in colorectal cancer models. Together, this study demonstrates that elevated lactate levels in CAFs reprogram the epigenetic landscape to promote tumor progression and immunosuppression, highlighting the potential of targeting CAF histone lactylation as a therapeutic strategy for colorectal cancer. Cancer cell-derived TGFβ activates glycolysis in cancer-associated fibroblasts to induce histone lactylation that facilitates extracellular matrix remodeling and T-cell exhaustion, identifying a metabolic-epigenetic-tumor microenvironment axis as a target to overcome immunosuppression.
中文摘要:肿瘤相关成纤维细胞驱动肿瘤恶性的关键方面。然而,由肿瘤相关成纤维细胞调控的细胞因子分泌和细胞间通讯的高度异质性使得针对这些分子的治疗策略对癌症大多无效。相比之下,探索肿瘤相关成纤维细胞的代谢重编程机制可能有利于结直肠癌的治疗干预。在本研究中,我们进行了代谢组学和单细胞RNA测序分析,发现与正常成纤维细胞相比,肿瘤相关成纤维细胞中糖酵解、细胞内乳酸和组蛋白乳酸化增加。肿瘤相关成纤维细胞中组蛋白3赖氨酸18乳酸化水平升高促进了其向肌成纤维细胞样肿瘤相关成纤维细胞的转变,增加了胶原沉积并增强了类器官生长。此外,在小鼠模型中特异性敲除成纤维细胞中的乳酸脱氢酶A减轻了体内结直肠癌的发生和进展。癌细胞来源的TGFβ加速了肿瘤相关成纤维细胞的代谢重编程和组蛋白乳酸化。核仁磷酸蛋白1作为P300的辅助因子发挥组蛋白伴侣功能,增强了ROCK1启动子的H3K18la水平并激活ROCK1转录。RhoA/ROCK1/肌球蛋白轻链2/myocardin相关转录因子A通路和细胞外基质重塑对于结直肠癌中肿瘤相关成纤维细胞组蛋白乳酸化的促肿瘤作用不可或缺。此外,肿瘤相关成纤维细胞的组蛋白乳酸化通过细胞外基质重塑限制了CD8+T细胞浸润并加剧了CD8+T细胞耗竭。靶向乳酸化的临床药物Stiripentol增强了结直肠癌模型中免疫治疗的疗效。综上所述,本研究证明肿瘤相关成纤维细胞中升高的乳酸水平重编程表观遗传景观以促进肿瘤进展和免疫抑制,突出了靶向肿瘤相关成纤维细胞组蛋白乳酸化作为结直肠癌治疗策略的潜力。癌细胞来源的TGFβ激活肿瘤相关成纤维细胞的糖酵解以诱导组蛋白乳酸化,进而促进细胞外基质重塑和T细胞耗竭,确定了一种代谢-表观遗传-肿瘤微环境轴作为克服免疫抑制的靶点。
Biomarker research IF 14.6 2026-11-15 PMID: 43035807
Reliable biomarkers for cancer early detection, prognostic stratification, recurrence surveillance, and treatment-response prediction remain clinically insufficient. tRNA-derived small RNAs (tsRNAs) are abundant, structurally compact, and recurrently dysregulated in malignancy, and have been widely proposed as liquid-biopsy analytes. Their biogenesis, mechanisms, and therapeutic prospects have been reviewed extensively. What has not been assessed is whether the reported clinical evidence supports the claims attached to it, and that is the question this review addresses. We appraise published circulating tsRNA studies against four criteria that govern progression toward clinical use: analytical validity, cohort design and comparator choice, independent validation, and demonstrated incremental clinical utility. Biology is summarized only where it bears on measurement-the distinct enzymatic routes that generate tRNA-derived fragments and tRNA halves, the terminal chemistries they impose, the modifications that bias library construction, and the extracellular biology that determines what is actually quantified in blood. Candidates are then re-classified by intended use and graded by validation level in a structured evidence table reporting cohort size, comparator group, platform, normalization, diagnostic performance, and validation status. Most candidates rest on single-center retrospective case-control comparisons against healthy donors. Detection in stage I disease has been conflated with early detection, and postoperative decline with rcrrence monitoring. Disease specificity is frequently untested, notably for glycine-GCC-derived fragments, which also rise in active inflammatory bowel disease. No circulating tsRNA has yet demonstrated incremental clinical value in a prospectively validated setting. tsRNAs remain a biologically compelling and analytically tractable biomarker reservoir. Realizing that potential will require standardized pre-analytics, clinically relevant comparators, transfer to analytically validated targeted assays, and independent multicenter validation. We provide a minimum reporting checklist and a nomenclature cross-walk to support this.
中文摘要:可靠的癌症早期检测、预后分层、复发监测和治疗反应预测生物标志物在临床上仍显不足。tRNA衍生小RNA(tsRNAs)丰度高、结构紧凑且在恶性肿瘤中反复失调,已被广泛提议作为液体活检分析物。其生物发生机制、作用机理及治疗前景已有大量综述。然而,现有报道的临床证据是否支持相关主张尚未得到评估,这正是本综述旨在解决的问题。我们根据四项决定临床应用进展的标准对已发表的循环tsRNA研究进行评估:分析有效性、队列设计与对照选择、独立验证以及明确的增量临床效用。仅在涉及测量时总结生物学背景,包括产生tRNA衍生片段和tRNA半片的独特酶促途径、它们施加的末端化学修饰、偏向文库构建的修饰以及决定血液中实际定量内容的细胞外生物学特性。随后根据预期用途对候选标志物重新分类,并通过结构化证据表按验证水平进行分级,表中报告了队列规模、对照组、平台、标准化方法、诊断性能及验证状态。大多数候选标志物仅基于单中心回顾性病例对照研究,以健康供体为对照。I期疾病的检测常被混淆为早期检测,术后下降被等同于复发监测。疾病特异性经常未经测试,特别是甘氨酸GCC衍生片段在活性炎症性肠病中也会升高。目前尚无循环tsRNA在前瞻性验证环境中证明具有增量临床价值。tsRNAs仍然是生物学上引人入胜且分析上可行的生物标志物库。实现这一潜力需要标准化的前处理、临床相关的对照、向分析验证的目标检测方法的转移以及独立的多中心验证。我们提供了最低限度的报告清单和命名法交叉对照以支持这一目标。
Biomarker research IF 14.6 2026-11-15 PMID: 43035799
CD8⁺ T cells are central cytotoxic effectors of anti-tumor immunity, but tumor-infiltrating CD8⁺ populations are functionally heterogeneous and include tumor-reactive, dysfunctional, and bystander states. Although the past decade of cancer immunology has focused largely on how local interactions within the tumor microenvironment shape these states, clinical observations linking chronic stress, sleep disruption, endocrine comorbidity, and circadian timing to immune checkpoint inhibitor (ICI) outcomes indicate that CD8⁺ T cell function is also modulated far beyond the tumor itself. In this review we adopt a whole-organism perspective to examine how autonomic and sensory neural circuits and the endocrine system act across anatomical compartments to govern CD8⁺ T cell priming, trafficking, metabolism, and exhaustion. We first analyze sympathetic, parasympathetic, and sensory neural axes as systemic effectors mediated by catecholamines, acetylcholine, neuropeptides, and brainstem-driven tone. We then examine endocrine regulation through the hypothalamic-pituitary-adrenal axis, metabolic hormones, and gonadal steroids. We integrate these axes within the tumor microenvironment, where nerve-derived signals, paracrine neuropeptides, and locally amplified glucocorticoid activity form a convergent suppressive network, and at the organismal level through stress amplification loops, sex dimorphism, gut-relayed microbial signaling, and circadian timing. Collectively, this evidence identifies neuro-endocrine signaling as an actionable, mechanistically stratified layer of systemic immune regulation and supports its evaluation as a source of biomarkers and pharmacological targets for sensitizing tumors to ICI therapy. This framework offered here is intended to bridge cancer neuroscience, endocrine oncology, and immunotherapy, and to define the criteria by which the next generation of systems-level immune sensitizers should be evaluated.
中文摘要:CD8+ T细胞是抗肿瘤免疫的核心细胞毒性效应细胞,但肿瘤浸润的CD8+ T细胞群体在功能上具有异质性,包括肿瘤反应性、功能障碍性和旁观者状态。尽管过去十年的癌症免疫学研究主要关注肿瘤微环境内的局部相互作用如何塑造这些状态,但临床观察表明,慢性压力、睡眠障碍、内分泌合并症和昼夜节律与免疫检查点抑制剂疗效之间的联系提示CD8+ T细胞功能还受到肿瘤以外远端因素的调节。本综述采用整体视角,考察自主神经和感觉神经回路以及内分泌系统如何跨越解剖隔室调控CD8+ T细胞的启动、 trafficking、代谢和耗竭。我们首先分析作为系统性效应器的交感、副交感和感觉神经轴,其通过儿茶酚胺、乙酰胆碱、神经肽和脑干驱动的张力进行介导。随后考察下丘脑-垂体-肾上腺轴、代谢激素和性腺类固醇的内分泌调节作用。我们将这些轴系整合到肿瘤微环境中,其中神经源性信号、旁分泌神经肽和局部放大的糖皮质激素活性形成汇聚性的抑制网络;并在生物体水平上通过压力放大环路、性别二态性、肠道介导的微生物信号和昼夜节律进行整合。综上所述,这些证据将神经内分泌信号识别为一种可操作的、机制分层的系统性免疫调节层,并支持将其作为生物标志物来源和药理学靶点以增敏肿瘤对免疫检查点抑制剂治疗的疗效。本框架旨在弥合癌症神经科学、内分泌肿瘤学和免疫治疗之间的鸿沟,并定义评估下一代系统级免疫增敏剂的标准。
Biomarker research IF 14.6 2026-11-15 PMID: 43035749
T-cell engagers (TCEs) are bispecific or multispecific immunotherapeutic molecules that specifically bridge and activate T cells to mediate tumor cell killing. Although TCEs have achieved remarkable clinical success in hematological malignancies, their efficacy in solid tumors remains limited by physical tumor barriers, an immunosuppressive tumor microenvironment, antigen heterogeneity, and off-tumor toxicity. This review systematically summarizes recent engineering strategies for TCEs in solid tumors, including miniaturization and novel expression and delivery technologies to enhance tumor penetration, affinity optimization, integration of costimulatory signals and immune checkpoint blockade, and tumor microenvironment-responsive prodrug designs to balance antitumor immune activity with treatment safety, as well as novel molecular architectures to overcome tumor antigen escape and heterogeneity. We further discuss biomarker-guided patient selection and engineering strategy selection, together with developability and chemistry, manufacturing, and controls (CMC) considerations for clinical translation, and highlight future directions toward precise activation, multimodal synergy, and efficient local enrichment, providing a framework for rational development of TCE-based immunotherapy for solid tumors.
中文摘要:T细胞衔接分子(TCEs)是一类特异性桥接并激活T细胞以介导肿瘤细胞杀伤的双特异性或多特异性免疫治疗分子。尽管TCEs在血液系统恶性肿瘤中取得了显著的临床成功,但其在实体瘤中的疗效仍受限于物理性肿瘤屏障、免疫抑制性肿瘤微环境、抗原异质性以及脱靶毒性。本综述系统总结了近年来针对实体瘤的TCEs工程化策略,包括用于增强肿瘤渗透性的微型化及新型表达与递送技术、亲和力优化、共刺激信号与免疫检查点阻断的整合、旨在平衡抗肿瘤免疫活性与治疗安全性的肿瘤微环境响应型前药设计,以及用于克服肿瘤抗原逃逸和异质性的新型分子架构。我们进一步讨论了生物标志物指导的患者选择及工程化策略选择,并探讨了临床转化中的可开发性及化学、制造与控制(CMC)考量,同时强调了向精确激活、多模态协同及高效局部富集发展的未来方向,为实体瘤TCEs免疫疗法的理性开发提供了框架。
Biomarker research IF 14.6 2026-11-15 PMID: 43035487
Alternative lengthening of telomeres (ALT) is a recombination-based telomere maintenance mechanism that sustains replicative immortality in approximately 10-15% of human cancers, particularly those of mesenchymal and neuroepithelial origin. As precision oncology increasingly demands biomarkers that accurately define telomere maintenance mechanisms, extrachromosomal telomeric C-circles - partially single-stranded, C-rich telomeric circular DNAs - have emerged as quantifiable indicators of ALT activity with growing diagnostic, prognostic, and therapeutic potential. Here, we summarize recent mechanistic and translational advances that establish C-circles as both functional readouts of ALT activity and clinically actionable biomarkers. We integrate emerging evidence into a unified model in which replication stress drives C-circle production through pathways that are dynamically shaped by telomeric DNA structures and DNA repair factors, linking the molecular origin of C-circle to specific vulnerabilities with therapeutic implications. We further critically evaluate current detection technologies, spanning the gold-standard C-circle assay and its quantitative PCR and high-throughput adaptations and single-cell native FISH, which collectively enable sensitive and scalable detection across tissue specimens and liquid biopsies, including exosome-protected C-circles. Therapeutically, the molecular circuitry underlying C-circle production exposes selective ALT dependencies on replication stress and DNA repair regulators. Perturbation of these nodes reshapes C-circle dynamics while revealing synthetic lethal vulnerabilities that can be exploited through helicase-, nuclease-, chromatin-, replication stress-, and G-quadruplex-targeted strategies. We also discuss the important caveat that telomerase-positive tumors with hyperextended telomeres can generate C-circles, emphasizing the need for cautious interpretation of C-circle measurements. Clinically, CC appear to define ALT status more reliably than surrogate genomic markers such as ATRX/DAXX loss and may refine patient stratification, with potential implications for patient outcomes and treatment selection. In addition, the detection of circulating CC in liquid biopsies raises the possibility of their use as biomarkers for treatment monitoring and disease surveillance. Collectively, CC have evolved from experimental hallmarks of ALT into mechanistically informative and potentially actionable biomarkers. Continued assay standardization and integration into tissue and liquid biopsy workflows will be essential to support their clinical translation.
中文摘要:替代性端粒延长是一种基于重组的端粒维持机制,在约10%至15%的人类癌症中维持复制永生状态,尤其多见于间充质和神经上皮来源的肿瘤。随着精准肿瘤学对能准确界定端粒维持机制的生物标志物的需求日益增加,细胞外染色体外端粒C环作为可量化的ALT活性指标,其诊断、预后和治疗潜力不断增长。本文总结了确立C环为ALT活性的功能读出及临床可操作生物标志物的近期机制与转化进展。我们将新证据整合为一个统一模型,在该模型中复制压力通过受端粒DNA结构和DNA修复因子动态影响的路径驱动C环产生,将C环的分子起源与其具有治疗意义的特定脆弱性联系起来。我们进一步批判性地评估了当前的检测技术,涵盖金标准C环检测及其定量PCR和高通量适应形式以及单细胞原位荧光杂交,这些技术共同实现了在组织标本和液体活检包括外泌体保护的C环中的敏感且可扩展的检测。在治疗方面,C环产生的分子电路暴露了对复制压力和DNA修复调节因子的选择性ALT依赖性。对这些节点的扰动重塑了C环动力学并揭示了合成致死脆弱性,可通过解旋酶、核酸酶、染色质、复制压力及G四链体靶向策略加以利用。我们还讨论了重要的注意事项即端粒酶阳性肿瘤在端粒过度延长的情况下也能产生C环,强调需谨慎解读C环测量结果。临床上,C环似乎比ATRX或DAXX缺失等替代基因组标志物更可靠地定义ALT状态,并可能细化患者分层,对患者结局和治疗选择具有潜在影响。此外液体活检中循环C环的检测使其作为治疗监测和疾病监测生物标志物的可能性成为现实。总体而言C环已从ALT的实验特征演变为机制信息丰富且潜在可操作的生物标志物。持续的检测标准化及其整合至组织和液体活检工作流程对于支持其临床转化至关重要。
Pharmacological research IF 12.2 2026-11-15 PMID: 43035200
Suboptimal responses and adaptive resistance remain major hurdles to immunotherapy, necessitating noninvasive dynamic in vivo monitoring of emerging immune checkpoints and the subsequent development of targeted interventions. TIM-3 is closely associated with T-cell exhaustion and immunotherapy resistance. Nevertheless, no remarkable breakthroughs have been achieved in TIM-3-targeted therapeutic strategies. Here, we report a first-in-class TIM-3-targeted radio-theranostic platform based on the humanized anti-TIM-3 antibody T21(TQB2618), radiolabeled with 89Zr (zirconium-89) for immunoPET imaging and 177Lu (lutetium-177) for radionuclide therapy. 89Zr-T21 exhibited high TIM-3 affinity and target specificity at protein and cellular levels and enabled clear visualization of TIM-3-positive expression tumors. In a hTIM-3 humanized animal model, 89Zr-T21 initially showed dominant splenic uptake and limited tumor accumulation, consistent with a peripheral TIM-3 antigen sink, whereby abundant TIM-3-expressing immune cells sequester the tracer outside the tumor. Pre-administration of unlabeled T21 reduced splenic sequestration and optimized tumor visualization, with maximal tumor uptake achieved at a 25-fold pre-dosing level. Notably, 89Zr-T21 enabled longitudinal and noninvasive monitoring of immunotherapy-induced TIM-3 remodeling in vivo, revealing time-dependent TIM-3 upregulation following PD-1 blockade and dose-dependent TIM-3 expression changes after immunotherapy. The matched therapeutic agent 177Lu-T21 significantly inhibited A549hTIM-3 tumor growth with favorable safety. Collectively, this study establishes the first TIM-3-directed radio-theranostic framework for imaging adaptive immune resistance and advancing TIM-3 targeted radioimmunotherapy.
中文摘要:免疫治疗反应不佳和适应性耐药仍是主要障碍,亟需对新兴免疫检查点进行非侵入性动态体内监测并开发靶向干预措施。TIM-3与T细胞耗竭及免疫治疗耐药密切相关,但针对TIM-3的治疗策略尚未取得显著突破。本研究报道了一种首创的TIM-3靶向放射性诊疗平台,基于人源化抗TIM-3抗体T21(TQB2618),利用锆-89进行免疫PET成像,利用镥-177进行核素治疗。在蛋白和细胞水平上,锆-89标记的T21表现出高TIM-3亲和力和靶点特异性,并能清晰可视化TIM-3阳性表达肿瘤。在人源化TIM-3动物模型中,锆-89标记的T21初期显示脾脏摄取占主导且肿瘤积累有限,这与外周TIM-3抗原汇现象一致,即大量表达TIM-3的免疫细胞在肿瘤外隔离示踪剂。预注射未标记的T21可减少脾脏隔离并优化肿瘤可视化,在25倍预给药水平下实现最大肿瘤摄取。值得注意的是,锆-89标记的T21实现了免疫治疗诱导的TIM-3重塑的纵向非侵入性体内监测,揭示了PD-1阻断后时间依赖性的TIM-3上调及免疫治疗后剂量依赖性的TIM-3表达变化。匹配的诊疗制剂镥-177标记的T21在安全性良好的前提下显著抑制了A549hTIM-3肿瘤生长。综上所述,本研究建立了首个TIM-3导向的放射性诊疗框架,用于成像适应性免疫耐药并推进TIM-3靶向放射免疫治疗。
Pharmacological research IF 12.2 2026-11-15 PMID: 43035198
Hepatocellular carcinoma (HCC) arises in chronically injured, often fibrotic or cirrhotic liver, where metabolism, immunity, vascular and stromal organization, disease etiology, tumor state, and hepatic reserve are tightly interconnected. Although immune checkpoint inhibitor (ICI)-based therapies have expanded treatment options for advanced HCC, responses remain heterogeneous because of both primary and acquired resistance. Metabolic reprogramming may shape these outcomes by altering nutrient availability, metabolite accumulation, antigen presentation, immune-cell fitness, stromal organization, and spatial immune access. This review provides an evidence-weighted assessment of major immunometabolic mechanisms in HCC, focusing on the glycolysis-hypoxia-lactate and tryptophan-kynurenine/IDO1 axes, lipid and cholesterol metabolism, purinergic signaling, mitochondrial and redox regulation, and ferroptosis. We emphasize that these pathways are context dependent, with effects determined by cellular source, differentiation state, spatial organization, and tumor-intrinsic versus immune-cell metabolic adaptation. Molecular heterogeneity, etiology, and cirrhosis are considered together, with WNT-β-catenin/CTNNB1-associated states illustrating their intersection with immune organization and ICI response. Because translational maturity varies widely, we distinguish mechanistic evidence, biomarker association, predictive validation, and clinical utility. We propose a framework integrating HCC specificity, primary human validation, cellular and spatial localization, causal immune-functional evidence, treatment-linked and longitudinal assessment, biomarker feasibility, and liver-specific safety. The framework also considers intervention timing and the distinction between primary and acquired ICI resistance. It may guide progression from metabolic discovery to spatially resolved mechanism, biomarker development, pharmacodynamic validation, and clinical evaluation while accounting for cirrhosis-associated remodeling, hepatic reserve, and treatment-related toxicity.
中文摘要:肝细胞癌(HCC)发生于慢性损伤、常伴有纤维化或肝硬化的肝脏中,其中代谢、免疫、血管及基质结构、疾病病因、肿瘤状态和肝功能储备紧密相连。尽管基于免疫检查点抑制剂(ICI)的治疗方案拓展了晚期HCC的治疗选择,但由于原发性和获得性耐药,患者反应仍存在异质性。代谢重编程可能通过改变营养可用性、代谢物积累、抗原呈递、免疫细胞适应性、基质结构和空间免疫可及性来影响这些结果。本综述对HCC中主要的免疫代谢机制进行了基于证据权重的评估,重点聚焦于糖酵解-缺氧-乳酸和色氨酸-犬尿氨酸/IDO1轴、脂质与胆固醇代谢、嘌呤能信号、线粒体与氧化还原调节以及铁死亡。我们强调这些通路具有情境依赖性,其效应由细胞来源、分化状态、空间组织以及肿瘤内在或免疫细胞的代谢适应所决定。分子异质性、病因和肝硬化被共同考量,其中WNT-β-catenin/CTNNB1相关状态展示了其与免疫组织和ICI反应的交叉点。鉴于转化成熟度差异显著,我们区分了机制证据、生物标志物关联、预测性验证和临床效用。我们提出一个整合框架,涵盖HCC特异性、原代人体验证、细胞与空间定位、因果性免疫功能证据、治疗相关及纵向评估、生物标志物可行性以及肝脏特异性安全性。该框架还考虑了干预时机以及原发性与获得性ICI耐药的区别。它可能指导从代谢发现向空间解析机制、生物标志物开发、药效动力学验证和临床评价的进展,同时兼顾肝硬化相关的重塑、肝功能储备和治疗相关毒性。
Science bulletin IF 20.7 2026-11-15 PMID: 42618434
Adoptive cell therapy with macrophages holds great promise for treating solid tumors, but its clinical impact has been limited. The problem is twofold: the immunosuppressive tumor microenvironment quickly silences the anti-tumor activity of transferred cells, and systemic activation strategies often provoke off-target toxicity. Here, we describe a simple yet effective approach to overcome these barriers. We engineered primary macrophages with anti-CD11b-functionalized zinc-aluminum layered double hydroxide micropatches (LDHMP)-a surface-anchoring strategy that leaves the cells otherwise unaltered. Once the engineered cells (Mip@MΦ) reach the acidic tumor microenvironment, the micropatches degrade, releasing Zn2+ that synergizes with tumor-derived DNA to activate the STING pathway and drive repolarization toward an M1 anti-tumor phenotype. At the same time, LDHMP consumes excess H+, neutralizing the acidic milieu that normally suppresses immune function. This dual action-in situ reprogramming plus microenvironment remodeling-elicits robust, localized anti-tumor immunity without systemic toxicity. In orthotopic breast and pancreatic tumor models, Mip@MΦ treatment significantly inhibited tumor growth, reduced metastasis, and established durable immune memory. By combining a straightforward micropatch engineering strategy with insights from single-cell sequencing, our approach offers a scalable, safe, and highly effective platform for macrophage-based adoptive cell therapy.
中文摘要:巨噬细胞过继细胞疗法在治疗实体瘤方面前景广阔,但其临床影响一直受限。该问题主要源于两方面:免疫抑制性肿瘤微环境会迅速使转移细胞的抗肿瘤活性沉默,而全身性激活策略常引发脱靶毒性。在此,我们描述了一种简单且有效的策略以克服这些障碍。我们利用抗CD11b功能化的锌铝层状双氢氧化物微贴片(LDHMP)对原代巨噬细胞进行工程化改造,这是一种表面锚定策略,使细胞其余部分保持未改变状态。当工程化细胞(Mip@MΦ)到达酸性肿瘤微环境时,微贴片降解并释放Zn2+,其与肿瘤来源的DNA协同作用激活STING通路,驱动细胞极化为M1抗肿瘤表型。同时,LDHMP消耗过量H+,中和通常抑制免疫功能的酸性环境。这种双重作用——原位重编程加上微环境重塑——在不引起全身毒性的情况下激发了强大且局部的抗肿瘤免疫反应。在原位乳腺癌和胰腺癌模型中,Mip@MΦ治疗显著抑制了肿瘤生长,减少了转移,并建立了持久的免疫记忆。通过将简单的微贴片工程化策略与单细胞测序见解相结合,我们的方法为基于巨噬细胞的过继细胞疗法提供了一个可扩展、安全且高效的平台。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42413382
Liver cancer (LC) is the third leading cause of cancer deaths worldwide, with the unsatisfactory clinical outcome due to high heterogeneity and metastasis. Unfortunately, it is still great challenging to achieve both effective screening and precise treatment of LC. Herein, a nanocomposite integrating dual-optical probes and gene regulation sequence was designed and prepared to simultaneously detect the novel gene biomarker and inhibit the metastasis-related gene function, achieving dual diagnostic and treatment functions for LC. Using the biosensing model based on surface-enhanced Raman spectroscopy (SERS) and fluorescence imaging, different expression of target circular RNA (cSMARCA5) in normal and LC cells can be characterized and quantified with an ultra-low limit of detection of 4.50 fM. Meanwhile, the specially-designed sequence loaded in the nanocomposite is capable of inhibiting the migration and invasion of LC cells in an in vitro model. Moreover, its ability of metastasis regulation for potential gene therapy can be further confirmed using optical imaging method via in vivo zebrafish transplantation tumor model. This work presents a dual-function nano-platform for simultaneous optical screening and gene treatment of LC, providing a unique strategy for precise medicine.
中文摘要:肝癌是全球第三大癌症死因,由于高异质性和转移性导致临床预后不佳。目前,实现肝癌的有效筛查和精准治疗仍面临巨大挑战。在此,设计并制备了一种整合双光学探针和基因调控序列的纳米复合材料,以同时检测新型基因生物标志物并抑制转移相关基因功能,从而实现肝癌的双重诊断和治疗功能。基于表面增强拉曼光谱和荧光成像的生物传感模型能够表征并定量正常细胞与肝癌细胞中靶标环状RNA(cSMARCA5)的不同表达,检测限低至4.50 fM。同时,纳米复合材料中加载的特殊设计序列能够在体外模型中抑制肝癌细胞的迁移和侵袭。此外,通过体内斑马鱼移植瘤模型的光学成像方法进一步证实了其在潜在基因治疗中的转移调控能力。这项工作提出了一种用于肝癌同步光学筛查和基因治疗的双功能纳米平台,为精准医疗提供了一种独特的策略。
Biomaterials IF 13.6 2026-11-14 PMID: 43051016
Cancer immunotherapy is limited by the inherently low immunogenicity of tumors and the highly immunosuppressive tumor microenvironment (TME). While reactive oxygen species (ROS)-based therapeutic modalities can induce immunogenic cell death (ICD), the existing nanoplatforms relying on simple physical combinations lack internal mechanism connection. Herein, we engineer a multifunctional nanoplatform (Mn-CD@CMS) by electrostatically assembling Mn-doped carbon dots (Mn-CDs) onto hollow Cu2MoS4 (CMS) nanocubes to program a ROS-triggered cascade amplification of anti-tumor immune response. Importantly, Mn doping endows CDs with the biological effect of "one stone, three birds", which not only narrows the bandgap to enhance the photodynamic therapy (PDT) effect, triggers optical redshift suitable for NIR applications, but also enables Mn-CD to activate the cGAS-STING pathway. Upon 808 nm laser irradiation, Mn-CD@CMS generates massive ROS through PDT, chemodynamic therapy (CDT), and regulating TME. Targeted metabolomics suggest that this large amount of ROS disrupts the tricarboxylic acid (TCA) cycle and rapidly consumes GSH, forcing metabolic reprogramming characterized by glycolysis inhibition. Mn-CD@CMS-triggered energy collapse greatly sensitizes tumor cells to Cu+-mediated cuproptosis. Concurrently, ROS-induced severe DNA damage leads to a large leakage of mtDNA, which synergizes with the released Mn2+ to achieve efficient amplification of the cGAS-STING activation. In a bilateral murine tumor model, this cascaded amplified anti-tumor immune response triggered by Mn-CD@CMS realizes the good inhibition of primary tumors, reverses the immunosuppressive TME, and elicits robust systemic T-cell immunity to suppress distant tumors. This work provides a new paradigm for designing efficient and synergistic anti-tumor nanomedicines through integrating tumor metabolic reprogramming, cuproptosis, and innate immune activation with ROS production.
中文摘要:癌症免疫疗法受限于肿瘤固有的低免疫原性和高度免疫抑制性肿瘤微环境。虽然基于活性氧的治疗模式可诱导免疫原性细胞死亡,但现有依赖简单物理组合的纳米平台缺乏内在机制联系。本研究通过静电组装将锰掺杂碳点负载于中空二硫化钼铜纳米立方体上,构建多功能纳米平台Mn-CD@CMS,以编程抗肿瘤免疫反应的活性氧触发级联放大效应。锰掺杂赋予碳点多重生物学效应,不仅缩小带隙以增强光动力治疗效果并触发适用于近红外应用的光学红移,还能激活cGAS-STING通路。在808nm激光照射下,Mn-CD@CMS通过光动力治疗、化学动力学治疗及调节肿瘤微环境产生大量活性氧。靶向代谢组学表明,大量活性氧破坏三羧酸循环并快速消耗谷胱甘肽,迫使以糖酵解抑制为特征的代谢重编程发生。Mn-CD@CMS触发的能量崩溃使肿瘤细胞对铜离子介导的铜死亡高度敏感。同时,活性氧诱导的严重DNA损伤导致线粒体DNA大量泄漏,与释放的锰离子协同实现cGAS-STING激活的高效放大。在双侧小鼠肿瘤模型中,Mn-CD@CMS触发的级联放大抗肿瘤免疫反应有效抑制原发肿瘤,逆转免疫抑制性肿瘤微环境,并引发强大的系统性T细胞免疫力以抑制远处肿瘤。该工作为通过整合肿瘤代谢重编程、铜死亡和先天免疫激活与活性氧产生来设计高效协同抗肿瘤纳米药物提供了新范式。
Advanced healthcare materials IF 11.0 2026-11-14 PMID: 43034276
Immunotherapy has emerged as a promising approach for osteosarcoma, but its clinical translation is hampered by the complexity of current therapeutic systems. Here, we developed a simple nanodrug composed of Cu2+ and liensinine (Lis) that amplifies tumor cell damage by simultaneously blocking autophagic flux and inducing cuproptosis. Mechanistically, Cu2+ depletes glutathione and disrupts intracellular redox homeostasis, thereby weakening antioxidant defenses and increasing copper-associated mitochondrial stress. This process is accompanied by FDX1 upregulation and cuproptosis-associated mitochondrial dysfunction. In parallel, liensinine impairs lysosomal integrity and blocks autophagosome clearance, thereby preventing the efficient removal of damaged mitochondria and allowing ROS accumulation to persist. Sustained oxidative stress then activates caspase-3, which cleaves GSDME to generate the pore-forming GSDME-N fragment, resulting in plasma membrane permeabilization and subsequent release of damage-associated molecular patterns, thereby enhancing hallmarks of immunogenic cell death and facilitating dendritic cell maturation. In vivo, Cu-Lis suppresses osteosarcoma growth, increases intratumoral immune-cell infiltration, and reduces pulmonary metastasis. Collectively, this work provides a streamlined strategy that integrates autophagic flux blockade with cuproptosis to potentiate antitumor immunity against osteosarcoma.
中文摘要:免疫治疗已成为骨肉瘤的一种有前景的方法,但其临床转化受到当前治疗系统复杂性的阻碍。本研究开发了一种由Cu2+和莲房素组成的简单纳米药物,通过同时阻断自噬流并诱导铜死亡来放大肿瘤细胞损伤。在机制上,Cu2+消耗谷胱甘肽并破坏细胞内氧化还原稳态,从而削弱抗氧化防御能力并增加铜相关的线粒体应激。该过程伴随FDX1上调和铜死亡相关线粒体功能障碍。同时,莲房素损害溶酶体完整性并阻断自噬体清除,从而防止受损线粒体的有效移除,使活性氧积累持续存在。持续的氧化应激随后激活半胱天冬酶3,后者裂解GSDME生成成孔的GSDME-N片段,导致质膜通透性增加及损伤相关分子模式的释放,从而增强免疫原性细胞死亡的标志并促进树突状细胞成熟。在体内实验中,Cu-Lis抑制骨肉瘤生长,增加肿瘤内免疫细胞浸润并减少肺转移。综上所述,这项工作提供了一种简化策略,将自噬流阻断与铜死亡相结合,以增强针对骨肉瘤的抗肿瘤免疫。
Acta biomaterialia IF 10.4 2026-11-14 PMID: 43034028
The blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) severely limited drug delivery into the brain, while aberrant aerobic glycolysis in the tumor microenvironment caused excessive lactate accumulation and drove immunosuppression. These factors together constituted the core obstacles to glioblastoma (GBM) therapy. From the perspective of metabolism-immune crosstalk, we engineered a brain‑targeted nucleic acid nanosphere (TE@siP‑DNS/DOX) featuring high BBB/BBTB penetrability, which orchestrated a "triple‑linked" strategy integrating glycolysis blockade, immune microenvironment remodeling, and synergistic therapeutic potentiation. The nanosphere was constructed with a self‑assembled core of PKM2‑targeting siRNA and framework nucleic acids loaded with doxorubicin (DOX), shielded by a biomimetic shell of T7 peptide‑modified macrophage extracellular vesicles. Leveraging transcytosis and T7‑mediated active targeting, TE@siP‑DNS/DOX efficiently traversed the barriers and preferentially accumulated at tumor sites. DOX simultaneously provoked chemotherapy and immunogenic cell death, igniting robust CD8⁺ T cell‑mediated antitumor immunity, whereas siRNA‑mediated PKM2 silencing curtailed glycolysis, lessened lactate production, rewired metabolic circuitry, and forced macrophage polarization toward the M1 antitumor phenotype, thereby dismantling the immunosuppressive tumor microenvironment (iTME). Transcriptomic analysis further confirmed that metabolic and immune-related pathways were significantly enriched following TE@siP-DNS/DOX treatment, providing transcriptional evidence for its dual modulation of the metabolic-immune feedback loop. In vivo studies substantiated that TE@siP‑DNS/DOX markedly inhibited tumor growth and prolonged survival in orthotopic GBM-bearing mice. Collectively, this nanoplatform, through a synergistic feedback loop integrating metabolic regulation and immune activation, provides a good therapeutic strategy and research paradigm for enhanced glioma therapy. STATEMENT OF SIGNIFICANCE: Glioblastoma therapy is impeded by a multifaceted barrier system encompassing the blood-brain barrier, metabolic dysregulation, lactate accumulation, and immunosuppression. Here, we engineered a brain-targeted nucleic acid nanosphere that integrates glycolysis blockade, immune remodeling, and chemotherapeutic sensitization via a single platform. By combining PKM2 silencing with doxorubicin-loaded framework nucleic acids and T7-modified macrophage vesicles, the nanosphere achieves efficient barrier penetration, lactate reduction, M1 macrophage repolarization, and immunogenic cell death. This metabolism-immune feedback loop synergistically suppresses orthotopic tumors and extends survival. Our study provides a paradigm for treating brain tumors through concurrent metabolic reprogramming and antitumor immunity, offering a translatable strategy for overcoming therapy resistance in glioblastoma.
中文摘要:血脑屏障(BBB)和血脑肿瘤屏障(BBTB)严重限制了药物向大脑的递送,而肿瘤微环境中异常的有氧糖酵解导致乳酸过度积累并驱动免疫抑制。这些因素共同构成了胶质母细胞瘤(GBM)治疗的核心障碍。从代谢-免疫串扰的角度出发,我们设计了一种具有高BBB/BBTB穿透能力的脑靶向核酸纳米球(TE@siP-DNS/DOX),该纳米球整合了糖酵解阻断、免疫微环境重塑和协同治疗增强的三重关联策略。该纳米球由自组装核心构成,包含靶向PKM2的siRNA和负载阿霉素(DOX)的框架核酸,外层包裹经T7肽修饰的巨噬细胞外囊泡仿生壳。利用转胞吞作用和T7介导的主动靶向,TE@siP-DNS/DOX有效穿过屏障并优先在肿瘤部位积累。DOX同时引发化疗和免疫原性细胞死亡,点燃强大的CD8+ T细胞介导的抗肿瘤免疫;而siRNA介导的PKM2沉默则限制了糖酵解,减少乳酸产生,重塑代谢回路,迫使巨噬细胞极化为M1抗肿瘤表型,从而瓦解免疫抑制性肿瘤微环境(iTME)。转录组学分析进一步证实,经TE@siP-DNS/DOX处理后,代谢和免疫相关通路显著富集,为其对代谢-免疫反馈环的双重调节提供了转录组证据。体内研究证实,TE@siP-DNS/DOX在原位GBM小鼠模型中显著抑制肿瘤生长并延长生存期。综上所述,该纳米平台通过整合代谢调节和免疫激活的协同反馈环,为增强胶质瘤治疗提供了良好的治疗策略和研究范式。SIGNIFICANCE STATEMENT:胶质母细胞瘤的治疗受到包含血脑屏障、代谢失调、乳酸积累和免疫抑制的多重障碍系统的阻碍。在此,我们设计了一种脑靶向核酸纳米球,通过单一平台整合糖酵解阻断、免疫重塑和化疗增敏。通过结合PKM2沉默与负载阿霉素的框架核酸及T7修饰的巨噬细胞囊泡,该纳米球实现了高效的屏障穿透、乳酸减少、M1巨噬细胞复极化和免疫原性细胞死亡。这种代谢-免疫反馈环协同抑制原位肿瘤并延长生存期。本研究为通过同时进行的代谢重编程和抗肿瘤免疫治疗脑肿瘤提供了范式,为克服胶质母细胞瘤的治疗耐药性提供了可转化的策略。
Seminars in immunology IF 11.5 2026-11-14 PMID: 43033651
Ferroptosis is an iron-dependent, lipid peroxidation-driven form of regulated cell death that is increasingly recognized as both a target and a regulator of immune responses. Emerging evidence reveals extensive bidirectional communication between ferroptotic cells and the immune system. Ferroptotic cells release damage-associated molecular patterns (DAMPs) and iron-related signals that shape innate and adaptive immunity, whereas immune cells and cytokines actively govern ferroptotic susceptibility by remodeling iron metabolism, antioxidant defenses, and lipid peroxidation pathways. These reciprocal interactions establish a dynamic ferroptosis-immune circuit (FIC) that integrates metabolic stress, cell death signaling, and immune regulation. Here, we review the molecular architecture of this circuit and examine its context-dependent functions in human disease. We discuss how ferroptosis interfaces with antitumor immunity and immunotherapy in cancer, drives inflammatory injury and remodeling in cardiovascular and neurological diseases, modulates immune dysregulation in autoimmune and inflammatory disorders, and influences host-pathogen interactions during infection. We further evaluate emerging therapeutic approaches targeting ferroptosis-immune circuit and propose future directions for translating mechanistic insights into disease-specific therapeutic strategies.
中文摘要:铁死亡是一种依赖铁的脂质过氧化驱动的调节性细胞死亡形式,日益被视为免疫反应的目标和调节因子。新证据揭示了铁死亡细胞与免疫系统之间广泛的双向交流。铁死亡细胞释放损伤相关分子模式(DAMPs)和铁相关信号,塑造先天性和适应性免疫,而免疫细胞和细胞因子通过重塑铁代谢、抗氧化防御和脂质过氧化途径主动调控铁死亡的易感性。这些相互作用建立了一个动态的铁死亡-免疫回路(FIC),整合了代谢应激、细胞死亡信号传导和免疫调节。本文回顾了该回路的分子架构,并考察了其在人类疾病中的上下文依赖功能。我们讨论了铁死亡如何与癌症中的抗肿瘤免疫和免疫治疗相互作用,驱动心血管和神经系统疾病中的炎症损伤和重塑,调节自身免疫和炎症性疾病中的免疫失调,以及影响感染期间的宿主-病原体相互作用。我们进一步评估了针对铁死亡-免疫回路的新型治疗方法,并提出了将机制见解转化为疾病特异性治疗策略的未来方向。
MedComm IF 14.1 2026-11 PMID: 43032684
Targeted conjugate therapeutics link tumor-directed vectors to cytotoxic drugs or radionuclides. Antibody-drug conjugates (ADCs) usually depend on cellular uptake and intracellular processing to deliver a pharmacological payload. Radionuclide-conjugated drugs (RDCs) deliver radiation over an emission-dependent range and can support imaging-based patient selection and absorbed-dose assessment. This review compares the two modalities through four linked areas: modular design, mechanisms of action, clinical translation, and resistance and next-generation engineering. We examine vector pharmacokinetics, linker and chelator chemistry, payload selection, and the biological effects of beta particles, alpha particles, and Auger electrons. Randomized trials establish the clinical value of selected human epidermal growth factor receptor 2 (HER2)-, TROP2-, and Nectin-4-directed ADCs and prostate-specific membrane antigen (PSMA)- and somatostatin-receptor-directed radioligands. Evidence for newer radionuclides, alternative targets, and combinations varies from preclinical studies to early clinical trials. The comparison separates ADC payload diffusion from physical radiation crossfire and distinguishes parent-radionuclide chelation from recoil-driven daughter redistribution. It also addresses imaging-therapy discordance, normal-organ exposure, biomarkers, manufacturing, and access. The proposed framework organizes design and evidence appraisal; it is not a validated treatment-selection model. Its practical value lies in identifying which delivery principles can be shared and which require modality-specific validation.
中文摘要:靶向偶联治疗将肿瘤导向载体与细胞毒性药物或放射性核素连接。抗体偶联药物通常依赖细胞摄取和胞内加工来递送药理载荷。放射性核素偶联药物在发射依赖范围内递送辐射,并支持基于影像的患者选择和吸收剂量评估。本综述通过四个相互关联的领域比较这两种模式:模块化设计、作用机制、临床转化以及耐药性和下一代工程。我们考察了载体药代动力学、连接子和螯合剂化学、载荷选择以及β粒子、α粒子和俄歇电子的生物效应。随机试验确立了特定人表皮生长因子受体2、TROP2和Nectin-4导向的抗体偶联药物以及前列腺特异性膜抗原和生长抑�受体导向的放射性配体药物的临床价值。关于新型放射性核素、替代靶点和联合治疗证据的差异从临床前研究到早期临床试验不等。该比较区分了抗体偶联药物的载荷扩散与物理辐射交叉火力,并区分了母体放射性核素螯合与反冲驱动的子体重新分布。它还涉及影像与治疗的不一致性、正常器官暴露、生物标志物、制造和可及性。提出的框架用于组织设计和证据评估;它并非经过验证的治疗选择模型。其实际价值在于识别哪些递送原则可以共享,哪些需要模式特异性验证。
MedComm IF 14.1 2026-11 PMID: 43032674
Oncolytic bacterial therapy has huge application potential for cancer treatment due to its tumor-targeting capabilities and immune microenvironment activation. However, the severe adverse effects of oncolytic bacteria limit their clinical applications. Enhancing biosafety while maintaining the efficacy of oncolytic bacteria is essential for advancing the clinical translation of live microbial cancer therapies. Here, we construct a mesenchymal stromal cell (MSC)-mediated tumor-targeted delivery system for Salmonella typhimurium VNP20009 (MSC-VNP), which significantly enhances the intertumoral enrichment and safety of VNP. This benefit arises from the tumor-homing chemotaxis of MSCs and the delayed release of intracellular VNP. To improve the therapeutic effect, we construct engineered MSCs that sustainably secrete PD-1 nanobodies (MSC-PD1nb) to treat melanoma in combination with MSC-VNP. This combination therapy improves antitumor efficacy in a mouse melanoma model by increasing antitumor effector cells (CD8 + T effector cells) and reducing protumor effector cells (CD4 + T regulatory cells). These data indicate that MSC-mediated combination immunotherapy offers a promising antitumor immune strategy, providing a prospect for expanding the therapeutic application of oncolytic bacteria in cancer.
中文摘要:溶菌细菌疗法凭借其肿瘤靶向能力和免疫微环境激活作用,在癌症治疗中具有巨大的应用潜力。然而,溶菌细菌严重的不良反应限制了其临床应用。在保持溶菌细菌疗效的同时提高生物安全性,对于推进活体微生物癌症疗法的临床转化至关重要。本研究构建了一种间充质干细胞(MSC)介导的沙门氏菌VNP20009肿瘤靶向递送系统(MSC-VNP),该系统显著提高了VNP的瘤内富集率和安全性。这一优势源于MSC的肿瘤归巢趋化性以及细胞内VNP的延迟释放。为改善治疗效果,我们构建了可持续分泌PD-1纳米抗体的工程化MSC(MSC-PD1nb),并将其与MSC-VNP联合用于黑色素瘤治疗。在小鼠黑色素瘤模型中,这种联合疗法通过增加抗肿瘤效应细胞(CD8+T效应细胞)并减少促肿瘤效应细胞(CD4+T调节细胞),提高了抗肿瘤疗效。这些数据表明,MSC介导的联合免疫疗法提供了一种有前景的抗肿瘤免疫策略,为扩大溶菌细菌在癌症治疗中的应用提供了前景。
Nature immunology IF 26.5 2026-11-13 PMID: 43026322
Dendritic cells (DCs) are central orchestrators of antitumor immunity, yet their therapeutic potential is constrained by dysfunction and inadequate activation within solid tumors. Here we report chimeric antigen receptor-engineered DCs (CAR-DCs) that prime T cells and reprogram the tumor microenvironment. We identify the intracellular domains of CLEC9A or LY75 (DEC205) as essential for functional CAR-DC activity, enabling enhanced antigen uptake and cross-presentation and driving T cell expansion and function. CARs incorporating the CLEC9A or DEC205 intracellular domains triggered SYK phosphorylation and downstream signaling. In both conventional and humanized mouse models, CAR-DC therapy suppressed tumor growth and promoted expansion of tumor-reactive T cells. These findings establish CAR-DCs as scalable and clinically translatable platforms for next-generation solid tumor immunotherapy.
中文摘要:树突状细胞是抗肿瘤免疫的核心调控者,但其治疗潜力受限于实体瘤中的功能障碍和激活不足。本研究报道了嵌合抗原受体工程化树突状细胞能够启动T细胞并重塑肿瘤微环境。我们鉴定出CLEC9A或LY75(DEC205)的胞内结构域对于功能性CAR-DC活性至关重要,可实现增强的抗原摄取和交叉呈递,并驱动T细胞的扩增和功能。包含CLEC9A或DEC205胞内结构域的嵌合抗原受体触发了SYK磷酸化及下游信号传导。在常规和小鼠模型中,CAR-DC疗法抑制了肿瘤生长并促进了肿瘤反应性T细胞的扩增。这些发现确立了CAR-DC作为下一代实体瘤免疫治疗的可扩展且具临床转化潜力的平台。
Cancer letters IF 11.8 2026-11-13 PMID: 43025794
T cell therapies with chimeric antigen receptor (CAR) T cells or T cell receptor (TCR) transgenic (tg) T cells are a promising approach in the treatment of solid malignancies but are limited by T cell exhaustion caused by chronic antigen stimulation. Clusterin (CLU) is a stress-associated molecular chaperone with cytoprotective functions in normal and malignant cells, but its role in therapeutic T cells is unclear. Here, we found that CLU expression is reduced in exhausted tumor-infiltrating lymphocytes and decreases after prolonged stimulation of Ewing sarcoma (EwS)-directed TCR-transgenic T cells and GD2 CAR-T cells. To test whether reconstituting CLU affects T cell fitness, we engineered CHM1/HLA-A*02:01-directed ChoTCR-T cells and GD2 CAR-T cells to overexpress CLU. In ChoTCR-T cells, CLU overexpression reduced exhaustion- and apoptosis-associated features after repetitive tumor stimulation while preserving cytotoxicity. CLU-engineered ChoTCR-T cells showed improved infiltration of EwS spheroids, and moderately improved antitumor activity in a metastatic EwS model. Supportive experiments in a GD2/Nalm6 chronic-stimulation model indicated preserved CAR-T cell function after repetitive antigen exposure. Mechanistically, proteomics together with direct measurements of global translation and stress-response activation support a model in which CLU reduces proteostasis-linked translational stress during chronic stimulation. These findings identify CLU overexpression as a promising strategy to attenuate chronic-stimulation-associated dysfunction in tumor-directed T cells, as shown in two therapeutic T cell models of cancer in the young.
中文摘要:嵌合抗原受体(CAR)T细胞或T细胞受体(TCR)转基因(tg)T细胞的免疫疗法是治疗实体恶性肿瘤的有前景的方法,但受限于慢性抗原刺激导致的T细胞耗竭。Clusterin(CLU)是一种应激相关的分子伴侣,在正常和恶性细胞中具有细胞保护作用,但其在治疗性T细胞中的作用尚不明确。研究发现,耗竭的肿瘤浸润淋巴细胞中CLU表达降低,且在Ewing肉瘤(EwS)靶向TCR转基因T细胞和GD2 CAR-T细胞经过长期刺激后,其表达也下降。为了验证重建CLU是否影响T细胞适应性,我们构建了过表达CLU的CHM1/HLA-A*02:01靶向ChoTCR-T细胞和GD2 CAR-T细胞。在ChoTCR-T细胞中,CLU过表达在保留细胞毒性的同时,减少了重复肿瘤刺激后的耗竭和凋亡相关特征。工程化CLU的ChoTCR-T细胞在EwS类球体中显示出改善的浸润能力,并在转移性EwS模型中表现出适度增强的抗肿瘤活性。在GD2/Nalm6慢性刺激模型中的支持性实验表明,重复抗原暴露后CAR-T细胞的功能得以保留。机制上,蛋白质组学结合对全局翻译和应激反应激活的直接测量支持一种模型,即CLU通过减少慢性刺激期间的蛋白稳态相关翻译压力发挥作用。这些发现确定CLU过表达是减轻肿瘤靶向T细胞中慢性刺激相关功能障碍的有前景的策略,这一结论在两种年轻患者癌症的治疗性T细胞模型中得到了证实。
Cancer letters IF 11.8 2026-11-13 PMID: 43025792
Aromatase inhibitors (AIs) have transformed the treatment of hormone receptor-positive breast cancer by suppressing estrogen biosynthesis. However, aromatase and estrogen signaling have also been implicated in several malignancies traditionally classified as non-hormone-dependent, where their effects on tumor progression, metabolism, and antitumor immunity appear to depend on tumor type, receptor context, and the tumor microenvironment. This emerging evidence has generated increasing interest in repurposing AIs beyond their conventional endocrine indications. In this review, we summarize the molecular mechanisms linking aromatase and estrogen signaling to oncogenic pathways, tumor metabolism, and modulation of the tumor microenvironment in non-hormone-dependent malignancies. We further discuss preclinical studies demonstrating that AIs not only inhibit intratumoral estrogen production but also enhance the efficacy of chemotherapy and immune checkpoint inhibitors by suppressing pro-survival signaling, reducing PD-L1 expression, reshaping lipid metabolism, and restoring antitumor immune responses. Finally, we critically examine the currently available clinical studies, highlighting both the encouraging biological rationale and the limitations of existing early-phase trials. Overall, aromatase can be considered a broad regulator of cancer biology. Addressing three major challenges - accurate patient stratification, precise identification of predictive biomarkers and design of prospective clinical trials -will be essential to realize the translational potential of AIs and determine whether they can enhance current anticancer treatments.
中文摘要:芳香酶抑制剂通过抑制雌激素生物合成,改变了激素受体阳性乳腺癌的治疗格局。然而,芳香酶和雌激素信号传导也被认为与传统上归类为非激素依赖性恶性肿瘤的多种癌症有关,其对肿瘤进展、代谢和抗肿瘤免疫的影响似乎取决于肿瘤类型、受体背景和肿瘤微环境。这些新出现的证据引发了人们将芳香酶抑制剂重新应用于其传统内分泌适应症之外的兴趣。本综述总结了将芳香酶和雌激素信号传导与非激素依赖性恶性肿瘤中的致癌通路、肿瘤代谢及肿瘤微环境调节联系起来的分子机制。我们进一步讨论了临床前研究,表明芳香酶抑制剂不仅抑制瘤内雌激素的产生,还通过抑制促生存信号、降低PD-L1表达、重塑脂质代谢和恢复抗肿瘤免疫反应来增强化疗和免疫检查点抑制剂的疗效。最后,我们批判性地审查了目前可用的临床研究,强调了令人鼓舞的生物学原理以及现有早期试验的局限性。总体而言,芳香酶可被视为癌症生物学的广泛调节因子。解决三个主要挑战——准确的患者的分层、预测性生物标志物的精确识别以及前瞻性临床试验的设计——对于实现芳香酶抑制剂的转化潜力并确定其是否能增强当前的抗癌治疗至关重要。
Gastroenterology IF 29.7 2026-11-13 PMID: 43025768
Pancreatic ductal adenocarcinoma (PDAC) exhibits a highly complex tumor microenvironment enriched with both inflammatory and immunosuppressive factors. Interleukin-18 (IL-18), a cytokine of the IL-1 family, is elevated in PDAC and correlates with poor patient outcomes. However, the functional role of IL-18 in PDAC progression and immune regulation remains poorly defined. We generated genetically engineered mouse models with IL-18 depletion in the context of spontaneous PDAC development. Single-cell RNA-sequencing and functional assays were used to analyze PDAC progression, macrophage phenotypes, and cancer cell-macrophage interactions. Mechanistic studies were performed to determine the effects of IL-18 on STAT1 signaling and CD47 expression. The role of IL-18 in therapeutic response was evaluated using KRAS inhibitor (KRASi) treatment models. Elevated IL-18 expression correlated with poor patient survival. Genetic depletion of IL-18 significantly suppressed spontaneous PDAC progression and prolonged survival in mice. Mechanistically, IL-18 promoted cancer cell survival by activating STAT1-dependent CD47 expression, thereby impairing macrophage-mediated phagocytosis of cancer cells. In addition, IL-18 depletion reshaped the tumor immune microenvironment by enriching macrophage populations with enhanced antigen-presenting and phagocytic phenotypes characterized by increased MHCII and CD11c expression. Notably, KRAS inhibitor treatment further increased IL-18 expression in PDAC cells, whereas IL-18 depletion enhanced macrophage-mediated clearance of KRASi-treated cancer cells and improved therapeutic efficacy. IL-18 promotes pancreatic cancer progression by enabling cancer cell survival and immune evasion through macrophage reprogramming. Targeting IL-18 may represent a therapeutic strategy to enhance macrophage-mediated anti-tumor immunity and improve responses to KRAS inhibitor therapies in PDAC.
中文摘要:胰腺导管腺癌具有高度复杂的肿瘤微环境,富含炎症和免疫抑制因子。白细胞介素18是IL-1家族细胞因子,在胰腺导管腺癌中升高并与患者不良预后相关,但其在疾病进展和免疫调节中的功能作用尚不明确。本研究构建了自发胰腺导管腺癌发生背景下内源性IL-18缺失的基因工程小鼠模型,利用单细胞RNA测序和功能实验分析肿瘤进展、巨噬细胞表型及癌细胞与巨噬细胞的相互作用,并通过机制研究确定IL-18对STAT1信号通路和CD47表达的影响。通过KRAS抑制剂治疗模型评估了IL-18在治疗效果中的作用。结果显示IL-18高表达与患者生存期缩短相关。基因敲除IL-18显著抑制小鼠自发胰腺导管腺癌进展并延长生存期。机制上,IL-18通过激活STAT1依赖性CD47表达促进癌细胞存活,从而损害巨噬细胞介导的癌细胞吞噬作用。此外,IL-18缺失通过富集具有增强抗原呈递和吞噬表型的巨噬细胞群重塑肿瘤免疫微环境,其特征为MHCII和CD11c表达增加。KRAS抑制剂治疗进一步增加了胰腺导管腺癌细胞中的IL-18表达,而IL-18缺失增强了巨噬细胞清除经KRAS抑制剂处理的癌细胞的能力并提高了治疗效果。IL-18通过促进癌细胞存活和免疫逃逸以及巨噬细胞重编程促进胰腺癌进展。靶向IL-18可能代表一种增强巨噬细胞介导的抗肿瘤免疫和改善胰腺导管腺癌对KRAS抑制剂治疗反应的策略。
Science advances IF 13.9 2026-11-13 PMID: 43024723
PRGN-3008 is a CD19 CAR T cell designed to overcome key limitations in ex vivo and in vivo CAR T manufacturing, cost, safety, and therapeutic durability. Featuring decentralized overnight manufacturing without ex vivo expansion, PRGN-3008 is engineered using a single nonviral transposon to encode CD19 CAR, membrane-bound interleukin-15 (mbIL-15) for improved persistence, PD-1-targeting microRNAs to prevent exhaustion, and an inducible safety switch for controlled in vivo elimination. Safety studies showed low vector copy numbers, favorable integration profile, and efficient CAR T ablation upon safety-switch activation. The combined mbIL-15 expression and PD-1 down-regulation preserved PRGN-3008 polyfunctionality and sustained cytotoxicity across repeated tumor challenges, outperforming nonarmored or singly modified CAR T cells. In xenograft models, overnight-manufactured PRGN-3008 without ex vivo expansion and activation achieved durable tumor clearance, prolonged tumor-free survival, robust antigen dependent expansion, and enrichment of memory T cell phenotypes linked to clinical durability. Notably, PRGN-3008 generated from heavily pretreated patients with systemic lupus erythematosus or lupus nephritis, maintained effector function, resisted terminal differentiation under chronic antigen exposure, and effectively depleted autoreactive B cells in a humanized mouse model. Transcriptomic analysis revealed that the combination of mbIL-15 expression and PD-1 down-regulation enhances the expression of genes associated with bioenergetic pathways, including oxidative phosphorylation, mitochondrial biogenesis, glycolysis, and glutamine utilization, thereby supporting resistance to exhaustion and sustained effector function. Collectively, these data support PRGN-3008 as a clinically translatable, scalable, and controllable CAR T with the potential to expand access to cell therapy across oncology and autoimmune indications.
中文摘要:PRGN-3008是一种CD19 CAR T细胞,旨在克服体外和体内CAR T制造、成本、安全性和治疗持久性方面的关键限制。该细胞采用去中心化过夜制造且无需体外扩增,利用单一非病毒转座子编码CD19 CAR、膜结合白细胞介素-15(mbIL-15)以增强持久性、靶向PD-1的微RNA以防止耗竭,以及诱导型安全开关以实现体内可控清除。安全性研究表明其具有低载体拷贝数、有利的整合谱系,并在安全开关激活时能高效清除CAR T细胞。mbIL-15表达与PD-1下调的组合保留了PRGN-3008的多功能性,并在反复肿瘤挑战中维持细胞毒性,优于非装甲或单修饰的CAR T细胞。在异种移植模型中,未经体外扩增和激活的过夜制造PRGN-3008实现了持久的肿瘤清除、延长的无瘤生存期、强大的抗原依赖性扩增以及与临床持久性相关的记忆T细胞表型富集。值得注意的是,来自系统性红斑狼疮或狼疮肾炎重度预处理患者的PRGN-3008在慢性抗原暴露下维持了效应功能并抵抗终末分化,在人源化小鼠模型中有效耗竭了自身反应性B细胞。转录组分析显示,mbIL-15表达与PD-1下调的组合增强了生物能量通路相关基因的表达,包括氧化磷酸化、线粒体生物发生、糖酵解和谷氨酰氨利用,从而支持抗耗竭能力和持续的效应功能。综上所述,这些数据支持PRGN-3008作为一种临床可转化、可扩展且可控的CAR T细胞,有望扩大细胞疗法在肿瘤学和自身免疫性疾病适应症中的可及性。
Science advances IF 13.9 2026-11-13 PMID: 43024708
Precision oncology still faces low clinical translation rates. This is largely because two-dimensional (2D) culture systems cannot reproduce tumor heterogeneity and microenvironmental stress. Here, we review the applications of 3D cancer models, including scaffold-free spheroids, patient-derived organoids (PDOs) biobanks, and microphysiological systems (MPSs), in drug resistance modeling and personalized therapy. These platforms effectively model metabolic gradients, lineage plasticity, and immunological features within the tumor microenvironment (TME), thereby bridging the genotype-phenotype gap. They also capture physical immune exclusion, T cell exhaustion, and antigen presentation to facilitate the evaluation of immunotherapies. Last, we discuss key translational bottlenecks such as standardization and throughput, proposing the integration of advanced biomanufacturing, artificial intelligence (AI)-driven phenomics, and computational modeling to develop 3D cancer platforms into clinical predictive systems for optimizing precision treatment strategies.
中文摘要:精准肿瘤学仍面临较低的临床转化率,这主要归因于二维培养系统无法重现肿瘤异质性和微环境应激。本文综述了三维癌症模型在耐药建模和个性化治疗中的应用,包括无支架球体、患者来源类器官生物库以及微生理系统。这些平台能有效模拟肿瘤微环境中的代谢梯度、谱系可塑性和免疫特征,从而弥合基因型与表型之间的差距。它们还能捕捉物理性免疫排斥、T细胞耗竭及抗原呈递现象,以辅助评估免疫疗法。最后,我们讨论了标准化和通量等关键转化瓶颈,并提出整合先进生物制造、人工智能驱动的表型组学及计算建模,将三维癌症平台发展为临床预测系统,以优化精准治疗策略。
Seminars in immunopathology IF 11.5 2026-11-13 PMID: 43024081
The persistent global burden of infectious diseases, compounded by environmental challenges, emerging pathogens, and antimicrobial resistance, underscores the urgent need for novel therapeutic strategies beyond conventional antimicrobial agents. Cell based immunotherapies, which harness the body's immune system to combat pathogens, have gained increasing attention for their potential to provide targeted, durable, and adaptive responses. Recently, we demonstrated that clinically licensed cytokine-induced killer (CIK) cells, used in cancer treatment, significantly reduced Plasmodium-infected erythrocytes in vitro. This review focuses on the emerging role of CIK cells in infectious disease therapy, positioning them alongside other prominent immune effector cells such as CTLs, γδT cells, and NK cells. We explore the biology, recognition mechanisms, their potential feature, and cytotoxic functions of these cell populations, distinguishing direct findings in infection-specific CIK studies from mechanisms characterized in oncology or other cytotoxic lymphocytes. While CTLs, γδT cells, and NK cells have been extensively studied for their roles in early and adaptive immune responses, CIK cells traditionally investigated in oncology, are now being recognized for their potential in antiviral and antimicrobial immunity. Alongside with CTLs, γδT cells, and NK cells, we detail CIK cell phenotypes, activation strategies, effector functions, and the limited but growing body of evidence supporting their application in some viral infections. The available findings support further investigation of CIK cells as a candidate approach in selected infectious settings, while their broader antimicrobial applicability, comparative efficacy, target specificity, safety, and clinical benefit require further evaluation in these settings.
中文摘要:全球传染病负担持续加重,叠加环境挑战、新发病原体及抗菌药物耐药性等因素,凸显了开发超越传统抗菌药物的新型治疗策略的紧迫性。利用人体免疫系统对抗病原体的细胞免疫疗法因其能提供靶向、持久且适应性反应而备受关注。近期我们证明临床获批用于癌症治疗的细胞因子诱导的杀伤(CIK)细胞在体外显著降低了疟原虫感染的红细胞数量。本综述聚焦于CIK细胞在传染病治疗中的新兴作用,将其与细胞毒性T淋巴细胞(CTL)、γδT细胞和自然杀伤(NK)细胞等其他主要免疫效应细胞并列探讨。我们深入分析了这些细胞群落的生物学特性、识别机制、潜在特征及细胞毒功能,区分了感染特异性CIK研究中的直接发现与在肿瘤学或其他细胞毒性淋巴细胞中表征的机制。尽管CTL、γδT细胞和NK细胞在早期和适应性免疫反应中的作用已得到广泛研究,但传统上在肿瘤学中研究的CIK细胞正逐渐被认可其在抗病毒和抗菌免疫中的潜力。结合CTL、γδT细胞和NK细胞,我们详细阐述了CIK细胞的表型、激活策略、效应功能以及支持其在部分病毒感染中应用的有限但日益增长的研究证据。现有发现支持将CIK细胞作为特定感染环境下的候选疗法进行进一步研究,但其更广泛的抗菌适用性、比较疗效、靶点特异性、安全性及临床获益仍需在这些环境中进一步评估。
Neuro-oncology IF 13.1 2026-11-13 PMID: 43023427
Atypical teratoid/rhabdoid tumors (ATRTs) are the most common malignant CNS tumor in infants, and patients suffer from low survival rates and treatment-related morbidities. These tumors frequently overexpress the pan-cancer antigen B7-H3 (CD276), which can be targeted with immunotherapy. We hypothesized that adding a B7-H3-targeting cytotoxic chimeric antigen receptor (CAR) to NK cells can enhance killing against ATRTs. We designed a library of variable affinity B7-H3-targeted CARs, which were transduced into primary healthy donor-derived NK cells. We verified B7-H3 expression in a panel of ATRT cell lines and further engineered luciferase and nuclear GFP-expressing ATRT (CHLA-04, CHLA-06, BT12, BT37) as well as a CHLA-06-derived B7-H3 knockout. We tested CAR-NK cell functionality using in vitro co-culture cytotoxicity assays. We delivered anti-B7-H3 CAR-NK cells intratumorally or intracerebroventricularly (ICV) to ATRT orthotopic xenografts and monitored for tumor growth and animal survival. B7-H3-targeted CAR-NK cells demonstrated target-specific cytotoxicity when compared to unmodified NK cells. Knockout of B7-H3 in target cells abolished the increased CAR-mediated target killing. When delivered intratumorally to CHLA-06 orthotopic xenograft-bearing mice, anti-B7-H3 CAR-NK cells eliminated tumor cells and prolonged survival. When CAR-NK cells were delivered ICV against a CNS disseminated tumor model of BT12, treated mice had significantly improved survival. Anti-B7-H3 CAR-NK cells effectively kill ATRTs in multiple pre-clinical in vitro and in vivo models in an antigen-specific manner. Evidence of efficacy in translationally relevant models provides support for using B7-H3-targeting CAR-NK cells in high-risk ATRT patients.
中文摘要:非典型畸胎样/横纹肌样瘤(ATRT)是婴儿中最常见的中枢神经系统恶性肿瘤,患者面临低生存率及治疗相关并发症。这些肿瘤常过表达泛癌抗原B7-H3(CD276),可作为免疫治疗靶点。我们假设将靶向B7-H3的细胞毒性嵌合抗原受体(CAR)引入自然杀伤(NK)细胞可增强对ATRT的杀伤作用。我们设计了可变亲和力的B7-H3靶向CAR库,并将其转导至健康供体来源的原代NK细胞中。我们在一系列ATRT细胞系中验证了B7-H3的表达,并进一步构建了表达荧光素酶和核绿色荧光蛋白(GFP)的ATRT细胞株(CHLA-04、CHLA-06、BT12、BT37)以及源自CHLA-06的B7-H3敲除株。通过体外共培养细胞毒性实验检测了CAR-NK细胞的功能。我们将抗B7-H3 CAR-NK细胞瘤内或脑室内(ICV)注射至ATRT原位异种移植模型中,监测肿瘤生长及动物生存情况。与未修饰的NK细胞相比,靶向B7-H3的CAR-NK细胞显示出靶点特异性的细胞毒性。靶细胞中B7-H3的敲除消除了CAR介导的杀伤增强效应。在CHLA-06原位异种移植小鼠模型中瘤内注射抗B7-H3 CAR-NK细胞可清除肿瘤细胞并延长生存期。在BT12中枢神经系统播散性肿瘤模型中脑室内注射CAR-NK细胞显著改善了治疗小鼠的生存率。抗B7-H3 CAR-NK细胞以抗原特异性方式在多种临床前体外和体内模型中有效杀伤ATRT。在转化相关模型中证实的有效性支持将B7-H3靶向CAR-NK细胞用于高危ATRT患者。
Signal transduction and targeted therapy IF 81.2 2026-11-13 PMID: 43020777
Cancer immunotherapy has transformed the treatment of multiple malignancies, yet primary and acquired resistance remain major barriers to attaining durable clinical benefit. Increasing evidence indicates that immunotherapy failure rarely results from a single mechanism but instead emerges from dynamic interactions within the tumor microenvironment (TME). Recent advances in single-cell, spatial multiomics, and longitudinal profiling have revealed the complex organization of TME-mediated resistance, which can be conceptualized within three interconnected suppressive modules: the tumor-cell-intrinsic module, myeloid-suppressive networks, and stromal barriers. The relative dominance of these modules varies across spatial niches, metastatic sites, disease stages, and treatment phases, leading to profound spatiotemporal heterogeneity and dynamic reorganization of dominant resistance axes. In this Review, we propose a spatiotemporal and systems-level framework for understanding TME-mediated immunotherapy resistance. We discuss how the tumor-cell-intrinsic module contributes to immune escape, how myeloid-suppressive networks and stromal barriers sustain and amplify immunosuppression, and how reciprocal crosstalk among these modules generates feed-forward loops that stabilize resistant states. We also review clinical strategies for remodeling the TME to increase the efficacy of immunotherapeutic approaches. Additionally, we discuss the opportunities and challenges associated with TME remodeling, including safety considerations, emerging biomarkers, and rational combination strategies. We propose that future TME-targeted therapies should transition from component-oriented interventions to dynamic and mechanism-matched strategies guided by dominant resistance axes. This approach aims to facilitate the development of more precise and durable cancer immunotherapies.
中文摘要:癌症免疫疗法已改变了多种恶性肿瘤的治疗方式,但原发性和获得性耐药仍是实现持久临床获益的主要障碍。越来越多的证据表明,免疫治疗失败很少由单一机制引起,而是源于肿瘤微环境中的动态相互作用。单细胞、空间多组学和纵向谱系分析的最新进展揭示了肿瘤微环境介导的耐药性的复杂组织结构,可将其概念化为三个相互关联的抑制模块:肿瘤细胞内在模块、髓系抑制网络和基质屏障。这些模块的相对主导地位在不同空间生态位、转移部位、疾病阶段和治疗阶段各不相同,导致主导耐药轴的空间和时间异质性及其动态重组。在本综述中,我们提出了一个时空和系统水平的框架来理解肿瘤微环境介导的免疫治疗耐药性。我们讨论了肿瘤细胞内在模块如何促进免疫逃逸,髓系抑制网络和基质屏障如何维持并放大免疫抑制,以及这些模块之间的相互串扰如何产生稳定耐药状态的反馈回路。我们还回顾了重塑肿瘤微环境以提高免疫治疗方法疗效的临床策略。此外,我们讨论了与肿瘤微环境重塑相关的机遇和挑战,包括安全性考量、新兴生物标志物和合理的联合治疗策略。我们提出,未来的肿瘤微环境靶向治疗应从基于成分的干预措施转向由主导耐药轴指导的动态和机制匹配策略。该方法旨在促进更精准和持久的癌症免疫疗法的发展。

2消化系统肿瘤 (27篇)

临床研究 (6篇)

Endoscopy IF 11.8 2026-11-19 PMID: 42843801
Underwater techniques are increasingly used in colorectal endoscopic submucosal dissection (ESD), but real-world data remain limited. We compared underwater and conventional colorectal ESD. This retrospective observational study included consecutive colorectal ESD lesions at a tertiary referral center between May 2010 and September 2024. The analysis used propensity score overlap weighting. Procedural outcomes included dissection speed, procedure time, resection outcomes, and adverse events. Intraoperative perforation and long-term outcomes were assessed descriptively. Among 1649 lesions, 1635 were included in the main analysis (conventional 914, underwater 721). Dissection speed was faster in the underwater group (speed ratio 1.23, 95%CI 1.14 to 1.32; P < 0.001), whereas procedure time was similar. Failure to complete ESD was less frequent in the underwater group, with no clear differences in en bloc resection, R0 resection, or adverse events. Among 56 intraoperative perforation cases, all perforation sites were closed endoscopically, no emergency surgery was required, and short-term clinical outcomes showed no clear differences. Median (interquartile range) survival follow-up was 3.09 (0.48-7.39) and 2.10 (0.56-3.72) years in the conventional and underwater groups, respectively; overall death occurred in 27/824 (3.3%) and 3/622 (0.5%) patients, with no colorectal cancer-related deaths. The underwater technique was associated with faster dissection speed, although this did not translate into a shorter procedure time or clear improvements in other procedural outcomes. These findings suggest a potential technical advantage during dissection, while its clinical relevance remains to be established.
中文摘要:水下技术在结直肠内镜黏膜下剥离术(ESD)中的应用日益广泛,但真实世界数据仍然有限。本研究比较了水下与常规结直肠ESD的效果。这是一项回顾性观察研究,纳入了2010年5月至2024年9月期间在三级转诊中心接受连续结直肠ESD治疗的患者病变。分析采用倾向评分重叠加权法。手术结果包括剥离速度、操作时间、切除结果和不良事件。术中穿孔和长期结果进行了描述性评估。在1649个病变中,1635个被纳入主要分析(常规组914例,水下组721例)。水下组的剥离速度更快(速度比1.23,95%CI 1.14至1.32;P < 0.001),而操作时间相似。水下组ESD完成失败的情况较少,但在整块切除、R0切除或不良事件方面无明显差异。在56例术中穿孔病例中,所有穿孔部位均通过内镜闭合,无需急诊手术,短期临床结果未见明显差异。常规组和地下组的生存随访中位数(四分位距)分别为3.09(0.48-7.39)年和2.10(0.56-3.72)年;两组分别有27/824(3.3%)和3/622(0.5%)的患者死亡,无结直肠癌相关死亡。水下技术与更快的剥离速度相关,但这并未转化为更短的操作时间或其他手术结果的明显改善。这些发现表明其在剥离过程中具有潜在的技术优势,但其临床相关性仍有待确立。
Cancer letters IF 11.8 2026-11-18 PMID: 43051478
Hepatobiliary cancers include hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC). We aimed to assess incidence, mortality, survival, and premature mortality of hepatobiliary cancers by subtype in China and progress toward Sustainable Development Goal (SDG) target 3.4. We conducted a nationwide population-based study using data on hepatobiliary cancer cases from 919 cancer registries in China, covering 44.9% of the national population. We estimated incidence, mortality, and premature mortality for 2024 using subtype distributions of HCC, ICC, ECC, and GBC. We quantified 2010-2019 trends using average annual percent changes (AAPCs). Age-standardized 5-year relative survival was estimated using data from 281 registries. Linear trend projections were applied to assess whether current trajectories are sufficient to meet SDG target. In 2024, an estimated 387,600 hepatobiliary cancer cases and 329,500 deaths occurred in China. Age-standardized incidence, mortality, and premature mortality declined, whereas overall 5-year relative survival remained stable at 14.8%. HCC showed sustained declines in incidence, mortality, and premature mortality. ICC incidence increased by 2.4% annually, while ECC mortality and premature mortality rose by 1.6% and 2.8% per year, respectively. HCC was the only subtype with improved survival and was projected to meet the SDG 3.4 premature mortality target by 2030. The disease burden of hepatobiliary cancers remains high in China. Rising ICC and ECC burdens underscore the need to shift from a predominantly HCC-focused approach toward subtype-specific, risk-targeted interventions.
中文摘要:肝胆癌包括肝细胞癌(HCC)、肝内胆管癌(ICC)、肝外胆管癌(ECC)和胆囊癌(GBC)。本研究旨在评估中国不同亚型肝胆癌的发病率、死亡率、生存率及过早死亡率,并分析其向可持续发展目标(SDG)3.4指标迈进的进展。我们利用中国919个癌症登记处涵盖全国44.9%人口的数据,开展了全国性人群研究。基于HCC、ICC、ECC和GBC的亚型分布,估算了2024年的发病率、死亡率和过早死亡率。通过平均年百分比变化(AAPCs)量化了2010至2019年的趋势。利用281个登记处的数据估算了年龄标准化5年相对生存率。采用线性趋势预测评估当前轨迹是否足以实现SDG目标。2024年中国估计有387,600例肝胆癌病例和329,500例死亡。年龄标准化发病率、死亡率和过早死亡率均呈下降趋势,而总体5年相对生存率稳定在14.8%。HCC的发病率、死亡率和过早死亡率持续下降。ICC发病率每年增加2.4%,而ECC死亡率和过早死亡率分别每年上升1.6%和2.8%。HCC是唯一生存率改善的亚型,预计将在2030年前实现SDG 3.4过早死亡率目标。中国肝胆癌的疾病负担仍然很高。ICC和ECC负担的上升凸显了从以HCC为主的策略转向针对特定亚型和风险因素的干预措施的必要性。
Ophthalmology IF 10.9 2026-11-18 PMID: 43051324
We evaluated presentation and management of uveal melanoma in the National Cancer Database (NCDB) from 2004-2023 with multivariable logistic regression. Enucleations decreased and globe-sparing radiation increased. Significant socioeconomic and geographic variation in treatment persisted.
中文摘要:我们利用多变量逻辑回归评估了2004至2023年间美国国家癌症数据库(NCDB)中葡萄膜黑色素瘤的临床表现及治疗管理情况。结果显示,眼球摘除术的使用率下降,而保留眼球的放射治疗使用率上升。然而,治疗方面仍存在显著的社会经济差异和地理分布差异。
Journal of hazardous materials IF 10.6 2026-11-17 PMID: 43057012
Evidence linking post-operative air pollution to colorectal cancer (CRC) survival remains limited. This multi-center cohort study included 7068 patients undergoing radical resection for CRC at four hospitals in Chongqing, China. Over a median follow-up of 56 months, 1540 all-cause deaths occurred. Residential exposures to fine particulate matter (PM2.5), inhalable particulate matter (PM10), ozone (O3), nitrogen dioxide (NO2), sulfur dioxide (SO2), and carbon monoxide (CO) were obtained from CHAP, whereas PM2.5 constituents, including sulfate (SO42-), nitrate (NO3-), ammonium (NH4+), organic matter (OM), and black carbon (BC), were obtained from TAP. Time-varying Cox models assessed associations between 1-year lagged moving-average exposures and all-cause mortality. In fully adjusted models, each 5 μg/m3 increase in PM2.5 and PM10 was associated with higher mortality, with hazard ratios (HRs) of 1.079 (95% CI: 1.045-1.115) and 1.050 (95% CI: 1.027-1.074), respectively. These associations were generally consistent across two-pollutant and sensitivity analyses. The inverse association observed for O₃ warrants cautious interpretation. Among PM2.5 constituents, OM showed the most consistent positive association (HR per IQR increase: 1.088; 95% CI: 1.028-1.152) and remained significant in residual and remaining-mass models. These findings link particulate pollution to CRC survival and highlight the potential relevance of PM2.5 constituents, particularly OM.
中文摘要:关于术后空气污染与结直肠癌生存关系的证据仍然有限。这项多中心队列研究纳入了中国重庆四家医院接受根治性切除手术的7068名结直肠癌患者。在中位随访56个月期间,共发生1540例全因死亡。从CHAP获取住宅环境中细颗粒物PM2.5、可吸入颗粒物PM10、臭氧O3、二氧化氮NO2、二氧化硫SO2和一氧化碳CO的暴露数据,而从TAP获取PM2.5成分包括硫酸盐SO42-、硝酸盐NO3-、铵盐NH4+、有机质OM和黑碳BC的数据。采用时间依赖性Cox模型评估1年滞后移动平均暴露与全因死亡之间的关联。在完全调整后的模型中,PM2.5和PM10每增加5μg/m3均与较高的死亡率相关,风险比分别为1.079(95%CI:1.045-1.115)和1.050(95%CI:1.027-1.074)。这些关联在双污染物模型和敏感性分析中总体保持一致。观察到的O3的负向关联需谨慎解读。在PM2.5成分中,OM显示出最一致的阳性关联(每IQR增加的风险比:1.088;95%CI:1.028-1.152),并在残差和剩余质量模型中保持显著。这些发现将颗粒物污染与结直肠癌生存联系起来,并突出了PM2.5成分特别是OM的潜在相关性。
Pharmacological research IF 12.2 2026-11-13 PMID: 43025528
Carbonic anhydrase IX (CAIX) is an attractive target for radioligand theranostics because it is constitutively overexpressed in clear-cell renal cell carcinoma (ccRCC) and induced by hypoxia in several solid tumors. Existing CAIX-targeted radiotracers are constrained by delayed imaging kinetics, limited tumor retention, incomplete therapeutic-labeling compatibility, or insufficient tumor-to-background contrast. Here we report GL-261, a CAIX-targeted radioligand that appends a nitroimidazole bioreductive retention module to a CAIX-targeting pharmacophore within a DOTA-chelated scaffold. This design enables paired radiolabeling with gallium-68 for PET imaging and lutetium-177 for radioligand therapy. Nitroimidazole conjugation conferred hypoxia-dependent cellular accumulation, greater internalization (64.6% versus 45.2%), and higher CAIX-dependent tumor uptake than the comparator DPI-4452 without compromising target specificity. In xenograft models spanning different CAIX expression levels, [68Ga]Ga-GL-261 PET stratified tumors by CAIX status and was suppressed by receptor blocking. [177Lu]Lu-GL-261 showed sustained tumor retention over 168 h and, at 37 MBq, produced marked tumor growth suppression without overt hematological or organ toxicity. In a first-in-human PET/CT study of 15 patients, [68Ga]Ga-GL-261 showed reproducible biodistribution, an effective dose of 8.45 × 10-2 mSv/MBq, and lesion uptake that correlated with CAIX immunohistochemical expression (r = 0.93, P = 0.007 at 60 min). These findings support hypoxia-responsive modification as a design strategy for CAIX-targeted radioligands and provide a translational basis for GL-261 in CAIX-expressing cancers. TRIAL REGISTRATION: Chinese Clinical Trail (registration No. ChiCTR2600127500).
中文摘要:碳酸酐酶IX(CAIX)是放射配体诊疗的诱人靶点,因其在透明细胞肾细胞癌(ccRCC)中组成性过表达并在多种实体瘤中受缺氧诱导。现有CAIX靶向放射性示踪剂受限于成像动力学延迟、肿瘤滞留有限、治疗标记兼容性不足或肿瘤与背景对比度不足。本研究报道了GL-261,这是一种CAIX靶向放射配体,在DOTA螯合支架的CAIX靶向药效团上连接了硝基咪唑生物还原滞留模块。该设计实现了用镓-68进行PET成像和用镥-177进行放射配体治疗的配对放射性标记。硝基咪唑结合赋予了缺氧依赖性细胞积累、更高的内吞率(64.6%对比45.2%)以及比对照物DPI-4452更高的CAIX依赖性肿瘤摄取,且不损害靶点特异性。在不同CAIX表达水平的异种移植模型中,[68Ga]Ga-GL-261 PET根据CAIX状态对肿瘤进行分层,并可通过受体阻断被抑制。[177Lu]Lu-GL-261在168小时内显示出持续的肿瘤滞留,在37 MBq剂量下产生显著的肿瘤生长抑制,且无明显血液学或器官毒性。在一项包含15名患者的首次人体PET/CT研究中,[68Ga]Ga-GL-261显示出可重复的生物分布、有效剂量为8.45×10-2 mSv/MBq,病灶摄取与CAIX免疫组化表达相关(r=0.93,P=0.007 at 60 min)。这些发现支持缺氧响应性修饰作为CAIX靶向放射配体的设计策略,并为GL-261在CAIX表达癌症中的转化提供基础。临床试验注册号:ChiCTR2600127500。
Cancer cell IF 56.1 2026-11-13 PMID: 43025422
Fusobacterium nucleatum has been linked to chemoresistance and immune evasion in colorectal cancer (CRC), but therapeutic strategies targeting this bacterium remain limited. In this multicenter, single-arm, phase 2 trial (NCT06356597), 33 patients with Fusobacterium nucleatum-positive, microsatellite-stable metastatic CRC received the combination treatment of tislelizumab, fruquintinib, and the antimicrobial metronidazole. The primary endpoint was met, with a median progression-free survival of 6.0 months. The objective response rate and disease control rate were 19.4% and 83.9%, respectively. Grade 3 treatment-related adverse events occurred in 30.3% of patients, with no grade 4 or 5 events. Metagenomic analysis showed that metronidazole reduced Fusobacterium nucleatum abundance. Exploratory analyses associated clinical benefit with enrichment of Lactobacillus species and nonresponse with Enterococcus. Fecal microbiota transplantation from responders sensitized germ-free mice to the treatment, which enhanced cytotoxic CD8+ T cell differentiation and reduced terminal exhaustion. These findings support further evaluation of this combination in Fusobacterium nucleatum-positive metastatic CRC.
中文摘要:具核梭杆菌与结直肠癌中的化疗耐药和免疫逃逸有关,但针对该细菌的治疗策略仍然有限。在这项多中心、单臂、II期临床试验(NCT06356597)中,33名具核梭杆菌阳性、微卫星稳定的转移性结直肠癌患者接受了替雷利珠单抗、呋喹替尼和抗菌药物甲硝唑的联合治疗。主要终点已达成,中位无进展生存期为6.0个月。客观缓解率和疾病控制率分别为19.4%和83.9%。30.3%的患者出现3级治疗相关不良事件,无4级或5级事件。宏基因组分析显示甲硝唑降低了具核梭杆菌的丰度。探索性分析表明临床获益与乳杆菌属的富集有关,而无响应与肠球菌有关。来自响应者的粪便微生物移植使无菌小鼠对治疗敏感,增强了细胞毒性CD8+ T细胞的分化并减少了终末耗竭。这些发现支持在具核梭杆菌阳性转移性结直肠癌中进一步评估该联合疗法。

基础研究 (21篇)

Cancer letters IF 11.8 2026-11-19 PMID: 43057411
Pancreatic cancer (PC) commonly develops intrinsic or acquired resistance to gemcitabine (GEM), limiting clinical benefit. To uncover the underlying chromatin and transcriptional programs and identify actionable targets, we integrated ATAC-seq and RNA-seq in a GEM-resistant AsPC-1 subline (AsPC-1 GR) and parental cells. Although global chromatin accessibility decreased in AsPC-1 GR, a set of resistance-specific open regions (Peak_up) emerged. Integrating Peak_up with resistance-upregulated genes (DEG_up) identified 916 candidate resistance-associated genes, and motif analysis further narrowed the regulatory candidates to 23 core transcription factors, with EGR1 prioritized. EGR1 knockdown increased GEM sensitivity and reduced clonogenic growth, whereas EGR1 overexpression promoted survival and tumor growth and weakened GEM efficacy in xenografts. Mechanistically, EGR1 suppressed GEM-induced pyroptosis, with reduced LDH release and decreased IL-1β, consistent with inhibited caspase-1/GSDMD signaling. Multi-evidence integration identified 26 EGR1-linked resistance genes; TCGA survival analysis and validation highlighted SERPINB1 as a key downstream effector. SERPINB1 promoted GEM tolerance by restraining caspase-1 activation, GSDMD cleavage, and cytokine release, indicating inhibition of pyroptosis. Immunoprecipitation-mass spectrometry revealed EGR1 interaction with WDR5, and WDR5/SET1A positively regulated SERPINB1. ChIP-seq data mining and ChIP-qPCR showed co-enrichment of EGR1, WDR5, SET1A, and H3K4me3 at the SERPINB1 promoter, supporting an EGR1-driven epigenetic activation model. Therapeutically, IT25, an inhibitor of EGR1 DNA-binding activity, downregulated SERPINB1, restored GEM-induced caspase-1/GSDMD-mediated pyroptosis, and enhanced the antitumor efficacy of GEM in vivo. Collectively, these findings identify the EGR1-WDR5/SET1A-H3K4me3-SERPINB1 axis as a key driver of GEM resistance in PC and suggest that IT25-based combination therapy may improve GEM efficacy by reactivating pyroptosis.
中文摘要:胰腺癌常对吉西他滨产生固有或获得性耐药,限制了临床疗效。为揭示潜在的染色质与转录调控机制并识别可干预靶点,本研究在吉西他滨耐药的AsPC-1亚系及其亲本细胞中整合了ATAC-seq与RNA-seq数据。尽管AsPC-1耐药株整体染色质开放性降低,但出现了一组耐药特异性开放区域。结合这些区域与耐药上调基因鉴定出916个候选耐药相关基因,并通过基序分析将调控候选者缩小至23个核心转录因子,其中EGR1被优先确定。EGR1敲低增加了吉西他滨敏感性并减少克隆形成能力,而EGR1过表达则促进存活与肿瘤生长并削弱吉西他滨在异种移植模型中的疗效。机制上,EGR1抑制了吉西他滨诱导的细胞焦亡,表现为LDH释放减少及IL-1β降低,这与caspase-1/GSDMD信号抑制一致。多证据整合鉴定出26个与EGR1相关的耐药基因;TCGA生存分析及验证突显SERPINB1为关键下游效应分子。SERPINB1通过抑制caspase-1激活、GSDMD裂解及细胞因子释放来促进吉西他滨耐受,表明其抑制了细胞焦亡。免疫沉淀-质谱分析揭示EGR1与WDR5相互作用,且WDR5/SET1A正向调控SERPINB1。ChIP-seq数据挖掘与ChIP-qPCR显示EGR1、WDR5、SET1A及H3K4me3在SERPINB1启动子区域共富集,支持了EGR1驱动的表观遗传激活模型。治疗方面,EGR1 DNA结合活性抑制剂IT25下调了SERPINB1表达,恢复了吉西他滨诱导的caspase-1/GSDMD介导的细胞焦亡,并在体内增强了吉西他滨的抗肿瘤疗效。综上,本研究确定了EGR1-WDR5/SET1A-H3K4me3-SERPINB1轴是胰腺癌吉西他滨耐药的关键驱动因素,并提示基于IT25的联合疗法可能通过重新激活细胞焦亡来提高吉西他滨疗效。
Cancer research IF 22.6 2026-11-19 PMID: 43055344
Pancreatic ductal adenocarcinoma (PDAC) develops in a nutrient-poor microenvironment and progresses from pancreatic intraepithelial neoplasia (PanIN) to invasive carcinoma. Serine metabolism supports tumor growth in many cancers, spurring the development of inhibitors of phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in serine biosynthesis. However, the limited clinical success of PHGDH inhibitors highlights the need to better understand the stage-specific role of de novo serine synthesis during PDAC progression. Here, we showed that PHGDH increases progressively from PanIN to invasive PDAC in human and mouse tissues. In genetically engineered mouse models with inducible PHGDH knockdown, PHGDH loss delayed PDAC development. Acute treatment with the PHGDH inhibitor BI-9593 suppressed de novo serine synthesis, induced cell death, and drove tumor regression. Unexpectedly, PHGDH-deficient tumors did not become more dependent on exogenous serine, and dietary serine/glycine manipulation did not affect tumor development. Instead, stable isotope tracing and metabolomic profiling showed that PHGDH loss reduced ASCT2 expression and impaired glutamine uptake and utilization, creating a metabolic liability that rendered PHGDH-deficient tumors selectively sensitive to the glutamine antagonist DRP-104. Together, these findings reveal a therapeutic vulnerability to combined metabolic targeting in PDAC.
中文摘要:胰腺导管腺癌(PDAC)发生于营养匮乏的微环境中,并从胰腺上皮内瘤变(PanIN)进展为浸润性癌。丝氨酸代谢支持多种癌症的肿瘤生长,推动了作为丝氨酸生物合成限速酶的磷酸甘油脱氢酶(PHGDH)抑制剂的开发。然而,PHGDH抑制剂临床疗效有限,凸显了深入理解从头丝氨酸合成在PDAC进展中阶段特异性作用的需求。本研究显示,在人及小鼠组织中,PHGDH表达从PanIN到浸润性PDAC逐渐增加。在具有可诱导PHGDH敲低的基因工程小鼠模型中,PHGDH缺失延缓了PDAC的发生。急性使用PHGDH抑制剂BI-9593处理抑制了从头丝氨酸合成,诱导细胞死亡并驱动肿瘤消退。出乎意料的是,PHGDH缺陷型肿瘤并未变得更加依赖外源性丝氨酸,且饮食中的丝氨酸/甘氨酸操纵也未影响肿瘤发展。相反,稳定同位素示踪和代谢组学分析显示,PHGDH缺失降低了ASCT2表达,损害了谷氨酰胺的摄取和利用,从而产生了一种代谢弱点,使PHGDH缺陷型肿瘤对谷氨酰胺拮抗剂DRP-104选择性敏感。综上所述,这些发现揭示了PDAC中联合代谢靶向治疗的治疗脆弱性。
Nucleic acids research IF 15.0 2026-11-19 PMID: 43053333
MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression that exhibit tissue- and condition-associated expression patterns. Interpreting their abundance in disease or experimental contexts requires a physiological reference. DIANA-miTED v2 expands its uniformly processed and manually curated collection from 15 183 to 49 630 human small RNA-sequencing profiles spanning healthy tissues, cell lines, and disease states. To our knowledge, this is the largest such collection of human miRNA expression profiles assembled to date. It adds 16 746 Genotype-Tissue Expression V10 profiles and expands the Sequence Read Archive collection from 4142 to 21 843, alongside the existing The Cancer Genome Atlas collection. Expression is quantified for 2656 mature miRNAs, with harmonized metadata covering 96 tissues or organs, 437 cell lines, and 503 diseases. Healthy-donor coverage increases from 709 to 23 281, with 1471 tumour-adjacent-normal profiles classified separately. The database distinguishes primary tissues and biofluids from cultured and derived preparations. A redesigned tissue-centric interface provides a body-map picker, sublocation refinement, multi-miRNA and multi-tissue querying, cohort summaries, and descriptive longitudinal browsing. Co-expression capabilities include pairwise Spearman correlation and precomputed WGCNA modules, with 263 overview and 105 source/project-specific reference networks. Quantified counts, reads per million values, metadata, and query results are available through downloads and a REST API. DIANA-miTED v2 is freely available, without registration, at http://microrna.gr/mitedv2.
中文摘要:MicroRNAs(miRNA)是基因表达的转录后调节因子,表现出组织特异性和条件相关的表达模式。在疾病或实验背景下解读其丰度需要生理参考标准。DIANA-miTED v2将其统一处理且经过人工审核的集合从15183个扩展至49630个人类小RNA测序谱系,涵盖健康组织、细胞系和疾病状态。据我们所知,这是迄今为止组装的最大规模的人类miRNA表达谱集合。该版本新增了16746个Genotype-Tissue Expression V10谱系,并将Sequence Read Archive集合从4142个扩展至21843个,同时保留了现有的The Cancer Genome Atlas集合。对2656种成熟miRNA进行了定量分析,元数据经过协调,覆盖96种组织或器官、437种细胞系和503种疾病。健康供体覆盖率从709增加至23281,其中1471个肿瘤邻近正常谱系被单独分类。该数据库区分原发组织和生物流体与培养及衍生制备物。重新设计以组织为中心的界面提供了身体地图选择器、亚位置细化、多miRNA和多组织查询、队列摘要以及描述性纵向浏览功能。共表达功能包括成对Spearman相关性和预计算的WGCNA模块,拥有263个概览和105个源/项目特定的参考网络。定量计数、每百万读数、元数据和查询结果可通过下载和REST API获取。DIANA-miTED v2可免费使用,无需注册,访问地址为http://microrna.gr/mitedv2。
Nucleic acids research IF 15.0 2026-11-19 PMID: 43053329
The Tumor Immune Single Cell Hub (TISCH) is a curated resource for exploring single-cell RNA sequencing (scRNA-seq) data from the tumor microenvironment. Here, we present TISCH3, which expands the single-cell collection from 190 to 408 datasets and introduces 69 spatial transcriptomics datasets, bringing the total to 477 datasets. The 218 newly added scRNA-seq datasets span 48 cancer types, and the spatial collection spans 27 cancer types. Spatial samples are curated and processed individually, and single-cell references enable estimation of cell-type composition at each spot. The spatial workspace comprises six modules: Overview, GeneExp, spatially variable genes (SVGs), CellAssoc, Communication, and Downloads. These modules provide sample metadata and quality-control views, spatial gene expression maps, ranking of SVG, cell-type correlation and conditional intra-spot co-occurrence analyses, inferred cell-cell communication networks, and downloadable data and results. TISCH3 retains the single-cell analysis capabilities of TISCH2 and extends them to spatial exploration of the tumor microenvironment. The database is freely available without registration at https://tisch3.compbio.cn/.
中文摘要:肿瘤免疫单细胞库(TISCH)是用于探索肿瘤微环境单细胞RNA测序数据的经过筛选的资源。在此,我们推出TISCH3,将单细胞数据集从190个扩展至408个,并引入69个空间转录组数据集,总数达到477个。新添加的218个单细胞RNA测序数据集涵盖48种癌种,空间数据集涵盖27种癌种。空间样本经过单独筛选和处理,单细胞参考数据可用于估算每个位点的细胞类型组成。空间工作区包含六个模块:概览、基因表达、空间可变基因、细胞关联、通讯和下载。这些模块提供样本元数据和质量控制视图、空间基因表达图谱、空间可变基因排名、细胞类型相关性和条件性原位共现分析、推断的细胞间通讯网络以及可下载的数据和结果。TISCH3保留了TISCH2的单细胞分析能力,并将其扩展至肿瘤微环境的空间探索。该数据库无需注册即可免费访问,网址为https://tisch3.compbio.cn/。
Molecular cell IF 16.0 2026-11-19 PMID: 42869010
The current paradigm of N6-methyladenosine (m6A) homeostasis is implemented by a "writer/eraser/reader" system. Whether or not signaling pathways may regulate m6A homeostasis remains unclear. Here, we identify a negative feedback mechanism between m6A reader IGF2BPs and writer METTL3/METTL14 in human cell lines, which is orchestrated by poly(ADP-ribose) polymerase 1 (PARP1)-catalyzed ADP ribosylation. Specifically, IGF2BPs recruit PARP1 to m6A-modified RNAs and stimulate PARP1 activity; the m6A writer METTL3/14 is then ADP ribosylated, which impairs its RNA-binding capability and reduces m6A deposition. Based on the "read-orchestrate-write" mechanism, we combined PARP inhibitor (PARPi) therapy and m6A-targeting strategies (by inhibiting IGF2BP2 or METTL3) and observed synergistic anti-tumor effects. Taken together, this work expands our understanding of the regulatory paradigm of m6A methylation and provides an opportunity to exploit these findings for cancer therapy.
中文摘要:N6-甲基腺苷(m6A)稳态的当前范式由「写入器/擦除器/读取器」系统实现。信号通路是否调节m6A稳态仍不清楚。本研究在人细胞系中鉴定出m6A读取蛋白IGF2BPs与写入蛋白METTL3/METTL14之间的负反馈机制,该机制由聚(ADP-核糖)聚合酶1(PARP1)催化的ADP核糖基化所调控。具体而言,IGF2BPs招募PARP1至m6A修饰的RNA并刺激其活性;随后m6A写入蛋白METTL3/14发生ADP核糖基化,损害其RNA结合能力并减少m6A沉积。基于「读取-协调-写入」机制,我们联合使用PARP抑制剂(PARPi)治疗与m6A靶向策略(抑制IGF2BP2或METTL3),观察到协同抗肿瘤效应。综上所述,本研究拓展了对m6A甲基化调控范式的理解,并为将这些发现应用于癌症治疗提供了机会。
Cell stem cell IF 23.3 2026-11-18 PMID: 43051155
Chimeric antigen receptor (CAR) T cell therapies are limited by poor infiltration and immunosuppression in solid tumors. We developed induced pluripotent stem cell (iPSC)-derived CAR macrophages (CAR-iMac) targeting glypican-3 (GPC3) for hepatocellular carcinoma (HCC), incorporating ID3 endowment and TGFBR2 deletion. Single-cell RNA sequencing associated these modifications with enhanced inflammatory and phagocytic programs and reduced TGF-β responses. In orthotopic HCC preclinical models, magnetic particle imaging (MPI) of labeled CAR-iMac monitored in vivo distribution and persistence, together with histological phenotyping and transcriptional profiling, revealed dose-associated phenotypic state changes to guide dose optimization. The optimized regimen showed antitumor activity and preliminary safety in humanized mice. Additionally, CAR-iMac inhibited orthotopic patient-derived xenograft growth and cooperated with patient-matched T cells in patient-derived HCC organoids to enhance tumor killing and pro-inflammatory cytokine production. These findings supported a scalable macrophage platform integrating functional enhancement, longitudinal cell tracking, and rational dosing.
中文摘要:嵌合抗原受体(CAR)T细胞疗法在实体瘤中因浸润不足和免疫抑制而受限。我们开发了靶向糖蛋白3(GPC3)的诱导多能干细胞(iPSC)来源CAR巨噬细胞(CAR-iMac),用于治疗肝细胞癌(HCC),并整合了ID3赋予功能和TGFBR2缺失。单细胞RNA测序表明,这些修饰与增强的炎症和吞噬程序以及降低的TGF-β反应相关。在原位HCC临床前模型中,通过标记CAR-iMac的磁粒子成像(MPI)监测体内分布和持久性,结合组织学表型分析和转录谱分析,揭示了剂量相关的表型状态变化以指导剂量优化。优化后的方案在人源化小鼠中显示出抗肿瘤活性和初步安全性。此外,CAR-iMac抑制了原位患者来源异种移植物的生长,并在患者来源的HCC类器官中与患者匹配的T细胞协同作用,增强肿瘤杀伤和促炎细胞因子产生。这些发现支持了一种可扩展的巨噬细胞平台,整合了功能增强、纵向细胞追踪和合理给药。
ACS nano IF 17.3 2026-11-17 PMID: 43043203
Disruption of the dynamic equilibrium between ferroptotic execution pathways and cellular defense mechanisms can trigger ferroptosis, providing a compelling strategy for tumor suppression and the circumvention of drug resistance. Here, we engineered a Trojan Horse-inspired nanotrap, MIPGPX4@aMOF@CM, that integrates biomimetic recognition, redox-responsive amorphous MOF (aMOF) chemistry, and molecular imprinting to disrupt metal homeostasis and disable key protective pathways, thereby triggering cascade-amplified ferroptosis. The inner core is a molecularly imprinted polymer (MIP) that selectively recognizes GPX4, while the outer shell consists of a novel iron-based aMOF acting as a redox-activated molecular gate and is further cloaked with a cancer cell membrane. This multifunctional nanoplatform enables tumor-specific iron delivery and spatially controlled GPX4 inhibition. Upon homotypic membrane-mediated tumor targeting and cellular internalization, elevated intracellular glutathione (GSH) triggers aMOF degradation, leading to GSH depletion, iron release, and on-demand exposure of the imprinted GPX4 binding sites. This gate-controlled cascade synergistically promotes Fenton chemistry and GPX4 inactivation, substantially disrupting the balance between ferroptotic execution and antioxidant defenses and enhancing tumor-selective ferroptotic responses. Collectively, this work highlights that precisely orchestrating metal homeostasis, redox regulation, and GPX4 inhibition represents a promising strategy for precision ferroptosis-based cancer therapy.
中文摘要:破坏铁死亡执行通路与细胞防御机制之间的动态平衡可触发铁死亡,为肿瘤抑制及克服耐药性提供了极具吸引力的策略。本研究设计了一种受特洛伊木马启发的纳米陷阱MIPGPX4@aMOF@CM,该材料整合了仿生识别、氧化还原响应的无定形金属有机框架(aMOF)化学及分子印迹技术,旨在破坏金属稳态并抑制关键保护通路,从而触发级联放大的铁死亡。其内核为选择性识别谷胱甘肽过氧化物4(GPX4)的分子印迹聚合物(MIP),外壳则由新型铁基aMOF构成,作为氧化还原激活的分子闸门,外层进一步包覆癌细胞膜。这一多功能纳米平台实现了肿瘤特异性铁递送及空间可控的GPX4抑制。在通过同型膜介导实现肿瘤靶向及细胞内吞后,升高的细胞内谷胱甘肽(GSH)触发aMOF降解,导致GSH耗竭、铁释放以及印迹GPX4结合位点的按需暴露。这种受闸门控制的级联反应协同促进了芬顿反应与GPX4失活,显著破坏了铁死亡执行与抗氧化防御之间的平衡,并增强了肿瘤选择性铁死亡响应。综上所述,本研究强调精确调控金属稳态、氧化还原调节及GPX4抑制是精准铁死亡癌症治疗的一种极具前景的策略。
Clinical and molecular hepatology IF 21.7 2026-11-17 PMID: 43041058
Cholangiocarcinoma (CCA) is a highly aggressive malignancy, and chemoresistance is a major cause of poor prognosis. This study aimed to elucidate the molecular mechanisms driving CCA progression from a tumor microenvironment perspective and to develop novel strategies to enhance chemosensitivity. Single-cell RNA-seq, untargeted metabolomics, and proteomics were used to identify the source of lactate in the CCA microenvironment and the metabolic reprogramming of cancer-associated fibroblasts (CAFs). To evaluate the impact of CAF-derived lactate on prognosis, we performed AAV-mediated MCT4 knockdown followed by hydrodynamic injection to induce a CCA model. Co-culture models were combined with genome-wide CUT&Tag, MeRIP-seq, and RIP-seq to resolve epigenetic and post-transcriptional regulatory mechanisms. The antitumor effects of 7ACC1 (a small molecule reported to inhibit lactate uptake), alone or in combination with gemcitabine, were assessed in subcutaneous and orthotopic liver xenograft models. CAFs undergo glycolytic reprogramming, resulting in aberrant lactate accumulation. Mechanistically, CAF-derived lactate induces H4K12 lactylation (H4K12la) in CCA cells, which in turn activates the IGF2BP3/ATF3 axis to upregulate oxidative phosphorylation and promote tumor progression. The lactate shuttle inhibitor 7ACC1, combined with gemcitabine, exerts promising antitumor effects. Clinically, high levels of MCT4, α SMA, and H4K12la are associated with poor prognosis in patients with CCA. These findings reveal that CAFs drive CCA progression via lactate-induced H4K12la, which activates the IGF2BP3/ATF3 axis. The findings provide a preclinical rationale for further evaluation of lactate-uptake-targeting strategies in combination with gemcitabine for CCA.
中文摘要:胆管癌是一种高度侵袭性的恶性肿瘤,化疗耐药是导致预后不良的主要原因。本研究旨在从肿瘤微环境角度阐明驱动胆管癌进展的分子机制,并开发增强化疗敏感性的新策略。利用单细胞RNA测序、非靶向代谢组学和蛋白质组学技术,鉴定了胆管癌微环境中乳酸的来源以及癌症相关成纤维细胞的代谢重编程情况。为了评估癌症相关成纤维细胞来源的乳酸对预后的影响,我们进行了AAV介导的MCT4敲低并通过水动力注射诱导胆管癌模型。结合共培养模型与全基因组CUT&Tag、MeRIP-seq和RIP-seq技术,解析了表观遗传和转录后调控机制。在皮下和原位肝脏异种移植模型中评估了7ACC1(一种已知抑制乳酸摄取的小分子)单独或与吉西他滨联合使用的抗肿瘤效果。癌症相关成纤维细胞发生糖酵解重编程,导致乳酸异常积累。在机制上,癌症相关成纤维细胞来源的乳酸诱导胆管癌细胞中的H4K12乳酸化,进而激活IGF2BP3/ATF3轴以上调氧化磷酸化并促进肿瘤进展。乳酸穿梭抑制剂7ACC1联合吉西他滨显示出良好的抗肿瘤效果。临床数据显示,MCT4、αSMA和H4K12la的高水平表达与胆管癌患者的不良预后相关。这些发现揭示癌症相关成纤维细胞通过乳酸诱导的H4K12la驱动胆管癌进展,该过程激活了IGF2BP3/ATF3轴。研究结果为进一步评估靶向乳酸摄取策略联合吉西他滨治疗胆管癌提供了临床前依据。
Advanced healthcare materials IF 11.0 2026-11-16 PMID: 43041075
Cuproptosis, a novel form of programmed cell death induced by intracellular copper overload, provokes mitochondrial tricarboxylic acid (TCA) cycle collapse and metabolic dysfunction. This process can be potentiated by reactive oxygen species (ROS)-burst strategies, including chemodynamic therapy (CDT) and photothermal therapy (PTT). Given the pronounced reliance of aggressive prostate cancer (PCa) cells on TCA cycle energy metabolism, therapeutic approaches that sensitize malignancies to cuproptosis hold significant promise. This study develops a tumor-targeted nanolock (HA@CuHPT-IR780) by coordinating copper ions with a catechol ligand, incorporating the photosensitizer IR780, and functionalizing the surface with hyaluronic acid for enhanced tumor targeting. The nanolock remains stable in a "locked" state under normal physiological conditions but disassembles upon exposure to glutathione (GSH), concurrently depleting GSH while releasing 2,3,6,7,10,11-hexahydroxytriphenylene (HPT), Cu+, and IR780. Liberated HPT elevates intracellular hydrogen peroxide (H2O2) levels, and Cu+ converts H2O2 into cytotoxic hydroxyl radicals (•OH) via a Fenton-like reaction. Near-infrared (NIR) irradiation further amplifies ROS generation via a photothermal effect and disrupts mitochondrial metabolism to potentiate cuproptosis. In vitro and in vivo experiments confirm cuproptosis induction in PCa cells via synergistic chemodynamic-photothermal therapy with minimal systemic toxicity. Collectively, this work proposes a promising multimodal therapeutic regimen for advanced PCa.
中文摘要:铜死亡是由细胞内铜过载诱导的新型程序性细胞死亡,可引发线粒体三羧酸循环崩溃及代谢功能障碍。该过程可通过活性氧爆发策略如化学动力学疗法和光热疗法加以增强。鉴于侵袭性前列腺癌细胞对三羧酸循环能量代谢的高度依赖,能够 sensitizing 恶性肿瘤至铜死亡的疗法具有重要前景。本研究开发了一种肿瘤靶向纳米锁(HA@CuHPT-IR780),通过将铜离子与儿茶酚配体配位、掺入光敏剂 IR780 并用透明质酸功能化以实现增强肿瘤靶向性。该纳米锁在正常生理条件下保持锁定状态稳定,但在暴露于谷胱甘肽时会解离,同时消耗谷胱甘肽并释放 2,3,6,7,10,11-六羟基三联苯、Cu+ 和 IR780。释放的 HPT 提高细胞内过氧化氢水平,Cu+ 通过类芬顿反应将过氧化氢转化为细胞毒性羟基自由基。近红外照射进一步通过光热效应放大活性氧生成并破坏线粒体代谢以增强铜死亡。体外和体内实验证实了前列腺癌细胞中通过协同化学动力学-光热疗法诱导铜死亡且全身毒性最小。总体而言,这项工作提出了一种针对晚期前列腺癌的有前景的多模式治疗方案。
Cancer letters IF 11.8 2026-11-16 PMID: 43039101
Cancer cachexia is a multifactorial metabolic syndrome driven by advanced malignancies and is closely linked to poor treatment tolerance and unfavorable prognosis. The neural-tumor-immune crosstalk within the tumor microenvironment is increasingly recognized as a key determinant of cachexia progression. Here, we show that gastric cancer (GC) patients with chronic stress (CS) exhibit poor outcomes that are closely associated with advanced N stage, perineural invasion, and cachexia. In vivo, CS accelerates GC growth and induces cachectic phenotypes, including gastrocnemius loosening, myofiber atrophy, and epididymal white adipose atrophy with browning. Mechanistically, CS enhances neutrophil extracellular traps (NETs) formation and promotes sustained release of NETs-derived DNA, which drives both tumor progression and systemic metabolic wasting. NETs-DNA acts as a damage-associated molecular pattern (DAMP) that persistently activates the cGAS-STING/NLRP3 inflammasome signaling axis in macrophages in a time-dependent manner, leading to amplified inflammatory responses that promote myocyte atrophy and impair lipid droplet formation. In parallel, CS strengthens neuro-tumor communication; nociceptive neurons sustain NETs formation via a feedforward CGRP-NGF signaling loop, whereas gastric vagotomy attenuates CS-induced NETs formation and consequently suppresses both tumor progression and cachexia. Importantly, combined inhibition of the CGRP/RAMP1 axis and the cGAS-STING/NLRP3 pathway produces synergistic suppression of GC growth and cachectic phenotypes. Collectively, these findings identify a stress-neuro-immune circuit that drives GC progression and cachexia, and highlight the CGRP/RAMP1 and cGAS-STING/NLRP3 axes as potential therapeutic targets.
中文摘要:癌症恶病质是一种由晚期恶性肿瘤驱动的多因素代谢综合征,与耐受性差和不良预后密切相关。肿瘤微环境中的神经-肿瘤-免疫串扰日益被视为恶病质进展的关键决定因素。本研究显示,患有慢性应激的胃癌患者预后较差,这与N分期较晚、神经周围浸润和恶病质密切相关。在体内实验中,慢性应激加速了胃癌生长并诱导恶病质表型,包括腓肠肌松弛、肌纤维萎缩以及附睾白色脂肪组织褐变性萎缩。机制上,慢性应激增强了中性粒细胞胞外诱捕网(NETs)的形成并促进NETs来源DNA的持续释放,从而驱动肿瘤进展和全身代谢消耗。NETs-DNA作为损伤相关分子模式,以时间依赖性方式持续激活巨噬细胞中的cGAS-STING/NLRP3炎症小体信号轴,导致放大的炎症反应,进而促进肌细胞萎缩并损害脂滴形成。同时,慢性应激加强了神经-肿瘤通讯;伤害性神经元通过正向CGRP-NGF信号环路维持NETs形成,而胃迷走神经切断术可减弱慢性应激诱导的NETs形成,从而抑制肿瘤进展和恶病质。重要的是,联合抑制CGRP/RAMP1轴和cGAS-STING/NLRP3通路可协同抑制胃癌生长和恶病质表型。综上所述,这些发现确定了一个驱动胃癌进展和恶病质的应激-神经-免疫回路,并强调CGRP/RAMP1和cGAS-STING/NLRP3轴作为潜在的治疗靶点。
Cancer research IF 22.6 2026-11-16 PMID: 42579812
The Tn antigen, a truncated O-glycan, is frequently elevated in pancreatic ductal adenocarcinoma (PDAC). Multiple therapeutic approaches targeting Tn have been developed, but they have not demonstrated clear efficacy signals in early-phase clinical studies. Improving Tn-targeted strategies in PDAC will require both overcoming the immunosuppressive tumor microenvironment and defining pathways by which truncated O-glycans promote growth and immune evasion. In this study, we show that Tn reshapes the tumor immune landscape of PDAC. Expression of Tn antigen on PDAC cells enhanced proliferation in vitro and tumor growth in vivo. Tn expression remodeled the immune microenvironment, skewing tumor-associated macrophages toward M2-like phenotypes, reducing cross-presenting dendritic cells, and expanding myeloid-derived suppressor cells (MDSC). Single-cell RNA sequencing confirmed the expansion of MDSCs and downregulation of antigen processing and presentation in the immune cell infiltrate of Tn+ tumors. Tumor-intrinsic transcriptomic analyses revealed the activation of TNFα/NF-κB signaling and induction of IL34, a cytokine linked to monocyte survival and differentiation in Tn antigen-expressing tumors. Additionally, high Tn expression in both organoids derived from patients with pancreatic cancer and in PDAC mouse models was associated with increased IL34 expression. The genetic deletion of Il34 in PDAC cells attenuated Tn-driven tumorigenesis and reduced MDSC infiltration, whereas recombinant IL34 promoted myeloid cell differentiation and proliferation in vitro. Together, these findings establish a glyco-immune-cytokine axis in which truncated O-glycans contribute to IL34-mediated immunosuppression, providing mechanistic insights and potential therapeutic targets in PDAC. Altered glycosylation stimulates TNF-α/NF-κB signaling and induces IL-34-mediated accumulation of suppressive myeloid cells in pancreatic cancer, providing a myeloid-mediated mechanism of immunosuppression that could guide the development of therapies targeting glycosylation.
中文摘要:Tn抗原是一种截短的O-聚糖,在胰腺导管腺癌(PDAC)中常升高。尽管开发了多种靶向Tn的治疗策略,但在早期临床试验中尚未显示出明确的疗效信号。改善PDAC中针对Tn的策略需要克服免疫抑制性肿瘤微环境,并明确截短O-聚糖促进生长和免疫逃逸的通路。本研究表明,Tn重塑了PDAC的肿瘤免疫景观。在PDAC细胞上表达Tn抗原增强了体外增殖能力和体内肿瘤生长。Tn的表达改变了免疫微环境,使肿瘤相关巨噬细胞向M2样表型偏移,减少交叉提呈树突状细胞,并扩增髓系来源抑制细胞(MDSC)。单细胞RNA测序证实了Tn阳性肿瘤免疫细胞浸润中MDSC的扩增以及抗原加工和提呈的下调。肿瘤内在转录组学分析揭示了TNFα/NF-κB信号通路的激活以及在表达Tn抗原的肿瘤中诱导IL34,这是一种与单核细胞存活和分化相关的细胞因子。此外,在源自胰腺癌患者的类器官和PDAC小鼠模型中,高Tn表达均与IL34表达增加相关。PDAC细胞中Il34的基因敲除减弱了Tn驱动的肿瘤发生并减少了MDSC浸润,而重组IL34则在体外促进了髓系细胞的增殖和分化。综上所述,这些发现确立了一种糖免疫细胞因子轴,其中截短O-聚糖有助于IL34介导的免疫抑制,为PDAC提供了机制见解和潜在的治疗靶点。改变的糖基化刺激TNF-α/NF-κB信号通路并诱导IL-34介导的抑制性髓系细胞积累,在胰腺癌中提供了一种髓系介导的免疫抑制机制,可能指导针对糖基化的治疗开发。
Pharmacological research IF 12.2 2026-11-15 PMID: 43035199
Heterogeneity in tumor regulatory programs, cellular composition and spatial organization complicates target prioritization for natural compounds. We developed a spatial-context heterogeneous graph neural network ranker (SC-HGNN-Rank) that combines relation-aware graph representations with ranking optimization to integrate compound-target associations, transcriptional regulation, interaction networks, and single-cell and spatial information. The model ranked 600 candidate axes in colon adenocarcinoma (COAD), hepatocellular carcinoma (LIHC) and gastric adenocarcinoma (STAD). Under matched training conditions, mean Spearman correlations with the reference ranking were 0.965, 0.967 and 0.976 for leave-one-cancer-out, compound-group holdout and target-group holdout evaluations, respectively. The composite ranking objective improved mean Spearman correlation by 0.049 over a simple objective using the same encoder, whereas removing the spatial module reduced it by 0.147. Model ranking and multilayer evidence prioritized Quercetin-CDK1/MYB-Myeloid in COAD, 4',5-dihydroxyflavone (4',5-DHF)-AR/HDAC1-T/NK in LIHC, and Eriodyctiol-HSP90AB1/HOPX-Fibroblast in STAD. Expanded spatial analyses with expression-matched gene controls assessed associations between target expression and mapped cell abundance. Cellular thermal shift and drug affinity responsive target stability assays showed increased retention of target proteins after compound treatment. In HCT116, JHH-6 and MKN45 cells, the compounds reduced viability, colony formation, migration and invasion cell counts, and increased apoptosis. Target knockdown produced similar growth-inhibitory phenotypes, whereas overexpression attenuated compound-induced effects, supporting the involvement of CDK1, AR and HSP90AB1 in the respective responses. The accompanying Explorer supports candidate searches, evidence inspection and data export. By incorporating regulatory and spatial contexts into natural-compound prioritization, this study provides a reusable approach and experimentally supported candidates for target-directed pharmacological research in digestive system cancers.
中文摘要:肿瘤调控程序、细胞组成及空间组织的异质性使得天然化合物靶点的优先级排序变得复杂。我们开发了一种空间上下文异构图神经网络排名器(SC-HGNN-Rank),该模型结合关系感知图表示与排名优化,整合了化合物-靶点关联、转录调控、相互作用网络以及单细胞和空间信息。该模型对结肠腺癌(COAD)、肝细胞癌(LIHC)和胃腺癌(STAD)中的600个候选轴进行了排名。在匹配的训练条件下,留一癌种交叉验证、化合物组留出验证和靶点组留出验证的平均Spearman相关系数分别为0.965、0.967和0.976。与使用相同编码器的简单目标相比,复合排名目标使平均Spearman相关系数提高了0.049,而移除空间模块则使其降低了0.147。模型排名和多层次证据优先推荐了COAD中的槲皮素-CDK1/MYB-髓系细胞、LIHC中的4',5-二羟基黄酮(4',5-DHF)-AR/HDAC1-T/NK以及STAD中的Eriodyctiol-HSP90AB1/HOPX-成纤维细胞。通过表达匹配的基因对照进行的扩展空间分析评估了靶点表达与映射细胞丰度之间的关联。细胞热位移和药物亲和力响应靶点稳定性测定显示,化合物处理后靶蛋白的保留量增加。在HCT116、JHH-6和MKN45细胞中,这些化合物降低了细胞活力、集落形成、迁移和侵袭细胞数量,并增加了凋亡。靶点敲低产生了相似的生长抑制表型,而过表达则减弱了化合物诱导的效果,支持CDK1、AR和HSP90AB1在各自反应中的参与作用。配套的Explorer工具支持候选搜索、证据检查和数据导出。通过将调控和空间上下文纳入天然化合物的优先级排序,本研究为消化道肿瘤靶向药理学研究提供了一种可复用的方法和实验支持的候选物。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42497546
Achieving intrinsic physical correlation between independent transduction pathways remains a key challenge in multimodal biosensing. Herein, an electrochromism-gated paradigm that synchronously regulates photoacoustic (PA) and electrochemiluminescent (ECL) outputs within a bipolar electrode (BPE) architecture was designed for exosome analysis. This platform was constructed using a bifunctional cathode composed of silver nanoparticles decorated tungsten oxide nanosheets (Ag NPs@WO3 NSs). In this design, WO3 NSs act as the core electrochromic component whose voltage-induced reduction significantly enhances optical absorption, thereby generating a strong PA signal under laser excitation. Concurrently, the integrated Ag NPs leverage the same voltage stimulus to catalyze the hydrogen evolution reaction, thereby amplifying the anodic ECL emission of luminol as a complementary signal output. This shared voltage-modulating mechanism ensures the intrinsic synchronization of both the optical and acoustic signals. To validate this unique co-mediation concept and explore its sensing applicability, a target-initiated proximity hybridization coupled with rolling circle amplification was employed to introduce copper nanoclusters-tagged DNA probes. These probes trigger a cascade that converts conductive Ag NPs into poorly conductive AgBr, thus dismantling the electrochromic and catalytic functions of Ag NPs@WO3 NSs cathode. As anticipated, this domino cascade effect leads to the synchronous attenuation of both ECL and PA outputs, enabling quantitative detection of colorectal cancer-derived exosomes over a concentration range from 103 to 108 particles/mL with high specificity. By exploiting voltage-gated PA generation via electrochromism, this work pioneers a paradigm-shifting sensing strategy that surpasses conventional indirect coupling methods, providing a promising avenue for developing advanced multimodally integrated diagnostic systems.
中文摘要:在多模态生物传感中实现独立转导通路之间的内在物理关联仍是一个关键挑战。本研究设计了一种电致变色门控范式,用于外泌体分析,该范式在双极电极架构内同步调节光声(PA)和电化学发光(ECL)输出。该平台由装饰有银纳米颗粒的氧化钨纳米片(Ag NPs@WO3 NSs)组成的双功能阴极构建而成。在此设计中,WO3纳米片作为核心电致变色组件,其电压诱导的还原反应显著增强了光吸收,从而在激光激发下产生强烈的PA信号。同时,集成的银纳米颗粒利用相同的电压刺激催化析氢反应,从而放大鲁米诺的阳极ECL发射作为互补信号输出。这种共享的电压调制机制确保了光学和声学信号的内在同步性。为了验证这一独特的共同介导概念并探索其传感适用性,采用靶标启动的近端杂交结合滚环扩增来引入铜纳米团簇标记的DNA探针。这些探针触发级联反应,将导电的银纳米颗粒转化为导电性差的溴化银,从而破坏Ag NPs@WO3 NSs阴极的电致变色和催化功能。正如预期,这种多米诺骨牌式的级联效应导致ECL和PA输出的同步衰减,实现了结直肠癌来源外泌体在10^3至10^8 particles/mL浓度范围内的高特异性定量检测。通过利用电致变色产生的电压门控PA生成,这项工作开创了一种范式转变的传感策略,超越了传统的间接耦合方法,为开发先进的多模态集成诊断系统提供了有前景的途径。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42492327
Carcinoembryonic antigen (CEA) is widely used for tumor monitoring, yet electrical biosensor readouts are commonly based on endpoint or steady-state signals and therefore discard information contained in the early transient response. We developed a learning-assisted readout for an existing AlGaN/GaN high-electron-mobility transistor (HEMT) aptasensor by integrating transient drain-source current sequences with four steady-state I-V descriptors in a bidirectional long short-term memory-multilayer perceptron (LSTM-MLP) model. Bias-voltage comparison identified V_DS = 0.5 V as the preferred operating point on the basis of response amplitude, noise, and signal-to-noise ratio. Eighteen independent response curves spanning six experimentally tested CEA concentrations were evaluated by grouped three-fold cross-validation at the original-curve level, yielding R2 = 0.998, RMSE(log10) = 0.078, and MAE(log10) = 0.062. Curve-level low-concentration measurements analyzed with a fixed decision threshold and logistic detection-probability model produced a model-assisted C95 of 3.20 pg/mL (95% bootstrap confidence interval: 2.83-3.52 pg/mL). Sequence-length analysis showed that 120 s was the earliest interval meeting prespecified performance-retention criteria relative to the complete 1000 s record. In 1:10 diluted pooled human serum, baseline-corrected recoveries were 97.6%, 98.0%, and 95.0% at 5, 500, and 50,000 pg/mL, respectively; comparison with 1:20 serum further demonstrated dilution-dependent matrix effects. These findings show that transient-response learning can extract quantitative information not fully used by steady-state analysis, while broader device-batch and clinical validation remains necessary.
中文摘要:癌胚抗原广泛用于肿瘤监测,但电学生物传感器的读数通常基于终点或稳态信号,从而丢弃了早期瞬态响应中包含的信息。我们通过在双向长短期记忆-多层感知机模型中整合瞬态漏源电流序列与四个稳态I-V描述符,为现有的AlGaN/GaN高电子迁移率晶体管适体传感器开发了学习辅助读数。基于响应幅度、噪声和信噪比的偏压比较确定V_DS=0.5 V为优选工作点。对跨越六种实验测试癌胚抗原浓度的18条独立响应曲线进行分组三折交叉验证(在原始曲线水平),得出R2=0.998,RMSE(log10)=0.078,MAE(log10)=0.062。使用固定决策阈值和逻辑检测概率模型分析曲线水平的低浓度测量值,得出模型辅助C95为3.20 pg/mL(95%自举置信区间:2.83-3.52 pg/mL)。序列长度分析显示,120 s是相对于完整1000 s记录满足预设性能保留标准的最早间隔。在1:10稀释的混合人血清中,基线校正后的回收率在5、500和50,000 pg/mL时分别为97.6%、98.0%和95.0%;与1:20血清的比较进一步证明了稀释依赖性基质效应。这些发现表明,瞬态响应学习可以提取稳态分析未充分利用的定量信息,而更广泛的器件批次和临床验证仍然必要。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42480447
Early detection of hepatocellular carcinoma (HCC) remains challenging due to the lack of sensitive and non-invasive diagnostic strategies. Urinary exosomes (or small extracellular vesicles, sEVs) represent a promising biomarker source, but technical challenges remain in achieving efficient and rapid separation coupled with immediate high-sensitivity analysis. To address this, we developed an alternating current dielectrophoresis-assisted microfluidic platform integrated with amphiphilic dendrimer supramolecular probes (ADSP) for rapid and sensitive detection. In this system, a non-uniform alternating electric field generated by comb-shaped electrodes actively drives exosomes toward an ADSP-modified nitrocellulose (NC) membrane via positive dielectrophoresis, while amphiphilic amphotericin B (AMB)-mediated supramolecular interactions enable stable capture through insertion into the exosomal lipid bilayer. The combined effect of electric-field enrichment and probe-mediated recognition significantly improves capture efficiency with a limit of detection (LOD) of 6 exosomes/μL, requiring only 52 μL of sample and 9 min for injection within a simple chip structure. Key operational parameters, including voltage, frequency, flow rate, and sample volume, were systematically optimized to maximize enrichment performance. The platform enabled highly sensitive fluorescence signal detection of exosomal biomarkers and successfully distinguished urine samples from HCC patients and healthy controls. Benefiting from the synergistic integration of electric-field-driven enrichment and supramolecular probe recognition, this strategy provides a simple, valid, and rapid approach for urinary exosome analysis, indicating its applicability to non-invasive liquid biopsy-based cancer detection.
中文摘要:由于缺乏敏感且无创的诊断策略,肝细胞癌(HCC)的早期检测仍然具有挑战性。尿液外泌体(或小细胞外囊泡,sEVs)是一种有前景的生物标志物来源,但在实现高效快速分离与即时高灵敏度分析方面仍面临技术挑战。为解决这一问题,我们开发了一种结合两亲性树枝状大分子超分子探针(ADSP)的交流介电泳辅助微流控平台,用于快速灵敏检测。在该系统中,梳状电极产生的非均匀交流电场通过正介电泳主动驱动外泌体向ADSP修饰的硝酸纤维素(NC)膜移动,而两亲性两性霉素B(AMB)介导的超分子相互作用则通过插入外泌体脂质双层实现稳定捕获。电场富集与探针介导识别的协同作用显著提高了捕获效率,检测限(LOD)低至6个外泌体/μL,仅需52 μL样本和9分钟注入时间即可在简单芯片结构中完成。我们系统优化了电压、频率、流速和样本体积等关键操作参数,以最大化富集性能。该平台实现了对外泌体生物标志物的高灵敏度荧光信号检测,并成功区分了HCC患者和健康对照组的尿液样本。得益于电场驱动富集与超分子探针识别的协同整合,该策略为尿液外泌体分析提供了一种简单、有效且快速的方法,表明其在基于无创液体活检的癌症检测中的应用潜力。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42456509
Accurate profiling of microRNAs (miRNAs) is often limited by the severe background leakage of conventional enzyme-free DNA amplification. Herein, we develop a 1D DNA nanowire-mediated dispersion-to-localization catalytic hairpin assembly (DL-CHA) platform for the highly sensitive detection of miRNAs. Methodologically, responsive hairpins are physically isolated on spatially dispersed nanowire scaffolds to rigorously suppress target-independent interactions. Upon specific recognition of miR-21, a pseudo-intramolecular cascade is triggered, dynamically cross-linking the scaffolds into a highly fluorescent DNA ladder. As a result, this DL-CHA platform yields an exceptional signal-to-background ratio of 12.4, a broad linear range of 0.05 to 250 nM, and an ultra-sensitive limit of detection of 50 pM without the need for exogenous enzymes. Furthermore, the rigid nanowire architecture ensures robust nuclease resistance and enables highly efficient, transfection-free internalization for the in situ imaging of endogenous miRNAs in living cells. Clinically, the platform accurately discriminated colorectal cancer patients from healthy controls using non-invasive liquid biopsies of human serum. This paradigm offers a robust, low-background molecular tool for precision cancer diagnostics.
中文摘要:微小RNA(miRNA)的精准谱系分析常受限于传统无酶DNA扩增中严重的背景泄漏问题。本研究开发了一种基于1D DNA纳米线介导的分散至定位催化发夹组装(DL-CHA)平台,用于miRNA的高灵敏度检测。在方法学上,响应性发夹被物理隔离在空间分散的纳米线支架上,以严格抑制非靶标依赖性相互作用。在特异性识别miR-21后,触发伪分子内级联反应,动态交联支架形成高荧光DNA梯状结构。结果显示,该DL-CHA平台无需外源酶即可实现12.4的卓越信噪比、0.05至250 nM的宽线性范围以及50 pM的超灵敏检测限。此外,刚性纳米线架构确保了强大的核酸酶抗性,并实现了高效且无转染的内化作用,用于活细胞内源性miRNA的原位成像。在临床应用中,该平台通过人体血清的非侵入性液体活检,准确区分了结直肠癌患者与健康对照组。该范式为精准癌症诊断提供了一种稳健、低背景的分子工具。
Biosensors & bioelectronics IF 11.8 2026-11-14 PMID: 43044444
Pancreatic cancer (PC) is one of the most fatal malignancies worldwide, partly attributable to the lack of robust tools for clinical screening and diagnosis. Although liquid biopsy holds great promise for PC diagnosis, unified analysis of extracellular-vesicle, nucleic-acid, and protein biomarkers remains challenging because of their distinct analytical requirements and large differences in abundance. Here, we report a microscale size-encoded deterministic lateral displacement platform for unified analysis of heterogeneous liquid-biopsy biomarkers. By integrating aptamer recognition, microscale size encoding, Exonuclease III-mediated signal amplification, deterministic lateral displacement (DLD) microfluidics, and a self-developed vacuum-driven microfluidic imaging system, glypican-1-positive extracellular vesicles (GPC1+ EVs), microRNA-21 (miR-21), and carbohydrate antigen 19-9 (CA19-9) are encoded into microspheres of distinct sizes for simultaneous quantification directly from diluted serum within 1 h without complex preprocessing. Notably, GPC1+ EVs are directly analyzed without extracellular-vesicle isolation through a dual-aptamer recognition strategy that minimizes interference from soluble GPC1. The platform achieved detection limits of 3.23 × 105 particles mL-1 for GPC1+ EVs, 536 fM for miR-21, and 5.5 × 10-2 U mL-1 for CA19-9, providing sufficient analytical sensitivity for direct analysis of diluted serum samples. Clinical validation in 240 individuals demonstrated robust diagnostic performance, with a three-biomarker support vector machine model achieving area under the receiver operating characteristic curve values of 0.9822 for PC versus healthy controls and 0.9782 for PC versus pancreatitis in an independent test cohort. This work establishes a microscale size-encoding strategy that extends DLD microfluidics from microscale particle analysis to unified analysis of heterogeneous liquid-biopsy biomarkers, providing a general framework for multidimensional cancer diagnostics.
中文摘要:胰腺癌是全球最致命的恶性肿瘤之一,部分原因在于缺乏用于临床筛查和诊断的可靠工具。尽管液体活检在胰腺癌诊断中前景广阔,但由于不同生物标志物的分析要求各异且丰度差异巨大,统一分析细胞外囊泡、核酸和蛋白质生物标志物仍具挑战性。本研究报道了一种基于微尺度尺寸编码的确定性侧向位移平台,用于异质性液体活检生物标志物的统一分析。通过整合适配体识别、微尺度尺寸编码、外切酶III介导的信号放大、确定性侧向位移微流控技术以及自主研发的真空驱动微流控成像系统,将糖蛋白1阳性细胞外囊泡、微小RNA-21和碳水化合物抗原19-9编码为不同尺寸的微球,从而在稀释血清中直接实现同时定量分析,整个过程无需复杂预处理且耗时仅1小时。值得注意的是,通过双适配体识别策略直接分析糖蛋白1阳性细胞外囊泡,最大限度地减少了可溶性糖蛋白1的干扰。该平台对糖蛋白1阳性细胞外囊泡、微小RNA-21和碳水化合物抗原19-9的检测限分别为3.23×10^5颗粒/mL、536 fM和5.5×10^-2 U/mL,为直接分析稀释血清样本提供了足够的分析灵敏度。在240名受试者中的临床验证表明其具有稳健的诊断性能,独立测试队列中三生物标志物支持向量机模型对胰腺癌与健康对照及胰腺炎的曲线下面积分别为0.9822和0.9782。这项工作确立了一种微尺度尺寸编码策略,将确定性侧向位移微流控技术从微尺度颗粒分析扩展至异质性液体活检生物标志物的统一分析,为多维癌症诊断提供了通用框架。
Advanced healthcare materials IF 11.0 2026-11-14 PMID: 43034275
Visualization of colorectal cancer (CRC) lesions is complicated by their location in the colon and tumor morphology. Reliance on a single surface biomarker for direct identification risks false negatives due to temporal changes and/or tumor heterogeneity. We developed a multiplexed system of complementary biomarker targets to capture a broader range of lesions with diverse temporal and/or phenotypic expression. We identified Mucin-1 (MUC1) and epithelial cell adhesion molecule (EPCAM) as useful targeting pairs by phenotyping CRC subtypes in a standard tissue array and surveying CRC cell lines in 2D and 3D formats to confirm expression of these surface biomarkers. Through a "universal" approach using Antibody-Protein L Microparticles (APL-MPs), we functionalized microparticle surfaces with antibodies recognizing either MUC1 or EPCAM. We generated heterogeneous CRC tumoroids and orthotopic animal models, expressing both MUC1 and EPCAM, and demonstrated that: (1) APL-MPs identified MUC1- and EPCAM-positive tumoroids in proportion to antigen expression; (2) APL-MPs detected CRC surface antigens on the luminal colon surface in vivo, and (3) concurrent targeting of multiple surface antigens enhanced detection sensitivity for heterogeneous CRC lesions. This approach supports broader applications of APL-MPs for detecting heterogeneous cancer lesions and offers a promising strategy for accurate tumor visualization in complex environments.
中文摘要:结直肠癌病灶的可视化因其位于结肠且形态复杂而面临挑战。依赖单一表面生物标志物进行直接识别,因时间变化或肿瘤异质性可能导致假阴性结果。我们开发了一种多重互补生物标志物靶点系统,以捕获具有不同时间和表型表达的更广泛范围的病灶。通过在标准组织阵列中对结直肠癌亚型进行表型分析,并在二维和三维格式中调查结直肠癌细胞系以确认这些表面生物标志物的表达,我们确定了粘蛋白1(MUC1)和上皮细胞黏附分子(EPCAM)作为有用的靶向组合。利用抗体-蛋白L微颗粒(APL-MPs)的通用方法,我们将识别MUC1或EPCAM的抗体功能化到微颗粒表面。我们构建了表达MUC1和EPCAM的异质性结直肠肿瘤类器官和原位动物模型,并证明:第一,APL-MPs根据抗原表达比例识别MUC1和EPCAM阳性的肿瘤类器官;第二,APL-MPs在体内检测结肠腔表面的结直肠癌表面抗原;第三,对多种表面抗原的同时靶向增强了对异质性结直肠病灶的检测灵敏度。该方法支持APL-MPs在检测异质性癌变病灶中的更广泛应用,并为复杂环境中的准确肿瘤可视化提供了一种有前景的策略。
Pharmacological research IF 12.2 2026-11-14 PMID: 43033883
Pancreatic ductal adenocarcinoma (PDAC) continues to be a lethal malignancy with limited effective treatment strategies due to modest intrinsic response to systemic chemotherapy. Moreover, the dense, fibrotic stroma and poor vasculature of pancreatic tumors severely restrict drug penetration and therapeutic efficacy. The transcription factor ELF3 acts as a key oncogenic driver that promotes tumor growth, metastasis, and chemoresistance. To address these delivery barriers and enhance therapeutic response, we developed a biomimetic nanoplatform using cancer cell membrane-coated ZIF-8 nanoparticles (CNPs) to co-deliver gemcitabine (GEM) and an ELF3-targeting shRNA (shELF3), aiming to improve tumor-targeting specificity and elucidate the underlying cell death mechanism. Efficient encapsulation of GEM and shRNA ELF3 within a biomimetic nanocarrier was successfully confirmed. In vitro evaluation demonstrated that GEM/shELF3-CNPs activated canonical caspase-3/gasdermin E (GSDME)-dependent pyroptosis, resulting in markedly enhanced cytotoxicity in 6606 PDA cells. Furthermore, in vivo administration yielded superior tumor accumulation, potent tumor growth suppression, and significantly prolonged survival in the murine PDAC model, alongside favorable biosafety profiles. Our findings demonstrate that combining ELF3 silencing with gemcitabine delivery via biomimetic nanocarriers presents a promising synergistic strategy to sensitize pancreatic tumors and enhance PDAC therapeutic outcomes. The graphical representation of the study is shown in Fig. 1.
中文摘要:胰腺导管腺癌(PDAC)因对全身化疗的固有反应率较低,仍是一种致死性恶性肿瘤且缺乏有效的治疗策略。此外,胰腺肿瘤致密的纤维化间质和贫乏的血管严重限制了药物的渗透和治疗效果。转录因子ELF3作为关键的致癌驱动因素,促进肿瘤生长、转移和化疗耐药。为了解决这些递送障碍并增强治疗反应,我们开发了一种利用癌细胞膜包被的ZIF-8纳米颗粒(CNPs)构建的生物模拟纳米平台,以共递送吉西他滨(GEM)和靶向ELF3的shRNA(shELF3),旨在提高肿瘤靶向特异性并阐明潜在的细胞死亡机制。研究成功证实了GEM和shRNA ELF3在生物模拟纳米载体中的高效包封。体外评估表明,GEM/shELF3-CNPs激活了经典的caspase-3/气体蛋白E(GSDME)依赖性焦亡,显著增强了6606 PDA细胞的细胞毒性。此外,体内给药在小鼠PDAC模型中实现了更优的肿瘤积累、强大的肿瘤生长抑制和显著延长的生存期,同时具有良好的生物安全性。研究结果表明,通过生物模拟纳米载体将ELF3沉默与吉西他滨递送相结合,是一种使胰腺肿瘤增敏并改善PDAC治疗结果的有前景的协同策略。本研究的结果如图1所示。
Cancer letters IF 11.8 2026-11-13 PMID: 43025793
Gallbladder cancer (GBC) is an aggressive malignancy with limited treatment options for advanced disease. Bortezomib (BTZ) has shown activity against biliary tract cancers, but acquired resistance severely undermines its clinical benefit. To elucidate the underlying mechanisms and identify strategies to reverse resistance, we established a BTZ-resistant GBC-SD cell line. Resistant cells overexpressed plasma membrane-localized P-glycoprotein (P-gp), exhibited efflux of multiple substrates, and acquired cross-resistance to other proteasome inhibitors, confirming multidrug resistance (MDR). Pharmacological inhibition with tariquidar or genetic ablation of ABCB1 reversed MDR in vitro and suppressed tumor growth in xenograft models. Whole-genome sequencing and bioinformatics revealed ABCB1 amplification within a putative circular amplicon, indicative of extrachromosomal DNA (ecDNA), and identified single-nucleotide polymorphisms associated with resistance. Proximity labeling coupled with mass spectrometry further identified histone H1 and HNRNPU as key regulators of the amplicon. Collectively, our findings demonstrate that ecDNA-mediated ABCB1 amplification drives P-gp overexpression and MDR in GBC, and that this resistance can be effectively reversed by targeting P-gp or the amplicon complex. This work provides a mechanistic foundation for developing therapeutic strategies to overcome ecDNA-driven drug resistance in GBC and other refractory malignancies.
中文摘要:胆囊癌是一种侵袭性恶性肿瘤,晚期疾病的治疗选择有限。硼替佐米对胆道癌症显示出活性,但获得性耐药严重削弱了其临床获益。为阐明潜在机制并确定逆转耐药的策略,我们建立了硼替佐米耐性的GBC-SD细胞系。耐药细胞过表达定位于质膜的P-糖蛋白,表现出多种底物的外排,并对其他蛋白酶体抑制剂获得交叉耐药,证实了多药耐药性。通过塔瑞吉达进行药理学抑制或ABCB1的基因消融在体外逆转了多药耐药性并在异种移植模型中抑制了肿瘤生长。全基因组测序和生物信息学分析揭示了位于推定的环状扩增子内的ABCB1扩增,提示存在染色体外DNA,并鉴定出与耐药相关的单核苷酸多态性。邻近标记结合质谱进一步鉴定组蛋白H1和HNRNPU为扩增子的关键调节因子。综上所述,我们的研究结果表明,染色体外DNA介导的ABCB1扩增驱动了胆囊癌中P-糖蛋白的过表达和多药耐药性,且通过靶向P-糖蛋白或扩增子复合物可有效逆转这种耐药性。这项工作为开发克服胆囊癌及其他难治性恶性肿瘤中染色体外DNA驱动的耐药性的治疗策略提供了机制基础。
Science advances IF 13.9 2026-11-13 PMID: 43013672
Pancreatic ductal adenocarcinoma (PDAC) remains difficult to treat, highlighting the need for strategies that selectively deliver cytotoxic agents to tumor cells. Trophoblast cell-surface antigen 2 (TROP2) has been proposed as a candidate therapeutic target in PDAC, but non-antibody-based delivery formats remain underexplored. Using protein-SELEX, we identified T17, a high-affinity aptamer that specifically binds to TROP2, and conjugated it to monomethyl auristatin E through an MC-Val-Cit-PAB linker to generate the aptamer-drug conjugate T17-M. Preclinical evaluation in cellular and animal models showed that T17-M retained TROP2-dependent binding, underwent clathrin-mediated internalization and lysosomal processing, and suppressed tumor growth in cell-line-derived and patient-derived xenografts. T17-M also reduced liver metastasis and induced calreticulin exposure, ATP release, and HMGB1 secretion, consistent with immunogenic cell death. In immunocompetent models, T17-M promoted dendritic-cell activation and CD8+ T cell infiltration, while its combination with PD-1 blockade further enhanced tumor control and prolonged survival. These findings provide preclinical proof-of-concept for T17-M as an alternative TROP2-targeted drug-delivery strategy for PDAC.
中文摘要:胰腺导管腺癌治疗困难,亟需能选择性将细胞毒性药物递送至肿瘤细胞的策略。滋养层细胞表面抗原2被提出作为胰腺导管腺癌的潜在治疗靶点,但非抗体类递送格式的研究仍不充分。通过蛋白质SELEX技术,我们鉴定出一种高亲和力且特异性结合TROP2的适配体T17,并通过MC-Val-Cit-PAB连接子将其与单甲基澳瑞他汀E偶联,生成适配体药物偶联物T17-M。在细胞和动物模型中的临床前评估显示,T17-M保留了依赖TROP2的结合能力,经历网格蛋白介导的内吞作用和溶酶体加工,并抑制了细胞系来源及患者来源异种移植瘤的生长。T17-M还减少了肝转移,诱导钙网蛋白暴露、ATP释放和HMGB1分泌,符合免疫原性细胞死亡特征。在免疫健全模型中,T17-M促进树突状细胞活化和CD8+ T细胞浸润,其与PD-1阻断联合使用进一步增强了肿瘤控制并延长了生存期。这些发现为T17-M作为胰腺导管腺癌的一种替代性TROP2靶向药物递送策略提供了临床前概念验证。

3乳腺癌 (20篇)

临床研究 (6篇)

Cancer discovery IF 29.5 2026-11-19 PMID: 43058942
The FDA approved giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer based on the results of the phase III evERA trial. In addition, the agency authorized the FoundationOne Liquid CDx assay for assessing ESR1 status to determine who would benefit from this treatment regimen.
中文摘要:美国食品药品监督管理局批准吉瑞替尼联合依维莫司用于治疗雌激素受体阳性、人表皮生长因子受体2阴性且存在ESR1突变的局部晚期或转移性乳腺癌,该批准基于III期evERA试验的结果。此外,该局还批准了FoundationOne Liquid CDx检测用于评估ESR1状态,以确定哪些患者能从该治疗方案中获益。
Journal of hematology & oncology IF 47.8 2026-11-18 PMID: 43053184
Rapid advances in antibody-drug conjugates (ADCs) and an expanding clinical evidence base are reshaping treatment options for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC). Randomized trials have demonstrated progression-free survival benefits over chemotherapy for individual ADCs in defined populations, including settings before and after metastatic chemotherapy. As additional ADCs become available and indications expand, attention is increasingly focused on whether individual agents can improve outcomes over endocrine-based regimens in selected endocrine-eligible patients and on which therapies beyond conventional chemotherapy may retain activity after ADC progression. Addressing these questions requires integration of clinical evidence with a mechanistic understanding of ADC activity and resistance. In this review, we summarize selected mechanisms of ADC action and critically examine the evolving clinical roles of individual agents across settings defined by prior therapy. We also discuss treatment strategies after ADC exposure and resistance mechanisms relevant to target and payload selection. Finally, we review exploratory studies of candidate biomarkers associated with clinical outcomes, ADC-based combinations, and next-generation designs, highlighting their biological rationale, emerging evidence, and priorities for further evaluation.
中文摘要:抗体药物偶联物(ADC)的快速进展及不断扩大的临床证据基础正在重塑激素受体阳性、人表皮生长因子受体2阴性(HR+/HER2-)转移性乳腺癌(mBC)的治疗选择。随机试验表明,在特定人群中,包括转移性化疗前后阶段,个体ADC相比化疗能带来无进展生存期的获益。随着更多ADC上市及适应症扩展,关注点日益集中于:在内分泌治疗适用患者中,个体药物能否改善内分泌联合方案的疗效;以及在ADC治疗后,哪些非传统化疗疗法仍能保持活性。解答这些问题需将临床证据与对ADC作用机制及耐药性的深入理解相结合。本综述总结了选定的ADC作用机制,并批判性评估了不同既往治疗背景下的个体药物不断演变的临床角色。我们还讨论了ADC暴露后的治疗策略及与靶点和载荷选择相关的耐药机制。最后,我们回顾了候选生物标志物、ADC联合疗法及下一代设计的探索性研究,强调其生物学原理、新兴证据及进一步评估的重点。
ESMO open IF 10.6 2026-11-17 PMID: 43044268
Quarterly echocardiographic surveillance during trastuzumab-based human epidermal growth factor receptor 2-directed therapy was established in the early 2000s. With lower left ventricular ejection fraction (LVEF) decline rates with newer regimens, the justification for frequent cardiac surveillance warrants re-evaluation. We carried out a systematic review and single-arm meta-analysis of clinical trials of patients receiving trastuzumab, trastuzumab emtansine (T-DM1), or trastuzumab deruxtecan (T-DXd), using pooled estimates of study-reported cardiac dysfunction, predominantly decreased LVEF, to evaluate echocardiographic surveillance strategies. For early-stage disease (12-month treatment duration), strategies evaluated included baseline echocardiography plus imaging at 6 months, baseline plus imaging at 6 and 12 months, and baseline plus imaging at 3, 6, 9, and 12 months. For metastatic disease (continuous treatment), strategies included baseline echocardiography plus annual imaging, baseline plus imaging every 6 months, and baseline plus imaging every 3 months. Fifty-seven studies conducted from 1999 to 2026 (37 847 patients) were included. Pooled rates of study-reported cardiac dysfunction, predominantly decreased LVEF, were 4.5%, 1.7%, and 1.4% for trastuzumab, T-DXd, and T-DM1, respectively, in early-stage disease, and 7.7%, 3.3%, and 2.3%, respectively, in metastatic disease; grade 3 events were rare. At a willingness-to-pay threshold of $120 000/quality-adjusted life year (QALY), baseline echocardiography plus one follow-up study at 6 months was preferred for early-stage trastuzumab, whereas baseline-only imaging was preferred for early-stage T-DM1 and T-DXd. Monitoring every 3 months was not cost-effective for any early-stage regimen, with incremental cost-effectiveness ratios (ICERs) of $12 974 923/QALY for trastuzumab, $3 033 636/QALY for T-DM1, and $4 388 134/QALY for T-DXd. In metastatic disease, baseline-only imaging was preferred for all three regimens; annual monitoring exceeded the willingness-to-pay threshold for trastuzumab, T-DM1, and T-DXd, with ICERs of $191 781/QALY, $537 175/QALY, and $353 098/QALY, respectively. Echocardiography every 3 months was not cost-effective for any regimen or disease setting. Monitoring should be regimen- and setting-specific, with prospective validation of less intensive strategies. These findings are only applicable to lower-risk, trial-eligible patients.
中文摘要:重新思考接受基于曲妥珠单抗的HER2靶向治疗的乳腺癌患者的心脏监测:一项荟萃分析和成本效果分析。在基于曲妥珠单抗的人表皮生长因子受体2靶向治疗期间每季度进行超声心动图监测的做法于21世纪初确立。随着较新方案中左心室射血分数(LVEF)下降率较低,频繁心脏监测的必要性值得重新评估。我们对接接受曲妥珠单抗、曲妥珠单抗美坦新(T-DM1)或曲妥珠单抗德鲁替康(T-DXd)治疗的患者的临床试验进行了系统综述和单臂荟萃分析,使用研究报道的心功能障碍(主要为LVEF下降)的合并估计值来评估超声心动图监测策略。对于早期疾病(治疗持续时间12个月),评估的策略包括基线超声心动图加6个月时影像检查、基线加6个月和12个月时影像检查,以及基线加3、6、9和12个月时影像检查。对于转移性疾病(持续治疗),策略包括基线超声心动图加每年影像检查、基线加每6个月影像检查,以及基线加每3个月影像检查。共纳入1999年至2026年开展的57项研究(37 847例患者)。研究报道的心功能障碍(主要为LVEF下降)的合并发生率在早期疾病中曲妥珠单抗、T-DXd和T-DM1分别为4.5%、1.7%和1.4%,在转移性疾病中分别为7.7%、3.3%和2.3%;3级事件罕见。在120 000美元/质量调整生命年(QALY)的支付意愿阈值下,对于早期阶段使用曲妥珠单抗,首选基线超声心动图加6个月时一次随访检查,而对于早期阶段T-DM1和T-DXd,仅基线影像为首选。每3个月监测对任何早期阶段方案均不具有成本效果,曲妥珠单抗、T-DM1和T-DXd的增量成本效果比(ICER)分别为12 974 923美元/QALY、3 033 636美元/QALY和4 388 134美元/QALY。在转移性疾病中,三种方案均首选仅基线影像;年度监测在曲妥珠单抗、T-DM1和T-DXd中均超过支付意愿阈值,ICER分别为191 781美元/QALY、537 175美元/QALY和353 098美元/QALY。每3个月超声心动图监测对任何方案或疾病阶段均不具有成本效果。监测应因方案和疾病阶段而异,并对强度较低的策略进行前瞻性验证。这些发现仅适用于较低风险且符合试验入选条件的患者。
EBioMedicine IF 11.2 2026-11-16 PMID: 43038904
Short preoperative immune induction could inform future breast-cancer trials, but it must not delay surgery. BreastVAX tested whether a single-dose preoperative regimen could be delivered within the planned surgical window while collecting safety and biological data. BreastVAX (NCT04454528) was a single-centre, open-label, phase 1b/2 window-of-opportunity trial. Adults with operable invasive breast cancer scheduled for upfront surgery received one 200 mg pembrolizumab infusion alone or with one 7 Gy tumour-directed radiotherapy fraction before or after pembrolizumab. The primary phase 1b endpoint was feasibility, defined as completion of assigned preoperative treatment within 21 days without delaying surgery by more than 14 days. Phase 2 had two descriptive interim reviews. In phase 1b, all six enrolled participants met the feasibility criterion. Across both phases, all 30 treated participants completed assigned preoperative therapy and underwent surgery without protocol-defined delay; median follow-up was 634 days (IQR 256-1120). Most adverse events were grade 1-2, with no deaths and no treatment-related grade 3 or higher events; the only grade 3 event was a surgical re-excision unrelated to treatment. Pathological and immune-correlative findings were exploratory and showed treatment-associated immune changes, including a neoepitope-reactive T-cell response in one responder. Pembrolizumab, with or without a single subablative tumour-directed radiotherapy fraction, was delivered within the preoperative window without protocol-defined surgical delay. Larger biomarker-informed studies should evaluate sequence prospectively, use endpoints suited to this short regimen, and prespecify harms monitoring. Philanthropic support to JCT and in-kind pembrolizumab supply from Merck Pharmaceuticals.
中文摘要:术前短期免疫诱导可为未来乳腺癌试验提供信息,但不得延误手术。BreastVAX研究旨在评估在计划的手术窗口期内能否完成单次术前治疗方案,同时收集安全性和生物学数据。BreastVAX(NCT04454528)是一项单中心、开放标签的1b/2期机会窗临床试验。接受初始手术的成年可切除浸润性乳腺癌患者,在帕博利珠单抗输注前或后接受单次200 mg帕博利珠单抗单独治疗或联合单次7 Gy肿瘤定向放疗。主要1b期终点为可行性,定义为在21天内完成指定的术前治疗且手术延误不超过14天。2期包含两次描述性中期审查。在1b期中,所有6名入组参与者均满足可行性标准。在两个阶段中,所有30名接受治疗的患者均完成了指定的术前治疗并接受了手术,无方案定义的延误;中位随访时间为634天(四分位距256-1120)。大多数不良事件为1至2级,无死亡病例,无与治疗相关的3级或更高级别事件;唯一的3级事件是与治疗无关的手术再切除。病理学和免疫相关性发现为探索性结果,显示治疗相关的免疫变化,包括在一例响应者中观察到新表位反应性T细胞反应。帕博利珠单抗单独或与单次亚消融剂量肿瘤定向放疗联合,在术前窗口期内完成且无方案定义的手术延误。更大规模的生物标志物指导研究应前瞻性评估顺序,使用适合该短程方案的终点,并预先规定不良事件监测。本研究得到慈善机构对JCT的支持以及默克制药提供的帕博利珠单抗实物支持。
Journal of hematology & oncology IF 47.8 2026-11-15 PMID: 43035449
Adjuvant treatment decisions for patients with small (T ≤ 1 cm), node-negative, human epidermal growth factor receptor 2 (HER2)-positive breast tumors remain challenging, particularly regarding whether oral chemotherapy is comparable to intravenous regimens. We therefore conducted a phase II trial evaluating the efficacy and safety of an oral chemotherapy plus trastuzumab regimen in this population. Eligible patients received either single-agent capecitabine (1000 mg/m2 twice daily on days 1-14 every 3 weeks) or vinorelbine capsules (60 mg/m2 on days 1, 8, and 15 every 3 weeks) plus trastuzumab, followed by trastuzumab monotherapy for a total of 12 months of therapy. The primary endpoint was disease-free survival (DFS). The secondary end points were distant disease-free survival (DDFS), overall survival (OS), and safety. This study is registered with ClinicalTrials.gov (NCT04296162). The analysis population included 182 patients, of whom 81% had tumors measuring ≤ 0.5 cm and 74% had hormone receptor (HR)-negative disease. Of the 181 treated patients, 176 (97.2%) received capecitabine and 5 (2.8%) vinorelbine, with agent selection at the physician's discretion. After a median follow-up of 5.7 years (range, 1.0-6.2 years), the 5-year DFS rate was 97.3% (90% Confidence interval [CI], 94.4-98.7). The lower bound of the 90% CI exceeded the prespecified threshold of 92%, meeting the primary endpoint. Among the 6 observed invasive disease events, 2 involved distant metastasis, 3 involved local or regional recurrence, and 1 involved contralateral breast cancer. Among the secondary endpoints, the 5-year DDFS rate was 97.2%, with a 5-year OS rate of 100% (no deaths) during follow-up. Among the 176 patients treated with capecitabine, the most common capecitabine-related adverse event (AE) was hand-foot syndrome, which occurred in 66.5% of patients, with 8.0% of patients experiencing a grade 3 event. Among women with HER2-positive, node-negative breast tumors measuring ≤ 1 cm, capecitabine-based oral chemotherapy plus 1 year of trastuzumab was associated with a low risk of cancer recurrence and favorable toxicity in this single-arm cohort, supporting further prospective evaluation.
中文摘要:对于肿瘤较小(T≤1 cm)、淋巴结阴性且人表皮生长因子受体2(HER2)阳性的乳腺癌患者,辅助治疗决策仍然具有挑战性,特别是关于口服化疗是否与静脉给药方案相当的问题。因此,我们开展了一项II期试验,评估该人群中口服化疗联合曲妥珠单抗方案的疗效和安全性。符合条件的患者接受单药卡培他滨(1000 mg/m2,第1-14天每日两次,每3周一次)或长春瑞滨胶囊(60 mg/m2,第1、8、15天,每3周一次)联合曲妥珠单抗治疗,随后进行为期总计12个月的曲妥珠单抗单药治疗。主要终点为无病生存期(DFS)。次要终点包括远处无病生存期(DDFS)、总生存期(OS)和安全性。本研究在ClinicalTrials.gov注册(NCT04296162)。分析人群包括182名患者,其中81%的患者肿瘤直径≤0.5 cm,74%的患者为激素受体(HR)阴性疾病。在181名接受治疗的患者中,176名(97.2%)接受卡培他滨治疗,5名(2.8%)接受长春瑞滨治疗,药物选择由医生决定。在中位随访时间为5.7年(范围1.0-6.2年)后,5年DFS率为97.3%(90%置信区间[CI],94.4-98.7)。90% CI的下限超过了预设的92%阈值,达到了主要终点。在观察到的6例侵袭性疾病事件中,2例涉及远处转移,3例涉及局部或区域复发,1例涉及对侧乳腺癌。在次要终点中,5年DDFS率为97.2%,随访期间5年OS率为100%(无死亡)。在176名接受卡培他滨治疗的患者中,最常见的卡培他滨相关不良事件(AE)是手足综合征,发生在66.5%的患者中,其中8.0%的患者出现3级事件。对于肿瘤直径≤1 cm的HER2阳性、淋巴结阴性乳腺癌女性,基于卡培他滨的口服化疗联合1年曲妥珠单抗与该单臂队列中较低癌症复发风险和良好的毒性特征相关,支持进一步的前瞻性评估。
Advanced healthcare materials IF 11.0 2026-11-13 PMID: 43026189
Blood-based measurement of carcinoembryonic antigen (CEA) and gross cystic disease fluid protein-15 (GCDFP-15; prolactin-inducible protein, PIP) remains the standard for breast cancer monitoring but is invasive. We present WearDOXXN+, a capillary-driven microfluidic patch for noninvasive sweat collection to investigate paired sweat-blood analysis. Ten participants wear the patch during exercise; matched sweat and blood samples are analyzed by enzyme-linked immunosorbent assay (ELISA). The platform collects sweat within 30 min, with 100% success. CEA was detected in sweat and showed a disease-stage-associated trend; however, concentrations in healthy participants and survivors remained below the assay's lower limit of quantification, highlighting analytical sensitivity as a limitation. PIP was measurable in blood, with the highest level observed in Stage III disease, although several values exceeded the assay's validated upper limit, while remaining undetectable in sweat. Validation showed the patch recovers 65% of loaded fluid, and recovered eluate retains loaded CEA concentration (recovery 108%, 92%, and 98%), confirming sample handling does not deplete the analyte. These findings represent, to our knowledge, the first paired sweat-blood comparison of CEA and PIP using a passive capillary-driven wearable patch and establish analytical requirements, including sample volume, analyte recovery, assay sensitivity, and biomarker selection, for noninvasive sweat-based breast cancer monitoring.
中文摘要:基于血液的癌胚抗原(CEA)和巨大囊肿疾病液蛋白15(GCDFP-15;催乳素诱导蛋白PIP)检测仍是乳腺癌监测的标准方法,但具有侵入性。我们提出了WearDOXXN+,这是一种毛细管驱动的微流控贴片,用于无创汗液收集以研究配对汗血分析。十名参与者在运动期间佩戴该贴片,对匹配的汗液和血液样本进行酶联免疫吸附测定(ELISA)分析。该平台在30分钟内收集汗液,成功率达100%。CEA在汗液中可检测到并显示出与疾病分期相关的趋势;然而,健康参与者及幸存者的浓度低于定量下限,凸显了分析灵敏度作为局限性。PIP在血液中可测量,III期疾病中观察到最高水平,尽管部分数值超过验证上限,而在汗液中未检出。验证显示贴片回收65%的加载液体,且回收洗脱液保留了加载的CEA浓度(回收率分别为108%、92%和98%),证实样本处理不会消耗分析物。这些发现据我们所知是首次使用被动毛细管驱动可穿戴贴片进行的CEA和PIP配对汗血比较,并确立了无创汗液基乳腺癌监测的分析要求,包括样本量、分析物回收率、检测灵敏度和生物标志物选择。

基础研究 (14篇)

Advanced healthcare materials IF 11.0 2026-11-19 PMID: 43059295
Carbon monoxide (CO) is a promising therapeutic agent for aggressive triple-negative breast cancer (TNBC) with limited effective treatments. Moreover, its precise and safe delivery to tumors remains a challenge. However, conventional CO-releasing strategies present inefficient substrate supply and poor spatiotemporal control. Here, we report a bioinspired photocatalytic nanomachine (g-C3N4-Au@Hb@MnCO3 nanoparticles, CAHM NPs) with a "catalytic core-capture layer mineralization shell" architecture that integrates CO2 generation, capture, and photocatalytic conversion with Mn2+-mediated immunomodulation for synergistic antitumor therapy. The system is constructed by immobilizing hemoglobin (Hb) on Au-deposited graphitic carbon nitride (g-C3N4-Au), followed by in situ mineralization of a pH-responsive manganese carbonate (MnCO3) shell. In the acidic tumor microenvironment, MnCO3 decomposes to release CO2 and Mn2+. The captured CO2 is efficiently photoreduced to CO under 650 nm laser irradiation, inducing immunogenic cell death, while the released Mn2+ activates the STING pathway to promote dendritic cell maturation and enhance antitumor immunity. In vitro and in vivo studies demonstrate that CAHM NPs in the Laser group effectively suppress tumor growth and elicit robust immune responses, with minimal toxicity. This work presents a novel strategy for spatially controlled CO therapy combined with STING activation, offering a promising platform for the treatment of TNBC.
中文摘要:一氧化碳(CO)是治疗侵袭性三阴性乳腺癌(TNBC)的一种有前景的治疗剂,而该病目前缺乏有效的治疗方案。此外,将CO精准且安全地递送至肿瘤部位仍是一个挑战。然而,传统的CO释放策略存在底物供应效率低下和时空控制能力差的问题。在此,我们报道了一种具有仿生光催化纳米机器(g-C3N4-Au@Hb@MnCO3纳米颗粒,CAHM NPs),其采用「催化核-捕获层-矿化壳」的架构,整合了CO2生成、捕获和光催化转化过程,并结合Mn2+介导的免疫调节以实现协同抗肿瘤治疗。该系统通过将血红蛋白(Hb)固定在沉积有金的石墨相碳氮化物(g-C3N4-Au)上构建,随后原位矿化形成pH响应性的碳酸锰(MnCO3)壳层。在酸性肿瘤微环境中,MnCO3分解释放CO2和Mn2+。捕获的CO2在650 nm激光照射下被高效光还原为CO,诱导免疫原性细胞死亡;同时释放的Mn2+激活STING通路,促进树突状细胞成熟并增强抗肿瘤免疫力。体外和体内研究表明,CAHM NPs在激光组中能有效抑制肿瘤生长并引发强烈的免疫反应,且毒性极小。这项工作提出了一种空间可控的CO治疗结合STING激活的新策略,为TNBC的治疗提供了一个有前景的平台。
Cell death and differentiation IF 13.6 2026-11-19 PMID: 43058217
Despite substantial advances in targeted therapeutic regimens for breast cancer (BC), clinical management remains challenging for refractory and therapy-resistant cases, especially for molecular subtypes lacking validated actionable targets. Here, we identified that FK506-binding protein 10 (FKBP10), a peptidyl-proline isomerases, was strikingly elevated in BC tissues and potentiated the malignant behaviors of BC cells in vitro and in vivo. Besides, we discovered that FKBP10 was positively correlated with enhanced homologous recombination (HR)-mediated DNA repair and drove broad resistance to multiple DNA-damaging therapies, including cisplatin, ionizing radiation (IR) and PARP inhibitor. Mechanistically, FKBP10 physically interacted with the core HR repair protein RAD51 via a proline 22-containing motif. This interaction competitively disrupted the recognition of RAD51 by heat shock cognate 70 (HSC70), thereby protecting RAD51 from chaperone-mediated autophagy (CMA)-dependent degradation. Furthermore, FKBP10 attenuated excessive CMA flux to further stabilize RAD51 in the manner of ATF6-mediated endoplasmic reticulum stress (ERS). Importantly, we characterized a clinically actionable repurposing strategy using selumetinib, which transcriptionally repressed FKBP10 by blocking the MEK/ERK/ELK1 signaling cascade. This pharmacological intervention robustly sensitized multiple preclinical BC models to chemoradiotherapy and PARP inhibition. Collectively, our findings uncover a previously unappreciated function of FKBP10 in driving BC progression and resistance to DNA-damaging therapies, underscoring its strong potential as a tractable therapeutic target for treatment-refractory BC subsets.
中文摘要:尽管乳腺癌靶向治疗取得了显著进展,但对于难治性和耐药性病例,尤其是缺乏有效靶点的分子亚型,临床管理仍然具有挑战性。本研究鉴定出肽酰脯氨酰异构酶FK506结合蛋白10(FKBP10)在乳腺癌组织中显著升高,并在体内外增强了乳腺癌细胞的恶性行为。此外,我们发现FKBP10与增强的同源重组介导的DNA修复呈正相关,并驱动了对多种DNA损伤治疗(包括顺铂、电离辐射和PARP抑制剂)的广泛耐药性。机制上,FKBP10通过含脯氨酸22的结构域与核心HR修复蛋白RAD51发生物理相互作用。这种相互作用竞争性破坏了热休克 cognate 70对RAD51的识别,从而保护RAD51免受伴侣介导的自噬依赖降解。此外,FKBP10以ATF6介导的内质网应激方式减弱过度的CMA通量,进一步稳定RAD51。重要的是,我们表征了一种具有临床可操作性的药物重定位策略,即使用selumetinib通过阻断MEK/ERK/ELK1信号级联转录性抑制FKBP10。这种药理学干预显著使多种临床前乳腺癌模型对放化疗和PARP抑制敏感。综上所述,我们的发现揭示了FKBP10在驱动乳腺癌进展和对DNA损伤治疗耐药方面的先前未被重视的功能,强调了其作为治疗难治性乳腺癌亚群的可靶向治疗靶点的巨大潜力。
Molecular cell IF 16.0 2026-11-19 PMID: 42838053
Cancer cells lacking BRCA1 or BRCA2 must adapt to proliferate despite pervasive genomic instability. To delineate BRCA1- and BRCA2-specific adaptation landscapes, we developed an isogenic screening platform enabling acute depletion of either protein. Genetic interaction profiling revealed hundreds of genes with shared, distinct, or opposing effects in the two BRCA-deficient states. We identified FANCM as essential in BRCA1-deficient cells. Conversely, FANCM is toxic in BRCA2-deficient cells, where it promotes replication fork degradation through RMI1/2 recruitment and sensitizes cells to PARP inhibition. FANCM loss restored fork integrity and alleviated genomic instability and proliferation defects without restoring homologous recombination or suppressing single-stranded DNA (ssDNA) gaps. Finally, we report a FANCM variant that disrupts RMI1/2 binding in a BRCA2m breast cancer patient that is associated with PARP-inhibitor resistance. These findings define fundamentally distinct adaptive routes to BRCA1 and BRCA2 loss and establish FANCM-RMI1/2 as a determinant of mutation-specific vulnerabilities and therapeutic responses.
中文摘要:缺乏BRCA1或BRCA2的癌细胞必须在普遍存在的基因组不稳定性下适应以进行增殖。为了描绘BRCA1和BRCA2特异性适应景观,我们开发了一种等基因筛选平台,能够实现这两种蛋白质的急性耗竭。遗传相互作用谱分析揭示了数百个基因在两种BRCA缺陷状态下具有共享、独特或相反的作用。我们发现FANCM是BRCA1缺陷细胞中必需的。相反,FANCM在BRCA2缺陷细胞中具有毒性,它通过招募RMI1/2促进复制叉降解并使细胞对PARP抑制剂敏感。FANCM缺失恢复了复制叉完整性,减轻了基因组不稳定性和增殖缺陷,且未恢复同源重组或抑制单链DNA缺口。最后,我们报告了一种FANCM变异体,该变异体在BRCA2突变乳腺癌患者中破坏了与RMI1/2的结合,并与PARP抑制剂耐药性相关。这些发现定义了BRCA1和BRCA2缺失根本不同的适应途径,并确立FANCM-RMI1/2复合物作为决定突变特异性脆弱性和治疗反应的关键因素。
Experimental hematology & oncology IF 17.5 2026-11-18 PMID: 43053226
Lymph node metastasis (LNM) is central to breast cancer staging and treatment decisions. Clinical observations indicate that luminal or hormone receptor-positive breast cancer may show a distinct clinical pattern of regional lymph node involvement, but the stromal and intracellular mechanisms remain unclear. We integrated Surveillance, Epidemiology, and End Results (SEER) data, a multicenter institutional cohort, public single-cell RNA sequencing data, spatial transcriptomics, and multiplex immunofluorescence. Fibroblast states and candidate cell-cell communication pathways were examined using CytoTRACE, pseudotime, and ligand-receptor analyses. Functional and mechanistic validation included co-culture and Transwell assays, a mouse footpad-popliteal lymph node metastasis model, immunoprecipitation-mass spectrometry, co-immunoprecipitation, protein stability assays, and ubiquitination assays. Group comparisons used parametric or nonparametric tests, as appropriate. The SEER and multicenter cohorts showed a higher proportion of lymph node involvement in HR-positive/HER2-negative breast cancer than in the HER2-positive and triple-negative groups. Single-cell analysis identified a TINAGL1 + CAF population enriched in lymph node metastases, and spatial analysis demonstrated its proximity to epithelial tumor cells. Ligand-receptor analysis and tissue imaging supported MDK-SDC4 as a candidate stromal-tumor communication axis. Fibroblast-derived MDK promoted tumor-cell migration and invasion, and these responses were attenuated by SDC4 knockdown. Mechanistically, SDC4 associated with RELB and regulated its ubiquitination and proteasomal stability. USP9X associated with SDC4 and RELB, and USP9X perturbation altered RELB ubiquitination and protein stability. In vivo, SDC4 knockdown and overexpression produced opposite changes in imaging signals and popliteal lymph node volume, while RELB or USP9X knockdown attenuated the phenotype associated with SDC4 overexpression. Histological and immunohistochemical examination provided additional tissue-level characterization of the lymph node lesions. Fibroblast-derived MDK promotes breast cancer cell migration and invasion through tumor-cell SDC4. In vitro and in vivo findings support an SDC4-USP9X-RELB regulatory axis involving RELB ubiquitination and stability, providing mechanistic insight into stromal-tumor communication in regional lymph node metastasis.
中文摘要:淋巴结转移是乳腺癌分期和治疗决策的核心。临床观察提示激素受体阳性乳腺癌可能呈现独特的区域淋巴结受累模式,但基质及细胞内机制尚不明确。本研究整合了SEER数据库、多中心队列、公共单细胞RNA测序数据、空间转录组学及多重免疫荧光技术。利用CytoTRACE、拟时序及配体-受体分析评估成纤维细胞状态及候选细胞间通讯通路。功能与机制验证包括共培养及Transwell实验、小鼠足垫-腘窝淋巴结转移模型、免疫沉淀-质谱分析、共免疫沉淀、蛋白稳定性检测及泛素化实验,组间比较采用参数或非参数检验。SEER及多中心队列显示HR阳性/HER2阴性乳腺癌的淋巴结受累比例高于HER2阳性及三阴性组。单细胞分析鉴定出富集于淋巴结转移灶的TINAGL1+CAF亚群,空间分析显示其邻近上皮肿瘤细胞。配体-受体分析及组织成像支持MDK-SDC4为候选基质-肿瘤通讯轴。成纤维细胞来源的MDK促进肿瘤细胞迁移与侵袭,该效应经SDC4敲低减弱。机制上,SDC4与RELB结合并调控其泛素化及蛋白酶体稳定性;USP9X与SDC4及RELB结合,干扰USP9X改变RELB泛素化及蛋白稳定性。体内实验中,SDC4敲低与过表达导致成像信号及腘窝淋巴结体积发生相反变化,而RELB或USP9X敲低减弱了SDC4过表达相关表型。组织病理及免疫组化进一步表征了淋巴结病变特征。成纤维细胞来源的MDK通过肿瘤细胞SDC4促进乳腺癌细胞迁移与侵袭。体内外结果支持涉及RELB泛素化及稳定性的SDC4-USP9X-RELB调控轴,为区域淋巴结转移中基质-肿瘤通讯提供了机制见解。
Nature communications IF 18.1 2026-11-17 PMID: 43045764
Identification of partial loss-of-function (hypomorphic), reduced penetrance pathogenic missense variants (RPPVs) and assessment of the clinical relevance of these variants is needed for improved hereditary cancer risk estimation. Here we show that 70 candidate hypomorphic missense variants in the DNA-binding domain of BRCA2 reduce homologous recombination DNA repair activity and endogenous cell survival, decrease RAD51 foci formation, and increase sensitivity to Poly(ADP-ribose) polymerase inhibitors. The 34 "strong" hypomorphs with greatest effects on function are associated with moderate risks of female breast cancer and later ages of diagnosis than pathogenic variants (PVs), and 14 of these variants can be classified as "likely pathogenic" by integration of functional data into a ClinGen BRCA1/2 variant curation model. In addition, 32% of tumors with hypomorphic variants and corresponding loss of heterozygosity for BRCA2 display homologous recombination deficiency (HRD) compared to 83% of tumors with PVs and 7% with benign variants. These RPPVs represent a class of BRCA2 variants that have implications for the clinical management of carriers.
中文摘要:识别部分功能丧失(低效)的致病错义变异并评估其临床相关性,对于改善遗传性癌症风险估算至关重要。本研究显示,BRCA2 DNA结合域中的70个候选低效错义变异会降低同源重组DNA修复活性及内源性细胞存活率,减少RAD51焦点形成,并增加对聚ADP核糖聚合酶抑制剂的敏感性。功能影响最大的34个强效低效变异与女性乳腺癌中度风险相关,且诊断年龄晚于致病变异,其中14个变异通过整合功能数据至ClinGen BRCA1/2变异评估模型可被归类为可能致病。此外,携带低效变异并伴有BRCA2杂合性缺失的肿瘤中,32%显示同源重组缺陷,而致病变异和良性变异对应的比例分别为83%和7%。这些部分功能丧失的致病错义变异构成一类具有临床管理意义的BRCA2变异。
ACS nano IF 17.3 2026-11-17 PMID: 43043229
Ligand binding identified during screening does not necessarily translate into improved nanocarrier delivery. Here, we report a membrane-context screening strategy that uses BT-549 cell membrane-functionalized silica microspheres to identify peptide ligands with preserved nanodelivery activity. From a 7-mer combinatorial library, P1 (KFYVSGT) was selected as a membrane-enriched peptide candidate based on its preferential retention by the membrane-functionalized stationary phase relative to bare silica. After conjugation to PEG-PCL micelles, P1 preserved the nanocarrier's size, charge, morphology, stability, and drug-loading capacity, yet markedly enhanced biological performance. P1-functionalized micelles increased BT-549 cellular uptake by approximately 5-fold and tumor accumulation by about 3-fold in a BT-549 xenograft model. When loaded with doxorubicin, P1 micelles restrained tumor expansion to 1.96-fold of the initial volume, compared with 4.83-fold for nontargeted micelles, with favorable preliminary systemic tolerance. Competitive uptake, energy depletion, peptide-affinity capture, inhibition, colocalization, and docking analyses suggest that P1 activity is associated with a Galectin-1-related membrane environment. This work establishes membrane-context screening as a practical route to function-preserving peptide ligands for targeted nanodelivery.
中文摘要:筛选过程中发现的配体结合并不一定能转化为纳米载体递送效率的提升。本研究报道了一种膜环境筛选策略,利用BT-549细胞膜功能化的二氧化硅微球来识别具有保留纳米递送活性的肽配体。从七肽组合文库中,P1(KFYVSGT)因其相对于裸二氧化硅在膜功能化固定相上的优先保留而被选为富含膜的肽候选物。与PEG-PCL胶束偶联后,P1保持了纳米载体的粒径、电荷、形态、稳定性和载药能力,但显著增强了生物性能。P1功能化的胶束使BT-549细胞摄取量增加约5倍,在BT-549异种移植模型中肿瘤蓄积量增加约3倍。负载阿霉素后,P1胶束将肿瘤扩张限制在初始体积的1.96倍,而非靶向胶束为4.83倍,且具有较好的初步全身耐受性。竞争性摄取、能量耗竭、肽亲和捕获、抑制、共定位及对接分析表明,P1活性与半乳糖凝集素-1相关的膜环境有关。这项工作确立了膜环境筛选作为获取功能保留型肽配体以实现靶向纳米递送的一种实用途径。
Cancer research IF 22.6 2026-11-16 PMID: 42743243
More than 3 decades have passed since the identification of BRCA1 as the first breast cancer susceptibility gene (BCSG). Since then, substantial progress has been made in pinpointing BCSGs and estimating the associated risk of developing breast cancer. Simultaneously, new challenges and open questions have also emerged, such as the potential associations between BCSGs and metastasis in patients with breast cancer. In this review, we discuss available data from clinical and experimental studies assessing the association between germline pathogenic variants (GPV) in BCSGs and metastasis patterns. To help guide future studies addressing the current knowledge gaps, the review outlines clinical outcomes and 4 variables to be considered: (i) age and ethnicity; (ii) clinical, molecular, and pathologic characteristics; (iii) treatment response; and (iv) the specificity of BCSG variants. The synthesis of data from mouse models and human-derived materials supports a speculative model in which the cross-talk between breast cancer cells and the microenvironment defines the metastasis pattern in carriers of GPVs in BCSGs. An experimental framework is proposed for testing this model in future studies that could parallel comprehensive clinical studies addressing the outlined clinical outcomes and variables.
中文摘要:自BRCA1被确认为首个乳腺癌易感基因(BCSG)以来,已逾三十年。此后,在确定BCSGs及评估相关乳腺癌发病风险方面取得了显著进展。同时,新的挑战和未解问题也随之出现,例如BCSGs与乳腺癌患者转移之间潜在的关联。本综述讨论了来自临床和实验研究的数据,旨在评估BCSGs中生殖系致病变异(GPV)与转移模式之间的关联。为引导未来研究填补当前的知识空白,该综述概述了临床结局及需考虑的四个变量:(i)年龄和种族;(ii)临床、分子和病理特征;(iii)治疗反应;以及(iv)BCSG变异的特异性。来自小鼠模型和人类衍生材料的综合数据支持一种推测性模型,即乳腺癌细胞与微环境之间的相互作用定义了携带BCSGs中GPV个体的转移模式。本文提出了一个实验框架,用于在未来研究中测试该模型,这些研究可与解决上述临床结局和变量的全面临床研究并行开展。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42541843
Simultaneous imaging of multiple intracellular RNA biomarkers is essential for precise molecular subtyping of cancers, but achieving orthogonal signal amplification with a low background remains a challenge. Herein, we design an entropy-driven palindromic DNA nanostructure by integrating four orthogonal catalytic circuits into a single nanostructure for accurate discrimination of different breast cancer cell subtypes based on multiplexed imaging of miRNA-21, miRNA-373, miRNA-155, and MnSOD mRNA. This system is constructed from two cruciform modules. Cruciform module 1 is formed by four substrate complexes with each consisting of a quencher-labeled template, a fluorophore-labeled reporter (Alexa Fluor 405, 488, 568, and 647) and an assistant strand carrying a palindromic arm for co-localizing the fluorophores and quenchers to suppress fluorescence. Cruciform module 2 is assembled from four fuel strands sharing the same palindromic sequence. Hybridization of two modules via their complementary palindromic arms generates self-assembled palindromic DNA nanostructure (SAPDN). Upon cellular internalization of SAPDN, each target RNA binds a specific toehold on its corresponding substrate complex to trigger an entropy-driven strand-displacement cascade, releasing a target-probe intermediate. Subsequent invasion by the fuel strand results in the liberation of intact target, the displacement of reporter strand, and the separation of fluorophore from the quencher to restore fluorescence. The liberated RNA targets can activate new substrate complexes to achieve catalytic signal amplification. By mapping the four fluorescence signatures inside living cells, the SAPDN platform can effectively differentiate different breast cancer subtypes, holding great promise in advanced molecular diagnostics.
中文摘要:同时成像多种细胞内RNA生物标志物对于癌症的精确分子分型至关重要,但实现正交信号放大并保持低背景仍具挑战性。本研究设计了一种熵驱动回文DNA纳米结构,将四个正交催化电路整合到单一纳米结构中,用于基于miRNA-21、miRNA-373、miRNA-155和MnSOD mRNA的多重成像来准确区分不同的乳腺癌细胞亚型。该系统由两个十字形模块构成。十字形模块1由四个底物复合物组成,每个复合物包含一个带有淬灭剂的模板、一个带有荧光标记的报告分子(Alexa Fluor 405、488、568和647)以及一条携带回文臂的辅助链,该回文臂用于共定位荧光基团和淬灭剂以抑制荧光。十字形模块2由四条共享相同回文序列的燃料链组装而成。两个模块通过其互补的回文臂杂交生成自组装回文DNA纳米结构(SAPDN)。在SAPDN进入细胞后,每个靶RNA与其对应底物复合物上的特定起始位点结合,触发熵驱动的链置换级联反应,释放靶探针中间体。随后燃料链的入侵导致完整靶标的释放、报告链的置换以及荧光基团与淬灭剂的分离从而恢复荧光。释放的RNA靶标可激活新的底物复合物以实现催化信号放大。通过在活细胞内映射四种荧光特征,SAPDN平台能有效区分不同的乳腺癌亚型,在高级分子诊断方面展现出巨大潜力。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42485703
The rapid identification and precise quantification of cancer biomarkers are essential for the purposes of diagnosis, classification, and therapeutic intervention. Traditional molecular diagnostic methodologies, such as polymerase chain reaction (PCR), provide considerable sensitivity; however, they depend on exponential amplification and advanced instrumentation, thereby constraining their applicability for point-of-care testing. In this study, we developed a Transcription-driven CRISPR Cascade Amplification (TCCA) for one-tube detection of mRNA at the concentration of 0.6 copies/μL within just 30 min. The target-induced assembly of a three-way junction (TWJ) facilitates the generation of a split T7 promoter, which initiates transcription and activates Cas13a collateral cleavage. The activated Cas13a subsequently cleaves cascade probes and releases new trigger strands, forming a transcription-driven cascade amplification circuit. The assay enables multiplex detection of breast cancer-associated mRNA biomarkers (HBB, KRT17, and CD55) in cell lysates, demonstrating robust performance in intricate biological matrices. Furthermore, incorporation of a multiplex OR-gated logic design enables parallel target recognition, thereby enhancing detection reliability for rapid and accurate clinical diagnostics.
中文摘要:癌症生物标志物的快速识别与精准定量对于诊断、分型及治疗干预至关重要。传统分子诊断方法如聚合酶链反应(PCR)虽具备较高灵敏度,但依赖指数扩增和先进仪器,限制了其在即时检测中的应用。本研究开发了一种转录驱动的CRISPR级联扩增技术(TCCA),可在30分钟内实现0.6 copies/μL浓度mRNA的单管检测。靶标诱导的三向连接体(TWJ)组装促进了分裂型T7启动子的生成,进而启动转录并激活Cas13a的旁路切割活性。被激活的Cas13a随后切割级联探针并释放新的触发链,形成转录驱动的级联扩增回路。该检测方法在细胞裂解液中实现了乳腺癌相关mRNA生物标志物(HBB、KRT17和CD55)的多重检测,在复杂的生物基质中表现出稳健的性能。此外,引入多重OR门逻辑设计实现了靶标的并行识别,从而提高了快速精准临床诊断的检测可靠性。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42480443
Real-time, multiplexed monitoring of sex hormones is essential for managing reproductive health and endocrine disorders. Traditional invasive blood sampling lacks the temporal resolution required to capture the dynamic hormonal fluctuations necessary for personalized clinical insights. Here, we present a wearable microneedle-based electrochemical aptamer platform (WMEP) for the continuous, minimally invasive monitoring of estradiol, progesterone, luteinizing hormone, and testosterone in interstitial fluid. The WMEP integrates a four-channel microneedle electrode array enhanced with gold nanoparticles (∼2.77-fold increase in electroactive area) and a miniaturized wireless potentiostat employing time-staggered acquisition to suppress inter-channel crosstalk. In vivo rat studies demonstrated real-time tracking of hormone dynamics and revealed size-dependent transvascular transport kinetics: small steroids exhibited rapid interstitial partitioning (Tmax≈40 min), while luteinizing hormone showed delayed exchange (Tmax≈60 min). Quantitative analysis confirmed high concordance with serum ELISA measurements (Pearson's R ≥ 0.932). Clinical validation using 45 human serum samples across healthy controls, pregnancy, polycystic ovary syndrome, and breast cancer cohorts demonstrated robust analytical accuracy. A random forest classifier achieved 95.56% diagnostic accuracy based on multiplexed profiles. Human on-body trials further confirmed the platform's practical utility, reliably tracking testosterone surges during exercise and maintaining signal stability over 5 days of continuous wear. This wearable platform enables personalized, longitudinal endocrine management and decentralized monitoring of reproductive health disorders.
中文摘要:实时监测多种性激素对于生殖健康和内分泌疾病的管理至关重要。传统的侵入性采血缺乏捕捉动态激素波动所需的时空分辨率,难以提供个性化的临床见解。本研究提出了一种基于微针的可穿戴电化学适配体平台(WMEP),用于连续、微创地监测间质液中的雌二醇、孕酮、黄体生成素和睾酮。该平台集成了经金纳米颗粒增强的四通道微针电极阵列(电化学活性面积增加约2.77倍)以及采用时间交错采集技术以抑制通道串扰的微型无线恒电位仪。大鼠体内实验实现了激素动态的实时追踪,并揭示了尺寸依赖性的跨血管转运动力学:小分子类固醇表现出快速间质分配(Tmax≈40分钟),而黄体生成素则显示延迟交换(Tmax≈60分钟)。定量分析证实了其与血清ELISA测量结果的高度一致性(Pearson's R≥0.932)。利用涵盖健康对照、妊娠、多囊卵巢综合征和乳腺癌队列的45个人类血清样本进行的临床验证展示了稳健的分析准确性。基于多重谱系的随机森林分类器达到了95.56%的诊断准确率。人体佩戴试验进一步证实了该平台的实用价值,能够可靠地追踪运动期间的睾酮激增并在连续佩戴5天内保持信号稳定。该可穿戴平台实现了个性化的纵向内分泌管理和生殖健康疾病的去中心化监测。
ACS sensors IF 10.9 2026-11-14 PMID: 43033087
The CRISPR-Cas12a system has revolutionized molecular diagnostics; however, the strict requirement of crRNAs and target DNA for collateral cleavage activation restricts its flexibility in non-nucleic acid diagnostics. Herein, we demonstrate that AsCas12a exhibits an RNA-free collateral cleavage activity with the presence of manganese ions (Mn2+), which preferentially cleaves single-stranded DNA efficiently. Mechanistically, kinetic analyses reveal that AsCas12a exhibits a significantly higher binding affinity for Mn2+ than for magnesium ion (Mg2+), while molecular dynamics simulations suggest that Mn2+ coordination induces conformational changes to expose the RuvC endonuclease domain. Harnessing this unique property, an enzymatic cascade-amplified electrochemical biosensor integrating manganese nanoflowers is reported for the diagnosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. By equipping screen-printed gold electrodes with DNA reporters, this diagnostic tool enables high-precision HER2 quantification and successfully distinguishes various HER2-related cell lines. Furthermore, the biosensor has been extended to analyze HER2-positive exosomes, facilitating the dynamic tracking of serum exosome levels in tumor-bearing nude mice to evaluate therapeutic efficacy and accurately distinguish HER2-positive breast cancer patients in clinical samples. This RNA-free Cas12a system may provide new insights into CRISPR-based non-nucleic acid detection, emerging as a powerful tool for dynamic tumor monitoring and precision oncology.
中文摘要:CRISPR-Cas12a系统彻底改变了分子诊断领域,然而其对crRNA和目标DNA的严格要求限制了其在非核酸诊断中的灵活性。本文证明AsCas12a在锰离子(Mn2+)存在下表现出无RNA的旁路切割活性,并优先高效切割单链DNA。机制上,动力学分析显示AsCas12a对Mn2+的结合亲和力显著高于镁离子(Mg2+),而分子动力学模拟表明Mn2+配位诱导构象变化以暴露RuvC核酸内切酶结构域。利用这一独特特性,报道了一种整合锰纳米花的酶级联放大电化学生物传感器,用于诊断人表皮生长因子受体2(HER2)阳性乳腺癌。通过在丝网印刷金电极上配备DNA报告分子,该诊断工具实现了高精度的HER2定量并成功区分了不同的HER2相关细胞系。此外,该生物传感器被扩展用于分析HER2阳性外泌体,促进了荷瘤裸鼠血清外泌体水平的动态追踪以评估疗效,并在临床样本中准确区分HER2阳性乳腺癌患者。这种无RNA的Cas12a系统可能为基于CRISPR的非核酸检测提供新见解,成为动态肿瘤监测和精准医疗的有力工具。
Acta biomaterialia IF 10.4 2026-11-13 PMID: 43025676
As the most prevalent malignancy in female population, triple-negative breast cancer is characterized by unfavorable prognosis and therapy resistance, driven by a significant and progressive accumulation of lipid droplets (LDs). As dynamic organelles, LDs play critical roles in lipid storage, oxidative stress mitigation, and metabolic buffering. Here, we developed a cationic lipid droplet-targeted nanoparticle chimera (LD·NanoTAC) functionalized with an LD-targeting moiety to achieve precise subcellular delivery. Meanwhile, the cationic charges boost autophagic flux, thus promoting selective lipophagy and subsequent degradation of LDs. To interfere with tumor cell metabolism, we focused on nicotinamide phosphoribosyltransferase (NAMPT), a rate-limiting enzyme in the mammalian nicotinamide adenine dinucleotide (NAD+) salvage pathway. Also, extracellular NAMPT promotes tumor progression through non-enzymatic mechanisms. Hence, a NAMPT-targeted protein degrader was encapsulated in LD·NanoTAC to afford LD·NanoTACNAMPT, inducing targeted degradation of NAMPT, leading to NAD+ reduction and subsequent inhibition of Warburg effect in tumor cells. The dual degradation triggered a catastrophic energetic impairment in tumor cells. Concurrently, the compensatory mitochondrial β-oxidation of lipophagy-derived fatty acids was suppressed, leading to complete LD clearance and a paradoxical state of substrate overload accompanied by bioenergetic failure. This cellular dysfunction subsequently initiated a cascade of events including reactive oxygen species accumulation, onset of mitochondrial dysfunction, and ultimately irreversible tumor cell death. In vivo, the dual-degradation strategy using LD·NanoTACNAMPT demonstrated potent antitumor efficacy in both orthotopic and metastatic 4T1 tumor models. It significantly suppressed primary tumor growth and pulmonary metastasis, and extended the median survival of 4T1 tumor-bearing mice. STATEMENT OF SIGNIFICANCE: Triple-negative breast cancer (TNBC) remains a major clinical challenge with poor prognosis and limited therapeutic options, largely driven by progressive accumulation of lipid droplets (LDs) that fuel tumor metabolic reprogramming. Existing protein degradation strategies face critical bottlenecks in subcellular precision and synergistic metabolic disruption. Here, we propose a cationic LD-targeted nanoparticle chimera (LD·NanoTAC) platform, which achieves concurrent targeted degradation of LDs and the key metabolic enzyme nicotinamide phosphoribosyltransferase (NAMPT). This dual-degradation paradigm triggers catastrophic energetic collapse, suppresses compensatory mitochondrial β-oxidation, and eliminates LDs, leading to irreversible TNBC cell death. The system demonstrates potent in vivo antitumor and anti-metastatic efficacy in orthotopic 4T1 models. This work establishes a subcellular-targeted dual degradation strategy, opening a new avenue for TNBC metabolic intervention.
中文摘要:三阴性乳腺癌是女性中最常见的恶性肿瘤,其特征为预后不良和治疗耐药,这主要由脂质体(LDs)显著且进行性积累驱动。作为动态细胞器,脂质体在脂质储存、氧化应激缓解和代谢缓冲中发挥关键作用。本研究开发了一种阳离子脂质体靶向纳米颗粒嵌合体(LD·NanoTAC),通过功能化脂质体靶向部分实现精确的亚细胞递送。同时,阳离子电荷增强自噬流,从而促进选择性脂噬及随后的脂质体降解。为干扰肿瘤细胞代谢,我们聚焦于烟酰胺磷酸核糖转移酶(NAMPT),它是哺乳动物烟酰胺腺嘌呤二核苷酸(NAD+)补救途径中的限速酶。此外,细胞外NAMPT通过非酶机制促进肿瘤进展。因此,将NAMPT靶向蛋白降解剂封装在LD·NanoTAC中构建LD·NanoTACNAMPT,诱导NAMPT靶向降解,导致NAD+减少并抑制肿瘤细胞的Warburg效应。双重降解引发肿瘤细胞灾难性能量损伤。同时,脂噬衍生的脂肪酸的补偿性线粒体β-氧化受到抑制,导致脂质体完全清除及伴随生物能量衰竭的底物过载悖论状态。这种细胞功能障碍随后启动了一系列事件,包括活性氧积累、线粒体功能障碍 onset 以及最终的不可逆肿瘤细胞死亡。在体内,使用LD·NanoTACNAMPT的双重降解策略在原位和转移性4T1肿瘤模型中显示出强大的抗肿瘤疗效。它显著抑制原发肿瘤生长和肺转移,并延长4T1荷瘤小鼠的中位生存期。研究意义:三阴性乳腺癌(TNBC)仍是一个主要的临床挑战,预后不良且治疗选择有限,这主要归因于脂质体进行性积累驱动的肿瘤代谢重编程。现有的蛋白降解策略在亚细胞精度和协同代谢破坏方面面临关键瓶颈。本研究提出了一种阳离子脂质体靶向纳米颗粒嵌合体(LD·NanoTAC)平台,实现脂质体和关键代谢酶NAMPT的同时靶向降解。这种双重降解范式引发灾难性能量崩溃,抑制补偿性线粒体β-氧化并消除脂质体,导致不可逆的TNBC细胞死亡。该系统在原位4T1模型中显示出强大的体内抗肿瘤和抗转移疗效。本研究确立了一种亚细胞靶向的双重降解策略,为TNBC代谢干预开辟了新途径。
Pharmacological research IF 12.2 2026-11-13 PMID: 43025527
Although the staphylococcal nuclease domain-containing protein 1 (SND1)-metadherin (MTDH) complex is a promising therapeutic target in triple-negative breast cancer (TNBC), its role in DNA damage repair (DDR) remains unclear. Here, we identified FANCD2 as a previously unrecognized downstream effector of the SND1-MTDH complex. SND1 and MTDH cooperate to stabilize FANCD2 mRNA, thereby sustaining FANCD2 expression and DDR in TNBC cells. Guided by our finding, we designed DP3, an MTDH-derived peptide inhibitor that binds SND1 with high affinity and selectively disrupts the SND1-MTDH interaction. DP3 promoted degradation of both SND1 and MTDH, destabilized FANCD2 mRNA, reduced FANCD2 expression, and consequently increased DNA damage accumulation. Functionally, DP3 suppressed TNBC cell proliferation, migration, invasion, and survival and showed potent antitumor activity in patient-derived organoids and xenograft models, with a favorable safety profile in vivo. Importantly, DP3 enhanced the antitumor activity of PARP inhibitors (PARPi) in TNBC models by further suppressing FANCD2 expression and promoting DNA damage accumulation. These findings identify the SND1-MTDH/FANCD2 axis as a previously unrecognized regulator of DDR and PARPi sensitivity and provide a rationale for combining SND1-MTDH interaction inhibitors with PARPi in TNBC.
中文摘要:尽管葡萄球菌核酸酶结构域蛋白1(SND1)-转移粘附蛋白(MTDH)复合物是三阴性乳腺癌(TNBC)中极具潜力的治疗靶点,但其在DNA损伤修复(DDR)中的作用尚不明确。本研究鉴定出FANCD2是SND1-MTDH复合物的一个先前未被认识的下游效应因子。SND1和MTDH协同作用以稳定FANCD2 mRNA,从而维持TNBC细胞中FANCD2的表达及DDR功能。基于这一发现,我们设计了DP3,这是一种源自MTDH的肽类抑制剂,它能高亲和力结合SND1并选择性破坏SND1-MTDH相互作用。DP3促进了SND1和MTDH的降解,使FANCD2 mRNA不稳定,降低了FANCD2表达,进而增加了DNA损伤积累。在功能上,DP3抑制了TNBC细胞的增殖、迁移、侵袭和存活,并在患者来源类器官和异种移植模型中显示出强大的抗肿瘤活性,且在体内具有良好的安全性特征。重要的是,DP3通过进一步抑制FANCD2表达和促进DNA损伤积累,增强了PARP抑制剂(PARPi)在TNBC模型中的抗肿瘤活性。这些发现将SND1-MTDH/FANCD2轴鉴定为DDR和PARPi敏感性的一个先前未被认识的调节因子,并为在TNBC中将SND1-MTDH相互作用抑制剂与PARPi联合使用提供了理论依据。
Science advances IF 13.9 2026-11-13 PMID: 43013645
Multiplexed profiling of diverse biomarkers is essential for precision diagnostics, but remains challenging for label-free sensors because signals typically scale with analyte mass. Here, we present a dynamic plasmonic imaging platform based on electromechanically driven nano-oscillators for multiplexed, label-free quantification of nucleic acids, proteins, and small molecules within a unified sensing architecture. Size-encoded nanoparticles tethered to a plasmonic surface are electrically actuated to oscillate vertically within the evanescent field and tracked by distance-resolved surface plasmon resonance imaging. Molecular binding alters the effective surface charge of each nano-oscillator, modulating the electrostatic-driven forces and changing oscillation amplitude. This charge-to-motion transduction mechanism reduces dependence on molecular mass and enhances sensitivity for low-molecular weight analytes. This platform simultaneously detects microRNAs, proteins, and small molecules spanning a ∼300-fold molecular weight range within a single field of view. We further demonstrate multiplexed profiling of tumor-associated microRNAs in pretreated supernatants from patient-derived breast cancer cells across 24 clinical samples. Dynamic plasmonic nano-oscillators provide a scalable architecture for multiplex molecular diagnostics.
中文摘要:多种生物标志物的多重分析对于精准诊断至关重要,但对于无标记传感器而言仍具挑战性,因为信号通常与分析物质量成正比。本文提出了一种基于机电驱动纳米振荡器的动态等离激元成像平台,用于在统一的传感架构中对核酸、蛋白质和小分子进行多重无标记定量。尺寸编码的纳米颗粒连接至等离激元表面,并在消逝场中通过电驱动垂直振荡,利用距离分辨的表面等离激元共振成像进行追踪。分子结合会改变每个纳米振荡器的有效表面电荷,从而调节静电驱动力并改变振荡振幅。这种电荷到运动的转导机制降低了对分子质量的依赖,并提高了对低分子量分析物的灵敏度。该平台在单个视场内同时检测跨越约300倍分子量范围的微小RNA、蛋白质和小分子。我们进一步展示了在来自24个临床样本的患者来源乳腺癌细胞预处理上清液中肿瘤相关微小RNA的多重分析结果。动态等离激元纳米振荡器为多重分子诊断提供了可扩展的架构。

4肺癌 (16篇)

临床研究 (8篇)

JAMA oncology IF 23.9 2026-11-19 PMID: 43056125
Long-term lung cancer (LC) survivors remain at risk of LC events (LCEs), including late recurrence and second primary LC, beyond 5 years after diagnosis, but the role of computed tomography (CT) surveillance beyond 5 years remains uncertain. To evaluate whether CT receipt beyond 5 years after LC diagnosis is associated with LCEs and survival. This nationwide population-based cohort study used sequential target trial emulation with monthly eligibility reassessment and time-updated propensity score matching based on data from the Korean National Health Insurance Service database. Patients diagnosed with LC from 2006 to 2019 were followed up through December 31, 2024. Long-term LC survivors were eligible for trial entry 5.5 years after diagnosis if they had no administrative evidence of active or recurrent LC, a prior LCE, or another primary cancer. Data were analyzed between January 1, 2026, and February 28, 2026. CT receipt beyond 5 years after LC diagnosis, defined as chest CT during the 1-month assessment window at each monthly trial baseline, compared with no CT receipt. The primary outcome was LCE occurrence, defined by new LC-specific special copayment registration after the monthly trial baseline. Secondary outcomes were all-cause mortality, surgical resection after LCE detection, and subsequent mortality. The cohort of 55 694 LC survivors (mean [SD] age, 63.3 [10.9] years; 58.0% male) contributed 2 629 462 eligible person-trials. Matching yielded 583 756 person-trials per group. During a median (IQR) follow-up of 2.74 (1.16-5.18) years, CT receipt was associated with a higher incidence of LCEs (2.49% vs 1.97% per year; hazard ratio [HR], 1.28 [95% CI, 1.26-1.29]) and lower all-cause mortality rate (2.62% vs 4.33% per year; HR, 0.66 [95% CI, 0.65-0.67]) compared with no CT receipt. Among patients with an LCE, CT receipt was associated with greater odds of surgical resection after LCE (odds ratio, 1.46 [95% CI, 1.41-1.52]) and a lower subsequent mortality risk (HR, 0.63 [95% CI, 0.61-0.64]). These associations were observed more frequently among females (HR, 0.47 [95% CI, 0.44-0.49]), older adults (HR, 0.57 [95% CI, 0.54-0.60]), and never smokers (HR, 0.55 [95% CI, 0.53-0.57]). In this cohort study, CT receipt beyond 5 years after LC diagnosis was associated with increased detection of LCEs, greater use of surgical resection after an LCE, and a lower all-cause mortality rate. These findings support further evaluation of risk-adapted CT surveillance beyond 5 years in selected LC survivors.
中文摘要:长期肺癌幸存者确诊五年后仍面临肺癌事件包括晚期复发和第二原发肺癌的风险但五年后计算机断层扫描监测的作用尚不明确本研究旨在评估确诊五年后进行CT检查与肺癌事件及生存率的关系这是一项基于全国人群的队列研究利用韩国国家健康保险服务数据库数据采用顺序目标试验模拟方法每月重新评估资格并基于时间更新的倾向评分进行匹配2006年至2019年确诊的肺癌患者随访至2024年12月31日长期肺癌幸存者在确诊5.5年后若无活跃或复发肺癌既往肺癌事件或其他原发癌症的证据则符合入组条件数据分析时间为2026年1月1日至2026年2月28日CT检查定义为每月试验基线时1个月评估窗口内的胸部CT与未进行CT检查相比主要结局为肺癌事件发生率由每月试验基线后新的肺癌特异性特殊支付注册定义次要结局包括全因死亡率肺癌事件检测后的手术切除及后续死亡率55694名肺癌幸存者组成的队列共贡献2629462个符合条件的个人试验匹配后每组产生583756个个人试验中位随访时间为2.74年相比未进行CT检查CT检查与更高的肺癌事件发生率每年2.49%对比1.97%风险比1.28和更低的全因死亡率每年2.62%对比4.33%风险比0.66相关在发生肺癌事件的患者中CT检查与更高的肺癌事件后手术切除几率比值比1.46和更低的后续死亡风险风险比0.63相关这些关联在女性风险比0.47老年人风险比0.57和不吸烟者风险比0.55中更为常见在本队列研究中确诊五年后进行CT检查与增加肺癌事件检测提高肺癌事件后手术切除使用率以及降低全因死亡率相关这些发现支持在选定的长期肺癌幸存者中进一步评估风险适应性的五年后CT监测
JAMA surgery IF 15.6 2026-11-18 PMID: 43050213
Stereotactic body radiation therapy (SBRT) is a well-established alternative to surgery for nonoperable patients with early-stage non-small cell (NSCLC) lung cancer. However, the role of SBRT in operable patients is unclear as 3 randomized clinical trials comparing SBRT with surgery were closed early because of poor accrual. Existing observational comparisons are limited by confounding because patients who receive SBRT are generally frailer and more comorbid. To compare cancer-specific mortality between surgery and SBRT using proximal causal inference to adjust for unmeasured confounding due to frailty and comorbidity using proxy variables. This cohort study was a national database analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset. Three treatment effect estimates were obtained with increasing control of confounding: unadjusted, standard-regression adjusted for measured confounders as in existing studies, and proximally adjusted for unmeasured confounders. Participants were patients with stage IA NSCLC who underwent sublobar resection or SBRT from 2010 to 2019, followed up through December 21, 2021. Data analysis was performed from April 2023 to August 2026. Sublobar resection vs SBRT. Negative control exposures were constructed from billing codes. Lung cancer-specific mortality. Negative control outcomes were constructed from other-cause mortality. Results are reported as hazard differences (HD) and 95% CI. A total of 4251 patients met inclusion and exclusion criteria; 2581 (60.7%) were female and 1670 (39.3%) were male. Their mean (SD) age was 75.6 (6.3) years. A total of 2558 patients underwent SBRT and 1693 underwent surgery. In the unadjusted and covariate-adjusted analyses, SBRT was associated with higher lung cancer cause-specific mortality, HD of 0.047 person-years (95% CI, 0.038-0.055) and 0.024 person-years (95% CI, 0.014-0.034), respectively. However, there was also compelling evidence of confounding due to a strong estimated association with other-cause mortality. In the proximal analysis, other-cause mortality together with negative control exposures were used to indirectly control for hidden confounders, yielding an HD of 0.012 person-years (95% CI, 0.0013-0.027). This study empirically showed that existing observational comparisons of SBRT and surgery are biased because of unmeasured confounding. When proximal causal inference was used to better control for confounding due to frailty and comorbidity, there continued to be a smaller but significant improvement in outcomes associated with surgery, though the effects of residual bias due to differences in pathologic and clinical staging could not be ruled out. This study demonstrates that proximal causal inference can be used to control for unmeasured confounders in a variety of settings.
中文摘要:立体定向体部放疗(SBRT)是早期非小细胞肺癌(NSCLC)不可手术患者的成熟替代方案。然而,SBRT在可手术患者中的作用尚不明确,因为三项比较SBRT与手术的随机临床试验因入组不良而提前关闭。现有的观察性比较受混杂因素限制,因为接受SBRT的患者通常更虚弱且合并症更多。本研究旨在使用近端因果推断方法,通过代理变量调整因虚弱和合并症导致的未测量混杂因素,以比较手术与SBRT的癌症特异性死亡率。该队列研究分析了SEER-Medicare数据库的国家数据。获得了三种治疗效应估计值,随着对混杂因素控制的增强分别为:未调整、针对现有研究中已测量混杂因素的标准回归调整,以及针对未测量混杂因素的近端调整。参与者为2010年至2019年接受亚肺叶切除或SBRT的IA期NSCLC患者,随访至2021年12月21日。数据分析于2023年4月至2026年8月进行。干预措施为亚肺叶切除与SBRT。使用账单代码构建阴性对照暴露因素。主要结局为肺癌特异性死亡率。使用其他原因死亡率构建阴性对照结局。结果以风险差异(HD)和95%置信区间(CI)报告。共有4251名患者符合纳入和排除标准;2581名(60.7%)为女性,1670名(39.3%)为男性。平均(标准差)年龄为75.6(6.3)岁。共2558名患者接受SBRT,1693名接受手术。在未调整和协变量调整分析中,SBRT与较高的肺癌特异性死亡率相关,HD分别为0.047人年(95% CI, 0.038-0.055)和0.024人年(95% CI, 0.014-0.034)。然而,也有令人信服的证据表明存在混杂因素,估计与其他原因死亡率有很强的关联。在近端分析中,其他原因死亡率和阴性对照暴露因素被用于间接控制隐藏混杂因素,得出HD为0.012人年(95% CI, 0.0013-0.027)。本研究实证表明,现有的SBRT与手术观察性比较因未测量混杂因素而存在偏差。当使用近端因果推断更好地控制因虚弱和合并症导致的混杂因素时,手术仍显示出较小但显著的结局改善,尽管不能排除由于病理和临床分期差异导致的残余偏倚影响。本研究证明,近端因果推断可用于各种情境中控制未测量的混杂因素。
ACS nano IF 17.3 2026-11-17 PMID: 43043207
Homogeneous immunoassays offer a streamlined alternative to traditional heterogeneous methods by eliminating separation and washing steps. However, they are often hampered by low sensitivity, matrix interference, and limited multiplexing capability. Herein, we reported a dual DNA nanomaterial-based homogeneous electrochemical immunoassay that achieved ultrasensitive, one-step, simultaneous detection of multiple biomarkers. The system comprised a cyclic DNA nanomaterial (C-DNM) and a Y-shaped DNA nanosphere (Y-DNM) that coordinated Ag+ and Hg2+ via base mismatching, and antibodies were conjugated by the biotin-streptavidin system. Specific antigen-antibody binding could exert spatial steric hindrance on C-DNM, thereby triggering cascade metal ions release from Y-DNM and producing a second burst of signal amplification. This mechanism enabled detection limits down to the ag/mL level. Utilizing this strategy, we successfully quantified urinary ESAT-6 and LAM for tuberculosis, as well as PD-L1/MUC1-positive small extracellular vesicles (SEVs) and circulating tumor cells for lung cancer. The whole detection could be completed within 30 min. Clinical validation was taken in 60 samples, and the receiver operating curve analysis demonstrated good diagnostic accuracy, which showed strong correlation with clinical imaging findings. This dual DNA nanomaterial strategy provided a universal, rapid, and ultrasensitive tool for homogeneous immunoassay-based precision diagnostics of diseases.
中文摘要:均相免疫测定通过消除分离和洗涤步骤,为传统异质方法提供了简化的替代方案。然而,其常受限于灵敏度低、基质干扰及多重检测能力不足。本研究报道了一种基于双重DNA纳米材料的均相电化学免疫测定法,实现了多种生物标志物的超灵敏一步同步检测。该系统由环状DNA纳米材料(C-DNM)和Y形DNA纳米球(Y-DNM)组成,二者通过碱基错配协调Ag+和Hg2+,抗体通过生物素-链霉亲和素系统偶联。特异性抗原-抗体结合可对C-DNM产生空间位阻,从而触发Y-DNM中金属离子的级联释放并产生二次信号放大效应。该机制使检测限低至ag/mL水平。利用该策略,我们成功定量了用于结核病诊断的尿ESAT-6和LAM,以及用于肺癌诊断的PD-L1/MUC1阳性小细胞外囊泡(SEVs)和循环肿瘤细胞。整个检测过程可在30分钟内完成。在60个临床样本中进行的验证显示,受试者工作特征曲线分析表明具有良好的诊断准确性,且与临床影像学结果呈强相关性。这一双重DNA纳米材料策略为基于均相免疫测定的疾病精准诊断提供了一种通用、快速且超灵敏的工具。
Drugs IF 14.7 2026-11-17 PMID: 43040186
Daraxonrasib (RASONQUE™) is an oral, multiselective, noncovalent RAS(ON) inhibitor being developed by Revolution Medicines for the treatment of solid tumours, including pancreatic ductal adenocarcinoma (PDAC), non-small-cell lung cancer and colorectal cancer. Daraxonrasib received its first approval in the USA on 26 August 2026 for the treatment of adults with metastatic PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. This article summarizes the milestones in the development of daraxonrasib leading to its first approval for metastatic PDAC.
中文摘要:Daraxonrasib(RASONQUE™)是一种口服的多选择性非共价RAS(ON)抑制剂,由Revolution Medicines公司开发,用于治疗实体瘤,包括胰腺导管腺癌(PDAC)、非小细胞肺癌和结直肠癌。2026年8月26日,Daraxonrasib在美国首次获批,用于治疗接受过至少一种全身治疗或无法接受多药联合全身治疗的转移性PDAC成人患者。本文总结了Daraxonrasib开发过程中导致其首次获批用于转移性PDAC的关键里程碑。
Cancer research IF 22.6 2026-11-16 PMID: 42615562
Spatial transcriptomic (ST) analyses provide spatially resolved gene expression data that can provide insights into complex biological processes. However, current ST approaches remain financially prohibitive and restricted in resolution, scalability, and gene coverage, limiting broader adoption for large-scale studies. In this study, we developed Contrastive Alignment of gene expRession for hematoxylin and eosin (H&E) images (CarHE), a multimodal pretraining framework that infers high-dimensional ST profiles from routine H&E-stained slides. By using contrastive learning to align cell type-specific transcriptomic information with histologic features, CarHE achieved high prediction accuracy across evaluated datasets and ST platforms. CarHE approximated spatially organized pathologic microenvironment features consistent with tertiary lymphoid structure-associated regions in breast cancer, lung cancer, melanoma, and clear-cell renal cell carcinoma. Additionally, CarHE inferred approximated three-dimensional (3D) ST context from two-dimensional (2D) images, providing more informative neighborhood context than 2D visualization. In a cohort of 880 patients with lung cancer, CarHE-derived features were associated with disease-free survival and outperformed current approaches. Overall, CarHE provides a cost-effective and scalable framework for H&E-based spatial inference, supporting further validation toward translational research applications. CarHE infers spatial transcriptomics landscapes from routine H&E slides that associate with patient outcomes, providing a powerful tool for localizing immune niches and microenvironmental programs within standard histological workflows.
中文摘要:空间转录组分析提供具有空间分辨率的基因表达数据,有助于揭示复杂的生物学过程。然而,当前的空间转录组方法在成本、分辨率、可扩展性和基因覆盖范围方面仍存在局限,限制了其在大规模研究中的广泛应用。本研究开发了基于苏木精和伊红染色图像的对比对齐基因表达框架(CarHE),这是一种多模态预训练框架,能够从常规H&E切片中推断高维空间转录组特征。通过采用对比学习将细胞类型特异性转录组信息与组织学特征进行对齐,CarHE在评估的数据集和空间转录组平台上均实现了较高的预测精度。CarHE能够近似重现与三级淋巴结构相关区域的空间病理微环境特征,涉及乳腺癌、肺癌、黑色素瘤和透明细胞肾细胞癌。此外,CarHE能够从二维图像中推断近似的三维空间转录组背景,提供比二维可视化更丰富的邻域上下文信息。在包含880名肺癌患者的队列中,基于CarHE推导的特征与无病生存期相关,且优于现有方法。总体而言,CarHE提供了一种经济高效且可扩展的基于H&E的空间推断框架,支持向转化研究应用的进一步验证。CarHE能够从常规H&E切片中推断出与患者预后相关的空间转录组景观,为在标准组织学工作流程中定位免疫生态位和微环境程序提供了有力工具。
ESMO open IF 10.6 2026-11-15 PMID: 43035066
EMPOWER-Lung 3 Part 2, a phase 3, double-blind, placebo-controlled study, demonstrated substantial survival benefits with cemiplimab plus chemotherapy versus placebo plus chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 alterations. Here, we report 5-year results from the subgroup analysis of patients with programmed death-ligand 1 (PD-L1) expression ≥1%. Eligible patients were randomized 2 : 1 to receive histology-specific platinum-doublet chemotherapy plus cemiplimab 350 mg or placebo every 3 weeks for up to 108 weeks. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS) and objective response rate (ORR). This analysis focuses on patients with PD-L1 ≥1% with 5-year follow-up (last patient last visit: 27 February 2025). Of 327 patients with PD-L1 ≥1% (out of 466 in the overall study), 217 received cemiplimab plus chemotherapy and 110 received placebo plus chemotherapy. After median follow-up of 60.5 months, median OS for cemiplimab plus chemotherapy was 24.0 months [95% confidence interval (CI) 20.9-28.4] versus 12.1 months (95% CI 10.1-15.7) for placebo plus chemotherapy [hazard ratio (HR) 0.54, 95% CI 0.41-0.70, P < 0.0001); median PFS was 8.3 months (95% CI 6.7-10.8) versus 5.5 months (95% CI 4.3-6.2, HR 0.50, 95% CI 0.39-0.65, P < 0.0001), and the ORR was 48.4% versus 22.7%, respectively. Improved efficacy over placebo plus chemotherapy was observed across squamous and nonsquamous histologies, in both locally advanced and metastatic disease, and in patients with PD-L1 1%-49% and ≥50%. Grade ≥3 treatment-emergent adverse events occurred in 48.8% of patients receiving cemiplimab plus chemotherapy versus 27.5% receiving placebo plus chemotherapy. No new toxicities were identified. First-line cemiplimab plus chemotherapy continued to show durable clinical benefit versus placebo plus chemotherapy after 5 years of follow-up in PD-L1-positive advanced NSCLC.
中文摘要:EMPOWER-Lung 3 Part 2是一项III期双盲安慰剂对照研究,证实了在未经治疗的晚期非小细胞肺癌(NSCLC)且无EGFR、ALK或ROS1突变的患者中,西米普利单抗联合化疗相比安慰剂联合化疗具有显著的生存获益。本文报告了程序性死亡配体1(PD-L1)表达≥1%亚组患者的5年结果。符合条件的患者按2:1随机分组接受组织学特异性含铂双药化疗加每3周一次的西米普利单抗350mg或安慰剂,持续最多108周。主要终点为总生存期(OS),次要终点包括无进展生存期(PFS)和客观缓解率(ORR)。该分析聚焦于PD-L1≥1%的患者,随访截止至2025年2月27日。在466名总体研究患者中,有327名PD-L1≥1%的患者被纳入分析,其中217名接受西米普利单抗联合化疗,110名接受安慰剂联合化疗。中位随访60.5个月后,西米普利单抗联合化疗组的中位OS为24.0个月(95%置信区间CI 20.9-28.4),而安慰剂联合化疗组为12.1个月(95% CI 10.1-15.7)[风险比HR 0.54,95% CI 0.41-0.70,P < 0.0001];中位PFS分别为8.3个月(95% CI 6.7-10.8)和5.5个月(95% CI 4.3-6.2,HR 0.50,95% CI 0.39-0.65,P < 0.0001),ORR分别为48.4%和22.7%。在鳞癌和非鳞癌组织学类型、局部晚期和转移性疾病以及PD-L1表达1%-49%和≥50%的患者中,均观察到相比安慰剂联合化疗的疗效改善。接受西米普利单抗联合化疗的患者中48.8%出现3级及以上治疗相关不良事件,而安慰剂联合化疗组为27.5%。未发现新的毒性反应。在PD-L1阳性的晚期NSCLC患者中,一线西米普利单抗联合化疗在5年随访后持续显示出比安慰剂联合化疗更持久的临床获益。
Cancer discovery IF 29.5 2026-11-14 PMID: 43031331
In the phase III Opti-TROP-Lung06 trial, patients with newly diagnosed PD-L1-negative, advanced nonsquamous non-small cell lung cancer without targetable alterations who received the TROP-2-directed antibody-drug conjugate sacituzumab tirumotecan and the PD-1 inhibitor pembrolizumab experienced a median progression-free survival (PFS) of 15 months. In comparison, those patients who received standard chemotherapy plus pembrolizumab experienced a median PFS of 5.7 months.
中文摘要:在III期Opti-TROP-Lung06试验中,新诊断为PD-L1阴性、无靶向突变的晚期非鳞状非小细胞肺癌患者接受TROP-2导向抗体偶联药物sacituzumab tirumotecan与PD-1抑制剂pembrolizumab治疗后,中位无进展生存期(PFS)为15个月。相比之下,接受标准化疗联合pembrolizumab治疗的患者中位PFS仅为5.7个月。
ACS sensors IF 10.9 2026-11-13 PMID: 43024743
Precise detection of trace miRNAs in liquid biopsies is critical for early lung cancer screening, yet current methods are frequently limited by complex reverse transcription procedures and potential enzymatic amplification biases. Herein, we developed a sequencing-free and highly portable dual-mode biosensing platform for decentralized clinical diagnostics by synergizing highly specific CRISPR/Cas13a recognition with exponential non-enzymatic catalytic hairpin assembly amplification (CHA). Trace target miRNAs activate Cas13a to trans-cleave the RNA trigger strand, while intact RNA triggers can precisely initiate downstream assembly networks. The Cas13a molecular lock completely eliminates spontaneous hairpin crosslinking interference. Based on this mechanism, we separately constructed a fluorescence and a multiplex surface-enhanced Raman scattering biosensing platform. The catalytic network drives reporter-embedded bimetallic nanoparticles to specifically bind plasmonic chips, forming sandwich resonance structures for absolute multiplex spectral quantification. The system synchronously processes and analyzes four lung cancer-associated miRNAs within 80 min, achieving an ultralow attomolar diagnostic limit and an exceptionally broad linear dynamic range spanning ten orders of magnitude. Clinical validation using 50 plasma samples demonstrated high quantitative agreement with standard qRT-PCR alongside exceptional anti-interference characteristics. Integrating a machine classification model to extract spectral features successfully clustered distinct pathological stages with the accuracy of 80.00 and 93.33%, respectively. The systematic framework, merging miniature programmable biochemical cascade pathways with multidimensional artificial intelligence predictions, provides a highly powerful novel diagnostic paradigm to overcome traditional barriers in complex liquid biopsy translational applications.
中文摘要:液体活检中痕量miRNA的精准检测对于早期肺癌筛查至关重要,然而现有方法常受限于复杂的逆转录程序和潜在的酶促扩增偏差。本研究通过协同高特异性CRISPR/Cas13a识别与指数级非酶促催化发夹组装扩增(CHA),开发了一种免测序且高度便携的双模生物传感平台,用于去中心化临床诊断。痕量靶标miRNA激活Cas13a反式切割RNA触发链,而完整的RNA触发链可精确启动下游组装网络。Cas13a分子锁完全消除了自发发夹交联干扰。基于该机制,我们分别构建了荧光和多重表面增强拉曼散射生物传感平台。催化网络驱动嵌入报告子的双金属纳米颗粒特异性结合等离激元芯片,形成三明治共振结构以实现绝对多重光谱定量。该系统在80分钟内同步处理并分析四种肺癌相关miRNA,实现了超低阿摩尔级诊断限和跨越十个数量级的极宽线性动态范围。利用50个血浆样本进行的临床验证显示,其定量结果与标准qRT-PCR高度一致且具备卓越的抗干扰特性。整合机器学习模型提取光谱特征后,成功以80.00%和93.33%的准确率聚类出不同的病理分期。该融合微型可编程生化级联通路与多维人工智能预测的系统框架,为克服传统液体活检转化应用中的复杂障碍提供了强大的新型诊断范式。

基础研究 (8篇)

Cancer research IF 22.6 2026-11-19 PMID: 43055329
Accurate prediction of treatment response remains challenging in cancer. To facilitate response prediction in non-small cell lung cancer (NSCLC), we developed PRISM, an interpretable multiscale graph-learning framework for estimating treatment-specific objective response from pretreatment H&E whole-slide images. PRISM integrated multiresolution tissue representations with a cell-level tumor microenvironment (TME) hypergraph, thereby treating higher-order microenvironmental organization as a learnable component of treatment-response prediction. Samples from 7,082 patients from four Chinese centers were screened. PRISM was evaluated across treatment specific cohorts receiving targeted therapy (T), EGFR-targeted therapy (T_EGFR), immune checkpoint inhibitor-based therapy (ICI), chemoimmunotherapy (CI), and chemotherapy (C) using patient-level internal cross-validation, independent multicenter external validation, and prospective silent validation. PRISM predicted early objective responses across prespecified systemic therapies in NSCLC. In comparison to 18 established multiple-instance learning and computational pathology baseline models, PRISM remained competitive, with numerical advantages in selected tasks. Multiscale attribution and exploratory H&E-derived TME analyses provided spatial context for model predictions. Overall, PRISM offers a morphology-based framework for estimating early response to prespecified systemic therapies and warrants further prospective multicenter evaluation.
中文摘要:癌症治疗反应的准确预测仍然具有挑战性。为了促进非小细胞肺癌(NSCLC)的反应预测,我们开发了PRISM,这是一种可解释的多尺度图学习框架,用于从预处理后的H&E全切片图像中估计特定治疗的目标反应。PRISM将多分辨率组织表示与细胞水平的肿瘤微环境超图相结合,从而将高阶微环境组织作为治疗反应预测的可学习组成部分。来自四个中国中心的7,082名患者的样本经过筛选。PRISM在接收靶向治疗、EGFR靶向治疗、免疫检查点抑制剂治疗、化疗免疫治疗和化疗的特定治疗队列中进行了评估,采用了患者层面的内部交叉验证、独立的多中心外部验证以及前瞻性盲法验证。PRISM预测了NSCLC患者在预设全身性治疗下的早期目标反应。与18个已建立的多实例学习和计算病理基线模型相比,PRISM保持了竞争力,并在某些任务中显示出数值优势。多尺度归因和探索性H&E衍生的肿瘤微环境分析为模型预测提供了空间背景。总体而言,PRISM提供了一种基于形态学的框架,用于估计对预设全身性治疗的早期反应,并值得进一步的前瞻性多中心评估。
Journal of the American Chemical Society IF 16.6 2026-11-18 PMID: 43053353
Extracellular vesicles (EVs) are critical mediators of tumor-stromal communication within the tumor microenvironment (TME), where reciprocal signaling between cancer cells and cancer-associated fibroblasts (CAFs) fuels malignant progression and therapeutic resistance. Here, we report a degrader-antibody conjugate (DAC) platform, Ctx-ETAC, in which the clinically approved anti-EGFR antibody cetuximab (Ctx) delivers an engineered proteolysis-targeting chimera (PROTAC) payload, ETAC, selectively into EGFR-expressing tumor cells and activated CAFs via receptor-mediated endocytosis. ETAC integrates indomethacin as the COX-2 ligand, a VHL-recruiting peptide, and a cathepsin B (Cat-B)-cleavable azidoacetyl-RR linker; conjugation to Ctx was achieved by a two-step bioorthogonal strategy, yielding an average drug-to-antibody ratio of 4.21. The resulting Ctx-ETAC ensures biomarker-selective payload activation in both tumor cells and activated CAFs, markedly reducing EV secretion by 95.5% and thereby disrupting their crosstalk. This disruption of EV-mediated communication reprograms CAFs toward a quiescent phenotype and reshapes the non-small cell lung cancer microenvironment into an antitumor state. In a xenograft model, Ctx-ETAC achieves markedly superior tumor suppression compared with Ctx monotherapy, without systemic toxicity. These findings establish receptor-guided targeted protein degradation as a strategy to disrupt EV-driven tumor-stromal communication and provide a new framework for microenvironment-directed cancer therapy.
中文摘要:细胞外囊泡(EVs)是肿瘤微环境(TME)中肿瘤-基质通讯的关键介质,其中癌细胞与癌症相关成纤维细胞(CAFs)之间的双向信号传导驱动恶性进展和治疗耐药。本研究报道了一种降解剂抗体偶联物(DAC)平台Ctx-ETAC,其中临床批准的抗EGFR抗体西妥昔单抗(Ctx)通过受体介导的内吞作用,将工程化的蛋白水解靶向嵌合体(PROTAC)载荷ETAC选择性递送至表达EGFR的肿瘤细胞和活化型CAFs中。ETAC整合了作为COX-2配体的吲哚美辛、VHL招募肽以及Cat-B可切割的叠氮乙酰基-RR连接子;通过两步生物正交策略实现与Ctx的偶联,平均药物抗体比为4.21。所得的Ctx-ETAC确保在肿瘤细胞和活化型CAFs中实现生物标志物选择性的载荷激活,将EV分泌量显著降低95.5%,从而破坏其通讯。这种对EV介导通讯的干扰使CAFs重编程为静息表型,并将非小细胞肺癌微环境重塑为抗肿瘤状态。在异种移植模型中,Ctx-ETAC相比单用Ctx实现了更显著的肿瘤抑制效果,且无系统性毒性。这些发现确立了受体引导的靶向蛋白降解作为破坏EV驱动的肿瘤-基质通讯的策略,并为微环境导向的癌症治疗提供了新框架。
Nature biomedical engineering IF 26.3 2026-11-16 PMID: 43039978
Extracellular vesicles (EVs) have shown great potential for disease detection from liquid biopsies. However, the lack of optimized isolation and detection methods limited their clinical application. Here we engineer a bioinspired, reconfigurable, self-powered bubble motor (Butor) microswarm to streamline intelligent isolation and ultrasensitive profiling of circulating EVs for cancer liquid biopsies. Butor microswarm shows jellyfish-like, self-propelled lifting locomotion along lumen-like vertical or inclined tubular path in parallel, allowing rapid isolation (10 min, near 90%) of EV subtypes via three-dimensional directional scanning capture even in high-viscosity biofluids. Furthermore, the buoyancy-activated Butors achieve ultrasensitive EV profiling near a single-particle level, enable early diagnosis of non-small cell lung cancer with an accuracy of up to 94% (95% sensitivity) in a pilot cohort and improve the outcome in cancer staging (I-IV) discrimination, response monitoring of surgical treatment and efficacy prediction of immunotherapy in patients with non-small cell lung cancer. Our self-powered motor represents an intelligent, fast, inexpensive, sensitive and multiplexed liquid biopsy tool for accurate cancer diagnostics and treatment monitoring in clinical settings.
中文摘要:细胞外囊泡在疾病检测方面展现出巨大潜力,但缺乏优化的分离和检测方法限制了其临床应用。本研究设计了一种仿生、可重构且自驱动的泡泡马达微群以简化循环细胞外囊泡的智能分离及超灵敏分析用于癌症液体活检。该微群表现出类似水母的自推进提升运动,沿管状垂直或倾斜路径并行移动,通过三维定向扫描捕获实现快速分离(10分钟,近90%),即使在高粘度生物流体中也能有效分离多种细胞外囊泡亚型。此外,浮力激活的泡泡马达实现了接近单粒子水平的超灵敏细胞外囊泡分析,在试点队列中以高达94%的准确率(95%灵敏度)实现非小细胞肺癌的早期诊断,并改善了癌症分期(I至IV期)的鉴别、手术治疗的疗效监测以及免疫治疗疗效预测。这种自驱动马达代表了一种智能、快速、廉价、灵敏且多路复用的液体活检工具,适用于临床环境中的精准癌症诊断和治疗监测。
Cancer research IF 22.6 2026-11-16 PMID: 42636215
Neutrophil extracellular traps (NET) have recently emerged as key modulators of cancer progression and metastasis. However, a more comprehensive understanding of the underlying mechanisms could help identify effective strategies to prevent and treat NET-mediated metastasis. In this study, we observed a marked accumulation of intratumoral NETs in metastatic primary lung adenocarcinoma (LUAD). Tumor cells with elevated CXCL2 expression not only recruited neutrophils via interactions with CXCR2 but also facilitated NET formation. In turn, NET-derived DNA (NET-DNA), through specific DNA motifs, directly bound to the extracellular domain of integrin β1 (ITGB1), thereby activating FAK signaling and promoting invasion and metastasis. NET-DNA was capable of enhancing CXCL2 expression through MAPK-ELK1, thereby establishing a positive feedback loop that maintained continuous neutrophil recruitment and NET formation. In both in vitro and in vivo models, targeting either NETs or ITGB1-FAK signaling significantly inhibited LUAD metastasis. These findings suggest that the CXCL2-NET-ITGB1-FAK signaling axis plays a pivotal role in driving NET-mediated metastasis, which provides a rationale for targeting this signaling pathway to inhibit LUAD metastasis. Tumor-secreted CXCL2 recruits neutrophils and induces formation of neutrophil extracellular traps that bind to integrin β1 to activate FAK signaling and enhance the metastatic potential of lung cancer.
中文摘要:中性粒细胞胞外诱捕网(NETs)近期被发现是癌症进展和转移的关键调节因子,但深入理解其潜在机制有助于制定预防和治疗NET介导转移的有效策略。本研究发现,在转移性原发性肺腺癌(LUAD)中肿瘤内NETs显著积聚。高表达CXCL2的肿瘤细胞不仅通过与CXCR2相互作用招募中性粒细胞,还促进NET形成。反过来,NET来源的DNA(NET-DNA)通过特定DNA基序直接结合整合素β1(ITGB1)的胞外结构域,从而激活FAK信号通路并促进侵袭和转移。NET-DNA能够通过MAPK-ELK1途径增强CXCL2表达,建立正反馈回路以维持持续的中性粒细胞招募和NET形成。在体外和体内模型中,靶向NETs或ITGB1-FAK信号通路均显著抑制了LUAD转移。这些发现表明CXCL2-NET-ITGB1-FAK信号轴在驱动NET介导的转移中起关键作用,为靶向该信号通路以抑制LUAD转移提供了理论依据。肿瘤分泌的CXCL2招募中性粒细胞并诱导形成NETs,后者结合整合素β1以激活FAK信号并增强肺癌的转移潜能。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42526210
Most clustered regularly interspaced short palindromic repeats (CRISPR)-based electrochemical biosensors lack controllable switching function and are vulnerable to false signals induced by intrinsic amplification signal crosstalk. Thus, exploring strategies that mitigate intrinsic amplification crosstalk with a precise switch would be extremely useful for reliable and accurate bioanalysis. Herein, we develop a photo-switchable CRISPR/Cas12a electrochemical (PSCE) system by introducing a photocleavable (PC) linker and adopting a light-responsive strategy, which enables output of de-interference electrochemical signals and achieves highly sensitive and accurate detection of gene mutations for non-small cell lung cancer (NSCLC). The system decouples nucleic acid amplification (NAA) from signal transduction and produces unique photo-switchable response signals by light irradiation to activate Cas12a activity. This architectural design further separates signal readout from sample pretreatment, suppressing intrinsic amplification-derived signal crosstalk rather than global biological interference to deliver an ultralow limit of detection (LoD). The PSCE achieves 98.1% sensitivity, 92.7% specificity, and 98.9% overall accuracy when tested with 67 clinical samples. Moreover, the exploration of PSCE system in flexible wearable electronics and machine-learning analysis of clinical patient samples demonstrates significant application potential clinical diagnosis of mutation-associated diseases.
中文摘要:大多数基于CRISPR的电化学生物传感器缺乏可控的开关功能,且容易受到内在扩增信号串扰引起的假信号影响。因此,探索能够利用精确开关减轻内在扩增串扰的策略对于可靠和准确的生物分析至关重要。在此,我们开发了一种光控CRISPR/Cas12a电化学系统,通过引入光裂解连接子并采用光响应策略,实现了去干扰的电化学信号输出,并实现了对非小细胞肺癌基因突变的高灵敏度和准确检测。该系统将核酸扩增与信号转导解耦,并通过光照激活Cas12a活性产生独特的光控响应信号。这种架构设计进一步将信号读取与样本前处理分离,抑制了由内在扩增引起的信号串扰,而非全局生物干扰,从而实现了超低检测限。在67个临床样本的测试中,该系统达到了98.1%的敏感性、92.7%的特异性和98.9%的整体准确率。此外,该光控系统在柔性可穿戴电子设备和临床患者样本机器学习分析中的应用探索展示了其在突变相关疾病临床诊断中的显著应用潜力。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42435664
Antiviral agents are a cornerstone of therapeutic strategies against viral infections; however, the early-stage discovery and optimization of viral inhibitors remain time-consuming, resource-intensive, and mechanistically opaque. Here, we introduce a mechanism-guided strategy for rapid antiviral candidate identification and evaluation using confocal Raman microscopy (CRM) imaging across cellular and animal models. CRM enables label-free, quantitative, and spatially resolved assessment of drug efficacy at the single-cell level by correlating subcellular biochemical distributions, specifically of lipids, nucleic acids, and proteins, with virus-induced morphological alterations. To validate this approach, we evaluated α-linolenic acid (ALA) against influenza A virus (IAV) strain H1N1 PR8 in human non-small cell lung carcinoma A549 cells. CRM imaging revealed that ALA treatment restored lipid homeostasis, preserved nucleic acid integrity, and normalized protein expression profiles, changes those were spatially concordant with recovery of cellular architecture. These mechanistic insights directly informed the rational design of subsequent in vivo studies in murine models, markedly reducing reliance on empirical trial-and-error. Moreover, CRM was extended to ex vivo analysis of lung tissue, enabling high-resolution interrogation of alveolar architecture and surfactant layer composition in infected tissues. Collectively, our work establishes CRM as a rapid, mechanism-informed platform for prioritizing antiviral candidates, bridging molecular pharmacology and phenotypic response, and thereby accelerating the translation of promising leads into preclinical development.
中文摘要:抗病毒药物是治疗病毒感染策略的基石,然而病毒抑制剂的早期发现和优化仍然耗时、资源密集且机制不明。在此,我们引入了一种基于机制指导的策略,利用共聚焦拉曼显微镜成像技术在细胞和动物模型中快速识别和评估抗病毒候选药物。该技术通过关联亚细胞生化分布(特别是脂质、核酸和蛋白质)与病毒诱导的形态学改变,实现了单细胞水平上无需标记的药物疗效定量及空间分辨评估。为验证该方法,我们在人非小细胞肺癌A549细胞中对α-亚麻酸针对甲型流感病毒H1N1 PR8株进行了评估。成像结果显示,ALA治疗恢复了脂质稳态,保持了核酸完整性并正常化了蛋白质表达谱,这些变化与细胞结构的恢复在空间上是一致的。这些机制见解直接指导了后续在小鼠模型中的体内研究设计,显著减少了对经验性试错的依赖。此外,该技术被扩展用于肺组织的离体分析,实现了对感染组织中肺泡结构和表面活性剂层组成的高分辨率检测。总之,我们的工作确立了共聚焦拉曼显微镜作为快速、基于机制的平台,用于优先筛选抗病毒候选药物,桥接分子药理学与表型反应,从而加速有前景的候选药物向临床前开发的转化。
Acta biomaterialia IF 10.4 2026-11-13 PMID: 43025677
The pulmonary mucus barrier is the principal bottleneck in inhaled nanomedicine, intercepting most deposited particles before they reach the epithelium. Because this barrier is remodeled differently in each disease, technology-centric carrier design has repeatedly stalled in clinical translation. This review advances a disease-adapted design framework that positions mucus barrier phenotyping as the foundation of rational formulation design. We first dissect the mucus biophysics of cystic fibrosis, chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis, and lung cancer, and distill quantitative barrier parameters including mesh pore size, solids content, viscoelasticity, and mucin composition. On this basis, we critically evaluate four strategy classes spanning surface chemistry, carrier platforms, physical parameter optimization, and mucolytic or mucin-suppressive adjuvants, and map each class to the disease phenotypes it best fits through quantitative design windows. We then appraise a tiered evaluation hierarchy from artificial mucus to precision-cut lung slices and large animals, and propose minimum reporting standards for mucus collection, processing, and particle-tracking analysis so that transport data become comparable across studies. Clinical trial lessons, manufacturing constraints, and chronic-administration safety define the remaining translational boundaries. Throughout, we distinguish between mucus transport as an intermediate design parameter and therapeutic efficacy as the endpoint, and between disease-adapted design and patient-specific precision nanomedicine. This framework offers formulation scientists, model developers, and translational teams a shared quantitative basis for matching carrier design to barrier phenotype. STATEMENT OF SIGNIFICANCE: Inhaled nanomedicines have been vigorously pursued for the treatment of pulmonary diseases; however, their clinical translation remains challenging because the pulmonary mucus barrier intercepts most deposited particles before they reach the epithelium. Because this barrier is remodeled differently in each disease, mucus barrier phenotyping has been advocated as the foundation of rational formulation design. Quantitative barrier phenotypes of cystic fibrosis, COPD, asthma, IPF, and lung cancer are now measurable, making it possible to establish a disease-driven framework in which carrier strategies are matched to the barrier of the target pathology. This review summarizes these disease-specific phenotypes, critically maps four strategy classes onto them, and appraises the evaluation models and translational boundaries that govern clinical success.
中文摘要:肺黏液屏障是吸入纳米医学的主要瓶颈,在颗粒到达上皮之前拦截了大部分沉积物。由于该屏障在不同疾病中重塑方式各异,以技术为中心的载体设计在临床转化中屡遭停滞。本综述提出了一种适应疾病的框架,将黏液屏障表型分析作为合理制剂设计的基础。我们首先剖析囊性纤维化、慢性阻塞性肺病、哮喘、特发性肺纤维化和肺癌的黏液生物物理学,并提炼出包括网格孔径、固体含量、粘弹性和黏蛋白成分在内的定量屏障参数。在此基础上,我们批判性地评估了涵盖表面化学、载体平台、物理参数优化以及黏液溶解或黏蛋白抑制辅助剂的四大策略类别,并通过定量设计窗口将每类策略映射到最适配的疾病表型。随后,我们从人工黏液到精准肺切片再到大型动物模型,评估了分层评价体系,并提出了关于黏液采集、处理和颗粒追踪分析的最低报告标准,以确保运输数据在不同研究中具有可比性。临床试验经验、制造约束和慢性给药安全性定义了剩余的转化边界。全文区分了作为中间设计参数的黏液运输与作为终点的治疗功效,以及适应疾病的设计与患者特异性精准纳米医学。该框架为制剂科学家、模型开发者和转化团队提供了将载体设计与屏障表型相匹配的共同定量基础。意义陈述:吸入纳米药物在治疗肺部疾病方面受到广泛关注;然而,由于肺黏液屏障在颗粒到达上皮前拦截了大部分沉积物,其临床转化仍然具有挑战性。由于该屏障在不同疾病中重塑方式不同,黏液屏障表型分析已被提倡作为合理制剂设计的基础。囊性纤维化、COPD、哮喘、IPF和肺癌的定量屏障表型现在可测量,使得建立以疾病为驱动的框架成为可能,在该框架中载体策略与目标病理的屏障相匹配。本综述总结了这些疾病特异性表型,批判性地将其映射到四大策略类别,并评估了决定临床成功的评估模型和转化边界。
Science advances IF 13.9 2026-11-13 PMID: 43013647
Super-carbon-chain compounds (SCCCs), marine long-carbon-chain polyketides featuring numerous carbon stereocenters, fall into untapped chemical space in between drug-like small molecules and biopolymers. Due to mass-material unavailability and flexible-structure complexity, the reliable stereochemical assignment of SCCCs has long remained stagnant. In this work, a modern microalgal biomass production-platform is created for pilot-scale cultivation of marine dinoflagellates to produce over 100 milligrams of minor SCCCs. The modular fragment-based identification (MFBI) approach is successfully employed to establish the relative and absolute configurations of SCCCs. As an example, 157.7 mg of a minor SCCC, named amphidiketol A, featuring a highly-flexible C76-linear carbon backbone and thirty-three carbon stereocenters, is obtained from Amphidinium sp. in our platform. Its hybrid architecture contains eleven‌ distinct modular fragments. Its relative and absolute configurations are successfully established by the MFBI approach. Collectively, an undescribed paradigm for stereochemical assignment of SCCCs is presented. Nine senescence-associated protein targets of amphidiketol A in lung cancer A549 cells are identified.
中文摘要:超级碳链化合物(SCCCs)是具有众多碳手性中心的海洋长碳链聚酮类化合物,处于药物样小分子与生物大分子之间未被充分开发的化学空间。由于缺乏足够的物质基础且结构具有柔性复杂性,SCCCs的可靠立体化学指派长期停滞不前。本研究建立了一个现代微藻生物质生产平台,用于大规模培养海洋甲藻以生产超过100毫克的微量SCCCs。成功采用模块化片段鉴定(MFBI)方法确立了SCCCs的相对和绝对构型。作为示例,从本平台培养的Amphidinium sp.中获得了157.7毫克名为amphidiketol A的微量SCCC,该化合物具有高度柔性的C76线性碳骨架和三十三个碳手性中心。其杂化架构包含十一个不同的模块化片段。通过MFBI方法成功确立了其相对和绝对构型。总体而言,本研究提出了一种用于SCCCs立体化学指派的新范式。鉴定出amphidiketol A在肺癌A549细胞中的九个衰老相关蛋白靶点。

5其他实体瘤 (16篇)

临床研究 (1篇)

Journal of the American Academy of Dermatology IF 12.3 2026-11-16 PMID: 43039042
Flat pigmented basal cell carcinoma (BCC) of the face is an underrecognized diagnostic pitfall that may mimic other facial pigmented lesions dermatoscopically. To characterize perifollicular crescentic pigmentation (PCP) as a novel dermatoscopic criterion of flat facial pigmented BCC, assess its educational impact, and compare its diagnostic utility with contemporary artificial intelligence (AI) models. A retrospective dataset of 120 flat facial pigmented lesions (60 BCCs, 20 lentigo maligna, 20 pigmented actinic keratoses, and 20 solar lentigines/seborrheic keratoses) was assembled. Twenty-six dermatology residents completed a diagnostic test before and one week after a structured educational session on PCP recognition. ADAE, ResNet34, PanDerm, and MedSigLIP were evaluated on the same dataset. PCP was identified in 63.3% of flat facial BCCs. Interobserver agreement was substantial (κ=0.780; 95% CI: 0.706-0.857). Following education, resident sensitivity increased from 73.7% to 88.0% (P < .001), and overall accuracy from 85.8% to 90.4% (P = .001). AI sensitivities ranged from 26.7% to 70.0%. PanDerm sensitivity increased to 96.7% after linear probing on the study dataset. Retrospective single-center design and potential recall bias. PCP is a reproducible and readily teachable dermatoscopic criterion that significantly improves the recognition of flat pigmented facial BCC.
中文摘要:面部平坦色素性基底细胞癌(BCC)是一种容易被忽视的诊断陷阱,在皮肤镜下可能与其他面部色素性病变相似。本研究旨在将毛囊周围新月形色素沉着(PCP)表征为平坦面部色素性BCC的新型皮肤镜标准,评估其教育影响,并比较其与当代人工智能(AI)模型的诊断效用。研究收集了120例平坦面部色素性病变的回顾性数据集,包括60例BCC、20例日光性黑子、20例色素性光化性角化病以及20例日光性雀斑/脂溢性角化病。26名皮肤科住院医师在结构化PCP识别教育培训前及一周后完成了诊断测试。ADAE、ResNet34、PanDerm和MedSigLIP模型在同一数据集上进行了评估。结果显示,63.3%的平坦面部BCC中发现了PCP。观察者间一致性较高(κ=0.780;95% CI: 0.706-0.857)。经过培训后,住院医师的敏感性从73.7%提高至88.0%(P < .001),总体准确率从85.8%提高至90.4%(P = .001)。AI模型的敏感性范围为26.7%至70.0%。在研究数据集上进行线性探测后,PanDerm的敏感性提高至96.7%。本研究存在回顾性单中心设计和潜在回忆偏倚。PCP是一种可重复且易于教学的皮肤镜标准,能显著改善对平坦色素性面部BCC的识别。

基础研究 (15篇)

Critical reviews in food science and nutrition IF 10.6 2026-11-19 PMID: 43055325
Straight‑chain, odd-numbered long-chain fatty acids (OLCFAs) are a class of bioactive lipids with relatively low abundance in nature and in the human body, yet they possess important health impacts. However, research advances about their biosynthesis pathways, metabolic regulation, and functioning mechanisms have not been sorted and analyzed in time, which greatly affects the development and utilization of these functional components. Here, the sources of OLCFAs were clarified to pave the way for nutritional optimization, distinguishing chain length, saturated and unsaturated chain. To establish a clear biosynthesis and regulation network for OLCFAs, key influencing factors and their intrinsic working mechanisms were elucidated at the genetic, cellular, and organismal levels. Furthermore, the major regulatory mechanisms governing the digestion, absorption, transport, and metabolism of OLCFAs in vivo were outlined. The biological functions such as anti-inflammation, cancer suppression, and glucose-lipid metabolism regulation were illustrated and discussed in view of saturated/unsaturated OLCFAs. Together, this review may provide a theoretical basis for optimizing OLCFAs biosynthesis strategies and further exploring their nutritional and health-promoting potential.
中文摘要:直链奇数长链脂肪酸(OLCFAs)是一类在自然界和人体中丰度相对较低但具有重要健康影响的生物活性脂质。然而,关于其生物合成途径、代谢调节及作用机制的研究进展尚未及时梳理和分析,这在很大程度上影响了这些功能性成分的开发与利用。本文明确了OLCFAs的来源,区分了碳链长度、饱和与不饱和链,为营养优化铺平了道路。为了建立清晰的OLCFAs生物合成与调控网络,阐明了关键影响因素及其在基因、细胞和个体水平的内在作用机制。此外,概述了OLCFAs在体内消化、吸收、转运和代谢的主要调控机制。结合饱和/不饱和OLCFAs,阐述并讨论了其抗炎、抗癌及调节糖脂代谢等生物学功能。综上所述,本综述可为优化OLCFAs生物合成策略以及进一步探索其营养和健康促进潜力提供理论基础。
Nature communications IF 18.1 2026-11-18 PMID: 43052268
Aneuploidy and chromosomal instability are common characteristics of cancer but remain underexploited therapeutically. Chromosomally unstable cells are often selectively vulnerable to inhibition of the kinesin KIF18A, and this dependence is related to altered mitotic control. Here, we identify the spindle and kinetochore-associated (SKA) complex as a mitotic regulator that establishes a similar dependency. SKA complex loss is tolerated in cells with a defective mitotic checkpoint, but when mitosis is prolonged, it leads to mitotic errors and loss of viability. Genetic analysis reveals that the SKA complex  and KIF18A are epistatic, although they function through mechanistically distinct mitotic pathways. SKA complex depletion selectively impacts chromosomally unstable cancer cells and mirrors the effects of KIF18A inhibition. We thus identify a cellular vulnerability associated with prolonged mitosis in chromosomally unstable cancers.
中文摘要:非整倍体和染色体不稳定是癌症的常见特征,但在治疗方面尚未得到充分开发。染色体不稳定的细胞通常对驱动蛋白KIF18A的抑制具有选择性脆弱性,这种依赖性与其改变的有丝分裂控制有关。在此,我们鉴定出纺锤体和着丝粒相关SKA复合物作为一种有丝分裂调节因子,建立了类似的依赖性。在有缺陷的有丝分裂检查点的细胞中,SKA复合物的缺失是可以耐受的,但当有丝分裂延长时,它会导致有丝分裂错误和活力丧失。遗传分析表明,SKA复合物与KIF18A存在上位关系,尽管它们通过机制不同的有丝分裂途径发挥作用。SKA复合物的耗竭选择性影响染色体不稳定的癌细胞,并反映了KIF18A抑制的效果。因此,我们鉴定出了一种与染色体不稳定癌症中延长的有丝分裂相关的细胞脆弱性。
Journal for immunotherapy of cancer IF 11.7 2026-11-18 PMID: 43051940
Cancer burden is increasing rapidly in Africa, yet its biology in this context remains insufficiently understood. Global cancer research relies disproportionately on data from high-income populations, overlooking interactions among infection, immune modulation, host diversity and the microbiome that may shape cancer risk, progression and therapeutic response across the continent. Endemic oncogenic infections, chronic immune activation and diverse microbial ecologies are therefore not peripheral variables but central components of the African cancer context. These dimensions remain fragmented across disciplines and under-represented in contemporary immuno-oncology. Here, we argue for an integrated research framework and propose The African Cancer Immunology and Infection Initiative (TACII), an Africa-led network designed to coordinate multidisciplinary research, shared infrastructure, harmonized cohorts and capacity strengthening. By linking infection, immunity, the microbiome and host context across African populations, TACII aims to generate context-relevant biomarkers and mechanisms while producing insights of global relevance to cancer biology and immunotherapy.
中文摘要:非洲的癌症负担正在迅速增加,然而该地区的癌症生物学特征仍未被充分理解。全球癌症研究过度依赖高收入人群的数据,忽视了感染、免疫调节、宿主多样性与微生物组之间的相互作用,而这些因素可能塑造整个大陆的癌症风险、进展和治疗反应。地方性致癌感染、慢性免疫激活以及多样的微生物生态因此并非边缘变量,而是非洲癌症背景中的核心组成部分。这些维度在当代免疫肿瘤学中仍跨学科分散且代表性不足。在此,我们主张建立一种整合的研究框架,并提出非洲癌症免疫与感染倡议(TACII),这是一个由非洲主导的网络,旨在协调多学科研究、共享基础设施、标准化队列以及加强能力建设。通过连接非洲人群中的感染、免疫、微生物组及宿主背景,TACII 旨在生成具有情境相关性的生物标志物和机制,同时产生对癌症生物学和免疫治疗具有全球意义的见解。
Annual review of medicine IF 18.8 2026-11-17 PMID: 43045052
Systemic autoinflammatory diseases result from pathogenic variants in genes governing innate and cell-intrinsic immune pathways, leading to dysregulated sterile or overexuberant inflammation. The field has expanded rapidly from a handful of hereditary fever syndromes to a diverse spectrum of conditions that are far more common than previously imagined. Key pathways found to be recurrently involved include the inflammasome, tumor necrosis factor (TNF)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and type I interferon signaling pathways. Mechanistic dissection of these disorders has driven the development of targeted therapies, including interleukin 1, TNF, and Janus kinase inhibitors. Such drugs have transformed patient outcomes for these genetic disorders and related common inflammatory conditions. This review examines the molecular pathophysiology, genetic paradigms, and emerging therapeutic strategies across the major categories of systemic autoinflammatory diseases.
中文摘要:系统性自身炎症性疾病源于调控先天性和细胞内在免疫通路的基因致病性变异,导致无菌性或过度炎症失调。该领域已从少数遗传性发热综合征迅速扩展为远比以前想象的更为常见的多种疾病谱系。研究发现反复涉及的关键通路包括炎小体、肿瘤坏死因子(TNF)/核因子 kappa 轻链增强子激活的 B 细胞(NF-κB)以及 I 型干扰素信号通路。对这些疾病的机制解析推动了靶向治疗的发展,包括白细胞介素 1、TNF 和 Janus 激酶抑制剂。此类药物已显著改善了这些遗传性疾病及相关常见炎症性疾病的患者预后。本综述探讨了系统性自身炎症性疾病主要类别中的分子病理生理学、遗传范式及新兴治疗策略。
Immunity IF 30.6 2026-11-17 PMID: 43044600
Progenitor CD4+ T (Tpex) cells retain developmental plasticity and replenish antigen-specific CD4+ T cell responses in settings of chronic infection and cancer. Given the sustained, elevated expression of the transcription factor TOX across all CD4+ TEX cell subsets during chronic infection, we examined how TOX impacts CD4+ TEX differentiation during chronic infection. Deletion of TOX in lymphocytic choriomeningitis virus (LCMV)-specific transgenic CD4+ T cells impaired Tpex cell survival and drove unrestrained TEX cell differentiation. Multiomic profiling revealed that this effector-like state was concomitant with loss of TCF-1 pathway activity and gain of NFAT, NF-κB, and RUNX-coordinated transcriptional circuitry. TOX also promoted the multipotent potential of CD4+ Tpex cells to differentiate into T helper (Th)1-like or Tfh-like cells by day 8 post-infection (p.i.) prior to establishment of chronic infection. These data reveal a TOX-driven transcriptional network that maintains CD4+ Tpex cell function and persistence, supporting a durable and malleable response during persisting antigen stimulation.
中文摘要:前体CD4+T(Tpex)细胞在慢性感染和癌症背景下保留发育可塑性并补充抗原特异性CD4+T细胞反应。鉴于转录因子TOX在慢性感染期间所有CD4+TEX细胞亚群中持续高表达,我们研究了TOX如何影响慢性感染期间的CD4+TEX分化。在淋巴细胞性脉络丛脑膜炎病毒(LCMV)特异性转基因CD4+T细胞中删除TOX会损害Tpex细胞的存活并驱动不受控制的TEX细胞分化。多组学分析显示,这种效应样状态伴随着TCF-1通路活性的丧失以及NFAT、NF-κB和RUNX协调的转录电路的获得。在慢性感染建立之前,TOX还促进了CD4+Tpex细胞在第8天(p.i.)分化为Th1样或Tfh样细胞的多能潜力。这些数据揭示了一个维持CD4+Tpex细胞功能和持久性的TOX驱动的转录网络,支持在持续抗原刺激期间产生持久且可塑的反应。
Signal transduction and targeted therapy IF 81.2 2026-11-17 PMID: 43039898
Chronic diseases are still treated largely with interventions that are constitutive, intermittently administered and poorly aligned with real-time physiology. Synthetic biology is changing this paradigm by treating gene circuits as programmable genetic software that can be deployed across cellular therapeutic hardware spanning from prokaryotic to eukaryotic systems, including probiotic cells, designer cells, immune cells and stem‑cell‑derived platforms. In this framework, engineered systems can sense disease-associated signals, compute them through synthetic or repurposed transduction pathways and adjust therapeutic output to maintain physiological variables within a desired range. Closed-loop therapeutics therefore begin to merge diagnosis, treatment and prevention within the same living platform. Across metabolism, inflammation, infection, cardiovascular regulation and cancer, early mammalian systems show that endogenous sensing, intracellular computation and therapeutic actuation can be combined in clinically relevant architectures. The emerging concept of setpoint medicine captures the clinical ambition of these systems: not simply to deliver a dose, but to keep physiology within an interpretable and therapeutically desirable range. Realizing this vision will require durable and modular control circuits, hardware-aware delivery strategies, interpretable safety frameworks, controller-style performance metrics and increasingly AI-assisted design, calibration and oversight. If these challenges can be met, the future of therapy may be defined less by intermittent dosing than by the continuous control of physiology.
中文摘要:慢性疾病的治疗仍主要依赖持续性、间歇性给药且与实时生理状态匹配度低的干预措施。合成生物学正在改变这一范式,将基因回路视为可编程的遗传软件,可部署于从原核生物到真核生物的细胞治疗硬件中,包括益生菌、设计细胞、免疫细胞和干细胞衍生平台。在此框架下,工程化系统能够感知疾病相关信号,通过合成或重用的转导通路进行计算,并调整治疗输出以将生理变量维持在期望范围内。因此,闭环治疗开始在同一活体平台中融合诊断、治疗和预防。在代谢、炎症、感染、心血管调节和癌症领域,早期哺乳动物系统显示,内源性感知、细胞内计算和治疗执行可以在临床相关架构中结合。新兴的设定点医学概念捕捉了这些系统的临床愿景:不仅仅是给药,而是将生理维持在可解释且治疗理想的范围内。实现这一愿景需要耐用且模块化的控制回路、硬件感知的递送策略、可解释的安全框架、控制器风格的性能指标以及日益增多的AI辅助设计、校准和监督。如果这些挑战得以解决,未来治疗的定义可能更少依赖于间歇性给药,而更多依赖于对生理的连续控制。
Nature methods IF 28.3 2026-11-16 PMID: 43040036
The ability of cells to adapt their behavior in response to genetic or environmental changes is a fundamental biological process that drives cellular diversity in both normal and pathological contexts, including in tumor evolution. Copy number alterations (CNAs), which can include large-scale changes in genomic ploidy, play a key role in creating adaptive advantages in evolving cell populations. However, tracing these populations across experiments and disentangling the role of CNAs from other sources of transcriptional variability remains challenging and expensive. Here we present Echidna, a Bayesian hierarchical model that integrates single-cell RNA sequencing and bulk whole-genome sequencing data to enable robust integrative inference of CNAs, jointly across samples and treatment time points, to better understand the impact of genomic events on cellular phenotype. Applying Echidna to patient tumor specimens, we demonstrate its superior performance in clonal reconstruction and derive insights into therapy resistance mechanisms.
中文摘要:细胞适应遗传或环境变化以调整其行为的能力是驱动正常及病理背景下包括肿瘤进化在内的细胞多样性的基本生物学过程。拷贝数变异(CNAs),可能涉及基因组倍性的大规模改变,在赋予进化细胞群体适应性优势方面发挥关键作用。然而,跨实验追踪这些细胞群体并厘清CNAs与其他转录变异性来源的作用既具挑战性又成本高昂。本文提出Echidna,这是一种贝叶斯分层模型,整合单细胞RNA测序与批量全基因组测序数据,以实现对CNAs的稳健整合推断,联合多个样本及治疗时间点,从而更好地理解基因组事件对细胞表型的影响。将Echidna应用于患者肿瘤标本,我们展示了其在克隆重建方面的优越性能,并揭示了治疗抵抗机制的见解。
Journal for immunotherapy of cancer IF 11.7 2026-11-16 PMID: 43039405
CD8+ T cells differentiate into terminally exhausted T cells, a hypofunctional state induced in tumor environments that leads to impaired antitumor immunity and poor cancer prognosis. Therapeutic approaches to improve effector CD8+ T-cell function by limiting or reversing tumor-mediated exhaustion are areas of active investigation. Terminally exhausted CD8+ T cells from tumors exhibit increased transcriptional repression of effector genes by tri-methylation of histone 3 lysine 27 (H3K27me3). Enhancer of zeste homolog 2 (Ezh2) is a crucial enzyme acting as the catalytic core of the polycomb repressive complex 2, which adds H3K27me3 in T cells. Using pharmacologic and genetic suppression of Ezh2, we evaluated its role in driving CD8+ T-cell exhaustion in vitro and in murine melanoma models in vivo, including its impact on functional restoration. Ezh2 expression is significantly increased in CD8+ T cells exposed to chronic stimulation. Suppression of Ezh2 significantly increased the proportion of CD8+ T cells expressing both tumor necrosis factor and interferon-γ when exposed to chronic stimulation in vitro or in the tumor. Ezh2-deficient CD8+ T cells also exhibited decreases in the exhaustion-mediated transcription factor Tox. Multiple genes were upregulated when Ezh2 was deleted, including cytokines related to type 1 (eg, Gzmc) and type 2 (eg, Il13) immunity, and treatment with interleukin (IL)-4 induced a significantly higher proportion of IL-13-expressing CD8+ T cells. These findings suggest that Ezh2 contributes to epigenetic modifications supporting T-cell exhaustion, and Ezh2 suppression or deletion can rescue effector functions of exhausted CD8+ T cells. Thus, Ezh2 may be a therapeutic target to improve antitumor immunity.
中文摘要:CD8+T细胞分化为终末耗竭T细胞,这是一种在肿瘤微环境中诱导的低功能状态,导致抗肿瘤免疫受损和癌症预后不良。通过限制或逆转肿瘤介导的耗竭来改善效应CD8+T细胞功能的疗法是当前研究的热点。来自肿瘤的终末耗竭CD8+T细胞表现出由组蛋白H3赖氨酸27三甲基化(H3K27me3)驱动的效应基因转录抑制增强。Ezh2是催化核心酶,作为多梳抑制复合物2的关键组成部分,在T细胞中添加H3K27me3。通过药理学和遗传学手段抑制Ezh2,我们评估了其在体外和小鼠黑色素瘤体内模型中驱动CD8+T细胞耗竭的作用及其对功能恢复的影响。暴露于慢性刺激的CD8+T细胞中Ezh2表达显著增加。在体外或肿瘤环境中暴露于慢性刺激时,抑制Ezh2显著增加了同时表达肿瘤坏死因子和干扰素γ的CD8+T细胞比例。Ezh2缺陷的CD8+T细胞还表现出耗竭介导的转录因子Tox减少。删除Ezh2后多个基因上调,包括与1型免疫相关的细胞因子(如Gzmc)和2型免疫相关的细胞因子(如Il13),且使用白细胞介素4处理诱导了显著更高比例的表达IL-13的CD8+T细胞。这些发现表明Ezh2有助于支持T细胞耗竭的表观遗传修饰,抑制或删除Ezh2可以挽救耗竭CD8+T细胞的效应功能。因此,Ezh2可能是改善抗肿瘤免疫的治疗靶点。
Cancer research IF 22.6 2026-11-16 PMID: 43037278
APOBEC proteins shape the somatic mutation spectrum of many cancers by binding and editing DNA. Modeling APOBEC-induced changes in cancer has been challenging due to the toxicity of these enzymes. Here, we overcame this barrier using a mutant form of APOBEC3A with impaired deaminase activity by changing arginine 128 to alanine (A3AR128A). Overexpressing A3AR128A in murine epithelium induced squamous cell carcinoma (SCC) in the skin, head and neck region, and cervix, mirroring the human disease spectrum. Tumor formation was further accelerated by concomitant Trp53 loss. A3AR128A cancers carried frequent alterations in the NOTCH and RAS-PI3K pathways, and recurrent mutations in genes encoding histone H3 were also observed. Cross-species analysis revealed how APOBEC accessibility influences cancer driver gene selection. A catalogue of 235,790 mutations was used to refine mutational signatures linked to A3A. These results shed light on how DNA damage from A3A contributes to tumorigenesis.
中文摘要:APOBEC蛋白通过结合和编辑DNA塑造许多癌症的体细胞突变谱。由于这些酶的毒性,对癌症中APOBEC诱导的变化进行建模一直具有挑战性。在此,我们利用改变精氨酸128为丙氨酸(A3AR128A)的APOBEC3A突变体形式克服了这一障碍,该突变体具有受损的脱氨酶活性。在小鼠上皮组织中过表达A3AR128A诱导了皮肤、头颈部和宫颈的鳞状细胞癌(SCC),模拟了人类疾病谱系。伴随Trp53缺失进一步加速了肿瘤形成。A3AR128A癌症携带NOTCH和RAS-PI3K通路中的频繁改变,并观察到编码组蛋白H3基因的反复突变。跨物种分析揭示了APOBEC可及性如何影响癌症驱动基因的选择。利用包含235790个突变的目录优化了与A3A相关的突变特征。这些结果阐明了A3A引起的DNA损伤如何促进肿瘤发生。
Medicinal research reviews IF 13.6 2026-11-15 PMID: 43035851
The phosphoinositide 3-kinase (PI3K) signaling pathway has emerged as a well-established therapeutic target in oncology, driving substantial efforts toward the rational development of small-molecule inhibitors. Over the last 20 years, diverse structural categories of PI3K inhibitors have been engineered through structure-based design and medicinal chemistry refinement, encompassing pan-PI3K inhibitors, isoform-selective agents, and dual PI3K/mTOR inhibitors. Notably, several compounds including idelalisib, alpelisib, and copanlisib have gained regulatory approval, demonstrating the clinical significance of targeting specific PI3K isoforms in particular cancer settings. However, despite these achievements, the clinical application of first-generation inhibitors has been constrained by off-target toxicities, limited therapeutic windows, and unfavorable pharmacokinetic profiles. These limitations have spurred continued investigation into next-generation inhibitors featuring enhanced selectivity, diminished toxicity, and improved drug-like properties. This review summarizes recent progress in PI3K inhibitor development from 2021 to the present, which will guide the further development of next-generation therapeutic agents.
中文摘要:磷脂酰肌醇3-激酶(PI3K)信号通路已成为肿瘤学中确立的治疗靶点,推动了小分子抑制剂合理开发的巨大努力。在过去20年中,通过基于结构的设计和药物化学优化,设计了多种结构类别的PI3K抑制剂,包括泛PI3K抑制剂、亚型选择性制剂以及双重PI3K/mTOR抑制剂。值得注意的是,包括依鲁替尼、阿培利司和考布利西布在内的几种化合物已获得监管批准,证明了在特定癌症背景下靶向特定PI3K亚型的临床意义。然而,尽管取得了这些成就,第一代抑制剂的临床应用受到脱靶毒性、有限的治疗窗口和不利的药代动力学特征的限制。这些局限性促使了对下一代抑制剂持续的研究,这些抑制剂具有增强的选择性、降低的毒性和改善的药物特性。本综述总结了2021年至今PI3K抑制剂开发的最新进展,这将指导下一代治疗药物的进一步开发。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42475861
This study reports a robust DNA polymer spherical nucleic acid (PSNA) nanomachine based on domain-crosslinked self-assembly for highly selective and ultrasensitive imaging of microRNAs (miRNAs) in living cells. The nanomachine is constructed from DNA micelles formed via self-assembly of amphiphilic monomers followed by radical-initiated polymerization. This design effectively overcomes key limitations of conventional spherical nucleic acids, including poor biostability, inefficient cellular uptake, and nonspecific signal leakage, by providing a covalently stabilized architecture with high DNA loading capacity. A target-recognizing lock-walking strand and a fluorophore-labeled track strand containing the substrate sequence are immobilized on two distinct PSNA particles, respectively. Upon specific activation by endogenous miRNA-21 within tumor cells, the DNA walker is released and initiates a cyclic walking process that binds to the substrate strands and triggers a fuel-driven strand displacement cycle, leading to significant signal amplification. This walking mode is multi-legged and spatially confined. It enables high-speed reaction kinetics, substantially enhances fluorescence signals, and improves imaging clarity. The resulting PSNA nanomachine exhibits excellent stability and amplification capability, permitting ultrasensitive miRNA detection under low-background conditions. Moreover, this platform has been successfully applied for in situ imaging of miRNA in various cell lines, demonstrating strong potential for early clinical diagnostics and real-time monitoring of therapeutic responses.
中文摘要:本研究报道了一种基于域交联自组装的稳健DNA聚合物球形核酸纳米机器,用于活细胞中microRNA的高选择性及超灵敏成像。该纳米机器由两亲性单体自组装形成的DNA胶束经自由基引发聚合而成。这种设计通过提供具有高DNA负载量的共价稳定结构,有效克服了传统球形核酸生物稳定性差、细胞摄取效率低及非特异性信号泄漏等关键局限性。目标识别锁步链与含有底物序列的荧光标记轨道链分别固定在两种不同的PSNA颗粒上。在内源性miRNA-21于肿瘤细胞内的特异性激活下,DNA步行者被释放并启动循环步行过程,该过程结合底物链并触发燃料驱动的链置换循环,从而实现显著的信号放大。这种多腿且空间受限的步行模式实现了高速反应动力学,大幅增强了荧光信号并提高了成像清晰度。所得PSNA纳米机器表现出优异的稳定性和扩增能力,使得在低背景条件下进行超灵敏miRNA检测成为可能。此外,该平台已成功应用于多种细胞系中miRNA的原位成像,显示出在早期临床诊断和治疗反应实时监测方面的巨大潜力。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42431050
Peptidylprolyl isomerase A (PPIA) catalyzes cis-trans isomerization of proline residues, a key process regulating protein folding and signal transduction. Its aberrant secretion is closely associated with tumor metastasis and progression, making it a promising biomarker. However, currently available immunoassays often suffer from insufficient sensitivity for low-abundance PPIA detection. Herein, we present an electrochemical biosensor that integrates self-propelled nanocarriers with DNA cascade amplification strategy for ultrasensitive PPIA detection. The biosensor employs PtNPs@COF particles that catalyze H2O2 decomposition to generate O2. This autonomous propulsion accelerates target binding in homogeneous solution and helps mitigate diffusion-limited binding kinetics. After PPIA binding, the liberated DNAzyme catalytically cleaves the co-immobilized substrate strands, generating numerous triggers for the catalytic hairpin assembly (CHA) reaction. The biosensor achieves a wide linear range from 1 pg/mL to 10 μg/mL with a detection limit of 0.330 pg/mL. It also exhibits excellent specificity and performs reliably in clinical lung adenocarcinoma serum specimens, demonstrating its promising applicability for early diagnosis of this malignancy.
中文摘要:肽基脯氨酰异构酶A(PPIA)催化脯氨酸残基的顺反异构化,这是调节蛋白质折叠和信号转导的关键过程。其异常分泌与肿瘤转移和进展密切相关,使其成为一种有前景的生物标志物。然而,现有的免疫测定法灵敏度往往不足,难以检测低丰度的PPIA。在此,我们提出了一种电化学生物传感器,该传感器整合了自推进纳米载体与DNA级联扩增策略,用于超灵敏检测PPIA。该生物传感器采用PtNPs@COF颗粒催化H2O2分解产生O2。这种自主推进加速了均相溶液中的靶标结合,并有助于缓解扩散限制的动力学结合过程。在PPIA结合后,释放出的DNAzyme催化裂解共固定的底物链,生成大量触发催化发夹组装(CHA)反应的触发器。该生物传感器实现了1 pg/mL至10 μg/mL的宽线性范围,检测限为0.330 pg/mL。它还表现出优异的特异性,并在临床肺腺癌血清样本中可靠运行,展示了其在早期诊断这种恶性肿瘤方面的广阔应用前景。
Journal of advanced research IF 17.1 2026-11-14 PMID: 43033909
Mitophagy, the selective clearance of defective mitochondria via the autophagy-lysosome pathway, is essential for maintaining mitochondrial health and cellular homeostasis. Dysregulation of mitophagy is strongly implicated in aging-related pathologies, including neurodegenerative diseases (Alzheimer's, Parkinson's), cancer, and metabolic disorders, highlighting the significance of elucidating its regulatory mechanisms. While existing methods using exogenous reporters enable genome-wide and high-throughput screening for mitophagy regulators, they constrain discoveries to specific pathways and introduce artifacts through ectopic expression. To overcome these limitations, we developed an effective and rapid platform for identifying mitophagy modulators by targeting endogenous proteins. Using CRISPR-Cas9 technology, we engineered HeLa cells expressing small molecular tags (GFP or NanoLuc) fused to the C-terminal of ATP5B, a mitochondrial inner membrane protein. Genome-wide screening for mitophagy regulatory genes were performed using a genome-wide CRISPR library coupled with flow cytometry. Additionally, an FDA-approved kinase inhibitor library was used to screen for mitophagy inducers. To evaluate the efficacy of a screened drug in Alzheimer's disease, cognitive behavior, pathological features and mitophagy events in 3 × Tg-AD mice with or without treatment were examined using the Morris water maze assay, enzyme-linked immunosorbent assay (ELISA) and transmission electron microscopy (TEM). These ATP5B-tagging cells provided a robust readout of mitophagy and enabled high-throughput genetic or pharmacological screening. With this platform, we identified several promising genes that regulate mitophagy and are significantly associated with Alzheimer's disease. Moreover, the FDA-approved drug Flupentixol emerged as a novel mitophagy inducer that acts by promoting adenosine monophosphate-activated protein kinase (AMPK) localization to mitochondria and exhibited strong therapeutic potential in a model of Alzheimer's disease. This study establishes a novel system for identifying mitophagy modulators, with the potential to accelerate the discovery of therapeutic strategies for Alzheimer's disease.
中文摘要:线粒体自噬是通过自噬溶酶体途径选择性清除缺陷线粒体的过程,对维持线粒体健康和细胞稳态至关重要。线粒体自噬失调与衰老相关病理改变密切相关,包括神经退行性疾病(阿尔茨海默病、帕金森病)、癌症和代谢紊乱,这凸显了阐明其调控机制的重要性。虽然现有的使用外源报告基因的方法能够实现全基因组和高通量筛选线粒体自噬调节因子,但它们将发现局限于特定通路,并通过异位表达引入人工假象。为了克服这些局限性,我们开发了一种针对内源性蛋白的有效且快速的平台来识别线粒体自噬调节剂。利用CRISPR-Cas9技术,我们构建了HeLa细胞,其ATP5B(一种线粒体内膜蛋白)的C端融合了小分子标签(GFP或NanoLuc)。使用全基因组CRISPR文库结合流式细胞术进行了线粒体自噬调节基因的全基因组筛选。此外,还使用了FDA批准的激酶抑制剂库来筛选线粒体自噬诱导剂。为了评估筛选出的药物在阿尔茨海默病中的疗效,通过莫里斯水迷宫实验、酶联免疫吸附测定(ELISA)和透射电子显微镜(TEM)检查了接受或不接受治疗的3×Tg-AD小鼠的认知行为、病理特征和线粒体自噬事件。这些ATP5B标记细胞提供了强大的线粒体自噬读数,并实现了高通量遗传或药理学筛选。利用该平台,我们鉴定了几个调节线粒体自噬并与阿尔茨海默病显著相关的有前景的基因。此外,FDA批准的药物氟哌噻吨作为一种新的线粒体自噬诱导剂出现,它通过促进腺苷单磷酸激活蛋白激酶(AMPK)定位到线粒体发挥作用,并在阿尔茨海默病模型中表现出强大的治疗潜力。本研究建立了一种识别线粒体自噬调节因子的新系统,有望加速阿尔茨海默病治疗策略的发现。
MedComm IF 14.1 2026-11 PMID: 43032669
Ubiquitination and deubiquitination are established as a reversible regulatory system controlling protein stability, localization, molecular interactions, and signaling duration. Ubiquitin is recognized not merely as a proteasomal degradation signal but as a molecular code whose output is determined by substrate identity, chain topology, and cellular context. Distinct ubiquitin signals are generated by E3 ubiquitin ligases (E3 ligases), remodeled by deubiquitinating enzymes (DUBs), and decoded by ubiquitinbinding domains. Beyond protein turnover, epigenetic and epitranscriptomic factors are directly regulated by ubiquitin signaling through control of their stability, activity, and interactions, thereby integrating chromatin and RNA regulation. In this review, the ubiquitin activating enzyme (E1)/ubiquitin conjugating enzyme (E2)/E3 cascade, ubiquitin chain architectures, DUBs, and signal recognition mechanisms are outlined in relation to key biological processes. The contribution of disrupted networks to cancer, neurodegeneration, and autoimmune diseases is discussed. Therapeutic strategies, including proteolysis targeting chimeras (PROTACs), molecular glues, DUB inhibitors, and E3 modulators, are presented with early clinical and preclinical developments highlighted to link mechanistic biology to therapeutic design. Shared principles of degradative and nondegradative ubiquitin signaling are identified across cellular networks, with emphasis on epigenetic and epitranscriptomic regulation. A nuanced framework is offered to interpret disease dysfunction, evaluate targeted therapies, and prioritize unresolved questions regarding substrate specificity and signaling context.
中文摘要:泛素化与去泛素化被确立为控制蛋白质稳定性、定位、分子相互作用及信号持续时间的可逆调控系统。泛素不仅被视为蛋白酶体降解信号,更被视为一种由底物身份、链拓扑结构和细胞环境决定其输出的分子代码。不同的泛素信号由E3泛素连接酶生成,经去泛素化酶重塑,并由泛素结合结构域解码。除蛋白质周转外,表观遗传和表观转录组因子也通过其稳定性、活性和相互作用的调控直接受泛素信号影响,从而整合染色质与RNA调控。本综述概述了泛素激活酶(E1)/泛素结合酶(E2)/E3级联反应、泛素链架构、去泛素化酶及信号识别机制与关键生物学过程的关系。讨论了网络紊乱对癌症、神经退行性疾病和自身免疫性疾病的贡献。提出了包括蛋白水解靶向嵌合体、分子胶、去泛素化酶抑制剂和E3调节剂在内的治疗策略,并强调了早期临床和前临床进展,以将机制生物学与治疗设计联系起来。在细胞网络中鉴定出降解性和非降解性泛素信号共享的原则,重点强调表观遗传和表观转录组调控。提供了一个细致的框架来解释疾病功能障碍、评估靶向疗法,并优先解决关于底物特异性和信号环境的不解之谜。
Cancer research IF 22.6 2026-11-13 PMID: 43024359
Non-mutational mechanisms, including copy number alterations and transcription factor dysregulation, are critical drivers of melanoma progression. Here, we identify the transcription factor MYBL2 as a key oncogenic driver located on frequently amplified chromosome 20q. MYBL2 overexpression promoted transformation and correlated with poor survival, yet paradoxically, the transactivation function of MYBL2 was dispensable for oncogenic activity. Instead, MYBL2 acquired a non-canonical RNA-binding function enabled by the melanoma-associated RNA landscape. Through these RNA interactions, MYBL2 reshaped the chromatin landscape toward an AP-1-permissive state and promoted chromatin association of the oncogenic transcription factors MAFG and FRA1, indirectly reprogramming tumor-promoting gene networks that predict poor outcomes across multiple cancers. Importantly, a decoy RNA that disrupts the MYBL2-RNA interaction impaired MYBL2 association with MAFG and FRA1 and suppressed melanoma cell growth. These findings establish MYBL2 as an RNA-binding-dependent, 20q gain-associated driver that promotes melanoma progression through chromatin and transcriptional network remodeling.
中文摘要:非突变机制包括拷贝数变异和转录因子失调是黑色素瘤进展的关键驱动因素。本研究鉴定出位于常扩增染色体20q上的转录因子MYBL2为关键致癌驱动因子。MYBL2过表达促进细胞转化并与不良生存期相关,然而其反式激活功能对致癌活性并非必需。相反,在黑色素瘤相关RNA景观的赋能下,MYBL2获得了非经典RNA结合功能。通过这些RNA相互作用,MYBL2重塑染色质景观向AP-1允许状态转变,并促进致癌转录因子MAFG和FRA1与染色质的结合,间接重编程预测多种癌症不良结局的促肿瘤基因网络。重要的是,一种破坏MYBL2-RNA相互作用的诱饵RNA削弱了MYBL2与MAFG和FRA1的结合并抑制黑色素瘤细胞生长。这些发现确立MYBL2为依赖RNA结合的20q增益相关驱动因子,通过染色质和转录网络重塑促进黑色素瘤进展。

6泌尿生殖肿瘤 (14篇)

临床研究 (1篇)

Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42537420
Urinary protein biomarker analysis holds immense promise for noninvasive tumor monitoring; however, current assays are limited by multi-step operations and matrix interference. Herein, we developed a one-pot fluorescence nano-immunomachine for ultrasensitive quantification of urinary bladder cancer-specific nuclear matrix protein 4 (BLCA-4), driven by cascaded confinement-mediated quantum dots encapsulation in DNA nanospheres. Programmed DNA self-assembly and phenyllactic acid-mediated framework condensation jointly established hierarchical structural confinement to cage QDs with minimal signal leakage. Upon streptavidin-biotin-directed antibody functionalization, the resulting QDs@DNS@Ab platform specifically recognized BLCA-4, triggering localized structural disassembly and spontaneous fluorescence recovery. This washing-free homogeneous assay was completed within 40 min, achieving a dynamic range of 10-5 × 104 ag/mL and a detection limit of 3.6 ag/mL. Clinical validation of 72 urine samples, including bladder cancer patients (n = 30), healthy controls (n = 20), and urological disease controls (n = 22), demonstrated strong diagnostic discrimination and good concordance with enzyme-linked immunosorbent assay measurements, achieving an area under the curve of 0.93, sensitivity of 93.3%, and specificity of 90.5%. Longitudinal paired analysis effectively tracked post-resection biomarker clearance, highlighting the responsive nanoplatform as a rapid, sensitive, and operationally simple adjunct tool for noninvasive bladder cancer risk stratification, postoperative surveillance, and future point-of-care diagnostics.
中文摘要:尿液蛋白生物标志物分析在无创肿瘤监测方面具有巨大潜力,然而现有检测方法受限于多步操作和基质干扰。本研究开发了一种单锅法荧光纳米免疫机器,用于超灵敏定量检测尿液中膀胱癌特异性核基质蛋白4(BLCA-4),该过程由级联限域介导的量子点封装于DNA纳米球中驱动。程序化DNA自组装与苯乳酸介导的骨架凝聚共同建立了层级结构限域,将量子点笼状包裹以实现最小信号泄漏。在链霉亲和素-生物素导向的抗体功能化后,所得QDs@DNS@Ab平台特异性识别BLCA-4,触发局部结构解体和自发荧光恢复。这种免洗涤均相检测在40分钟内完成,动态范围为10^-5至10^4 ag/mL,检测限为3.6 ag/mL。对72份尿液样本(包括30例膀胱癌患者、20例健康对照和22例泌尿系统疾病对照)的临床验证显示其具有强大的诊断区分能力和与酶联免疫吸附测定良好的相关性,曲线下面积为0.93,灵敏度为93.3%,特异度为90.5%。纵向配对分析有效追踪了术后生物标志物的清除情况,表明该响应性纳米平台是一种快速、灵敏且操作简便的辅助工具,适用于膀胱癌风险分层、术后监测及未来的即时诊断。

基础研究 (13篇)

Science advances IF 13.9 2026-11-20 PMID: 43050551
RICTOR plays an essential role in regulating mechanistic target of rapamycin complex 2 (mTORC2) kinase activity, but it remains largely elusive how RICTOR is aberrantly activated in human prostate cancer (PrCa). Here, we identify RICTOR as a substrate of Cullin 3-based ubiquitin ligase adaptor SPOP, an important tumor suppressor in PrCa. SPOP deficiency or cancer-derived SPOP mutations disrupt SPOP-mediated degradation of RICTOR, thereby promoting PrCa progression. Furthermore, we identify USP8 as its upstream deubiquitinase, and inhibition of USP8 specifically suppresses RICTOR/mTORC2 activity without affecting mTORC1. As such, the USP8 inhibitor induces RICTOR degradation concomitant with marked tumor suppression in vivo. Hence, these findings reveal an SPOP-USP8-RICTOR regulatory circuit that underlies PrCa tumorigenesis and provides a rationale for targeting RICTOR via USP8 inhibition as a therapeutic strategy for patients with PrCa.
中文摘要:RICTOR在调节机械靶标雷帕霉素复合物2(mTORC2)激酶活性中发挥关键作用,但其在人类前列腺癌(PrCa)中异常激活的机制尚不明确。本研究将RICTOR鉴定为基于Cullin 3的泛素连接酶适配蛋白SPOP的底物,SPOP是PrCa中的重要肿瘤抑制因子。SPOP缺失或癌症衍生的SPOP突变会破坏SPOP介导的RICTOR降解,从而促进PrCa进展。此外,我们将USP8鉴定为其上游去泛素化酶,USP8的抑制特异性地抑制RICTOR/mTORC2活性而不影响mTORC1。因此,USP8抑制剂在体内诱导RICTOR降解并伴随显著的肿瘤抑制效果。综上所述,这些发现揭示了一个调控PrCa发生发展的SPOP-USP8-RICTOR调节回路,并为通过抑制USP8靶向RICTOR作为PrCa患者的治疗策略提供了理论依据。
Science advances IF 13.9 2026-11-20 PMID: 43050535
Both intrinsic and acquired resistance to poly (ADP-ribose) polymerase inhibitors (PARPis) have emerged as a formidable challenge in clinical practice. Here, we report that the transcription factor E-twenty-six (Ets)-related gene (ERG) was highly expressed in PARPi-resistant prostate cancer and was correlated with PARPi resistance in castration-resistant prostate cancer (CRPC) cells. ERG was posttranslationally modified by tripartite motif-containing 28 (TRIM28) as SUMOylation at lysine 389 (K389), which promotes DNA homologous recombination repair (HRR), thereby weakening the efficacy of PARPis. Mechanistically, the SUMOylation of ERG (K389) inhibited protein degradation mediated by the SPOP-mediated ubiquitin-proteasome pathway, thereby stabilizing the protein. Concurrently, this posttranslational modification increased HRR capacity by inhibiting 53BP1 expression, which in turn reduced PARPi sensitivity. Blockade of ERG K389 SUMOylation can effectively impair DNA repair efficacy and overcome PARPi resistance. These findings suggest that TRIM28-mediated ERG SUMOylation conveys resistance to PARPis by inhibiting 53BP1 expression; combined TRIM28/ERG targeting and PARPi therapy may improve outcomes for ERG-positive CRPC patients.
中文摘要:多聚ADP核糖聚合酶抑制剂(PARPis)的原发性和获得性耐药已成为临床实践中的严峻挑战。本研究报道,转录因子E-twenty-six相关基因(ERG)在PARPi耐药的前列腺癌中高表达,并与去势抵抗性前列腺癌(CRPC)细胞中的PARPi耐药相关。三结构域基序蛋白28(TRIM28)通过SUMO化修饰将ERG在赖氨酸389(K389)位点进行翻译后修饰,从而促进DNA同源重组修复(HRR),削弱PARPis的疗效。机制上,ERG(K389)的SUMO化抑制了由SPOP介导的泛素-蛋白酶体途径所介导的蛋白降解,从而稳定该蛋白。同时,这种翻译后修饰通过抑制53BP1的表达增加了HRR能力,进而降低了PARPi敏感性。阻断ERG K389 SUMO化可有效损害DNA修复效率并克服PARPi耐药。这些发现表明,TRIM28介导的ERG SUMO化通过抑制53BP1表达传递对PARPis的耐药性;联合靶向TRIM28/ERG与PARPi治疗可能改善ERG阳性CRPC患者的预后。
Nature methods IF 28.3 2026-11-19 PMID: 43058207
Metastases arise when cancer cells disseminate from the primary tumor, or other metastases, and seed tumors at distant anatomical sites. Reconstructing migration histories from DNA sequencing data is key to understanding the cellular mechanisms underlying metastatic dissemination. While the data often support many equally plausible histories, current methods return a single solution or sample alternatives without guarantees of optimality or completeness. Here we introduce MACH2, which enumerates all optimal migration histories and summarizes them to identify high-confidence migrations. MACH2 combines existing parsimony criteria with a new criterion that minimizes the number of clones assigned to locations where they were not observed, and includes MACH2-viz, an interactive tool for exploring solutions. Using simulated tumors with known ground truth, we show that MACH2 outperforms existing methods. Across 145 lung, ovarian, breast and prostate cancers, MACH2 reveals extensive uncertainty in migration histories, infers histories consistent with orthogonal experimental data, and finds metastasis-to-metastasis seeding and linear progression to be common.
中文摘要:转移发生于癌细胞从原发肿瘤或其他转移灶播散,并在远处解剖部位定植形成新肿瘤的过程。从DNA测序数据重建迁移历史对于理解转移播散的细胞机制至关重要。尽管数据往往支持多种同样合理的迁移历史,但现有方法仅返回单一解或采样替代方案,且无法保证最优性或完整性。本文介绍MACH2,该方法枚举所有最优迁移历史并对其进行汇总以识别高置信度的迁移事件。MACH2将现有的简约性标准与一种最小化未观察克隆分配至其所在位置的准则相结合,并包含一个名为MACH2-viz的交互式工具用于探索解决方案。利用具有已知真实情况的模拟肿瘤数据,我们证明MACH2优于现有方法。在145例肺癌、卵巢癌、乳腺癌和前列腺癌样本中,MACH2揭示了迁移历史中存在广泛的确定性不足,推断出与正交实验数据一致的迁移历史,并发现转移灶至转移灶的播种以及线性进展是常见现象。
Pharmacological research IF 12.2 2026-11-19 PMID: 43057632
Dysregulated apoptosis is a critical factor contributing to the emergence of drug resistance in cancer chemotherapy. Survivin, a key member of the inhibitor of apoptosis protein (IAP) family, is frequently overexpressed in various cancers and plays a pivotal role in apoptosis regulation. In our study, we identified CRL3SPOP as a canonical E3 ligase for survivin, mediating its ubiquitination and subsequent degradation. Intriguingly, prostate cancer-associated SPOP mutants lose the ability to bind survivin, thereby impairing its degradation which leads to diminished apoptosis, enhanced cell survival, and increased chemotherapy resistance in prostate cancer cells harboring SPOP mutations. Importantly, we demonstrated that depletion of survivin in SPOP-mutated cells significantly enhances apoptosis and restores chemosensitivity. This study provides a direct mechanism for the reduced level of apoptosis in prostate cancer with SPOP mutations, and demonstrated that survivin might be a therapeutic target for SPOP-mutated patients and provided new strategies to overcome chemotherapy resistance.
中文摘要:凋亡失调是癌症化疗中产生耐药性的关键因素。Survivin作为凋亡抑制蛋白家族的关键成员,在多种癌症中常过表达并在凋亡调控中发挥核心作用。本研究鉴定出CRL3SPOP是survivin的经典E3连接酶,介导其泛素化及随后的降解。有趣的是,前列腺癌相关的SPOP突变体丧失结合survivin的能力,从而损害其降解,导致携带SPOP突变的前列腺癌细胞凋亡减少、细胞存活增强及化疗耐药性增加。重要的是,我们证明在SPOP突变细胞中耗竭survivin可显著增强凋亡并恢复化学敏感性。本研究为前列腺癌中SPOP突变导致的凋亡水平降低提供了直接机制解释,并表明survivin可能是SPOP突变患者的治疗靶点,为克服化疗耐药提供了新策略。
Cancer letters IF 11.8 2026-11-19 PMID: 43057410
Cisplatin resistance critically limits muscle-invasive bladder cancer (MIBC) therapy, yet the underlying regulatory mechanisms remain incompletely understood. Here, we report that NOP2, an RNA m5C methyltransferase, is upregulated in cisplatin-resistant bladder cancer cells and clinical tumor samples, correlating with poor chemotherapeutic response. Mechanistically, P300-catalyzed lactylation at NOP2 K772 disrupts its association with the E3 ligase PJA2, thereby evading K48-linked ubiquitination and proteasomal degradation. Stabilized NOP2 deposits m5C modifications within the coding sequence of GLS1 mRNA, which are recognized by the reader YBX1 to enhance GLS1 transcript stability and translation. Elevated GLS1 reprograms glutamine metabolism, augments glutathione and NADPH pools, suppresses ferroptosis, and drives cisplatin resistance. Notably, genetic depletion of NOP2 or GLS1, or pharmacological targeting with the GLS1 inhibitor CB-839, restores cisplatin sensitivity and synergizes with the ferroptosis inducer RSL3 in vitro and in vivo. Our findings uncover a lactylation-dependent stabilization of NOP2 and define a NOP2-GLS1 epitranscriptomic-metabolic axis that links m5C remodeling to ferroptosis evasion in chemoresistant MIBC, suggesting that interrupting this cascade represents a viable therapeutic strategy to overcome cisplatin resistance.
中文摘要:顺铂耐药严重限制了肌层浸润性膀胱癌(MIBC)的治疗,但其潜在的调控机制尚不完全清楚。本研究报道了RNA m5C甲基转移酶NOP2在顺铂耐药的膀胱癌细胞及临床肿瘤样本中表达上调,且与化疗反应不良相关。机制上,P300催化的NOP2 K772位点乳酸化修饰破坏了其与E3连接酶PJA2的结合,从而逃避K48连接的泛素化及蛋白酶体降解。稳定的NOP2在GLS1 mRNA编码区沉积m5C修饰,这些修饰被阅读器YBX1识别,进而增强GLS1转录本的稳定性和翻译效率。GLS1的升高重编程了谷氨酰胺代谢,增加了谷胱甘肽和NADPH池,抑制了铁死亡,并驱动顺铂耐药。值得注意的是,NOP2或GLS1的基因敲除,或使用GLS1抑制剂CB-839进行药理学靶向,在体外和体内均能恢复对顺铂的敏感性,并与铁死亡诱导剂RSL3产生协同作用。我们的发现揭示了一种依赖乳酸化的NOP2稳定机制,并定义了一个将m5C重塑与MIBC化疗耐药中逃避铁死亡联系起来的NOP2-GLS1表观转录组代谢轴,表明阻断这一级联反应是克服顺铂耐药的一种可行的治疗策略。
Pharmacological research IF 12.2 2026-11-18 PMID: 43051566
Castration-resistant prostate cancer (CRPC), particularly the prevalent PSMA-negative subtype, lacks effective imaging-guided therapy options. Here, we report a nucleolus-penetrating peptide platform targeting DDX24, an oncogenic RNA helicase overexpressed in CRPC. Using bacterial surface display with iterative MACS/FACS screening, a leading DDX24-binding peptide (TDP-2, Kd = 17.63 ± 7.72μM) is identified. This single peptide is engineered into two imaging-guided therapy modalities: (1) a 64Cu-labeled PET probe ([64Cu]Cu-DOTA-TDP-2, >99% radiochemical purity) enabling specific, non-invasive imaging of DDX24-positive CRPC tumors in vivo (SUVmean 0.55 ± 0.08, T/M ratio 6.59 ± 0.71); and (2) a peptide-based PROTAC (TDP-2-PROTAC) that recruits the VHL E3 ligase to induce targeted, proteasome-dependent degradation of DDX24 (DC50 =49.1μM). TDP-2-PROTAC selectively suppresses CRPC cell proliferation (PC-3, DU145) while sparing non-malignant cells, and significantly inhibits tumor growth in xenograft models, accompanied by a reduction in tumoral [18F]FDG uptake and influx ([18F]FDG PET: SUV 1.29 ±0.45 vs 2.48 ± 0.24 in controls, p < 0.001). This integrated platform establishes DDX24 as a viable target for PSMA-negative CRPC and demonstrates the power of peptide-based tools for accessing intracellular oncogenic drivers.
中文摘要:去势抵抗性前列腺癌(CRPC),尤其是常见的PSMA阴性亚型,缺乏有效的影像引导治疗选择。本研究报道了一种靶向CRPC中过表达的致癌RNA解旋酶DDX24的核仁穿透肽平台。通过细菌表面展示结合迭代MACS/FACS筛选,鉴定出一种主要的DDX24结合肽(TDP-2,Kd = 17.63 ± 7.72μM)。该单肽被工程化为两种影像引导治疗模式:一是标记为64Cu的PET探针([64Cu]Cu-DOTA-TDP-2,放射化学纯度>99%),可在体内特异性、无创地成像DDX24阳性的CRPC肿瘤(SUVmean 0.55 ± 0.08,T/M比值6.59 ± 0.71);二是基于肽的PROTAC(TDP-2-PROTAC),可招募VHL E3连接酶以诱导DDX24靶向、蛋白酶体依赖性降解(DC50 = 49.1μM)。TDP-2-PROTAC选择性抑制CRPC细胞增殖(PC-3,DU145)同时保留非恶性细胞,并在异种移植模型中显著抑制肿瘤生长,伴随肿瘤内[18F]FDG摄取和流入减少([18F]FDG PET:对照组SUV为2.48 ± 0.24,治疗组为1.29 ± 0.45,p < 0.001)。这一综合平台确立了DDX24作为PSMA阴性CRPC的可行靶点,并展示了基于肽的工具在靶向细胞内致癌驱动因子方面的潜力。
Environmental science & technology IF 12.2 2026-11-18 PMID: 43048911
Significant gaps remain in the health risk assessment methodologies for the PFOS (perfluorooctanesulfonic acid) alternative 6:2 Cl-PFESA (6:2 chlorinated polyfluoroalkyl ether sulfonate, F-53B), which has been widely recognized as the alternative to PFOS in China. To address this research gap, our study integrated multidimensional techniques to mechanistically construct an Adverse Outcome Pathway (AOP) for F-53B-induced ovarian cancer progression. Our findings demonstrated that exposure to environmentally relevant concentrations of F-53B significantly enhanced the migratory and invasive capabilities of ovarian cancer cells. Within the AOP framework of F-53B-induced hybrid epithelial-mesenchymal transition (EMT) and enhanced tumor stemness, the upregulation of C5aR1─triggered by ERα acting as a noncanonical receptor of F-53B─constitutes the molecular initiating event (MIE). Following this MIE, the recruitment of β-arrestin1 and Src was induced, leading to the assembly of a C5aR1/β-arrestin1/Src signaling complex. This complex facilitated the binding of β-arrestin1 to β-catenin and drove the nuclear translocation of β-catenin, ultimately activating hybrid EMT and stemness of tumor cells. Administration of the C5aR1 inhibitor PMX205 effectively abrogated subsequent key events (KEs) caused by F-53B exposure. Through in vitro and in vivo validation, our study established an AOP framework that provides a novel perspective for evaluating the potential risk of PFAS substitutes in promoting cancer progression.
中文摘要:针对PFOS(全氟辛烷磺酸)替代品6:2 Cl-PFESA(6:2氯化聚氟烷基醚磺酸,即F-53B)的健康风险评估方法仍存在显著空白,该物质已被广泛认为是中国在PFOS方面的替代品。为填补这一研究空白,本研究整合多维技术,机制性地构建了F-53B诱导卵巢癌进展的不良结果通路(AOP)。研究结果表明,暴露于环境相关浓度的F-53B显著增强了卵巢癌细胞的迁移和侵袭能力。在F-53B诱导的混合上皮间质转化(EMT)和增强肿瘤干性的AOP框架中,由ERα作为F-53B的非经典受体触发的C5aR1上调构成了分子起始事件(MIE)。在此MIE之后,诱导了β-arrestin1和Src的招募,进而组装成C5aR1/β-arrestin1/Src信号复合物。该复合物促进了β-arrestin1与β-catenin的结合,并驱动β-catenin的核转位,最终激活肿瘤细胞的混合EMT和干性。给予C5aR1抑制剂PMX205有效消除了F-53B暴露引起的后续关键事件(KEs)。通过体外和体内验证,本研究建立了一个AOP框架,为评估PFAS替代品促进癌症进展的潜在风险提供了新视角。
Medicinal research reviews IF 13.6 2026-11-16 PMID: 43036254
Protein kinases coordinate cellular proliferation, differentiation, survival, metabolism, and stress responses, and dysregulated kinase signalingf is a defining feature of many malignancies. From 2021 through 2025, the U.S. Food and Drug Administration (U.S. FDA) approved 26 small-molecule kinase inhibitors for cancer therapy, extending precision treatment across non-small-cell lung cancer, hematologic malignancies, breast and ovarian cancers, cholangiocarcinoma, renal cell carcinoma, glioma, and other kinase-driven tumors. The approved agents illustrate advances in medicinal chemistry and translational pharmacology that include covalent inhibitors such as sotorasib and futibatinib, mutation-selective inhibitors such as taletrectinib and zongertinib, allosteric inhibitors such as asciminib and mirdametinib, and multitarget or combination strategies such as avutometinib plus defactinib. Improvements in central nervous system exposure, mutant selectivity, dosing durability, and biomarker-defined patient selection have broadened clinical utility. This Review integrates the discovery background, mechanism of action, synthetic route, pharmacological properties, clinical efficacy, safety, and regulatory context of these agents. It also evaluates acquired resistance, target-related and off-target toxicities, heterogeneous evidence supporting accelerated approvals, and the uncertain translation of biochemical potency into durable survival benefit. Successful kinase drug development therefore requires molecular design to be aligned with clinically achievable exposure, validated biomarkers, resistance surveillance, and confirmatory evidence.
中文摘要:蛋白激酶协调细胞增殖、分化、存活、代谢及应激反应,激酶信号失调是许多恶性肿瘤的特征性表现。2021年至2025年间,美国食品药品监督管理局批准了26种小分子激酶抑制剂用于癌症治疗,将精准治疗扩展至非小细胞肺癌、血液系统恶性肿瘤、乳腺癌和卵巢癌、胆管癌、肾细胞癌、胶质瘤及其他激酶驱动型肿瘤。获批药物体现了药物化学和转化药理学方面的进展,包括索托拉西布和伏比替尼等共价抑制剂,塔雷曲替尼和宗替尼等突变选择性抑制剂,阿司米尼布和米尔达美替尼等变构抑制剂,以及阿武替尼联合德法替尼等多靶点或联合策略。中枢神经系统渗透性、突变选择性、给药持续性和生物标志物定义的患者选择方面的改进扩大了其临床效用。本综述整合了这些药物的发现背景、作用机制、合成路线、药理学特性、临床疗效、安全性及监管背景。同时评估了获得性耐药、靶点相关和非靶点毒性、支持加速审批的证据异质性,以及生化效力转化为持久生存获益的不确定性。因此,成功的激酶药物开发要求分子设计与临床上可实现的暴露量、验证的生物标志物、耐药监测及确认性证据相一致。
Cancer research IF 22.6 2026-11-16 PMID: 42691240
Cervical cancer can progress from high-grade squamous intraepithelial lesions driven by persistent human papillomavirus (HPV) infection. Identifying the gatekeepers restraining malignant transformation could reveal strategies to prevent and treat cervical cancer. In this study, we integrated single-cell transcriptomics, CRISPR-Cas9 screening, and organoid modeling to dissect this process. Single-cell analysis of patient samples revealed progressive activation of rat sarcoma virus (RAS) and proliferation programs along epithelial differentiation paths. A focused CRISPR screen in HPV-positive pretumoroids identified neurofibromin 1 (NF1) as the top suppressor of malignant transition. NF1 loss accelerated carcinogenesis in organoids, substantially shortening the experimental interval required for the emergence of malignant phenotypes and recapitulating basal cell expansion, altered differentiation marker expression, and tumorigenicity. Mechanistically, NF1 loss enhanced RAS-mitogen-activated protein kinase and phosphoinositide 3-kinase-protein kinase B signaling, promoted proliferative programs, and remodeled chromatin accessibility at regulatory regions enriched for activator protein 1 motifs. Conversely, NF1 restoration in cancer organoids induced apoptosis and suppressed malignant maintenance. Artificial intelligence-guided modeling was used to design a minimal NF1-derived peptide predicted to interact with RAS GTP-binding protein. The NF1-GAP-mimetic peptide reduced tumor organoid viability and cervical lesion-associated bioluminescence in an HPV16-driven mouse model and was associated with local immune-related changes without marked alterations in selected splenic T-cell populations. Together, these findings establish NF1 as a critical constraint on HPV-associated epithelial evolution and provide a time-compressed organoid model of cervical carcinogenesis, offering proof of concept for NF1-inspired therapeutic interception of RAS-associated signaling. Single-cell atlas and organoid screening identified NF1 loss as a driver of cervical carcinogenesis, which can be rescued with an AI-designed NF1 mimetic peptide that offers a therapeutic paradigm to intercept tumorigenesis.
中文摘要:宫颈癌可由持续人乳头瘤病毒(HPV)感染驱动的高级别鳞状上皮内病变进展而来。鉴定抑制恶性转化的守门基因可能揭示预防和治疗宫颈癌的策略。本研究整合单细胞转录组学、CRISPR-Cas9筛选和类器官模型以解析这一过程。对患者样本的单细胞分析显示,沿上皮分化路径存在RAS病毒(ras)和增殖程序的渐进性激活。在HPV阳性前肿瘤类器官中进行的聚焦CRISPR筛选鉴定出神经纤维瘤蛋白1(NF1)为恶性转化的最强抑制因子。NF1缺失加速了类器官中的致癌过程,显著缩短了出现恶性表型所需的实验间隔,并重现了基底细胞扩增、分化标志物表达改变和致瘤性。在机制上,NF1缺失增强了RAS-丝裂原活化蛋白激酶和磷脂酰肌醇3-激酶-蛋白激酶B信号通路,促进了增殖程序,并重塑了富含激活蛋白1基序的调控区域的染色质可及性。相反,癌症类器官中NF1的恢复诱导了细胞凋亡并抑制了恶性维持。利用人工智能指导建模设计了一种预测与RAS鸟苷酸结合蛋白相互作用的最小NF1衍生肽。该NF1-GAP模拟肽降低了HPV16驱动的鼠模型中肿瘤类器官的活力和宫颈病变相关的生物发光,并与局部免疫相关变化相关,而选定的脾脏T细胞群没有显著改变。综上所述,这些发现确立NF1为HPV相关上皮演化的关键约束,并提供了一种时间压缩的宫颈癌发生类器官模型,为通过NF1启发的治疗手段阻断RAS相关信号提供了概念验证。单细胞图谱和类器官筛选鉴定出NF1缺失是宫颈癌发生的驱动因素,该缺陷可通过AI设计的NF1模拟肽进行挽救,提供了一种拦截肿瘤发生的治疗范式。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42541842
Given the challenges posed by late diagnosis of prostate cancer, rapid point-of-care testing is crucial to facilitate early intervention and enhance treatment effectiveness. In this context, 3D-printed immunosensors represent a promising alternative for the development of low-cost, miniaturized, and reliable diagnostic tools. Accordingly, a neodymium-based metal-organic framework (Nd-MOF) was integrated onto conductive 3D-printed electrodes to develop a label-free voltammetric immunosensor for the monitoring of prostate-specific antigen (PSA). Spectroscopic characterizations indicated the anchoring of the PSA antibody through the free carboxylic groups in the Nd-MOF structure. This platform exhibited redox behavior resulting from methylene blue adsorbed Nd-MOF, while its functional groups enabled PSA antibody immobilization. The different steps for the construction of 3D-printed immunosensor and the evaluation of PSA biorecognition were assessed by cyclic voltammetry. The 3D-printed immunosensor exhibited excellent analytical performance over a linear range of 0.50 to 50.0 ng mL-1, with a low limit of detection of 0.15 ng mL-1. Moreover, the platform showed remarkable repeatability (RSD <4.80%) and stability over successive measurements, confirming its reliability for accurate PSA monitoring. In addition, the 3D-printed immunosensor demonstrated sensitivity for PSA determination in spiked serum samples. The simple fabrication, and integration of methylene blue adsorbed Nd-MOF with 3D-printed electrodes highlight the potential of platform for point-of-care diagnostics, especially in resource-limited settings.
中文摘要:鉴于前列腺癌晚期诊断带来的挑战,快速即时检测对于促进早期干预和提高治疗效果至关重要。在此背景下,3D打印免疫传感器为开发低成本、微型化和可靠的诊断工具提供了有前景的替代方案。因此,本研究将基于钕的金属有机框架(Nd-MOF)集成到导电3D打印电极上,开发了用于监测前列腺特异性抗原(PSA)的无标记伏安免疫传感器。光谱表征表明,PSA抗体通过Nd-MOF结构中的游离羧基被锚定。该平台表现出由吸附了亚甲基蓝的Nd-MOF引起的氧化还原行为,其功能基团实现了PSA抗体的固定。通过循环伏安法评估了3D打印免疫传感器的构建步骤以及PSA生物识别的评估结果。该3D打印免疫传感器在0.50至50.0 ng/mL的线性范围内表现出优异的分析性能,检测限低至0.15 ng/mL。此外,该平台在连续测量中显示出显著的重复性(RSD <4.80%)和稳定性,证实了其在准确监测PSA方面的可靠性。另外,该3D打印免疫传感器对加标血清样本中的PSA测定表现出敏感性。简单的制造工艺以及将吸附亚甲基蓝的Nd-MOF与3D打印电极的结合,突显了该平台在即时诊断中的应用潜力,特别是在资源有限的环境中。
Cancer letters IF 11.8 2026-11-14 PMID: 43034010
Lysine lactylation (Kla) is a post-translational modification implicated in tumor metabolic reprogramming, yet its functional significance in bladder cancer remains largely unexplored. Here, we identify lactylation of Lamin A in bladder cancer and elucidate its regulatory mechanisms in cisplatin resistance. Integrated lactylome and proteome profiling combined with mass spectrometry reveal that Lamin A is lactylated at K233 and K417, which are significantly elevated in bladder cancer tissues. Functional characterization demonstrates that lactylation of Lamin A suppresses tumor proliferation, inhibits migration, induces G1 cell cycle arrest, promotes apoptosis, and thus enhances cisplatin sensitivity, whereas lactylation-deficient mutants abrogate these effects, with K233 and K417 as the critical functional residues. Mechanistically, Lamin A delactylation enhances the binding between MRE11 and ATM, promotes the recruitment of MRE11 to DSB sites and activates the downstream CHK1/CHK2 signaling pathway, thereby promoting DNA repair and conferring cisplatin resistance. We further identify HDAC2 and KAT2A as the delactylase and lactyltransferase of Lamin A, respectively, with HDAC2 driving malignant phenotypes through K233 and K417 delactylation. Pharmacological inhibition of HDAC2 with entinostat effectively suppresses xenograft tumor growth in vivo in a Lamin A lactylation-dependent manner. Collectively, our findings define Lamin A lactylation as a tumor-suppressive modification and uncover the HDAC2/KAT2A-Lamin A axis as a critical factor of cisplatin response, suggesting that targeting this pathway may represent a promising therapeutic strategy for bladder cancer.
中文摘要:赖氨酸乳酸化(Kla)是一种与肿瘤代谢重编程相关的翻译后修饰,但其在膀胱癌中的功能意义尚不明确。本研究鉴定了膀胱癌中Lamin A的乳酸化并阐明了其在顺铂耐药中的调控机制。整合乳酸组学和蛋白质谱分析显示,Lamin A在K233和K417位点发生乳酸化,且在膀胱癌组织中显著升高。功能表征表明,Lamin A的乳酸化抑制肿瘤增殖、迁移,诱导G1期细胞周期停滞并促进凋亡,从而增强顺铂敏感性;而乳酸化缺陷突变体则消除这些效应,其中K233和K417是关键的功能性残基。机制上,Lamin A去乳酸化增强了MRE11与ATM的结合,促进MRE11招募至DNA双链断裂位点并激活下游CHK1/CHK2信号通路,从而促进DNA修复并赋予顺铂耐药性。我们进一步鉴定HDAC2和KAT2A分别为Lamin A的去乳酸酶和乳酸转移酶,其中HDAC2通过K233和K417去乳酸化驱动恶性表型。药理学抑制HDAC2(使用恩替诺特)在体内以Lamin A乳酸化依赖的方式有效抑制异种移植瘤生长。综上所述,我们的研究将Lamin A乳酸化定义为一种抑癌修饰,并揭示HDAC2/KAT2A-Lamin A轴是顺铂反应的关键因素,提示靶向该通路可能成为膀胱癌的一种有前景的治疗策略。
Biosensors & bioelectronics IF 11.8 2026-11-13 PMID: 43038939
Magnetic levitation (Maglev) has emerged as a powerful tool for biosensing. However, conventional Maglev biosensing strategies generally rely on readout of the levitation height of the overall microbeads that act as the reaction carriers, which cannot resolve ultratrace biomarker-induced binding events. Herein, we establish a new concept of digital Maglev immunosensing platform (dMaglev), in which each microbead serves as the reaction carrier as well as the independent Maglev signal output unit. Specifically, a single target molecule immunoreaction introduces abundant magnetic nanoparticles onto the payload microbead to alter its magnetic levitation height, enabling obvious spatial separation between the target-loading microbeads and target-free ones. Therefore, by digitally counting the number of microbeads with altered levitation height, attomolar-level protein biomarkers can be detected with high sensitivity, specificity, and generality. It is also demonstrated that the dMaglev can distinguish the serum samples of prostate cancer patients from those of healthy people. This work pioneers a novel digital counting readout principle and quantification method for Maglev biosensing, providing new opportunities for next-generation digital bioassays.
中文摘要:磁悬浮技术已成为生物传感领域的有力工具。然而,传统的磁悬浮生物传感策略通常依赖于读取作为反应载体的整体微球的悬浮高度,无法解析由超痕量生物标志物诱导的结合事件。在此,我们建立了一种新的数字磁悬浮免疫传感平台概念(dMaglev),其中每个微球既作为反应载体,也作为独立的磁悬浮信号输出单元。具体而言,单个靶分子免疫反应会在载荷微球上引入大量磁性纳米颗粒,从而改变其磁悬浮高度,使负载靶标的微球与无靶标微球之间产生明显的空间分离。因此,通过数字计数悬浮高度发生改变的微球数量,可以高灵敏度、高特异性和高通用性检测阿托摩尔水平的蛋白质生物标志物。研究还证明,dMaglev能够区分前列腺癌患者与健康人的血清样本。这项工作开创了磁悬浮生物传感的新颖数字计数读出原理和定量方法,为下一代数字生物测定提供了新机遇。
Cancer research IF 22.6 2026-11-13 PMID: 43024049
Epithelial ovarian cancers (EOCs) comprise biologically distinct histotypes that arise within shared anatomical niches where tumor-stroma interactions shape tumor behavior and therapeutic response. However, most classification frameworks rely on bulk profiling that conflates epithelial and stromal contributions, limiting the understanding of crosstalk between the different compartments. Here, we performed compartment-resolved transcriptomic and epigenomic profiling of matched carcinoma and stroma across clear cell (CCOC), endometrioid (ENOC), and high-grade serous ovarian cancers (HGSC). Carcinoma profiles segregated strongly by histotype, whereas stromal profiles showed minimal histotype specificity and instead resolved into four shared groups (S1-S4). The S4 subtype, marked by a desmoplastic, myofibroblast-rich program, was enriched in omental tumors and corresponded to the HGSC C1/Mesenchymal signature. This subtype largely reflected tumor-extrinsic programs and was present beyond HGSC. Compartment-resolved analyses also refined the interpretation of other molecular carcinoma subtypes and revealed distinct carcinoma-intrinsic EMT-like programs. Together, these findings define a histotype-agnostic stromal architecture across epithelial ovarian cancers, clarify the cellular basis of canonical high-grade serous molecular subtypes, and reveal carcinoma-intrinsic EMT programs. This study underscores the value of physically separating epithelial and stromal compartments before molecular analysis and position this dataset as a multi-purpose reference resource for the EOC research community.
中文摘要:上皮性卵巢癌包含生物学上不同的组织学亚型,这些亚型在共享的解剖生态位中发生,肿瘤与间质的相互作用塑造了肿瘤行为和治疗反应。然而,大多数分类框架依赖于混合分析,混淆了上皮和间质成分,限制了对不同隔室间串扰的理解。在此,我们对透明细胞癌、子宫内膜样癌和高级别浆液性卵巢癌的匹配癌组织和间质进行了隔室分辨的转录组和表观基因组分析。癌组织特征按组织学亚型强烈分离,而间质特征显示最小的组织学特异性,并解析为四个共享组。S4亚型以成纤维化、富含肌成纤维细胞的程序为标志,在网膜肿瘤中富集,并与HGSC C1/间充质特征相对应。该亚型主要反映了肿瘤外源性程序,且存在于HGSC之外。隔室分辨分析还细化了其他分子癌亚型的解释,并揭示了独特的癌内EMT样程序。总之,这些发现定义了上皮性卵巢癌中组织学无关的间质架构,阐明了经典高级别浆液性分子亚型的细胞基础,并揭示了癌内EMT程序。本研究强调了在分子分析前物理分离上皮和间质隔室的价值,并将此数据集定位为EOC研究社区的多用途参考资源。

7神经系统肿瘤 (11篇)

临床研究 (5篇)

Molecular biomedicine IF 13.0 2026-11-18 PMID: 43049983
Glioblastoma (GB) is the most aggressive form of malignant glioma, characterized by a low survival rate and minimal improvements in patient outcomes over the past three decades. This study investigates the feasibility of detecting circulating cell-free DNA (cfDNA) and analyses its dynamic fluctuations in a cohort of 59 patients undergoing chemoradiation treatment according to the standardized "Stupp protocol". In our cohort, longitudinal cfDNA levels remained broadly stable at the population level over the follow-up period; however, substantial inter-individual variability in individual trajectories was observed, highlighting the complexity of cfDNA dynamics in GB. At the individual level, longitudinal monitoring revealed that cfDNA levels generally declined following surgery and chemoradiotherapy, yet increased prior to or coinciding with radiological progression, supporting its potential utility as a biomarker for tumour burden estimation and treatment response monitoring. We further developed a cfDNA index model correlating preoperative cfDNA levels with gross tumour volume and clinical target volume, demonstrating a statistically significant association with radiological progression. To the best of our knowledge, this is the first study to propose a mathematically derived cfDNA index in GB. This simple, low-cost, and minimally invasive approach may offer a valuable tool for early risk stratification at diagnosis, complement longitudinal clinical assessment, and support individualized treatment planning and surveillance. Overall, these findings reinforce the potential of cfDNA quantification as an accessible biomarker to advance precision medicine in GB.
中文摘要:胶质母细胞瘤(GB)是恶性胶质瘤中最具侵袭性的类型,其特征为生存率低且过去三十年患者预后改善甚微。本研究旨在探讨在遵循标准化「Stupp方案」接受放化疗的59名患者队列中检测循环游离DNA(cfDNA)的可行性,并分析其动态波动情况。在该队列中,纵向cfDNA水平在随访期间总体保持稳定;然而,个体轨迹存在显著的个体间差异,突显了GB中cfDNA动力学的复杂性。在个体层面,纵向监测显示cfDNA水平通常在手术和放化疗后下降,但在放射学进展前或同时升高,支持其作为肿瘤负荷估算和治疗反应监测生物标志物的潜在效用。我们进一步开发了一个cfDNA指数模型,将术前cfDNA水平与大体肿瘤体积及临床靶体积相关联,结果显示其与放射学进展存在统计学显著关联。据我们所知,这是首个在GB中提出数学推导cfDNA指数的研究。这种简单、低成本且微创的方法可能为诊断时的早期风险分层提供有价值的工具,补充纵向临床评估,并支持个体化治疗规划和监测。总体而言,这些发现强化了cfDNA定量作为可及性生物标志物以推动GB精准医学的潜力。
Neuro-oncology IF 13.1 2026-11-14 PMID: 43035941
Artificial intelligence (AI) has become central to neuro-oncological imaging, impacting clinical and scientific workflows. In clinical practice, AI-based image reconstruction and noise reduction expedite the generation of advanced multiparametric MRI and PET scans. Automated segmentation and volumetric analysis improve reproducibility, speed, and standardization of tumor quantification and response assessment. In research, large language and multimodal models extract structured information from radiology reports and medical records. Collaborative initiatives, such as BraTS and FeTS, have established standardized, privacy-compliant frameworks for large-scale quantitative analyses. Tumor-specific applications include noninvasive molecular profiling in gliomas, grading and recurrence prediction in meningiomas, detection and response assessment in brain metastases, and pediatric-specific modeling aligned with RAPNO. However, AI models remain sensitive to technical and biological variations across institutions, limiting their clinical utility unless appropriate training and validation is performed. Nevertheless, progress is evident in prospective, biopsy-validated infiltration mapping, assessment of resection extent aligned with RANO-Resect, and standardization through AI-RANO. Emerging directions include foundation models, uncertainty estimation, federated learning, AI-enhanced ultra-low-field MRI, and dual-tracer PET. When used as a decision-support tool rather than a replacement for the imaging team, AI can increasingly improve the utility, reproducibility, and efficiency of quantitative, multiparametric imaging in patients with brain tumors.
中文摘要:人工智能已成为神经肿瘤成像的核心,影响着临床和科学工作流程。在临床实践中,基于人工智能的图像重建和降噪加速了高级多参数MRI和PET扫描的生成。自动分割和体积分析提高了肿瘤量化和疗效评估的可重复性、速度和标准化水平。在研究方面,大型语言和多模态模型从放射学报告和病历中提取结构化信息。BraTS和FeTS等协作倡议已建立了标准化的、符合隐私保护要求的框架,用于大规模定量分析。针对肿瘤的特定应用包括胶质瘤的非侵入性分子特征分析、脑膜瘤的分级与复发预测、脑转移瘤的检测与疗效评估,以及与RAPNO对齐的儿科专用模型。然而,除非进行适当的训练和验证,否则人工智能模型对跨机构的技术和生物变异仍然敏感,这限制了其临床效用。尽管如此,前瞻性活检验证的浸润映射、与RANO-Resect一致的切除范围评估以及通过AI-RANO实现的标准化方面已取得明显进展。新兴方向包括基础模型、不确定性估计、联邦学习、人工智能增强的超低场MRI以及双示踪剂PET。当作为决策支持工具而非替代成像团队使用时,人工智能可以不断提高脑肿瘤患者定量多参数成像的效用、可重复性和效率。
Neuro-oncology IF 13.1 2026-11-13 PMID: 43023458
The IDH1/2 inhibitor vorasidenib demonstrated efficacy in residual or recurrent grade 2 IDH1/2-mutant gliomas after surgery. However, there is lack of knowledge regarding factors predicting the probability of response. We conducted a prospective single-centre study on 54 grade 2 IDH1/2-mutant astrocytomas and IDH1/2-mutant 1p/19q-codeleted oligodendrogliomas treated with vorasidenib. MRI response (2D and 3D) and seizure outcome were longitudinally assessed. Factors associated with response were explored using regression models. With a median follow-up of 17.5 months, vorasidenib induced progressive tumour shrinkage on MRI, with median volume reductions of - 12.2% at cycle 6, -27.8% at cycle 12, and -55.5% at cycle 18. Best volumetric response was CR in 1 patient, PR in 5, MR in 9, SD in 31 and PD in 7. The ORR (CR + PR + MR) was 28%. Eighteen patients who had focal grade 3 areas showed similar volumetric response and ORR. 9/12 (75%) patients with baseline seizures achieved ≥50% reduction or seizure freedom. MRI response correlated with early treatment initiation and early seizure reduction. Vorasidenib was generally well tolerated, with liver enzyme elevation being the main adverse event. Vorasidenib induced sustained tumour shrinkage and seizure control. Early treatment initiation and early seizure reduction were associated with MRI response.
中文摘要:IDH1/2抑制剂伏拉瑞尼在手术后残留或复发的IDH1/2突变胶质瘤中显示出疗效。然而,目前缺乏关于预测反应概率因素的知识。我们开展了一项前瞻性单中心研究,纳入54例接受伏拉瑞尼治疗的IDH1/2突变星形细胞瘤和IDH1/2突变1p/19q共缺失少突胶质细胞瘤(均为2级)。纵向评估了MRI反应(2D和3D)及癫痫结局。使用回归模型探索与反应相关的因素。中位随访时间为17.5个月,伏拉瑞尼在MRI上诱导进行性肿瘤缩小,第6周期体积中位减少-12.2%,第12周期为-27.8%,第18周期为-55.5%。最佳体积反应中,完全缓解(CR)1例,部分缓解(PR)5例,微小缓解(MR)9例,疾病稳定(SD)31例,疾病进展(PD)7例。客观缓解率(ORR,即CR+PR+MR)为28%。18例伴有局灶性3级区域的患者显示出相似的体积反应和ORR。基线有癫痫的12例患者中有9例(75%)实现了≥50%的减少或癫痫无发作。MRI反应与早期治疗启动及早期癫痫减少相关。伏拉瑞尼总体耐受性良好,肝酶升高是主要不良事件。伏拉瑞尼诱导了持续的肿瘤缩小和癫痫控制。早期治疗启动和早期癫痫减少与MRI反应相关。
Neuro-oncology IF 13.1 2026-11-13 PMID: 43021670
Most studies evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET for glioblastoma progression rely on single-scan assessments, leaving diagnostic uncertainties in cases with borderline tracer uptake. We evaluated metabolic activity evolution during the transition of glioblastoma progression using serial FET PET to determine whether longitudinal parameter changes improve diagnostic certainty. Between 2016 and 2026, 182 patients with glioblastoma undergoing 690 dynamic FET PET scans (median, 3; range, 2-12) were retrospectively evaluated. Eligible cases required documented progressive disease according to RANO 2.0 criteria and serial FET PET at least 2 time points (at suspected progression and within a 6-month prior window). Static PET parameters, ie tumor-to-brain ratios (TBRmean, TBRmax) and metabolic tumor volume (MTV), and their longitudinal changes were evaluated according to PET RANO 1.0 criteria, alongside additional dynamic PET parameters (time-to-peak). Single-scan metrics and serial changes were compared in cases with borderline uptake. Ninety patients with 102 confirmed progression events met all selection criteria (median interscan interval, 2.7 months). At progression, TBRmean, TBRmax, and MTV increased significantly (P < .001). Median percentage increases were modest for TBRmean (+4%) and TBRmax (+17%), whereas MTV exhibited a substantial expansion (+182%). In cases with borderline uptake, applying a longitudinal MTV increase criterion of ≥40% per PET RANO 1.0 substantially improved progression detection to up to 89%, yielding a 14% higher diagnostic detection rate compared to single-scan thresholds. In glioblastomas with documented RANO 2.0 progression, integrating longitudinal MTV changes markedly improves diagnostic certainty over single-scan uptake metrics, particularly in challenging cases with borderline uptake.
中文摘要:大多数评估O-(2-[18F]-氟乙基)-L-酪氨酸(FET)PET用于胶质母细胞瘤进展的研究依赖于单次扫描评估,在示踪剂摄取处于临界值的情况下存在诊断不确定性。本研究利用连续FET PET评估胶质母细胞瘤进展过渡期间的代谢活性演变,以确定纵向参数变化是否能提高诊断确定性。回顾性评估了2016年至2026年间接受690次动态FET PET扫描(中位数3次;范围2至12次)的182名胶质母细胞瘤患者。符合条件的病例需有根据RANO 2.0标准记录的疾病进展证据,并在至少两个时间点(疑似进展时及此前6个月窗口内)进行连续FET PET检查。根据PET RANO 1.0标准评估了静态PET参数即肿瘤脑比值(TBRmean、TBRmax)和代谢肿瘤体积(MTV)及其纵向变化,以及额外的动态PET参数(达峰时间)。在摄取处于临界值的病例中比较了单次扫描指标和连续变化。90名患者共102例确认的进展事件符合所有选择标准(扫描间隔中位数为2.7个月)。在进展时,TBRmean、TBRmax和MTV显著增加(P < .001)。TBRmean(+4%)和TBRmax(+17%)的中位数百分比增加幅度较小,而MTV表现出显著扩张(+182%)。在摄取处于临界值的病例中,应用基于PET RANO 1.0标准的纵向MTV增加≥40%的标准将进展检测率大幅提高至89%,与单次扫描阈值相比诊断检测率高出14%。在具有RANO 2.0进展证据的胶质母细胞瘤中,整合纵向MTV变化显著提高了诊断确定性,优于单次扫描摄取指标,特别是在摄取处于临界值的挑战性病例中。
Neuro-oncology IF 13.1 2026-11-13 PMID: 43021570
Glioblastoma is the most common malignant brain tumor in adults. Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter is the only clinically used biomarker predicting response to alkylating agents such as temozolomide and is associated with improved survival. However, its predictive accuracy is limited by an intermediate gray zone and variability in assessment methods. To reduce overtreatment of patients, improved stratification strategies are needed, potentially through integration of additional biomarkers such as MGMT protein expression. We performed a systematic review to evaluate studies comparing the prognostic value for progression-free survival and overall survival of MGMT promoter methylation and MGMT protein expression in glioblastoma patients treated with temozolomide, including 33 independent cohorts with a total of 4,691 patients. We searched three databases up to May 2025. Risk of bias was assessed with a modified Quips tool. Methylation-specific PCR and pyrosequencing indicated stronger prognostic value than immunohistochemical assessment of MGMT protein expression with hazard ratios (HRs) of 2.07 (95%CI 1.61-2.66), 2.13 (95%CI 1.64-2.75), and 1.50 (95%CI 1.26-1.79), respectively. An inverse correlation between MGMT promoter methylation and protein expression was observed in only 52% of assessed studies, suggesting that promoter methylation and protein expression may contribute independently to prognosis. Substantial variability in methylation assays and protein cut-offs underscores the need for methodological harmonization in future studies and clinical practice. Integration of MGMT protein expression with promoter methylation refines identification of primary temozolomide-resistant tumors and supports the debate of withholding temozolomide in patients unlikely to benefit.
中文摘要:胶质母细胞瘤是成人最常见的恶性脑肿瘤。O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子甲基化是唯一用于预测替莫唑胺等烷化剂反应的临床生物标志物,且与生存改善相关。然而,其预测准确性受限于中间灰区及评估方法的变异性。为减少患者过度治疗,需要改进的分层策略,可能通过整合MGMT蛋白表达等其他生物标志物实现。我们进行了系统评价,以评估替莫唑胺治疗的胶质母细胞瘤患者中MGMT启动子甲基化与MGMT蛋白表达对无进展生存期和总生存的预后价值,纳入33个独立队列共4691名患者。检索了截至2025年5月的三个数据库。使用改良的Quips工具评估偏倚风险。甲基化特异性PCR和焦磷酸测序显示出比免疫组化评估MGMT蛋白表达更强的预后价值,风险比(HR)分别为2.07(95%CI 1.61-2.66)、2.13(95%CI 1.64-2.75)和1.50(95%CI 1.26-1.79)。仅在52%的评估研究中观察到MGMT启动子甲基化与蛋白表达之间的负相关,表明启动子甲基化和蛋白表达可能独立影响预后。甲基化检测和蛋白截断值的显著变异性强调了未来研究和临床实践中方法学标准化的必要性。整合MGMT蛋白表达与启动子甲基化有助于更精准地识别原发性替莫唑胺耐药肿瘤,并支持对不太可能受益的患者暂停使用替莫唑胺的讨论。

基础研究 (6篇)

Science advances IF 13.9 2026-11-20 PMID: 43050510
Pediatric brain tumors are the leading cause of disease-related death in children, yet effective treatment remains a major clinical challenge. These aggressive tumors have limited therapeutic options capable of crossing the blood-brain barrier (BBB) and frequently recur due to genetic or epigenetic alterations and treatment resistance. Gene therapy offers a promising strategy to address these limitations by modifying gene expression, correcting mutations, or introducing functional genes. Nanoparticle (NP) delivery systems facilitate this approach by protecting genetic cargo and enabling BBB penetration and tumor-specific uptake. This review summarizes current genetic engineering strategies and NP-based delivery systems for pediatric brain tumors, including their design principles and delivery mechanisms, highlights key therapeutic approaches under preclinical and clinical investigations, and discusses the major challenges and future directions in NP-mediated gene therapy for pediatric neuro-oncology. By critically evaluating these developments, we aim to underscore the transformative potential of NP-mediated gene therapies in reshaping treatment paradigms and improving outcomes and quality of life for children.
中文摘要:儿童脑肿瘤是儿童疾病相关死亡的主要原因,然而有效的治疗仍面临重大临床挑战。这些侵袭性肿瘤的治疗选择有限,难以穿透血脑屏障(BBB),且常因遗传或表观遗传改变及治疗耐药性而复发。基因治疗通过调节基因表达、纠正突变或引入功能性基因,为克服上述局限提供了极具前景的策略。纳米颗粒(NP)递送系统通过保护基因货物并实现血脑屏障穿透及肿瘤特异性摄取,促进了该策略的实施。本综述总结了当前针对儿童脑肿瘤的基因工程策略和基于纳米颗粒的递送系统,包括其设计原理和递送机制,强调了处于临床前和临床研究阶段的关键治疗方法,并讨论了纳米颗粒介导的儿童神经肿瘤基因治疗面临的主要挑战及未来方向。通过批判性评估这些进展,我们旨在强调纳米颗粒介导的基因疗法在重塑治疗范式以及改善儿童预后和生活质量方面的变革潜力。
Neuro-oncology IF 13.1 2026-11-19 PMID: 43055346
Insulin-like growth factor (IGF) signaling drives progression of glioblastoma (GBM), the most aggressive brain cancer. While sphingolipid metabolism is implicated in gliomagenesis, the mechanism by which it regulates GBM growth and therapy response is poorly understood. Through bioinformatic analyses of human gliomas, we identified sphingolipid metabolism genes with potential functional significance in glioma. Using patient-derived cells, a Drosophila glioma model, and xenograft mouse models, we investigated the functional role of Dihydroceramide desaturase 1 (DEGS1). Lipidomics profiling and RNA sequencing were performed in patient-derived cells to reveal the mechanism by which DEGS1 regulates glioma growth. Additionally, we tested the effect of a DEGS1 inhibitor on GBM cell growth and their resistance to IGF1R-targeted therapy. Our data demonstrate that the expression of sphingolipid metabolism gene DEGS1 is associated with aggressive glioma biomarkers and worse patient survival. DEGS1 is required for glioma growth in patient-derived cells, a Drosophila glioma model, and xenograft mouse models. Lipidomics profiling reveals that DEGS1 deficiency results in reduced ceramides and complex sphingolipids and accumulation of their precursors. Disrupted sphingolipid homeostasis impairs lipid raft biogenesis and lipid raft-associated IGF signaling. Targeting DEGS1 decreases GBM cell growth and their resistance to IGF1R inhibition. These findings establish that targeting DEGS1-regulated sphingolipid metabolism is a viable avenue to inhibit IGF signaling-driven GBM growth.
中文摘要:胰岛素样生长因子(IGF)信号驱动胶质母细胞瘤(GBM,最具侵袭性的脑癌)的进展。尽管鞘脂代谢与神经胶质瘤发生有关,但其调节GBM生长和治疗反应的机制尚不清楚。通过对人类神经胶质瘤进行生物信息学分析,我们鉴定了具有潜在功能意义的鞘脂代谢基因。利用患者来源细胞、果蝇神经胶质瘤模型和异种移植小鼠模型,我们研究了二氢神经酰胺去饱和酶1(DEGS1)的功能作用。对患者来源细胞进行脂质组学分析和RNA测序,以揭示DEGS1调节神经胶质瘤生长的机制。此外,我们测试了DEGS1抑制剂对GBM细胞生长及其对IGF1R靶向治疗耐药性的影响。我们的数据表明,鞘脂代谢基因DEGS1的表达与侵袭性神经胶质瘤生物标志物及较差的患者生存率相关。在患者来源细胞、果蝇神经胶质瘤模型和异种移植小鼠模型中,DEGS1是神经胶质瘤生长所必需的。脂质组学分析显示,DEGS1缺陷导致神经酰胺和复杂鞘脂减少及其前体积累。鞘脂稳态的破坏损害了脂筏的生物发生及脂筏相关的IGF信号传导。靶向DEGS1可降低GBM细胞生长及其对IGF1R抑制的耐药性。这些发现确立了一个观点,即靶向DEGS1调控的鞘脂代谢是抑制IGF信号驱动GBM生长的可行途径。
Acta biomaterialia IF 10.4 2026-11-18 PMID: 43051511
Genetic screens have transformed functional genomics but remain poorly suited for interrogating invasion phenotypes in defined three-dimensional (3D) microenvironments due to low nucleofection efficiencies and the lack of high-content, quantifiable invasion assays. Here we present a chemically defined hyaluronan-based hydrogel platform that enables quantitative, single-cell-resolved measurement of cell invasion and is compatible with arrayed CRISPR-Cas9 perturbation. Specifically, hyaluronan-oxime (HAox) was used to study the invasion of multiple patient-derived cell lines, modelling the invasive properties in two diseases - glioblastoma and lymphangioleiomyomatosis. Efficient CRISPR/Cas9 knockout of 93 genes allowed identification of potential invasion-suppressing targets, including effects detectable only at single-cell resolution. This framework expands functional genetic screening to complex invasion behaviours in controlled 3D microenvironments and may be broadly applicable to other heterogeneous disease models. STATEMENT OF SIGNIFICANCE: Cellular invasion in cancer drives tumour recurrence and metastasis. Identification of target genes which correspond to a quantitative functional loss of invasion is challenging due to the lack of physiologically relevant microenvironments to model cell invasion in vitro, and robust nucleofection protocols to efficiently knock out target genes. We report HAox, a hyaluronan-based hydrogel platform, designed based on components enriched in the diseased cell microenvironment. HAox can robustly identify invasiveness of diseased cells compared to healthy controls in two model diseases characterized by diffuse cellular invasion. HAox, coupled with efficient electroporation protocols to perform targeted gene knockout, enabled efficient knockout of 93 genes and quantification of cellular invasion, providing a platform for researchers to perform high-content screening against invasion phenotypes.
中文摘要:基因筛选已改变功能基因组学,但由于电转效率低且缺乏高含量、可量化的侵袭检测手段,其在评估定义明确的三维微环境中的侵袭表型方面仍不适用。本研究提出了一种化学定义的透明质酸基水凝胶平台,该平台可实现细胞侵袭的定量及单细胞分辨率测量,并兼容阵列式CRISPR-Cas9扰动实验。具体而言,利用透明质酸-肟(HAox)研究了多种患者来源细胞系的侵袭性,模拟了胶质母细胞瘤和淋巴管平滑肌瘤病这两种疾病中的侵袭特性。通过对93个基因进行高效的CRISPR/Cas9敲除,鉴定出潜在的侵袭抑制靶点,其中包括仅在单细胞分辨率下才可检测到的效应。该框架将功能遗传筛选扩展至受控三维微环境中的复杂侵袭行为,并可能广泛适用于其他异质性疾病模型。细胞侵袭驱动肿瘤复发和转移。由于缺乏模拟体外细胞侵袭的生理相关微环境以及高效敲除靶基因的电转方案,鉴定对应于侵袭功能定量丢失的靶基因极具挑战。我们报道了HAox,这是一种基于疾病细胞微环境中富集成分设计的透明质酸基水凝胶平台。在两种以弥漫性细胞侵袭为特征的模型疾病中,与对照组相比,HAox能稳健地识别病变细胞的侵袭性。HAox结合用于靶向基因敲除的高效电转方案,实现了93个基因的高效敲除及细胞侵袭定量,为研究人员针对侵袭表型进行高含量筛选提供了平台。
Pharmacology & therapeutics IF 13.5 2026-11-15 PMID: 43035157
The Hippo-YAP/TEAD signaling axis regulates tissue growth, cellular identity, and organ homeostasis. Dysregulation of this pathway, through NF2 loss, LATS1 or LATS2 inactivation, or YAP1- or WWTR1-derived gene fusions, results in persistent nuclear localization of YAP/TAZ, driving TEAD-dependent transcriptional programs. NF2-deficient and YAP1/TAZ-driven tumors, such as mesothelioma, schwannoma, meningioma, and epithelioid hemangioendothelioma, exemplify Hippo-pathway dependency and are potential therapeutic targets. Targeting TEAD disrupts transcriptional circuits sustaining tumor growth, plasticity, and immune suppression while modulating metabolic and stromal dependencies. Pharmacologic interventions targeting YAP/TEAD include TEAD palmitate-binding pocket inhibitors, direct YAP/TEAD protein-protein interaction disruptors, PROTAC-mediated TEAD degraders, and YAP-directed antisense oligonucleotide strategies. Early-phase trials have demonstrated preliminary clinical activity, particularly with TEAD palmitate-binding pocket inhibitors in mesothelioma and have been associated with mild drug-related toxicities, such as proteinuria. YAP/TEAD inhibition may also be a rational combinatorial approach given the emergence of adaptive resistance mechanisms to EGFR/KRAS inhibitors and immunotherapies. Collectively, these findings provide rationale and early proof-of-concept for the pharmacologic targeting of the YAP/TEAD pathway. In this review, we describe the biological underpinnings of the YAP/TEAD pathway in cancer medicine, the anti-cancer strategies targeting this pathway, and discuss future directions in the field.
中文摘要:Hippo-YAP/TEAD信号轴调控组织生长、细胞身份和器官稳态。该通路的失调,如NF2缺失、LATS1或LATS2失活,或YAP1或WWTR1衍生的基因融合,会导致YAP/TAZ持续核定位,驱动TEAD依赖性转录程序。NF2缺陷型和YAP1/TAZ驱动的肿瘤(如间皮瘤、神经鞘瘤、脑膜瘤和上皮样血管瘤)体现了Hippo通路依赖性,是潜在的治疗靶点。靶向TEAD可破坏维持肿瘤生长、可塑性和免疫抑制的转录回路,同时调节代谢和基质依赖性。针对YAP/TEAD的药理学干预包括TEAD棕榈酸结合口袋抑制剂、直接YAP/TEAD蛋白相互作用破坏剂、PROTAC介导的TEAD降解剂以及YAP靶向反义寡核苷酸策略。早期临床试验已显示出初步临床活性,特别是TEAD棕榈酸结合口袋抑制剂在间皮瘤中的应用,并伴有轻度药物相关毒性(如蛋白尿)。鉴于对EGFR/KRAS抑制剂和免疫疗法的适应性耐药机制的出现,YAP/TEAD抑制可能是一种合理的联合治疗策略。综上所述,这些发现为药理学靶向YAP/TEAD通路提供了依据和早期概念验证。本综述描述了YAP/TEAD通路在癌症医学中的生物学基础、针对该通路的抗癌策略,并讨论了该领域的未来方向。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42497545
Glioma ranks among the most intractable malignancies. Given the intricate anatomy of the brain, complete surgical resection is seldom achievable, making radiotherapy a necessary adjunct. Nevertheless, radioresistance, which is closely linked to recurrence, still represents a critical clinical barrier. Effective tumor biomarkers and novel detection methods are urgently required to predict treatment resistance and monitor therapeutic response. Here, we employed surface-enhanced Raman spectroscopy (SERS) coupled with proteomics to profile, for the first time, the characteristic spectral patterns of exosomes secreted by our established radioresistant glioma cells. We further uncovered specific shifts in protein expression during the development of radioresistance, including glycolysis-related proteins (ALDOA and GAPDH) and ribosomal proteins (RPS5 and RPLP0). These proteins are correlated with glioma prognosis. Moreover, bioinformatic analysis revealed that expression levels of all four genes positively correlate with tumor malignancy grade. Furthermore, we established a machine learning-based diagnostic model, Principal component analysis and convolutional neural network (PCA-CNN), for the accurate identification of exosomes derived from radioresistant glioma cells. These findings validate exosomes as a strong candidate biomarker for predicting radioresistance. This approach enables rapid and reliable assessment of radiotherapy resistance in glioma, paving the way for personalized and precise clinical management.
中文摘要:胶质瘤属于最难治的恶性肿瘤之一。鉴于脑部解剖结构的复杂性,完全手术切除往往难以实现,因此放疗成为必要的辅助手段。然而,与复发密切相关的放射抵抗性仍然是关键的临床障碍。亟需有效的肿瘤生物标志物和新型检测方法以预测治疗抵抗并监测治疗反应。本研究首次采用表面增强拉曼光谱结合蛋白质组学技术,对已建立的放射抵抗性胶质瘤细胞分泌的外泌子特征光谱模式进行谱系分析。我们进一步揭示了放射抵抗性发展过程中蛋白质表达的特异性变化,包括糖酵解相关蛋白(ALDOA和GAPDH)及核糖体蛋白(RPS5和RPLP0)。这些蛋白与胶质瘤预后相关。此外,生物信息学分析显示这四个基因的表达水平均与肿瘤恶性程度呈正相关。我们进一步建立了基于机器学习的诊断模型主成分分析与卷积神经网络用于准确识别源自放射抵抗性胶质瘤细胞的外泌子。上述结果验证了外泌子作为预测放射抵抗性的强候选生物标志物。该方法实现了胶质瘤放疗抵抗的快速可靠评估,为个性化和精准临床管理铺平了道路。
ACS sensors IF 10.9 2026-11-14 PMID: 43033019
Systemic immune dysfunction is a hallmark of glioblastoma (GBM) progression and therapeutic resistance, yet rapid, minimally invasive methods for sensing dynamic immune-cell state changes remain limited. Here, we introduce a label-free surface-enhanced Raman spectroscopy (SERS) immune-sensing framework that uses peripheral blood mononuclear cell (PBMC) biochemical profiles as an accessible readout of GBM-associated systemic immunosuppression. Ag nanoparticle-decorated black silicon SERS substrates were used to profile PBMCs in GBM-PBMC coculture models representing early and progressed tumor-immune interaction states over 3-72 h. Multivariate spectral analysis, correlation-network mapping, pseudotime analysis, partial least-squares regression, and transfer learning were then used to define Raman-detected immune remodeling. SERS detected GBM-induced PBMC biochemical divergence within 3 h and resolved distinct intermediate remodeling trajectories that converged by 72 h into a shared immunosuppressive signature separated from astrocyte-interacted controls. Partial least-squares regression organized the PBMC spectra into a time-associated immunosuppression trajectory with strong predictive performance (R2 = 0.84). These results were corroborated by flow cytometry, which demonstrated reduced T-cell activation and time-dependent myeloid remodeling over the co-culture period. A ResNet-1D model trained only on the in vitro SERS dataset classified 6 independent GBM patient buffy coat samples as GBM-like with >99.9% confidence, and similarity analysis showed close correspondence between patient spectra and GBM-conditioned PBMC signatures. These results establish SERS-based immune-cell profiling as a label-free strategy for sensing and modeling GBM-associated systemic immune remodeling and support its further development for minimally invasive liquid-biopsy applications.
中文摘要:系统性免疫功能障碍是胶质母细胞瘤(GBM)进展和治疗耐药的特征,但用于感知动态免疫细胞状态变化的快速、微创方法仍然有限。本研究引入了一种无标记的表面增强拉曼光谱(SERS)免疫传感框架,利用外周血单个核细胞(PBMC)的生物化学谱作为可及的读出指标,以反映GBM相关的系统性免疫抑制。使用银纳米颗粒修饰的黑硅SERS基底对代表早期和进展期肿瘤免疫相互作用状态的GBM-PBMC共培养模型中的PBMC进行谱分析,时间跨度为3至72小时。随后采用多变量光谱分析、相关性网络映射、伪时间分析、偏最小二乘回归和迁移学习来定义拉曼检测到的免疫重塑。SERS在3小时内检测到GBM诱导的PBMC生化差异,并解析出不同的中间重塑轨迹,这些轨迹在72小时汇聚成一种与星形胶质细胞相互作用对照组分离的共同免疫抑制特征。偏最小二乘回归将PBMC光谱组织为具有强预测性能的时间相关免疫抑制轨迹(R2 = 0.84)。流式细胞术验证了这些结果,显示T细胞活化减少以及共培养期间随时间变化的髓系重塑。仅在体外SERS数据集上训练的ResNet-1D模型以超过99.9%的置信度将6个独立的GBM患者buffy coat样本分类为GBM样,相似性分析显示患者光谱与GBM条件化PBMC特征之间存在密切对应关系。这些结果确立了基于SERS的免疫细胞谱分析作为一种无标记策略,用于感知和建模GBM相关的系统性免疫重塑,并支持其进一步开发用于微创液体活检应用。

8肿瘤基础/转化 (11篇)

基础研究 (11篇)

Molecular cell IF 16.0 2026-11-19 PMID: 42933402
Single-stranded DNA (ssDNA) gaps are a hallmark of BRCA-deficient cells, yet the mechanisms that safeguard these lesions remain unclear. Using a genome-wide CRISPR screen in isogenic BRCA2-proficient and -deficient cancer cells, we identified the RAD9A-HUS1-RAD1 (9-1-1) complex as essential for BRCA2-deficient cell survival through an ATR-independent mechanism. In this context, loss of 9-1-1 leads to accumulation of PRIMPOL-dependent gaps that fail to undergo post-replicative repair, resulting in pathological expansion and increased DNA damage. Excessive EXO1-mediated degradation drives this genomic instability, as EXO1 depletion rescues the phenotype. We further demonstrate that the 9-1-1 complex contributes to POLζ-dependent gap filling. We propose a model in which ssDNA gaps, when extended beyond a critical length, become inaccessible to translesion synthesis (TLS)-mediated repair and rely entirely on homologous recombination. These findings establish the 9-1-1 complex as a key regulator of ssDNA gap stability and as a promising therapeutic target in BRCA2-deficient cancers.
中文摘要:单链DNA缺口是BRCA缺陷细胞的标志,但保护这些损伤的机制尚不清楚。利用同基因BRCA2野生型和缺陷型癌细胞的全基因组CRISPR筛选,我们发现RAD9A-HUS1-RAD1复合物通过ATR非依赖性机制对BRCA2缺陷型细胞的存活至关重要。在此背景下,9-1-1复合物的缺失导致PRIMPOL依赖性缺口积累,这些缺口无法进行复制后修复,从而导致病理性扩张和DNA损伤增加。过度的EXO1介导降解驱动了这种基因组不稳定性,因为EXO1的耗竭可挽救该表型。我们进一步证明9-1-1复合物参与POLζ依赖性缺口填补。我们提出一个模型:当单链DNA缺口延伸超过临界长度时,将难以被跨损伤合成介导的修复所识别,从而完全依赖同源重组进行修复。这些发现确立了9-1-1复合物作为单链DNA缺口稳定性的关键调节因子,并使其成为BRCA2缺陷型癌症中极具前景的治疗靶点。
Journal of hematology & oncology IF 47.8 2026-11-18 PMID: 43053150
Research on tumor metabolic reprogramming has long centered on glucose, lipids and free amino acids. By contrast, di/tripeptides, which lie at the interface between protein breakdown products and functional metabolic signals, have only recently begun to be recognized as a distinct molecular tier in cancer biology. Compared with longer peptides, di/tripeptides display greater metabolic mobility and a clearer dependence on dedicated transport systems. Here we systematically review the sources, transport, metabolic use, biological functions and clinical translational potential of di/tripeptides in cancer. Current evidence indicates that di/tripeptides arise from endogenous protein degradation, dietary digestion and microbial metabolism. Under nutrient limitation, tumor cells can recover amino acids through carnosine dipeptidase 2 (CNDP2)-mediated extracellular cleavage of dipeptides or uptake of intact di/tripeptides followed by intracellular hydrolysis. Beyond their role as nutrient substrates, selected di/tripeptides directly influence tumor cell proliferation, invasion, metastasis and drug resistance, and shape the tumor microenvironment by modulating acid base balance, redox homeostasis, angiogenesis and immune cell function. At the clinical translational level, di/tripeptides have emerged as candidate metabolomic and peptidomic biomarkers, transporter targeted imaging probes, functionally modified therapeutic agents and engineered delivery modules. Di/tripeptides should be viewed as molecular nodes that connect tumor nutrient adaptation, signaling control, microenvironmental remodeling and clinical translation, with significance extending beyond their role as transient intermediates in protein metabolism.
中文摘要:关于肿瘤代谢重编程的研究长期以来以葡萄糖、脂质和游离氨基酸为中心。相比之下,二肽和三肽作为蛋白质降解产物与功能性代谢信号之间的界面分子,直到最近才开始被确认为癌症生物学中一个独特的分子层级。与较长肽段相比,二肽和三肽表现出更高的代谢流动性以及对专用转运系统的更明确依赖。本文系统综述了二肽和三肽在癌症中的来源、转运、代谢利用、生物学功能及临床转化潜力。现有证据表明,二肽和三肽来源于内源性蛋白降解、饮食消化和微生物代谢。在营养限制条件下,肿瘤细胞可通过肌肽二肽酶2介导的细胞外二肽裂解或完整二肽三肽摄取后进行的细胞内水解来回收氨基酸。除了作为营养底物的作用外,特定的二肽和三肽还直接影响肿瘤细胞的增殖、侵袭、转移和耐药性,并通过调节酸碱平衡、氧化还原稳态、血管生成和免疫细胞功能来塑造肿瘤微环境。在临床转化层面,二肽和三肽已成为候选代谢组和肽组生物标志物、转运体靶向成像探针、功能修饰的治疗制剂以及工程化递送模块。二肽和三肽应被视为连接肿瘤营养适应、信号控制、微环境重塑和临床转化的分子节点,其意义超越了其在蛋白质代谢中作为短暂中间体的角色。
Nature IF 56.1 2026-11-18 PMID: 43052444
Ferroptosis, a form of cell death induced by overwhelming membrane lipid peroxidation, is a vulnerability of many cancers, including cancers resistant to current molecular and immune-based therapies1-7. Triggering of ferroptosis therefore provides an opportunity to achieve elimination of difficult-to-treat cancers1-4,8,9. Studies in mouse cancer models have demonstrated that anticancer immunity, mediated by dendritic cells (DCs) and CD8+ T cells, is essential for effective tumour eradication by ferroptosis-inducing strategies10-13. However, ferroptotic cells limit this response8-10,14, resulting in immune escape and tumour growth through mechanisms that remain unclear. Here we demonstrate that ferroptotic cancer cells activate a molecular program resulting in aberrant production of prostaglandin E2 (PGE2), which limits the stimulation of anticancer CD8+ T cell responses by type 1 conventional DCs (cDC1s), thereby promoting immune escape. In ferroptotic cancer cells, lipid peroxidation-mediated membrane permeabilization enables Ca2+ influx, which activates p38 MAPK signalling and thereby drives PGE2 production. This signalling axis is uncoupled from cancer cell death and can be targeted to selectively interfere with immune-inhibitory PGE2 production while preserving ferroptotic cancer cell elimination. In the context of cancer cell ferroptosis, ablation of PGE2 production or disrupting PGE2 signalling restores cDC1-mediated anticancer CD8+ T cell responses and leads to effective tumour elimination. Our findings identify a key mechanism that limits antitumour immunity and prevents tumour elimination upon ferroptosis induction in cancer cells, which could be exploited for cancer therapy.
中文摘要:铁死亡是一种由过度膜脂质过氧化诱导的细胞死亡形式,是许多癌症包括对当前分子和免疫治疗耐药的癌症的弱点。因此,触发铁死亡为消除难治性癌症提供了机会。在小鼠癌症模型中的研究表明,由树突状细胞(DCs)和CD8+ T细胞介导的抗癌免疫对于通过铁死亡诱导策略有效根除肿瘤至关重要。然而,铁死亡细胞限制了这一反应,导致免疫逃逸和肿瘤生长,其机制尚不清楚。本研究证明,铁死亡癌细胞激活了一种分子程序,导致前列腺素E2(PGE2)异常产生,从而限制I型常规树突状细胞(cDC1s)对抗癌CD8+ T细胞反应的刺激,进而促进免疫逃逸。在铁死亡癌细胞中,脂质过氧化介导的膜通透性改变使Ca2+内流,激活p38 MAPK信号通路并驱动PGE2产生。该信号轴与癌细胞死亡解耦,可被靶向以选择性干扰免疫抑制性PGE2的产生,同时保留铁死亡癌细胞的消除。在癌细胞铁死亡背景下,消除PGE2产生或破坏PGE2信号可恢复cDC1介导的抗癌CD8+ T细胞反应并导致有效肿瘤消除。我们的研究结果确定了一种限制抗肿瘤免疫并在诱导癌细胞铁死亡时防止肿瘤根除的关键机制,该机制可用于癌症治疗。
ACS nano IF 17.3 2026-11-17 PMID: 43043215
Enzyodynamic therapy (EDT) represents a promising cancer therapeutic modality; however, its efficacy is constrained by the catalytic activity of nanozymes and intrinsic tumor-adaptive defense mechanisms. Leveraging the atomic-nano structure and nanoconfined effect of single-atom nanoislands (SANIs), a SANI-based nanozyme (CPH) is elaborately constructed through vapor filling and spatially confined reduction/growth of metal species, featuring ultrasmall Pt nanoislands with embedded Ce single atoms confined within the channels of hollow carbon spheres. CPH exhibits multienzymatic activities resembling those of oxidase, catalase, peroxidase, glucose oxidase, glutathione peroxidase, and nicotinamide adenine dinucleotide oxidase, sustaining a self-reinforcing catalytic cascade that disrupts redox homeostasis and blocks energy metabolism. This process facilitates H2O2 self-supplementation while alleviating hypoxia and elicits reactive oxygen species storm and lipid peroxidation, thereby establishing an apoptosis/ferroptosis dual-pathway therapeutic strategy. Mechanism investigation reveals that the enhanced catalytic properties can be ascribed to the favorable shift of the d-band center and synergistic effects among multiactive centers after Ce single-atom embedding. Concurrently, the nanoconfined photothermal effect facilitates heat concentration while minimizing thermal dissipation, further augmenting the catalytic efficiency and enabling synergistic mild-photothermal therapy (mild-PTT)/EDT synergistic therapy. This study provides a proof of concept of SANI-based nanozymes as efficient therapeutic tools toward tumor ablation.
中文摘要:酶动力学疗法(EDT)是一种极具前景的癌症治疗模式,但其疗效受限于纳米酶的催化活性和肿瘤固有的适应性防御机制。利用单原子纳米岛(SANIs)的原子纳米结构和纳米限域效应,本研究通过金属物种的气相填充及空间受限还原/生长工艺,精心构建了基于SANIs的纳米酶CPH。该材料具有嵌入中空碳球通道内的超小铂纳米岛和铈单原子特征。CPH表现出类似氧化酶、过氧化氢酶、过氧化物酶、葡萄糖氧化酶、谷胱甘肽过氧化物酶及烟酰胺腺嘌呤二核苷酸氧化酶的多重酶活性,维持着自我强化的催化级联反应,从而破坏氧化还原稳态并阻断能量代谢。该过程实现了过氧化氢的自我补充,同时缓解缺氧状态,引发活性氧风暴和脂质过氧化,进而建立凋亡/铁死亡双通路治疗策略。机制研究表明,铈单原子嵌入后d带中心的有利偏移及多活性中心间的协同作用是催化性能增强的原因。同时,纳米限域光热效应促进了热量聚集并最小化了热耗散,进一步提高了催化效率,实现了协同温和光热疗法(mild-PTT)与EDT的联合治疗。本研究提供了基于SANIs的纳米酶作为高效肿瘤消融治疗工具的初步概念验证。
Cancer research IF 22.6 2026-11-16 PMID: 42708806
Single-stranded DNA (ssDNA) gaps represent an underappreciated vulnerability that directly shapes therapeutic response in BRCA-deficient models. Current clinical biomarkers remain anchored to the double-strand break-centric model of homologous recombination deficiency, and there are currently no tools available to detect replication-associated gaps in the clinical setting. In this study, we developed a scalable, clinically adaptable assay that enables real-time, drug-free detection of gaps. This assay demonstrated that gaps are intrinsically elevated in BRCA-deficient cells independent of exogenous DNA damage. These gaps arose during DNA replication and were generated through PRIMPOL-dependent repriming at abasic sites and nuclease-mediated processing. Across diverse cell line models, PARP inhibitor (PARPi) sensitivity was associated with gap burden irrespective of BRCA status, extending the relevance of this vulnerability beyond canonical BRCA-mutant contexts. Integration with artificial intelligence-driven image analysis enabled automated, unbiased quantification of gap levels in xenograft tumor specimens. In BRCA-deficient xenografts, elevated gap levels were associated with PARPi sensitivity, supporting their translational relevance in relation to therapeutic response. Together, these findings establish ssDNA gaps as a real-time functional readout associated with chemotherapy response and introduce an assay with potential for future clinical translation. Single-stranded DNA gaps are an intrinsic feature of therapy-sensitive cancer cells, representing a functional biomarker that captures replication-associated vulnerabilities.
中文摘要:单链DNA缺口代表一种被低估的脆弱性,直接塑造BRCA缺陷模型中的治疗反应。当前的临床生物标志物仍锚定于以双链断裂为中心的同源重组缺陷模型,且目前尚无工具可在临床环境中检测复制相关的缺口。在本研究中,我们开发了一种可扩展且适应临床的检测方法,能够实现无药物的实时缺口检测。该实验表明,无论是否存在外源性DNA损伤,BRCA缺陷细胞中的缺口水平均内在升高。这些缺口产生于DNA复制过程中,通过PRIMPOL依赖的从头引发机制在脱碱基位点形成,并经过核酸酶介导的加工处理。在多种细胞系模型中,PARP抑制剂敏感性始终与缺口负荷相关,且独立于BRCA状态,从而扩展了该脆弱性在经典BRCA突变背景之外的相关性。结合人工智能驱动图像分析实现了异种移植瘤标本中缺口水平的自动化、无偏量化。在BRCA缺陷异种移植瘤中,升高的缺口水平与PARP抑制剂敏感性相关,支持其在治疗反应方面的转化意义。这些发现确立了单链DNA缺口作为与治疗反应相关的实时功能读出指标的地位,并引入了一种具有未来临床转化潜力的检测方法。单链DNA缺口是治疗敏感癌细胞的内在特征,代表了一种捕捉复制相关脆弱性的功能性生物标志物。
Cancer research IF 22.6 2026-11-16 PMID: 42599212
KRAS mutations are a major driver of pancreatic ductal adenocarcinoma (PDAC). RASA2, a RAS GTPase-activating protein, modulates KRAS protein levels in wild-type (WT) contexts, suggesting that it could play a potential role in PDAC. In this study, we systematically investigated the biological function and molecular mechanisms of RASA2 in PDAC. Integrative analyses of multiple datasets and clinical samples demonstrated that RASA2 was consistently upregulated in KRAS-mutant PDAC and significantly associated with poor prognosis and metastatic progression. Gain- and loss-of-function studies revealed that RASA2 markedly enhanced PDAC cell migration and invasion in both KRAS-mutant and KRAS-WT models, suggesting that its prometastatic activity is largely independent of KRAS mutational status. Transcriptomic and mechanistic analyses revealed that RASA2 activated GLI1 through a TGFβ2-dependent, noncanonical Hedgehog pathway. Mechanistically, RASA2 interacted with RTF1 to promote H2BK120 ubiquitination at the TGFB2 promoter, thereby enhancing TGFB2 transcription and activating downstream GLI1 signaling. Pharmacologic inhibition of TGFβ signaling or genetic silencing of GLI1 effectively suppressed RASA2-driven migratory, invasive, and metastatic phenotypes in vitro and in vivo. Collectively, these findings reveal a mechanism by which RASA2-dependent epigenetic and transcriptional reprogramming promotes metastatic progression and nominate the RASA2-TGFβ2-GLI1 axis as a potential therapeutic target in PDAC. RASA2, preferentially upregulated in KRAS-mutant pancreatic cancer, promotes metastasis through an epigenetically regulated, TGFβ2-induced noncanonical Hedgehog/GLI1 axis, revealing a targetable pathway underlying aggressive tumor progression.
中文摘要:KRAS突变是胰腺导管腺癌(PDAC)的主要驱动因素。RASA2是一种RAS GTP酶激活蛋白,在野生型背景下调节KRAS蛋白水平,提示其在PDAC中可能发挥作用。本研究系统探讨了RASA2在PDAC中的生物学功能和分子机制。对多个数据集和临床样本的综合分析表明,RASA2在KRAS突变型PDAC中持续上调,且与不良预后和转移进展显著相关。功能获得与缺失研究揭示,RASA2在KRAS突变型和野生型模型中均显著增强PDAC细胞的迁移和侵袭能力,表明其促转移活性主要独立于KRAS突变状态。转录组学与机制分析显示,RASA2通过TGFβ2依赖的非经典Hedgehog通路激活GLI1。机制上,RASA2与RTF1相互作用,促进TGFB2启动子处的H2BK120泛素化,从而增强TGFB2转录并激活下游GLI1信号。药理学抑制TGFβ信号或基因沉默GLI1可有效抑制体外和体内RASA2驱动的迁移、侵袭及转移表型。综上所述,这些发现揭示了RASA2依赖的表观遗传与转录重编程促进转移进展的机制,并将RASA2-TGFβ2-GLI1轴确定为PDAC的潜在治疗靶点。RASA2在KRAS突变型胰腺癌中优先上调,通过表观遗传调控的TGFβ2诱导的非经典Hedgehog/GLI1轴促进转移,揭示了侵袭性肿瘤进展的可靶向通路。
Carbohydrate polymers IF 13.2 2026-11-15 PMID: 42907040
Natural polysaccharides derived from plants, fungi, macroalgae, cyanobacteria, and other marine microorganisms have attracted increasing interest as adjuvant candidates for pancreatic cancer management due to their biocompatibility, structural diversity, and multi-target activities. This review consolidates current knowledge on their anti-pancreatic cancer activities, integrating findings from in vitro, in vivo, and mechanistic studies. We delineate the multi-level regulatory networks through which polysaccharides exert anti-tumor effects via four interconnected mechanisms: direct actions on cancer cells including proliferation inhibition, apoptosis and ferroptosis induction, cell cycle arrest, metastasis suppression, and autophagy modulation; immunomodulation via M1 macrophage polarization, natural killer cell activation, and cytotoxic T lymphocyte mediated killing; restoration of gut microbial homeostasis through beneficial taxa enrichment, intestinal barrier integrity enhancement, short-chain fatty acid elevation, and lipopolysaccharide driven inflammation reduction; and indirect tumor suppression by ameliorating obesity and type 2 diabetes mellitus. The polysaccharide gut microbiota axis emerges as a critical hub integrating these pathways. Structure-activity relationship analysis indicates that low molecular weight, high galacturonic acid content, arabinose and galactose richness, and sulfation may influence activity, although robust attribution requires structurally defined polysaccharides. More than twenty well characterized polysaccharides are documented, with several showing synergistic effects with chemotherapeutics. Despite encouraging preclinical evidence, challenges remain in structural characterization, bioavailability, and clinical validation.
中文摘要:源自植物、真菌、大型藻类、蓝细菌及其他海洋微生物的天然多糖因其生物相容性、结构多样性和多靶点活性,作为胰腺癌管理的辅助候选药物受到越来越多的关注。本综述整合了体外、体内及机制研究中的发现,总结了当前关于天然多糖抗胰腺癌活性的知识。我们描绘了多糖通过四种相互关联的机制发挥抗肿瘤作用的多层次调控网络:包括对癌细胞直接作用如抑制增殖、诱导凋亡和铁死亡、细胞周期阻滞、抑制转移及调节自噬;通过M1巨噬细胞极化、自然杀伤细胞激活及细胞毒性T淋巴细胞介导的杀伤进行免疫调节;通过富集有益菌群、增强肠道屏障完整性、提升短链脂肪酸水平及降低脂多糖驱动的炎症来恢复肠道微生物稳态;以及通过改善肥胖和2型糖尿病间接抑制肿瘤。多糖-肠道微生物轴被视为整合这些通路的关键枢纽。构效关系分析表明,低分子量、高半乳糖醛酸含量、丰富的阿拉伯糖和半乳糖以及硫酸化可能影响活性,尽管需要结构明确的天然多糖才能进行可靠的归因分析。文献记录了二十多种特征明确的天然多糖,其中几种显示出与化疗药物的协同效应。尽管临床前证据令人鼓舞,但在结构表征、生物利用度和临床验证方面仍面临挑战。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42546383
Sulfur dioxide and its physiological forms bisulfite (HSO3-) and sulfite (SO32-), along with intracellular viscosity, are involved in regulating many physiological processes and are closely related to diseases and cancer development. Therefore, developing probes capable of selectively responding to HSO3-/SO32- and viscosity is of great significance and practical application value for exploring the pathological mechanism of related diseases and realizing early biological detection. An aggregation-induced near-infrared emission-based Ir(III) complex probe named Ir-TH was designed and synthesized, in which the ester-linked thiophene unit serves a dual role: it not only acts as an AIE-active rotor to track viscosity changes through the restriction of intramolecular rotation but also provides the supramolecular binding sites for HSO3-. The probe exhibits a high sensitivity and selectivity toward viscosity, good photostability, and a favorable luminescent response to HSO3- with a fast response time (5 min), low detection limit (0.022 μM, 3σ/k) and wide linear range (0-80 μM). Moreover, Ir-TH can specifically track changes in intracellular HSO3-, as well as monitor dynamic changes in intracellular viscosity during ferroptosis, providing a valuable reference for the construction of multifunctional sensors.
中文摘要:二氧化硫及其生理形式亚硫酸氢根(HSO3-)和亚硫酸根(SO32-),以及细胞内粘度,参与调节许多生理过程,并与疾病和癌症发展密切相关。因此,开发能够选择性响应HSO3-/SO32-和粘度的探针对于探索相关疾病的病理机制及实现早期生物检测具有重要的意义和应用价值。本研究设计并合成了一种基于聚集诱导发光(AIE)的近红外发射铱(III)配合物探针Ir-TH,其中酯键连接的噻吩单元具有双重作用:它既作为AIE活性转子,通过限制分子内旋转来追踪粘度变化,又为HSO3-提供超分子结合位点。该探针表现出对粘度极高的灵敏度和选择性、良好的光稳定性,以及对HSO3-有利的发光响应,具有快速响应时间(5分钟)、低检测限(0.022 μM, 3σ/k)和宽线性范围(0-80 μM)。此外,Ir-TH能够特异性追踪细胞内HSO3-的变化,并在铁死亡过程中监测细胞内粘度的动态变化,为多功能传感器的构建提供了有价值的参考。
Redox biology IF 16.2 2026-11-13 PMID: 43050874
The BCL-2 family proteins govern cell fate decisions by functioning as modulators of programmed cell death. These proteins are tightly regulated, in which changes in their expression or function are frequently associated with aberrant growth and therapy resistance across different human cancers. Interestingly, accumulating evidence supports a critical role of BCL-2 family proteins in integrating diverse stress-induced signals, including those arising from therapeutic interventions and reactive oxygen species, into regulatory networks that govern both apoptotic and non-apoptotic forms of cell death. Here we critically discuss the functions of the BCL-2 family proteins from the standpoint of effector pathways dictating various forms of regulated cell death, including but not limited to apoptosis, autophagy, necroptosis, ferroptosis and pyroptosis, as well as how their pleiotropic functions in cell death regulation could be therapeutically exploited through a one-two punch strategy for cancer treatment.
中文摘要:BCL-2家族蛋白通过作为程序性细胞死亡的调节因子来调控细胞命运决定。这些蛋白受到严格调控,其表达或功能的改变常与不同人类癌症中的异常生长和治疗耐药性相关。有趣的是,越来越多的证据支持BCL-2家族蛋白在整合多种应激诱导信号(包括来自治疗干预和活性氧的信号)方面发挥关键作用,这些信号被纳入调控凋亡和非凋亡形式细胞死亡的调节网络中。本文从决定各种形式受控细胞死亡的效应通路角度,批判性地讨论了BCL-2家族蛋白的功能,涵盖但不限于凋亡、自噬、坏死性凋亡、铁死亡和焦亡,并探讨了如何通过双重打击策略利用其在细胞死亡调控中的多效性功能来治疗癌症。
Science advances IF 13.9 2026-11-13 PMID: 43024719
Chromosomal instability (CIN) is an established driver of aneuploidy and cell death. Here, we investigate the role of apoptosis as a barrier against CIN-driven aneuploidy in B lymphocytes. We found that impairment of their spindle assembly checkpoint via deletion of Mitotic Arrest Deficient 2-Like 1 or mutation of Monopolar Spindle 1 kinase curtails B cell survival. A CRISPR screen identified intermediates of mitochondrial apoptosis as critical, which we confirmed in vivo by overexpression of a B cell-restricted BCL2 transgene, outperforming loss of P53. Notably, cell death inhibition by BCL2 was insufficient to cause aneuploidy-driven B cell transformation, while loss of P53 strongly synergized with tumors featuring stochastic aneuploidies. In contrast, high cell death rates rapidly select for specific karyotypes, facilitating aneuploid tumor cell survival in Eμ-Myc transgenic mice. Hence, cell death inhibition fails to allow CIN-driven aneuploidies to prevail. In contrast, BCL2-regulated apoptosis selects viable aneuploid tumor karyotypes in the presence of oncogenic MYC, a notion with implications for the clinical use of BCL2-targeting therapies.
中文摘要:染色体不稳定性(CIN)是驱动非整倍体和细胞死亡的重要因素。本研究探讨了凋亡作为抵御CIN驱动的非整倍体在B淋巴细胞中的作用。我们发现,通过删除Mitotic Arrest Deficient 2-Like 1或突变Monopolar Spindle 1激酶破坏纺锤体组装检查点会限制B细胞的存活。CRISPR筛选鉴定出线粒体凋亡的中间产物是关键因素,我们通过过表达B细胞特异性BCL2转基因在体内证实了这一点,其效果优于P53缺失。值得注意的是,仅抑制由BCL2介导的细胞死亡不足以导致非整倍体驱动的B细胞转化,而P53缺失与具有随机非整倍体的肿瘤存在强烈的协同作用。相比之下,高细胞死亡率会快速筛选出特定的核型,促进Eμ-Myc转基因小鼠中非整倍体肿瘤细胞的存活。因此,抑制细胞死亡并不能使CIN驱动的非整倍体占据优势。相反,在致癌MYC存在的情况下,BCL2调控的凋亡会选择具有活力的非整倍体肿瘤核型,这一发现对BCL2靶向治疗的临床应用具有重要意义。
Science advances IF 13.9 2026-11-13 PMID: 43024705
The delivery of nucleic acids using nonviral vectors represents a promising approach for cancer therapy. Nevertheless, nucleic acid-based drugs suffer from poor potency and rapid degradation. Herein, we report a carrier-free nucleic acid delivery system termed Arg-CpG, which is easily constructed through charge-driven assembly of poly(l-arginine) (Arg) and the immune adjuvant unmethylated cytosine-phosphate-guanine oligonucleotide (CpG). This Arg-CpG functions as both a carrier and a therapeutic agent, thereby eliminating the need for a conventional drug delivery vehicle and minimizing potential toxicity. The guanidinium groups of Arg endow Arg-CpG with dual functionalities: enhancing cellular uptake and serving as the nitrogen donor for iNOS-mediated nitric oxide (NO) generation. This NO production further synergizes with CpG to drive macrophage reprogramming toward an antitumor phenotype. Notably, Arg-CpG exhibits cell-type-dependent modulation of autophagy. It disrupts autophagic machinery in 4T1 tumor cells while preserving functional autophagy in RAW264.7 macrophages. This differential activity results in selective killing of tumor cells without compromising the viability or function of normal immune cells. Consequently, Arg-CpG elicits a robust antitumor immune response in vivo. Moreover, the modular design of Arg-CpG enables its straightforward assembly with CpG oligonucleotides and other nucleic acid payloads (e.g., anti-miR oligonucleotides and siRNA), establishing a versatile and promising platform for nucleic acid-based cancer therapy.
中文摘要:利用非病毒载体递送核酸是癌症治疗中一种极具前景的策略。然而,基于核酸的药物存在效力低下和降解迅速的问题。在此,我们报告了一种名为Arg-CpG的无载体核酸递送系统,该系统通过聚L-精氨酸(Arg)与免疫佐剂未甲基化胞嘧啶-磷酸-鸟嘌呤寡核苷酸(CpG)之间的电荷驱动自组装轻松构建而成。Arg-CpG既作为载体又作为治疗剂发挥作用,从而消除了对传统药物递送载体的需求并最大限度地降低了潜在毒性。Arg的胍基赋予Arg-CpG双重功能:增强细胞摄取并作为一氧化氮合酶介导的一氧化氮(NO)生成的氮供体。这种NO的产生进一步与CpG协同作用,驱动巨噬细胞向抗肿瘤表型重编程。值得注意的是,Arg-CpG表现出细胞类型依赖性的自噬调节作用。它在4T1肿瘤细胞中破坏自噬机制,同时保留RAW264.7巨噬细胞中的功能性自噬。这种差异活性导致肿瘤细胞的选择性杀伤,而不损害正常免疫细胞的活力或功能。因此,Arg-CpG在体内引发强大的抗肿瘤免疫反应。此外,Arg-CpG的模块化设计使其能够与CpG寡核苷酸和其他核酸载荷(如抗miR寡核苷酸和siRNA)直接组装,建立了一个通用且前景广阔的基于核酸的癌症治疗平台。

9临床/流行病学 (10篇)

临床研究 (7篇)

Biomarker research IF 14.6 2026-11-19 PMID: 43058824
Plasma cell-free DNA (cfDNA) analysis provides a minimally invasive approach to breast cancer assessment across early detection, minimal residual disease (MRD) monitoring, and treatment adaptation in advanced disease. This review evaluates these applications by distinguishing analytical validity, clinical detection performance, prognostic validity, and clinical utility. In early detection, assays integrating genomic, epigenomic, fragmentomic, and protein-based features have shown encouraging performance in evaluated cohorts; however, sensitivity remains limited in low-burden disease, particularly stage I breast cancer. Their potential clinical role depends on the incremental information they provide beyond established imaging and diagnostic pathways. In the curative-intent setting, circulating tumor DNA detection after treatment is associated with recurrence risk and can precede clinical or radiographic relapse, supporting prognostic stratification and the design of MRD-guided intervention trials. Whether such interventions improve clinical outcomes remains a central unresolved question. In advanced breast cancer, plasma genotyping supports treatment selection in defined molecular contexts. Randomized trials of ESR1 mutation-guided endocrine switching have demonstrated progression-free survival benefits with specific treatment strategies, providing evidence beyond biomarker-outcome associations, although overall survival benefit remains to be established. Across applications, interpretation depends on assay characteristics, molecular input, disease setting, sampling schedule, and the clinical decision being evaluated. Future studies should connect assay performance to patient benefit through comparison with existing care, clinically meaningful endpoints, and assessment of treatment burden and downstream investigations. This approach will help define where cfDNA testing can contribute meaningfully to breast cancer management.
中文摘要:血浆游离DNA分析为乳腺癌的评估提供了微创方法,涵盖早期检测、微小残留病灶监测以及晚期疾病的治疗适应。本综述通过区分分析有效性、临床检测性能、预后有效性和临床效用,对这些应用进行了评估。在早期检测方面,整合基因组、表观基因组、片段组学和蛋白质特征的分析在已评估队列中显示出令人鼓舞的性能;然而,在低负荷疾病特别是I期乳腺癌中,敏感性仍然有限。其潜在的临床作用取决于它们相较于现有影像和诊断路径所提供的增量信息。在治愈性治疗背景下,治疗后循环肿瘤DNA的检测与复发风险相关,且可早于临床或影像学复发,支持预后分层及微小残留病灶引导干预试验的设计。此类干预措施是否能改善临床结局仍是一个未解决的核心问题。在晚期乳腺癌中,血浆基因分型支持在特定分子背景下的治疗选择。ESR1突变指导的内分泌转换随机对照试验已证明特定治疗策略在无进展生存期方面的获益,提供了超越生物标志物与结局关联的证据,尽管总生存期获益尚待确立。在所有应用中,解释依赖于分析特征、分子输入、疾病背景、采样计划以及所评估的临床决策。未来研究应通过与现有护理的比较、临床有意义的终点以及对治疗负担和后续检查的评估,将分析性能与患者获益联系起来。这种方法将有助于明确游离DNA检测在乳腺癌管理中何处能做出有意义贡献。
JAMA oncology IF 23.9 2026-11-19 PMID: 43056109
Lung cancer screening with low-dose computed tomography (LDCT) has been shown to identify lung cancers at earlier stages and to significantly reduce lung cancer mortality in prior randomized clinical trials. However, the benefit of LDCT screening for small cell lung cancer (SCLC), an aggressive subtype of lung cancer, is unclear. To investigate the characteristics and outcomes of SCLC diagnosed after a lung cancer screening examination using a large database of Medicare beneficiaries. In this retrospective cohort study, Medicare data linked to the Surveillance Epidemiology End Results Program's cancer registry data were analyzed. Patients in the US aged 65 to 78 years who were diagnosed with SCLC from 2015 to 2021 were identified for analysis, with follow-up data through 2022. Patients who underwent 1 or more LDCT lung cancer screening examinations during the 12 months preceding their SCLC diagnosis were included in the screened group. All other patients were included in the unscreened group. Data were analyzed from January to August 2026. One or more LDCT lung cancer screenings during the 12 months preceding SCLC diagnosis. The primary outcomes were stage at SCLC diagnosis and overall survival after SCLC diagnosis in the screened and unscreened groups. A total of 17 099 patients (median [IQR] age, 72.0 [69.0-75.0] years; 8999 [52.6%] female) met study inclusion criteria, of which 949 (5.5%) were included in the screened group and 16 150 (94.5%) were included in the unscreened group. When compared with patients in the unscreened group, patients in the screened group were significantly less likely to be diagnosed with distant disease (419 of 949 [44.2%] vs 11 376 of 16 150 [70.4%]; P < .001). Patients in the screened group also had significantly better overall survival when compared with patients in the unscreened group (3-year overall survival, 28.0% [95% CI, 24.9%-31.2%] vs 10.8% [95% CI, 10.3%-11.3%]; P < .001). Both findings were consistent in propensity score-matched analysis. Results of this cohort study of Medicare beneficiaries diagnosed with SCLC suggest that receipt of lung cancer screening was associated with a shift toward earlier-stage SCLC at diagnosis and improved overall survival.
中文摘要:低剂量计算机断层扫描(LDCT)肺癌筛查在既往随机临床试验中已被证明能够更早发现肺癌并显著降低肺癌死亡率。然而,LDCT筛查对一种侵袭性较强的肺癌亚型小细胞肺癌(SCLC)的益处尚不明确。本研究旨在利用美国医疗保险受益人大型数据库,调查经肺癌筛查检查确诊为SCLC患者的特征及预后。这是一项回顾性队列研究,分析了与美国癌症登记监测流行病学和结果计划(SEER)数据链接的医疗保险数据。研究对象为2015年至2021年间在美国被诊断为SCLC且年龄在65至78岁之间的患者,随访数据截至2022年。在SCLC诊断前12个月内接受过1次或多次LDCT肺癌筛查的患者纳入筛查组,其余患者纳入非筛查组。数据分析时间为2026年1月至8月。主要结局指标为筛查组与非筛查组患者在SCLC确诊时的分期及确诊后的总生存期。共17099名患者(中位年龄[IQR]为72.0岁[69.0-75.0]岁;女性8999名[52.6%])符合研究纳入标准,其中949名(5.5%)纳入筛查组,16150名(94.5%)纳入非筛查组。与非筛查组患者相比,筛查组患者确诊为远处转移性疾病的比例显著较低(949名中的419名[44.2%] vs 16150名中的11376名[70.4%];P < .001)。与非筛查组患者相比,筛查组患者的总生存期也显著更好(3年总生存率:28.0% [95% CI, 24.9%-31.2%] vs 10.8% [95% CI, 10.3%-11.3%];P < .001)。倾向评分匹配分析结果一致。这项针对确诊SCLC的医疗保险受益人队列研究结果表明,接受肺癌筛查与SCLC确诊时向早期分期转变及总生存期改善相关。
Endoscopy IF 11.8 2026-11-18 PMID: 42667933
The optimal self-expandable metal stent (SEMS) for endoscopic drainage of unresectable extrahepatic malignant biliary obstruction (MBO) with endoscopic retrograde cholangiopancreatography (ERCP) remains unclear due to limited randomized controlled trial (RCT) evidence. Prior meta-analyses have relied on observational data, introducing heterogeneity and bias. To overcome these limitations, an RCT-only network meta-analysis was performed to evaluate the efficacy and safety of SEMS types. A literature search was conducted to identify RCTs assessing fully covered SEMS (FCSEMS), partially covered SEMS (PCSEMS), and/or uncovered SEMS (UCSEMS) for ERCP drainage of unresectable extrahepatic MBO. Study outcomes included recurrent biliary obstruction (RBO), specific causes of RBO, overall survival, and adverse events. A frequentist network meta-analysis was performed to estimate hazard ratios (HRs) and incidence rate ratios (IRRs) with their 95%CIs and overall P-scores. 10 RCTs (1659 patients) were included. There were no significant differences in time to RBO, incidence of any RBO, or overall survival between stent types. UCSEMS had the lowest rates of stent migration, tumor overgrowth, and sludge occlusion, whereas FCSEMS most effectively prevented tumor ingrowth. Adverse event rates were similar across groups; however, FCSEMS, but not PCSEMS, had significantly higher rates of acute cholecystitis than UCSEMS in patients with an intact gallbladder. There were no differences in RBO, overall survival, or adverse events excluding acute cholecystitis between SEMS types, although each type has its advantages and disadvantages. FCSEMS was associated with a higher risk of acute cholecystitis, emphasizing the need for careful patient selection, particularly regarding gallbladder status.
中文摘要:由于随机对照试验证据有限,经内镜逆行胰胆管造影术治疗不可切除的肝外恶性胆道梗阻的最佳自膨式金属支架尚不明确。既往荟萃分析多依赖观察性数据,存在异质性和偏倚风险。为克服这些局限,本研究对评估全覆膜、部分覆膜及裸支架疗效与安全性的随机对照试验进行了网络荟萃分析。文献检索旨在识别相关随机对照试验,研究结局包括胆道再梗阻时间、再梗阻发生率、总生存期及不良事件。纳入10项随机对照试验共1659例患者。结果显示不同支架类型在胆道再梗阻时间、再梗阻发生率及总生存期方面无显著差异。裸支架的支架迁移、肿瘤过度生长和污泥堵塞率最低,而全覆膜支架预防肿瘤向内生长的效果最佳。各组不良事件发生率相似,但在胆囊完整患者中,全覆膜支架急性胆囊炎发生率显著高于裸支架,部分覆膜支架则无此差异。除急性胆囊炎外,不同支架类型在再梗阻、总生存期及其他不良事件方面无差异,各类型各有优劣。全覆膜支架与较高的急性胆囊炎风险相关,强调了需根据胆囊状态谨慎选择患者。
Gastroenterology IF 29.7 2026-11-17 PMID: 43044915
Serrated neoplasia represents an increasingly recognized pathway in colorectal carcinogenesis, accounting for up to 30% of colorectal cancers (CRC) and disproportionately implicated in post-colonoscopy CRC. Serrated polyps remain under-detected, incompletely resected, and inconsistently classified histologically, presenting challenges for both non-invasive and colonoscopy-based screening programs. In this comprehensive review, we address advances in the understanding of the serrated pathway, integrating molecular pathways with key histologic classification updates from the 6th edition of the World Health Organization Classification of Digestive Tumor System. We further appraise contemporary evidence regarding the epidemiology and risk factors for serrated polyps, and discuss thresholds for detection via colonoscopy, specifically the sessile serrated lesion detection rate, which is an independent predictor of post-colonoscopy CRC risk. Finally, we address advances in endoscopic detection and resection and synthesize current international surveillance guidelines. With increasing awareness and rising detection benchmarks, a thorough and up to date understanding of the serrated neoplasia is essential for gastroenterologists, pathologists, and primary care providers involved in CRC prevention, in order to reduce its substantial contribution to the burden of CRC worldwide.
中文摘要:锯齿状肿瘤发生是结直肠癌发生中日益被认可的途径,占结直肠癌的30%,且在结肠镜后结直肠癌中占比过高。锯齿状息肉仍存在漏诊、切除不全和组织学分类不一致的问题,为非侵入性和基于结肠镜的筛查项目带来挑战。本综述全面探讨了锯齿状通路理解的进展,将分子通路与世界卫生组织消化系统肿瘤分类第6版的关键组织学分类更新相结合。我们进一步评估了关于锯齿状息肉流行病学和风险因素的当代证据,并讨论了通过结肠镜检测的阈值,特别是作为结肠镜后结直肠癌风险独立预测因子的无蒂锯齿状病变检出率。最后,我们探讨了内镜检测和切除方面的进展,并综合了当前的国际监测指南。随着意识提高和检测基准上升,胃肠病学家、病理学家和参与结直肠癌预防的初级保健提供者必须对锯齿状肿瘤发生有全面且最新的了解,以减少其对全球结直肠癌负担的重大贡献。
ESMO open IF 10.6 2026-11-17 PMID: 43044269
Preclinical evidence suggests synergy between poly-ADP-ribose inhibitors and camptothecin chemotherapy. We tested the talazoparib and irinotecan combination (TI) in the neoadjuvant setting in the I-SPY2 trial in patients with HER2-negative locally advanced breast cancer. I-SPY2 is a phase II platform trial for stage 2/3 early breast cancer at high risk of recurrence. Participants were adaptively randomized to one of several experimental neoadjuvant therapies or control based on receptor subtypes defined by hormone receptor (HR), HER2 status, and MammaPrint risk (MP1, MP2). The primary endpoint was pathological complete response (pCR). Treatments 'graduate' if/when they achieve an 85% Bayesian probability of success in a subtype-specific phase III trial. Only HER2-negative patients were eligible for randomization to the TI arm. All patients received weekly paclitaxel for 12 weeks, followed by doxorubicin/cyclophosphamide and surgery. Participants randomized to the TI arm received daily oral talazoparib and irinotecan infusions every other week. Pathway-specific biomarkers were assessed for response prediction. The combination of talazoparib and irinotecan failed to graduate from the I-SPY2 trial, with a 19% modeled posterior probability of pCR in the TI arm compared with 20% in the control arm among all patients with HER2-negative breast cancer. The most common adverse events were neutropenia and anemia in the TI arm and neuropathy and fatigue in the control arm. pCR rates were highest in patients with germline Breast Cancer Gene 1 or 2 (BRCA1/2) mutations receiving TI (pCR rate 50%) and in those with tumors expressing a DNA repair deficiency signature. TI will not be further explored as a combination given lack of improved efficacy over control (paclitaxel) for neoadjuvant treatment in patients with HER2-negative breast cancer. pCR rates were highest (50%) among patients with germline BRCA1/2 mutations, likely due to the efficacy of talazoparib alone. Further combinations could be explored in patients with HER2-negative breast cancer and a germline BRCA1/2 or PALB2 mutation.
中文摘要:临床前证据表明聚ADP核糖聚合酶抑制剂与喜树碱类化疗药物具有协同作用。我们在I-SPY2试验中测试了talazoparib和irinotecan联合方案(TI)在HER2阴性局部晚期乳腺癌新辅助治疗中的应用。I-SPY2是一项针对具有高复发风险的II/III期早期乳腺癌的平台性II期临床试验。参与者根据激素受体、HER2状态及MammaPrint风险评分进行亚型分类,并自适应随机分配至多种实验性新辅助治疗方案或对照组。主要终点为病理完全缓解率(pCR)。若某方案在特定亚型的III期试验中达到85%的成功贝叶斯概率,则该方案可获准进入下一阶段。仅HER2阴性患者有资格被随机分配至TI组。所有患者均接受每周一次紫杉醇治疗12周,随后进行多柔比星/环磷酰胺治疗及手术。TI组患者每日口服talazoparib并每两周接受一次irinotecan输注。研究评估了通路特异性生物标志物以预测疗效。结果显示,talazoparib与irinotecan联合方案未能通过I-SPY2试验的验证,在所有HER2阴性乳腺癌患者中,TI组的模型后验pCR概率为19%,而对照组为20%。TI组最常见的不良事件为中性粒细胞减少和贫血,对照组则为神经病变和疲劳。接受TI治疗的胚系BRCA1/2突变患者pCR率最高(50%),表达DNA修复缺陷特征的患者pCR率也较高。鉴于该联合方案在HER2阴性乳腺癌新辅助治疗中未显示出优于对照组的疗效,不再进一步探索其联合应用。在胚系BRCA1/2或PALB2突变的HER2阴性乳腺癌患者中,pCR率最高可达50%,这可能与talazoparib单药的疗效有关。未来可在携带胚系BRCA1/2或PALB2突变的HER2阴性乳腺癌患者中探索其他联合方案。
Cancer treatment reviews IF 10.6 2026-11-13 PMID: 43044180
The role of neoadjuvant systemic therapy in resectable biliary tract cancer (BTC) remains uncertain. We conducted a systematic review and meta-analysis to assess the feasibility, surgical outcomes, radiological activity, and survival associated with neoadjuvant treatment. PubMed/MEDLINE, Embase, and CENTRAL were searched through April 30, 2026 for prospective phase II-III trials evaluating neoadjuvant systemic therapy followed by surgery in resectable BTC. Binary outcomes were pooled using random-effects models. Individual patient data were reconstructed from published Kaplan-Meier curves, and landmark survival estimates were synthesized using random-effects meta-analysis. Six prospective trials comprising seven active neoadjuvant treatment arms were included. Pooled neoadjuvant-to-surgery completion and curative-intent resection rates were 79.0% (95% CI, 63.0-89.0) and 71.0% (95% CI, 54.0-84.0), respectively. The pooled objective response rate was 21.2% (95% CI, 9.0-42.3), and the intention-to-treat R0 resection rate was 63.6% (95% CI, 44.7-79.0). Pooled overall survival was 84.0% (95% CI, 78.0-89.0), 63.0% (55.0-71.0), and 51.0% (44.0-59.0) at 12, 24, and 36 months, respectively. Corresponding recurrence-related survival estimates were 60.0% (51.0-69.0), 41.0% (33.0-50.0), and 37.0% (30.0-45.0). Findings were consistent across sensitivity analyses. Neoadjuvant systemic therapy is feasible in selected patients with resectable BTC, although a substantial proportion do not ultimately undergo curative surgery. Emerging prospective evidence supports further evaluation of perioperative strategies, particularly in high-risk disease, but randomized trials against contemporary surgery-first approaches are required before routine adoption.
中文摘要:新辅助全身治疗在可切除胆道癌(BTC)中的作用尚不明确。我们进行了系统评价和荟萃分析,以评估新辅助治疗的可行性、手术结果、放射学活性和相关生存率。通过2026年4月30日检索PubMed/MEDLINE、Embase和CENTRAL数据库,筛选评估可切除BTC患者在新辅助全身治疗后接受手术的 prospective II-III期试验。采用随机效应模型汇总二分类结局。从已发表的Kaplan-Meier曲线重建个体患者数据,并使用随机效应荟萃分析合成地标生存估计值。纳入六项前瞻性试验,包含七个活性新辅助治疗组。汇总的新辅助治疗至手术完成率为79.0%(95% CI, 63.0-89.0),根治性切除率为71.0%(95% CI, 54.0-84.0)。汇总的客观缓解率为21.2%(95% CI, 9.0-42.3),意向治疗R0切除率为63.6%(95% CI, 44.7-79.0)。汇总的总生存率在12、24和36个月时分别为84.0%(95% CI, 78.0-89.0)、63.0%(95% CI, 55.0-71.0)和51.0%(95% CI, 44.0-59.0)。相应的复发相关生存估计值分别为60.0%(95% CI, 51.0-69.0)、41.0%(95% CI, 33.0-50.0)和37.0%(95% CI, 30.0-45.0)。敏感性分析结果一致。新辅助全身治疗在选定的可切除BTC患者中是可行的,尽管相当比例的患者最终未接受根治性手术。新兴的前瞻性证据支持进一步评估围手术期策略,特别是在高危疾病中,但在常规采用之前,需要与当代的手术优先策略进行随机对照试验。
Neuro-oncology IF 13.1 2026-11-13 PMID: 43021633
People with neurofibromatosis type 1 (NF1) are at risk for developing peripheral nerve sheath tumors (PNSTs) ranging from benign neurofibromas to high-grade sarcomas. PNSTs known as atypical neurofibromas are at increased risk for malignant transformation. In 2017 the term ANNUBP (atypical neurofibromatous neoplasm of uncertain biologic potential) was proposed for PNSTs at increased risk for malignant transformation based on histopathologic features. Subsequently it was recognized that PNSTs not meeting ANNUBP criteria could still have concerning clinical, imaging and molecular features. A State of the Science conference addressed how to define these pre-cancerous PNSTs and reached consensus regarding clinical management and priority areas of research. Key recommendations from this symposium include: (1) using a combination of histologic, molecular and imaging features to define pre-malignant "at-risk" PNST; (2) recognizing that people with NF1 may be divided into "higher-risk" and "average-risk" for MPNST based on features such as their germline NF1 variant, internal tumor burden and history of malignancy or radiotherapy and; (3) the need to validate consensus screening and surveillance strategies based on personal and tumor-related risk factors. These recommendations will advance the ability to standardize care, and potentially fuel research that enables early diagnosis, prevention of malignant transformation and improved outcomes.
中文摘要:1型神经纤维瘤病(NF1)患者面临从良性神经鞘瘤发展至高级别肉瘤的周围神经鞘肿瘤(PNST)风险。被称为非典型神经鞘瘤的PNST具有更高的恶变风险。2017年,基于组织病理学特征,提出了ANNUBP(生物学潜能不确定的非典型神经纤维瘤性肿瘤)这一术语用于描述具有较高恶变风险的PNST。随后认识到,不符合ANNUBP标准的PNST仍可能表现出令人担忧的临床、影像学和分子特征。一次科学状态会议探讨了如何定义这些癌前PNST,并在临床管理和研究优先领域达成共识。本次研讨会的关键建议包括:(1)结合组织学、分子和影像学特征来定义癌前「高风险」PNST;(2)认识到NF1患者可根据胚系NF1变异、内部肿瘤负荷以及恶性肿瘤或放疗史等特征分为MPNST的「高风险」和「平均风险」群体;(3)需要基于个人和肿瘤相关风险因素验证共识筛查和监测策略。这些建议将提高标准化护理的能力,并可能推动促进早期诊断、预防恶变和改善预后的研究。

基础研究 (3篇)

Biomarker research IF 14.6 2026-11-18 PMID: 43053253
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, largely due to tumor heterogeneity, late diagnosis, and high recurrence rates even after curative treatment. Although HCC is potentially curable when detected at an early stage, suboptimal surveillance, particularly in patients with underlying cirrhosis or metabolic risk factors, limits the proportion of patients eligible for curative therapies. Current surveillance strategies for at-risk populations have intrinsic limitations, and the performance of imaging and serum biomarkers remains suboptimal. Moreover, the lack of reliable prognostic biomarkers for detecting early recurrence hampers post-treatment surveillance and impacts clinical outcomes. In this context, circulating biomarkers have emerged as promising tools for improving both early detection and prognostic stratification. Liquid biopsy has the potential to enable early, non-invasive diagnosis of HCC and allows longitudinal assessment of tumor progression through serial sampling. In early-stage HCC, blood candidates may complement or outperform conventional approaches by enabling earlier diagnosis and more accurate risk stratification. In this review, we summarize recent advances and current challenges in the clinical translation of circulating biomarkers. We focus on key liquid biopsy components, including circulating cell-free DNA, particularly circulating tumor DNA, circulating tumor cells, non-coding RNAs, extracellular vesicles, proteins and metabolites, such as bile acids and lipids, highlighting their diagnostic and prognostic potential and their possible integration into personalized management strategies for patients with early-stage HCC.
中文摘要:肝细胞癌(HCC)仍是全球癌症相关死亡的主要原因,这主要归因于肿瘤异质性、晚期诊断以及即使在接受根治性治疗后仍具有高复发率。尽管早期发现的 HCC 具有治愈潜力,但次优的监测策略,特别是在存在基础肝硬化或代谢危险因素的患者中,限制了接受根治性治疗的患者比例。针对高危人群的现有监测策略存在内在局限性,且影像学和血清生物标志物的表现仍不理想。此外,缺乏用于检测早期复发的可靠预后生物标志物阻碍了治疗后监测并影响临床结局。在此背景下,循环生物标志物已成为改善早期检测和预后分层的重要工具。液体活检有望实现 HCC 的早期、无创诊断,并通过连续采样纵向评估肿瘤进展。在早期 HCC 中,血液候选标志物可通过实现更早的诊断和更准确的风险分层来补充或超越传统方法。本综述总结了循环生物标志物临床转化方面的最新进展和当前挑战。我们重点关注关键的液体活检成分,包括循环游离 DNA(特别是循环肿瘤 DNA)、循环肿瘤细胞、非编码 RNA、细胞外囊泡以及蛋白质和代谢物(如胆汁酸和脂质),强调其诊断和预后潜力及其在早期 HCC 患者个性化管理策略中可能的整合应用。
Clinical and molecular hepatology IF 21.7 2026-11-17 PMID: 43041060
Hepatocellular carcinoma (HCC) exhibits profound metabolic heterogeneity, yet the functional lipid metabolites driving tumor progression and immune microenvironment remodeling remain insufficiently defined. This study aimed to construct a metabolomic atlas of HCC and identify clinically relevant metabolic vulnerabilities. Untargeted metabolomic profiling was performed in 91 paired HCC and adjacent non-tumor tissues. Integrated metabolomic, transcriptomic, clinicopathological, and immune analyses characterized metabolic heterogeneity. Nervonic acid was evaluated in HCC cells, immunocompetent and immunodeficient mouse models, and knockdown and rescue experiments targeting ATP citrate lyase (ACLY). HCC showed extensive metabolic remodeling with limited metabolite-gene concordance. Clustering identified four metabolomic subtypes. The high-risk subtype MS1 exhibited poor prognosis, pronounced very-long-chain fatty acid remodeling, and immunosuppressive features. Nervonic acid, a very-long-chain monounsaturated fatty acid, was enriched in MS1, increased in HCC tissues, and associated with unfavorable survival. It promoted HCC cell proliferation, migration, invasion, and tumor growth. In immunocompetent models, nervonic acid reduced CD8+ T-cell infiltration and increased M2-like macrophage enrichment. Exploratory CD8 depletion suggested attenuation of the nervonic acid-associated tumor growth increment. Coordinated lipid remodeling included altered free fatty acid composition, enhanced fatty acid uptake, increased cholesterol abundance, and changes in membrane lipid order. Nervonic acid induced an ACLY-centered lipogenic program; in HCC cells, ACLY knockdown attenuated malignant phenotypes and lipid accumulation, and ACLY rescue restored these responses. Nervonic acid marks an aggressive HCC subtype with distinct immune features. Knockdown and rescue in HCC cells implicate ACLY in lipid remodeling. The prognostic value of tumor nervonic acid requires independent validation.
中文摘要:肝细胞癌(HCC)表现出显著的代谢异质性,但驱动肿瘤进展和免疫微环境重塑的功能性脂质代谢物尚不明确。本研究旨在构建HCC的代谢组图谱并识别具有临床意义的代谢脆弱性。对91对HCC及配对癌旁非肿瘤组织进行非靶向代谢组学分析。整合代谢组学、转录组学、临床病理及免疫分析以表征代谢异质性。在HCC细胞、免疫健全与免疫缺陷小鼠模型以及针对ATP柠檬酸裂解酶(ACLY)的敲低和挽救实验中评估神经酸的作用。HCC表现出广泛的代谢重塑,且代谢物与基因的一致性有限。聚类分析鉴定出四种代谢组亚型。高风险亚型MS1预后较差,具有显著的极长链脂肪酸重塑及免疫抑制特征。神经酸作为一种极长链单不饱和脂肪酸,在MS1中富集,在HCC组织中表达增加,并与不良生存期相关。它促进HCC细胞增殖、迁移、侵袭及肿瘤生长。在免疫健全模型中,神经酸减少CD8+ T细胞浸润并增加M2样巨噬细胞富集。探索性CD8耗竭实验表明,神经酸相关的肿瘤生长增量减弱。协调的脂质重塑包括游离脂肪酸组成改变、脂肪酸摄取增强、胆固醇丰度增加及膜脂质有序性变化。神经酸诱导以ACLY为中心的脂生成程序;在HCC细胞中,ACLY敲低减弱恶性表型和脂质积累,而ACLY挽救恢复这些反应。神经酸标记具有独特免疫特征的侵袭性HCC亚型。HCC细胞中的敲低与挽救实验提示ACLY参与脂质重塑。肿瘤神经酸的预后价值需独立验证。
Circulation research IF 18.0 2026-11-13 PMID: 43023213
Macrophage polarization and complement activation play a pivotal role in the pathogenesis of myocardial ischemia-reperfusion (I/R) injury. FGF13 (fibroblast growth factor 13) is a critical regulator of cardiac homeostasis. However, the role and mechanism of FGF13 in myocardial I/R injury remain unclear. FGF13 expression was detected in cardiomyocytes after hypoxia/reoxygenation and in hearts subjected to myocardial I/R. Cardiomyocyte-specific FGF13 knockout and adeno-associated virus serotype 9-mediated overexpression mice were generated. Transcriptomic and proteomic analyses identified key downstream mechanisms. Immunoprecipitation-mass spectrometry, co-immunoprecipitation, and glycoproteomics identified PGRN (progranulin) as an FGF13-interacting protein and mapped its glycosylation site. Mechanistic studies were performed using Transwell cocultures of neonatal mouse cardiomyocytes and bone marrow-derived macrophages, together with molecular and biochemical approaches. Virtual screening and molecular dynamics simulations identified a small-molecule FGF13 inhibitor. FGF13 was upregulated in cardiomyocytes after myocardial I/R. Cardiomyocyte-specific FGF13 knockout alleviated, whereas overexpression exacerbated, cardiac dysfunction and myocardial injury after I/R. Mechanistically, FGF13, through its asparagine 121 residue, competitively occupied the asparagine 263 glycosylation site of PGRN, sterically preventing STT3A (STT3 oligosaccharyltransferase complex catalytic subunit A)-mediated glycosylation of asparagine 263 and suppressing PGRN secretion. FGF13 depletion restored PGRN glycosylation and secretion, which activated macrophage TNFR2/PI3K/AKT (tumor necrosis factor receptor 2/phosphoinositide 3-kinase/protein kinase B) signaling in a paracrine manner, promoted M2 polarization while suppressing M1 polarization, and inhibited complement activation and inflammation. The small-molecule FGF13 inhibitor CWD8 (1-[2-amino-2-methylpropyl]-5,5-dimethylpiperidin-3-ol) also attenuated myocardial I/R injury. Our findings highlight the critical role of FGF13 in myocardial I/R injury and reveal a competitive mechanism by which FGF13 hinders STT3A-mediated PGRN glycosylation. We identify the PGRN glycosylation-PI3K/AKT axis as the key downstream pathway mediating FGF13-regulated macrophage polarization and complement activation, suggesting that small-molecule FGF13 inhibitors may represent a promising therapeutic strategy for myocardial I/R injury.
中文摘要:巨噬细胞极化和补体激活在心肌缺血再灌注损伤的发病机制中起关键作用。成纤维细胞生长因子13是心脏稳态的重要调节因子,但其在心肌缺血再灌注损伤中的作用和机制尚不清楚。本研究检测了缺氧/复氧后的心肌细胞及经历心肌缺血再灌注的心脏中的FGF13表达。构建了心肌细胞特异性FGF13敲除和小鼠腺相关病毒血清型9介导的过表达模型。通过转录组学和蛋白质组学分析确定了关键下游机制。利用免疫沉淀-质谱、共免疫沉淀和糖蛋白质组学技术,鉴定出前调蛋白为与FGF13相互作用的蛋白并定位其糖基化位点。采用新生小鼠心肌细胞与骨髓来源巨噬细胞的Transwell共培养体系,结合分子生物学和生化方法开展机制研究。通过虚拟筛选和分子动力学模拟鉴定出一种小分子FGF13抑制剂。结果显示,心肌缺血再灌注后心肌细胞中FGF13上调。心肌细胞特异性敲除FGF13可减轻缺血再灌注后的心脏功能障碍和心肌损伤,而过表达则加重损伤。在机制上,FGF13通过其天冬酰胺121残基竞争性占据前调蛋白的天冬酰胺263糖基化位点,空间上阻碍STT3A介导的天冬酰胺263糖基化并抑制前调蛋白分泌。耗竭FGF13恢复了前调蛋白的糖基化和分泌,旁分泌激活巨噬细胞的TNFR2/PI3K/AKT信号通路,促进M2型极化并抑制M1型极化,从而抑制补体激活和炎症反应。小分子FGF13抑制剂CWD8也能减轻心肌缺血再灌注损伤。本研究结果突显了FGF13在心肌缺血再灌注损伤中的关键作用,揭示了FGF13阻碍STT3A介导的前调蛋白糖基化的竞争性机制。研究确定前调蛋白糖基化-PI3K/AKT轴是介导FGF13调控巨噬细胞极化和补体激活的关键下游通路,提示小分子FGF13抑制剂可能是治疗心肌缺血再灌注损伤的有前景策略。

10其他 (23篇)

临床研究 (2篇)

Cancer discovery IF 29.5 2026-11-18 PMID: 43049344
The rapid expansion of antibody therapeutics is shifting the clinical bottleneck from drug availability to precise patient selection. We systematically characterize 87 clinically actionable tumor-associated antigens across solid tumors by integrating transcriptomic, proteomic, spatial, and single-cell profiles from more than 32,000 specimens to define expression prevalence, intratumoral heterogeneity, immune contexture, internalization and payload-sensitivity pathways, and translational relevance. We establish ANCHOR, a coordinate reference framework for standardizing patient RNA-seq data, and develop ReSort, a two-tiered scoring system for scalable target prioritization. ReSort enables virtual basket and umbrella trial matching, demonstrates concordance with clinical assays, predicts therapeutic response in patient-derived models, and identifies repurposing opportunities in rare malignancies. We develop an AI-based decision-support agent for antibody trial matching and construct a multimodal feature space integrating tumor- and protein-intrinsic attributes to guide systematic target discovery and prioritization. This work provides a scalable, clinically actionable approach for precision antibody-based therapies and next-generation target development.
中文摘要:抗体疗法的快速扩展正将临床瓶颈从药物可及性转向精准的患者选择。我们整合了来自32000多份样本的转录组、蛋白质组、空间及单细胞图谱,系统表征了泛癌种中87个具有临床行动性的肿瘤相关抗原,以明确其表达普遍性、瘤内异质性、免疫微环境、内化及载荷敏感通路和转化相关性。我们建立了ANCHOR坐标参考框架以标准化患者RNA-seq数据,并开发了ReSort双层评分系统以实现可扩展的目标优先级排序。ReSort支持虚拟篮式和伞式试验匹配,与临床检测具有一致性,能在患者衍生模型中预测治疗反应,并识别罕见恶性肿瘤中的药物重定位机会。我们开发了基于人工智能的抗体试验匹配决策支持代理,并构建了整合肿瘤及蛋白质固有属性的多模态特征空间,以指导系统性的目标发现与优先级排序。本研究为精准抗体疗法和下一代靶点开发提供了一种可扩展且具有临床行动性的方法。
Science bulletin IF 20.7 2026-11-15 PMID: 42888065
Comparative data evaluating the predictive performance of various obesity and metabolic indices for multiple noncommunicable diseases (NCDs) remain limited. We used the data sourced from the Health Evaluation and risk Reduction through nationwide Teamwork cohort (ChinaHEART), a national population-based study that enrolled 4,258,033 Chinese adults and followed them for more than 20 million person-years between November 2014 and December 2023. Fifteen obesity and metabolic indices were categorized into three groups: (1) body shape-related indices, including body mass index (BMI), body roundness index (BRI), waist-to-height ratio (WHtR), a body shape index (ABSI), weight-adjusted waist index (WWI), and conicity index (CI); (2) visceral fat-related indices, including lipid accumulation product (LAP) and Chinese visceral adiposity index (CVAI); and (3) metabolic function-related indices, including triglyceride-glucose index (TyG), TyG-BMI, TyG-BRI, TyG-WHtR, TyG-ABSI, TyG-WWI, and TyG-CI. The study outcomes comprised composite events of death or first hospitalization attributable to each of cardiovascular diseases (CVD), diabetes mellitus (DM), cancers, and chronic obstructive pulmonary disease (COPD) individually. Composite obesity and metabolic indices reflecting visceral adiposity accumulation and insulin resistance, respectively exhibited enhanced predictive accuracy for cardiovascular and diabetic risk, whereas their performance for cancer and COPD was comparatively limited. These findings support the paradigm that weight management strategies should be guided by risk assessments rather than relying solely on body weight or body shape. Furthermore, the development of diverse definitions for obesity measurement and management tailored to different population subgroups is warranted.
中文摘要:目前评估各种肥胖和代谢指数对多种非传染性疾病预测性能的对比数据仍然有限。本研究使用了来自中国HEART队列的数据,这是一个全国性的基于人群的研究,在2014年11月至2023年12月期间纳入了4,258,033名中国成年人并随访了超过2000万人年的观察时间。我们将十五种肥胖和代谢指数分为三类:第一类为体型相关指数,包括体重指数、身体圆度指数、腰高比、身体形状指数、体重调整腰围指数和圆锥指数;第二类为内脏脂肪相关指数,包括脂质积累产物和中国内脏脂肪指数;第三类为代谢功能相关指数,包括甘油三酯葡萄糖指数及其与BMI、身体圆度指数、腰高比、身体形状指数、体重调整腰围指数和圆锥指数的组合。研究结局包括分别归因于心血管疾病、糖尿病、癌症和慢性阻塞性肺疾病的死亡或首次住院复合事件。反映内脏脂肪积累和胰岛素抵抗的复合肥胖和代谢指数在预测心血管和糖尿病风险方面表现出增强的准确性,而在癌症和慢性阻塞性肺疾病方面的表现相对有限。这些发现支持体重管理策略应由风险评估指导而非仅依赖体重或体型的范式。此外,有必要开发针对不同人群亚组的多样化肥胖测量和管理定义。

基础研究 (21篇)

Nucleic acids research IF 15.0 2026-11-20 PMID: 43059394
The CIViC (Clinical Interpretations of Variants in Cancer) knowledgebase (https://civicdb.org) remains one of the few free, unrestricted knowledgebases for the distribution of somatic cancer variant interpretations. CIViC leverages public curation and expert moderation to address the bottleneck problem of cancer variant interpretation for patient care. As the curation platform for ClinGen Somatic Cancer, the CIViC knowledge model is informed by multiple experts across disparate fields in cancer and, in turn, acts as a model for cancer variant classification and representation. In order to capture a wider range of genomic variations, several updates to CIViC's data and curation model have been made with a focus on maintaining familiar workflows and user interface layouts. A new top-level entity called the Feature represents Genes, Fusions, Regions for large-scale structural variations, and Factors for genome-wide biomarkers. Accompanying Variants capture information unique to each genomic event. Molecular Profiles enable the curation of complex combinations of these Variants. CIViC has also developed a system for approval and submission of Assertions to ClinVar, guidance for the use of AI in curation and moderation of content, and additional capabilities such as source retraction monitoring and an advanced query builder.
中文摘要:CIViC(癌症体细胞变异临床解读)知识库仍是少数几个免费且无限制使用的体细胞癌症变异解读分发知识库之一。CIViC利用公共策展和专家审核来解决患者护理中癌症变异解读的瓶颈问题。作为ClinGen Somatic Cancer的策展平台,CIViC的知识模型受到来自癌症不同领域多位专家的指导,并反过来作为癌症变异分类和表示的模型。为了捕捉更广泛的基因组变异,对CIViC的数据和策展模型进行了多项更新,重点在于保持熟悉的工作流程和用户界面布局。一个新的顶层实体称为Feature,代表基因、融合基因、用于大规模结构变异的区域以及用于全基因组生物标志物的因子。伴随的Variants捕获每个基因组事件特有的信息。Molecular Profiles支持对这些Variants复杂组合的策展。CIViC还开发了向ClinVar提交和批准Assertions的系统、关于在内容策展和审核中使用AI的指导,以及其他功能如来源撤回监控和高级查询构建器。
Nucleic acids research IF 15.0 2026-11-20 PMID: 43059400
FusionGDB has served diverse biological, health, and clinical research communities as a unique functional annotation knowledgebase of human fusion genes. In this study, we report an updated resource of human fusion gene annotation (FusionGDB 3.0), available at https://compbio.uth.edu/FusionGDB/. FusionGDB 3.0 includes substantial content updates: 156K up-to-date human fusion genes established by integrating 216K RNA-seq-based and 100K WGS-based breakpoint events, comprehensive open reading frame annotations, protein domain retention searches, and 1.13 million personalized fusion protein sequences reflecting individual nsSNVs from TCGA and CCLE, as well as N- and C-truncated protein sequences alongside canonical in-frame products. Furthermore, it incorporates 18K potential tumorigenic scenarios, supported by evidence from the literature, spanning drug-targetable gene group fusions, the epigenomic architecture around breakpoint junctions, and therapeutic prioritization scoring. FusionGDB 3.0 establishes a systematic framework for the functional annotation of coding structural variants. FusionGDB 3.0 serves as a pivotal reference knowledgebase for the genomics, oncology, and precision pharmacology communities, while also functioning as a foundational benchmark dataset for training and validating machine learning models, structural biology platforms, and AI-driven therapeutic discovery pipelines.
中文摘要:FusionGDB作为人类融合基因的功能注释知识库,服务于多样化的生物、健康及临床研究社区。本研究报道了更新的人类融合基因注释资源FusionGDB 3.0,可通过https://compbio.uth.edu/FusionGDB/访问。FusionGDB 3.0包含大量内容更新:整合216K个基于RNA-seq和100K个基于全基因组测序(WGS)的断点事件,建立了156K个最新的人类融合基因;提供全面的开放阅读框注释、蛋白质结构域保留搜索,以及反映来自TCGA和CCLE个体非同义单核苷酸变异(nsSNVs)的113万个个性化融合蛋白序列,包括N端和C端截短蛋白序列及典型的移码产物。此外,该数据库整合了18K个潜在致瘤场景,其证据来源于文献,涵盖药物可靶向基因组融合、断点连接处的表观基因组架构以及治疗优先级评分。FusionGDB 3.0建立了编码结构变异功能注释的系统框架。它作为基因组学、肿瘤学和精准药理学社区的关键参考知识库,同时作为训练和验证机器学习模型、结构生物学平台及人工智能驱动的治疗发现管道的基准数据集。
Nucleic acids research IF 15.0 2026-11-20 PMID: 43059368
canSAR (https://cansar.ai) serves as the world's largest public platform for cancer drug discovery and translational research. It serves as an exploration and hypothesis generation platform for drug discovery through (i) fully integrating large, multidisciplinary data from public resources, as well as bespoke curated data, creating a connected, navigable drug discovery knowledge map; and (ii) applying a suite of machine learning and AI tools to generate novel insights. We share the latest updates to canSAR highlighting growth across all data, enhancements to the predictive algorithms, and continued improvements to the user experience. We leverage our latest open science chemical handling and druggability prediction tools to provide traceable insights. An increased focus of the platform is to provide "in-line" support and guidance to drug discovery exploration. We report the first incarnation of our high-fidelity, agentic-AI-generated, context-specific summaries, which we provide across the website for all human proteins to further aid users in synthesis and distillation of key information.
中文摘要:canSAR(https://cansar.ai)是全球最大的癌症药物发现与转化研究公共平台。它通过整合来自公共资源的大型多学科数据以及定制化的策展数据,构建连接且可导航的药物发现知识图谱,并应用一系列机器学习和人工智能工具生成新颖见解,从而作为药物发现的探索与假设生成平台。我们分享了canSAR的最新更新,重点介绍了所有数据的增长、预测算法的增强以及用户体验的持续改进。我们利用最新的开放科学化学处理和成药性预测工具提供可追溯的见解。该平台更加侧重于为药物发现探索提供在线支持和指导。我们报告了首个高保真、代理式人工智能生成的上下文特定摘要的首次应用,这些摘要覆盖网站上的所有人类蛋白质,以进一步帮助用户综合和提炼关键信息。
Nucleic acids research IF 15.0 2026-11-20 PMID: 43059364
Cancer is driven by alterations across multiple molecular layers, but whether multi-omics drivers carry prognostic weight has received little systematic attention. DriverDBv5 (https://driverdb.bioinfomics.org/) extends DriverDB from driver identification to prognostic evaluation. It has been expanded to 187 cohorts, 43 862 patients, and 129 655 samples, with 154 cohorts from non-TCGA (The Cancer Genome Atlas) repositories reconciled by a generalized multi-omics barcode. Driver genes can be evaluated with Cox and mixture cure models, with machine learning on the full multi-omics feature matrix, and for the joint prognostic effect of alterations in two omics layers. The Customized Analysis module has grown from 4 to 10 tools for user-defined gene sets, subgroups, and covariates, and a human body map offers an anatomical entry point. DriverDBv5 thus reveals not only which alterations drive a tumor, but also which of them relate to patient outcome.
中文摘要:癌症由多层分子层面的改变驱动,但多组学驱动基因是否具有预后价值尚未得到系统关注。DriverDBv5(https://driverdb.bioinfomics.org/)将DriverDB从驱动基因鉴定扩展至预后评估。数据库已扩展至187个队列、43862名患者和129655个样本,其中来自非TCGA(The Cancer Genome Atlas)存储库的154个队列已通过广义多组学条形码进行协调。可利用Cox模型和混合治愈模型评估驱动基因,通过机器学习分析完整的多组学特征矩阵,并评估两个组学层面改变的联合预后效应。自定义分析模块已从4个工具增长至10个,支持用户定义基因集、亚组和协变量,人体图谱提供了解剖学入口。DriverDBv5因此不仅揭示哪些改变驱动肿瘤,还揭示其中哪些与患者预后相关。
Nucleic acids research IF 15.0 2026-11-19 PMID: 43053331
The Drug-Gene Interaction Database (DGIdb; https://dgidb.org) is an open-access aggregate knowledgebase that normalizes and centralizes drug-gene interaction and gene annotation data from diverse therapeutic and biomedical sources. Since its previous update, DGIdb has expanded its data content and added new tooling to better support programmatic access and local deployment. This release updates existing sources and incorporates three new sources of interaction data, including annotation data from the Molecular Oncology Almanac, the PRISM Repurposing Dataset, and the Broad Institute Drug Repurposing Hub. To streamline data access for computational workflows, we have developed dgiPy and dgiR, Python and R client libraries that provide standardized access to the DGIdb API. We additionally now provide versioned Docker images and a public data repository containing current and historical DGIdb data releases in TSV and SQL formats. Together with continued improvements to the web interface, these new resources expand FAIR, transparent, and reproducible access to drug-gene interaction data in the bioinformatics community.
中文摘要:药物基因相互作用数据库(DGIdb;https://dgidb.org)是一个开放获取的聚合知识库,它标准化并集中了来自多种治疗和生物医学来源的药物基因相互作用及基因注释数据。自上次更新以来,DGIdb扩大了数据内容并增加了新工具,以更好地支持程序化访问和本地部署。本次发布更新了现有来源,并纳入了三个新的相互作用数据来源,包括来自《分子肿瘤学年鉴》、PRISM重新利用数据集以及Broad研究所药物重新利用枢纽的注释数据。为了简化计算工作流的数据访问,我们开发了dgiPy和dgiR这两个Python和R客户端库,提供对DGIdb API的标准访问。此外,我们现在还提供版本化的Docker镜像以及一个公共数据存储库,其中包含以TSV和SQL格式存储的当前和历史DGIdb数据发布版本。结合Web界面的持续改进,这些新资源扩大了生物信息学社区对药物基因相互作用数据的FAIR(可发现、可访问、可互操作、可重用)、透明和可重复访问。
Molecular cell IF 16.0 2026-11-19 PMID: 42906543
Protein arginine methyltransferases (PRMTs) are promising anti-cancer targets, but their tumorigenic mechanisms remain incompletely understood. Here, we show that arginine methylation drives global 3'UTR shortening, thereby promoting oncogenic short isoforms. Inhibition of asymmetric dimethylation reverses this shift, with combined inhibition of asymmetric and symmetric dimethylation (DMAi) producing an even greater effect across human cancer cell lines, patient-derived organoids, and activated murine T cells, while also counteracting the shortening induced by reduced CFIm25 expression. Arginine methylation promotes PCF11 association with the cleavage and polyadenylation machinery, enabling efficient processing of weak proximal poly(A) sites within transcripts characterized by high GC content, large distances between alternative poly(A) sites, and a position-dependent sequence code. These findings establish physiologic roles of PRMTs in promoting 3'UTR shortening, which could be exploited for patient stratification of PRMT-targeting therapies in oncology and immune-related diseases.
中文摘要:蛋白质精氨酸甲基转移酶是极具潜力的抗癌靶点,但其致瘤机制尚不完全清楚。本研究显示,精氨酸甲基化驱动全局性3'UTR缩短,从而促进致癌短异构体的产生。抑制不对称二甲基化可逆转这一转变,而在多种人类癌细胞系、患者来源类器官及活化的小鼠T细胞中,联合抑制不对称与对称二甲基化产生的效果更为显著,同时还能抵消由CFIm25表达降低引起的缩短效应。精氨酸甲基化促进PCF11与切割和多聚腺苷酸化机制的结合,使得富含GC含量、替代多聚腺苷酸位点间距离较大且存在位置依赖性序列特征的转录本能够高效处理弱近端多聚腺苷酸位点。这些发现确立了PRMTs在促进3'UTR缩短中的生理作用,该机制可用于肿瘤及免疫相关疾病中PRMT靶向治疗的患者分层。
Journal of the American Chemical Society IF 16.6 2026-11-18 PMID: 43053394
The chemical and structural diversity of peptide phage or mRNA-display libraries can be expanded by chemical modification, such as with cyclization reagents or by incorporation of unnatural amino acids, but the number of different non-natural building blocks introduced has been modest so far. To expand the chemical diversity in peptide display libraries, we developed a strategy for efficient parallel chemical diversification of phage display libraries based on capturing phage on a solid support via a polyhistidine tag and chemical modification. We applied chemically diverse building blocks in a 96-well format that allowed high-throughput experimentation, including parallel phage panning. Selections against the oncology target MCL-1 identified binders containing unnatural building blocks that were important for binding, such as thienylpyridine. This demonstrated the effectiveness of the approach and emphasized the advantages of an increased chemical diversity. This strategy may be particularly attractive for generating short peptide-based ligands, where the number of combinations based on proteinaceous amino acids is limited, for generating membrane-permeable peptides required for oral application or intracellular targeting.
中文摘要:肽噬菌体或mRNA展示库的化学与结构多样性可通过化学修饰如环化试剂或非天然氨基酸的引入来扩展,但迄今为止引入的不同非天然构建模块数量仍然有限。为了扩大肽展示库的化学多样性,我们开发了一种基于将噬菌体通过多组氨酸标签捕获至固相支持物并进行化学修饰的策略,以实现噬菌体展示库的高效并行化学多样化。我们在96孔板格式中应用了化学多样的构建模块,实现了包括平行噬菌体淘选在内的高通量实验。针对肿瘤学靶点MCL-1进行的筛选鉴定出了含有对结合至关重要的非天然构建模块的结合物,例如噻吩基吡啶。这证明了该方法的有效性并强调了增加化学多样性的优势。该策略对于生成基于短肽的配体特别具有吸引力,因为仅基于蛋白质氨基酸的组合数量有限,同时也适用于生成需要口服应用或细胞内靶向的膜通透性肽。
Journal of the American Chemical Society IF 16.6 2026-11-18 PMID: 43053356
The precise resolution of single-molecule events is often limited by the stochastic thermal motion of analytes, which traverse nanoscale sensing zones too rapidly for conventional detection bandwidths. This remains a fundamental challenge in nanopore chemistry, particularly for small and flexible peptides. Here, we report a chemically intuitive molecular programming strategy─steric blockage-enabled slow translocation (SLOW-Trans)─that overcomes this physical limitation through the rational design of sterically demanding probe molecules. By site-specifically conjugating rigid aromatic steric tags with precisely defined dimensions to peptide substrates, we actively reshape the translocation energy landscape within the ∼1.2 nm constriction of the M2MspA nanopore. Systematic variation of tag size and rigidity enables deterministic control over peptide residence time, transforming transient stochastic events into stable and highly discriminable current signatures. Using this strategy, we achieve a six-order-of-magnitude dynamic range (0.001-1000 ng/mL) for matrix metalloproteinases (MMP-1, -2, and -9). In a cohort of 231 clinical urine samples, the nanopore-derived MMP activity profiles showed excellent agreement with ELISA-derived measurements and, when integrated with a machine-learning classifier, enabled classification of urothelial carcinoma with 96.2% accuracy. As a proof-of-concept extension, the modular probe design was further adapted for PSA/KLK3 activity analysis in clinical serum samples, supporting the feasibility of extending the approach to an additional protease target. This work establishes a general chemical framework for programming molecular behavior in confined nanoscale environments, bridging molecular design principles with functional nanopore sensing.
中文摘要:单分子事件的精确解析通常受限于分析物的随机热运动,这些分析物以超过传统检测带宽的速度穿过纳米级传感区域。这在纳米孔化学中仍是一个根本性挑战,特别是对于小分子和柔性肽段。在此,我们报告了一种直观的分子编程策略─空间位阻介导的慢速易位(SLOW-Trans)─通过合理设计具有空间位阻需求的探针分子来克服这一物理限制。通过将具有精确定义尺寸的刚性芳香族空间位阻标签定点偶联到肽底物上,我们主动重塑了M2MspA纳米孔约1.2nm狭窄处的易位能量景观。系统性地改变标签的尺寸和刚性实现了对肽段驻留时间的确定性控制,将瞬态随机事件转化为稳定且具有高区分度的电流信号。利用该策略,我们实现了基质金属蛋白酶(MMP-1、-2和-9)六个数量级的动态范围(0.001-1000 ng/mL)。在231例临床尿液样本队列中,纳米孔衍生的MMP活性谱与ELISA衍生的测量结果表现出极好的一致性,当结合机器学习分类器时,能够以96.2%的准确率对尿路上皮癌进行分类。作为概念验证的延伸,模块化探针设计进一步被调整为用于临床血清样本中的PSA/KLK3活性分析,支持了将该方法扩展至其他蛋白酶靶点的可行性。这项工作建立了在受限纳米环境中编程分子行为的一般化学框架,弥合了分子设计原理与功能性纳米孔传感之间的鸿沟。
Journal of the American Chemical Society IF 16.6 2026-11-18 PMID: 43053355
Targeting mitochondria is a promising strategy for precision tumor therapy, yet ligand-free mitochondrial drug delivery remains challenging. Here, we report a minimalist, intrinsically mitochondria-targeting noncanonical tetrapeptide, X-GNNpY, comprising one glycine, two (S)-2-amino-3-(naphthalen-1-yl)-propanoic acid residues (N), and one phosphorylated tyrosine (pY). Without external targeting ligands, X-GNNpY selectively accumulates in tumor-cell mitochondria through enzyme-instructed self-assembly. Conjugating chlorambucil (CLB) yields CLB-GNNpY, which efficiently redirects CLB to mitochondria. CLB-GNNpY exhibits good cellular selectivity, induces mitochondrial stress and immunogenic cell death, promotes M1-like macrophage polarization, and markedly enhances antitumor phagocytosis. This proof-of-concept study establishes noncanonical peptide self-assembly as a ligand-free supramolecular strategy for mitochondrial drug delivery and immune modulation in tumor therapy.
中文摘要:靶向线粒体是精准肿瘤治疗的一种有前景策略,然而无配体的线粒体药物递送仍然具有挑战性。本文报道了一种极简的、内在具有线粒体靶向性的非经典四肽X-GNNpY,其由一个甘氨酸、两个(S)-2-氨基-3-(萘-1-基)丙酸残基(N)和一个磷酸化酪氨酸(pY)组成。无需外部靶向配体,X-GNNpY通过酶指导的自组装选择性地积聚在肿瘤细胞线粒体中。将氯苯脒(CL B)与X-GNNpY偶联得到CLB-GNNpY,该复合物能高效地将CLB重定向至线粒体。CLB-GNNpY表现出良好的细胞选择性,诱导线粒体应激和免疫原性细胞死亡,促进M1样巨噬细胞极化,并显著增强抗肿瘤吞噬作用。这项概念验证研究确立了非经典肽自组装作为一种无配体的超分子策略,用于肿瘤治疗中的线粒体药物递送和免疫调节。
Environmental science & technology IF 12.2 2026-11-17 PMID: 43043261
Coal tar-based driveway sealants (CTS) are a widespread but underrecognized source of human exposure to mutagenic polycyclic aromatic hydrocarbons (PAHs). We used Duplex Sequencing, an error-corrected sequencing technology, to assess the mutagenicity of a complex PAH mixture extracted from a CTS in MutaMouse male mice. We observed significant dose-dependent increases in mutation frequency (MF) in liver and bone marrow, with mutation spectra dominated by C:G > A:T substitutions, closely resembling a mutational signature linked to human cancers associated with tobacco smoking. In germ cells, we did not observe a statistically significant increase in MF, although there was a positive dose-response trend and enrichment of C:G > A:T mutations at higher doses. The mutagenic effects of CTS in germ cells were supported by a statistically significant increase in mutant frequency measured using the plaque-based lacZ assay. Tissue-specific analyses revealed greater mutation susceptibility and potency in liver, likely reflecting its central role in PAH metabolism. Mutation spectrum analysis showed that the mutagenic profile of the CTS extract largely resembled that of benzo(a)pyrene; however, detailed spectral analysis indicated additional contributions from other PAHs or PAH metabolites that produced distinct mutational patterns. Collectively, our findings demonstrate that the CTS extract induces tissue-specific mutagenic responses driven by characteristic C:G > A:T mutations, offering mechanistic insight into how environmental PAH mixtures contribute to mutation burden and cancer risk.
中文摘要:煤焦油基车道密封剂(CTS)是人类暴露于致突变性多环芳烃(PAHs)的广泛但被低估的来源。我们利用纠错测序技术Duplex Sequencing,评估了从CTS中提取的复杂PAH混合物对MutaMouse雄性小鼠的致突变性。我们在肝脏和骨髓中观察到突变频率(MF)呈显著的剂量依赖性增加,突变谱以C:G > A:T替换为主,这与人类癌症中吸烟相关的突变特征非常相似。在生殖细胞中,尽管在高剂量下存在正向剂量反应趋势以及C:G > A:T突变的富集,但我们未观察到MF的统计学显著增加。使用基于噬菌斑的lacZ测定法测量的生殖细胞突变频率的统计学显著增加支持了CTS在生殖细胞中的致突变效应。组织特异性分析显示肝脏具有更高的突变易感性和效力,这可能反映了其在PAH代谢中的核心作用。突变谱分析表明,CTS提取物的致突变特征与苯并[a]芘 largely 相似;然而,详细的谱分析表明其他PAHs或PAH代谢物也产生了独特的突变模式。综上所述,我们的研究结果表明,CTS提取物通过特征性的C:G > A:T突变诱导组织特异性致突变反应,为环境PAH混合物如何导致突变负荷和癌症风险提供了机制见解。
Annals of the rheumatic diseases IF 24.0 2026-11-16 PMID: 43039800
Gout and calcium pyrophosphate deposition (CPPD) disease cause clinically similar flares and are treated with largely overlapping drugs, yet their systemic inflammatory responses have rarely been compared directly in patients. We compared the circulating inflammatory proteome of both diseases during flares and over time in gout to investigate how these mediators evolve after flare resolution. Proximity extension assay measured 92 inflammation-related proteins in plasma from 71 gout and 86 patients with CPPD during flares, and 96 middle-aged controls. Candidate biomarkers were validated in synovial fluid, crystal-stimulated peripheral blood mononuclear cells (PBMCs) and whole blood, murine air pouch model, and an independent gout cohort. Gout and CPPD flare proteomes were similar, with increased TNFSF14 (false discovery rate [FDR] = 1.49-24), interleukin 6 (FDR = 4.93-36), transforming growth factor-α (FDR = 2.18-23), and colony stimulating factor-1 (FDR = 1.58-20) vs controls. Tumor necrosis factor superfamily member 14 (TNFSF14), previously validated in gout, was detected in CPPD synovial fluid and calcium pyrophosphate (CPP)-stimulated air pouch tissue. In contrast, caspase-8 (CASP-8) was higher in gout than in CPPD during flare (FDR = 7.57 × 10-12). Both monosodium urate and CPP crystals induced CASP-8 in PBMCs and whole blood, whereas CASP-8 inhibition attenuated crystal-induced immune responses. Longitudinally, CASP-8 remained elevated during the intercritical phase and after serum urate target was achieved, showing that its elevation in gout was not flare-restricted. Other persistently altered proteins were enriched in Mitogen-Activated Protein Kinases, tumor necrosis factor, and responses to endogenous stimuli, whereas flare-responsive proteins decreased after flare. Higher CASP-8 was moderately associated with impaired kidney function. TNFSF14 is a candidate shared therapeutic target. CASP-8 distinguished gout from CPPD during flares, whereas its persistence across gout stages supports a broader role in sustained low-grade inflammation.
中文摘要:痛风与焦磷酸钙沉积病引起的临床发作相似且治疗药物重叠,但两者的系统性炎症反应在患者中鲜有直接比较。本研究对比了这两种疾病在发作期及痛风随时间变化过程中的循环炎症蛋白质组,以探究这些介质在发作缓解后的演变情况。采用邻近延伸测定法检测了71例痛风患者、86例焦磷酸钙沉积病患者(均在发作期)以及96名中年对照者的血浆中92种炎症相关蛋白。候选生物标志物在滑液、晶体刺激的周围血单核细胞及全血、小鼠气囊模型及独立痛风队列中得到验证。痛风与焦磷酸钙沉积病发作期的蛋白质组相似,与对照组相比,肿瘤坏死因子超家族成员14(TNFSF14)、白细胞介素6、转化生长因子α和集落刺激因子1升高。此前已在痛风中验证的TNFSF14在焦磷酸钙沉积病滑液及焦磷酸钙刺激的气囊组织中被检测到。相比之下,发作期痛风的半胱天冬酶8高于焦磷酸钙沉积病。单钠尿酸盐与焦磷酸钙晶体均诱导周围血单核细胞和全血中的半胱天冬酶8表达,而抑制半胱天冬酶8可减弱晶体诱导的免疫反应。纵向观察显示,在间歇期及达到血清尿酸目标后,半胱天冬酶8仍保持升高状态,表明其在痛风中的升高并非仅限于发作期。其他持续改变的蛋白富集于丝裂原活化蛋白激酶、肿瘤坏死因子及对内源性刺激的反应通路,而发作响应性蛋白在发作后减少。较高的半胱天冬酶8水平与肾功能受损中度相关。TNFSF14是候选的共同治疗靶点。半胱天冬酶8在发作期可区分痛风与焦磷酸钙沉积病,其在痛风各阶段的持续性支持其在维持低度炎症中发挥更广泛的作用。
Signal transduction and targeted therapy IF 81.2 2026-11-16 PMID: 43035493
Drug delivery systems (DDS) have become central determinants of therapeutic feasibility with modern medicines increasingly expanding beyond small molecules to biologics, nucleic acid therapeutics, and living medicines. As therapeutic modalities have continually diversified, delivery technologies, ranging from synthetic nanomaterials and molecular conjugates to biological carriers and hybrid systems have rapidly expanded. The increasing complexity of delivery strategies has thus necessitated conceptual frameworks enabling systematic comparison across platforms while accounting for engineering principles, biological barriers, and disease-specific therapeutic requirements. Accordingly, major delivery modalities now encompass lipid nanoparticles, polymeric and inorganic nanoparticles, targeted molecular conjugates, viral and non-viral vectors, cell- and bacteria-mediated delivery systems, extracellular vesicles, hydrogels, and device-assisted technologies. Although the mechanisms, clinical maturity, and therapeutic applications of these platforms differ substantially, they share common challenges associated with biological complexity, safety, manufacturability, and clinical translation. This review proposes a unified systems-level framework for contemporary drug delivery systems by organizing diverse delivery platforms according to carrier identity, payload class, and targeting mechanism. Engineering principles are integrated with a multiscale biological barrier framework encompassing systemic, tissue-level, cellular, and intracellular processes, thus providing a common mechanistic basis for comparing delivery performance across platforms. Clinical applications are further reorganized as per disease-specific biological barriers and delivery challenges spanning oncology, neurodegenerative, cardiovascular, metabolic, and autoimmune disorders, shifting the focus from platform-centered descriptions toward context-dependent therapeutic deployment. Emerging directions, including AI-enabled design, integrated delivery architectures, manufacturing scalability, and precision deployment, are discussed along with the shared translational bottlenecks that continue to limit broader clinical implementation. By synthesizing the engineering, biological, and clinical perspectives within a common conceptual framework, this review provides an integrated view of contemporary drug delivery systems and highlights the common engineering and translational principles facilitating the rational design, evaluation, and clinical implementation of future drug delivery systems.
中文摘要:药物递送系统已成为现代药物治疗可行性的核心决定因素,随着治疗手段从小分子扩展至生物制剂、核酸疗法和活体药物。随着治疗模式的多样化,从合成纳米材料、分子偶联物到生物载体及混合系统的递送技术迅速扩张。递送策略复杂性的增加 necessitated 概念框架以实现对不同平台的系统性比较,同时兼顾工程原理、生物屏障及疾病特异性治疗需求。目前主要递送模式包括脂质纳米颗粒、聚合物与无机纳米颗粒、靶向分子偶联物、病毒与非病毒载体、细胞及细菌介导的递送系统、细胞外囊泡、水凝胶及设备辅助技术。尽管这些平台在机制、临床成熟度及治疗应用上存在显著差异,但它们共同面临生物复杂性、安全性、可制造性及临床转化等挑战。本综述通过根据载体身份、载荷类别及靶向机制对多样化递送平台进行分类,提出了当代药物递送系统的统一系统级框架。工程原理与涵盖系统性、组织水平、细胞内及亚细胞过程的多尺度生物屏障框架相结合,为跨平台比较递送性能提供了共同的机制基础。临床应用进一步按照跨越肿瘤学、神经退行性疾病、心血管疾病、代谢性疾病及自身免疫性疾病的疾病特异性生物屏障和递送挑战进行重组,将焦点从以平台为中心的描述转向情境依赖的治疗部署。讨论了包括人工智能辅助设计、集成递送架构、制造可扩展性及精准部署在内的新兴方向,以及继续限制更广泛临床实施的共同转化瓶颈。通过在同一概念框架内综合工程、生物学及临床视角,本综述提供了当代药物递送系统的整合视图,并强调了促进未来药物递送系统合理设计、评估及临床实施的共同工程与转化原则。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42546385
Manipulation of ligand-receptor interactions (LRIs) in a user-defined manner is one of the effective ways to regulate cell motility and disease progression. Molecular engines orchestrate LRIs to regulate cell motility by harnessing various forms of energy within physiological surroundings. However, engineering chemical engines remains largely unexplored, primarily due to the insufficient chemical cue density, uncertain conformational changes of scaffolds, and a limited repertoire of environment-responsive switchable scaffolds. Enzymatic biofuel cells (EBFCs) are electrochemical devices that convert biofuels into other accessible energy through electrochemical reaction for the construction of self-powered molecular tools, offering a viable strategy to overcome the above limitations. Here, we present an enzyme biofuel cell-based self-powered molecular engine (EBFC-SME) for rewiring chemical cues-based LRIs and regulating cell motility. We employ EBFC-SME as a proof-of-concept platform for reprogramming proton-responsive HGF/c-Met interaction. The system comprises a glucose dehydrogenase (GDH)-incorporated bioanode and a bilirubin oxidase (BOD)/functional nucleic acids (FNAs)-encapsulated iron-alginate (IA) hydrogel-coated biocathode. Through glucose-initiated redox reactions, this configuration enables the EBFC-SME to generate abundant protons and release FNAs. These products subsequently mediate the in-situ assembly on tumor cell membrane, which blocks c-Met pathway activation and ultimately suppresses tumor cell migration. Different from conventional chemical engines, the EBFC-SME efficiently regenerates chemical cues via intrinsic energy conversion reactions for the manipulation of scaffold-mediated LRIs. This EBFC-SME platform provides a robust "sensing-conversion-initiation" tool for the chemical regulation of cellular motility, holding significant promise in precision biomedicine.
中文摘要:以用户定义的方式调控配体受体相互作用是调节细胞运动和疾病进展的有效途径之一。分子引擎通过利用生理环境中的各种能量形式来编排配体受体相互作用,从而调节细胞运动。然而,由于化学信号密度不足、支架构象变化不确定以及环境响应型可切换支架种类有限,工程化化学引擎的研究仍 largely 未开发。酶燃料电池是将生物燃料通过电化学反应转化为其他可用能量的电化学装置,用于构建自供能分子工具,为克服上述限制提供了可行的策略。在此,我们提出了一种基于酶燃料电池的自供能分子引擎,用于重写基于化学信号的配体受体相互作用并调节细胞运动。我们将该引擎作为概念验证平台,用于重新编程质子响应的肝细胞生长因子与c-Met相互作用。该系统包含掺入葡萄糖脱氢酶的生物阳极和包裹有胆红素氧化酶及功能核酸的铁藻酸盐凝胶涂层生物阴极。通过葡萄糖引发的氧化还原反应,该配置使分子引擎产生大量质子并释放功能核酸。这些产物随后介导在肿瘤细胞膜上的原位组装,阻断c-Met通路激活并最终抑制肿瘤细胞迁移。与传统化学引擎不同,该自供能分子引擎通过内在能量转换反应高效再生化学信号,以操纵支架介导的配体受体相互作用。该平台为细胞运动的化学调控提供了强大的传感转换启动工具,在精准生物医学领域具有广阔前景。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42531648
Sensitive and accurate detection of tumor markers is crucial for disease diagnosis, yet numerous challenges still exist due to limitations of single-mode assays. This work constructed a universal dual-mode sensing platform combining closed bipolar electrode (cBPE) and split-type immunoassay, which realized simultaneous electrochemiluminescence (ECL) and electrochromic detection of proteins upon a single potential stimulus. Specifically, on the cBPE, L012 served as the ECL emitter at the anode, while Prussian blue (PB) film at the cathode acted as the electrochromic sensing unit. Applying a single potential stimulus could trigger simultaneous ECL emission and the color change from blue PB to white Prussian white. By virtue of MgO2@GOx-Ab2 signal probes as bioprobe, a split-type immunoassay was developed for prostate-specific antigen (PSA) detection. The target-induced production of H2O2 from cascade glucose oxidation and MgO2 hydrolysis greatly enhanced the anodic ECL signal and facilitated the cathodic PB reduction. Consequently, the strategy achieved the highly sensitive and visual dual-mode assay for PSA, yielding the limits of detection of 2.7 × 10-12 g/mL for ECL detection and 3.1 × 10-9 g/mL for electrochromic sensing, respectively. The study opened up an avenue for developing simultaneous multi-mode sensing platforms toward more biomarkers.
中文摘要:肿瘤标志物的敏感准确检测对疾病诊断至关重要,但单一模式检测仍存在诸多局限。本研究构建了一种结合闭合双电极(cBPE)与分体式免疫测定的通用双模传感平台,在单一电位刺激下实现蛋白质的同时电化学发光(ECL)和电致变色检测。具体而言,在cBPE上,L012作为阳极的ECL发射体,而阴极上的普鲁士蓝(PB)薄膜作为电致变色传感单元。施加单一电位刺激可同时触发ECL发光及蓝色PB向白色普鲁士白的颜色变化。利用MgO2@GOx-Ab2信号探针作为生物探针,开发了用于前列腺特异性抗原(PSA)检测的分体式免疫测定。靶标诱导的H2O2产生通过级联葡萄糖氧化和MgO2水解显著增强了阳极ECL信号并促进了阴极PB还原。该策略实现了PSA的高灵敏度及可视化双模检测,ECL检测的检测限为2.7×10-12 g/mL,电致变色传感的检测限为3.1×10-9 g/mL。本研究为开发面向更多生物标志物的同时多模态传感平台开辟了新途径。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42508242
Carcinoembryonic antigen (CEA) detection is crucial for early cancer diagnosis and prognostic monitoring. However, traditional CEA detection is mainly based on blood samples, which is invasive and less conducive to point-of-care testing (POCT). Therefore, in this study, we developed a flexible paper-based microneedle (MN) array electrochemical sensor, integrated with portable electronics and a mobile application, to detect CEA in interstitial fluid (ISF). The MN array was fabricated from a composite of UV-curable biocompatible resin and microcrystalline cellulose on a paper substrate impregnated with flexible UV-curable resin. The MN array was functionalized as an electrochemical sensor to detect CEA by modification with conductive ink, rGO/Thi/AuNPs nanocomposites and anti-CEA antibodies. The performance of the MN array electrochemical sensor was validated through in vitro and in vivo experiments, and the sensor demonstrated high sensitivity, good selectivity, broad linear ranges, robust stability, and strong concordance with reference methods. This study provides a new tool for CEA monitoring and offers new insights into the development of minimally invasive biomarker detection devices for POCT.
中文摘要:癌胚抗原(CEA)检测对于癌症早期诊断和预后监测至关重要。然而,传统的 CEA 检测主要基于血液样本,具有侵入性且不利于即时检测(POCT)。因此,本研究开发了一种柔性纸质微针(MN)阵列电化学传感器,该传感器集成了便携式电子设备和移动应用程序,用于检测间质液(ISF)中的 CEA。MN 阵列由紫外线固化生物相容性树脂与微晶纤维素复合而成,制备于浸渍有柔性紫外线固化树脂的纸基底上。通过涂覆导电墨水、rGO/Thi/AuNPs 纳米复合材料及抗 CEA 抗体,将 MN 阵列功能化为电化学传感器以检测 CEA。通过体外和体内实验验证了该 MN 阵列电化学传感器的性能,结果显示该传感器具有高灵敏度、良好的选择性、宽线性范围、稳健的稳定性以及与参考方法的高度一致性。本研究为 CEA 监测提供了一种新工具,并为开发用于 POCT 的微创生物标志物检测设备提供了新思路。
Biosensors & bioelectronics IF 11.8 2026-11-15 PMID: 42492329
The 10-23 DNAzyme is a potent catalytic nucleic acid for biosensing; however, traditional single-blocker designs suffer from high background signal leakage due to spontaneous thermal "breathing." To overcome this, we engineered a triangular DNA probe-DNAzyme (TDPzyme) that spatially separates the enzyme components onto a rigid 3D scaffold. By splitting the binding arms and catalytic center, the TDPzyme functions as a fault-tolerant logic "AND" gate, strictly requiring the simultaneous displacement of multiple blocker strands by the target miR-21. This architectural constraint physically shields the probe from nuclease degradation and virtually eliminates false-positive activation, yielding a near-zero background state. Functionalized with a Cy3-BHQ2 pair and an AS1411 aptamer for targeted, carrier-free cellular delivery, the TDPzyme achieved an approximately 18-fold enhancement in sensitivity over conventional closed-arm designs, establishing a linear range of 0.1 nM to 40.0 nM and a limit of detection of 50.3 pM (3σ). Furthermore, time-lapse dynamic imaging demonstrated that the TDPzyme enables highly reliable, high-contrast discrimination of miR-21 expression between tumor and normal cells. Ultimately, the TDPzyme design offers a robust, structurally controllable platform for developing highly sensitive, low-background biosensors applicable to demanding live-cell imaging and precision molecular diagnostics.
中文摘要:10-23 DNAzyme是一种用于生物传感的强效催化核酸,然而传统单阻断剂设计因自发热呼吸导致背景信号泄漏严重。为解决这一问题,我们构建了一种三角形DNA探针-DNAzyme(TDPzyme),将酶组分空间分离至刚性三维支架上。通过拆分结合臂和催化中心,TDPzyme作为容错逻辑与门运作,严格依赖靶标miR-21同时置换多个阻断链。这种架构约束物理屏蔽探针免受核酸酶降解,几乎消除假阳性激活,实现近零背景状态。经Cy3-BHQ2对及AS1411适配子功能化以实现靶向无载体细胞递送,TDPzyme灵敏度较传统闭合臂设计提高约18倍,建立0.1 nM至40.0 nM线性范围及50.3 pM(3σ)检测限。此外,延时动态成像显示TDPzyme能在肿瘤与正常细胞间实现高对比度miR-21表达的高可靠性区分。最终,TDPzyme设计为开发高灵敏度、低背景生物传感器提供了稳健且结构可控的平台,适用于严苛活细胞成像及精准分子诊断。
Nucleic acids research IF 15.0 2026-11-14 PMID: 43031546
CROST (https://ngdc.cncb.ac.cn/crost) is a public spatial transcriptomics resource that offers curated datasets, standardized analytical results, structured spatial knowledge, and interactive exploration tools. In version 2.0, our collection has expanded to 544 projects and 3538 samples, nearly a three-fold increase from version 1.0 (182 projects and 1033 samples). We have also substantially expanded the derived resources for spatial colocalization and spatially variable cancer genes. To facilitate spatial microenvironment analysis, CROST 2.0 introduces an analytical framework comprising niche-associated differential expression, spatially resolved gene-set activity analysis, spatial interaction hotspot and topic analyses, and molecular and cell-type niche analysis. CROST 2.0 also provides the Spatial Compare function to compare spatial gene expression, cell-type distributions, and niche composition across samples. It introduces the Cancer NicheDE module to systematically characterize cancer niche-associated differential expression and integrates an online cell-type annotation tool, SCType, enabling the use of single-cell reference information in spatial transcriptomic analysis. These updates extend CROST into an integrated spatial transcriptomics resource for characterizing spatial microenvironments, investigating cancer-associated spatial features, and comparing spatial patterns across samples.
中文摘要:CROST(https://ngdc.cncb.ac.cn/crost)是一个公共空间转录组学资源,提供经过筛选的数据集、标准化的分析结果、结构化的空间知识以及交互式探索工具。在2.0版本中,我们的数据量扩展至544个项目和3538个样本,较1.0版(182个项目和1033个样本)增加了近三倍。我们还大幅扩展了用于空间共定位和空间可变癌症基因的衍生资源。为促进微环境分析,CROST 2.0引入了一个包含生态位相关差异表达、空间分辨基因集活性分析、空间相互作用热点及主题分析和分子与细胞类型生态位分析的分析框架。CROST 2.0还提供Spatial Compare功能,用于比较不同样本间的空间基因表达、细胞类型分布和生态位组成。该版本引入的Cancer NicheDE模块系统表征了癌症生态位相关的差异表达,并整合了在线细胞类型注释工具SCType,使得在空间转录组学分析中能够利用单细胞参考信息。这些更新将CROST扩展为一个集成的空间转录组学资源,用于表征空间微环境、调查与癌症相关的空间特征以及比较不同样本间的空间模式。
Nature chemical biology IF 15.8 2026-11-13 PMID: 43026305
Histone succinylation is a conserved lysine acylation, yet its acting mechanism and functional importance in transcription remain elusive. Here we identify well-characterized nuclear receptor coactivators NCOA1-NCOA3 (NCOA1/2/3), as histone succinyltransferases (HSTs) responsible for bulk histone succinylation in mammalian cells. Unlike classic acetyltransferases such as CBP/p300 that possess multiple acyltransferase activities, NCOA1/2/3 exhibit only HST activity and drive phase-separation condensate formation through their HST activity. In vitro binding assays identified the Mediator complex as the specific 'reader' for succinylated histone tail peptides and nucleosomes. Epigenome profiling demonstrated that NCOA1/2/3-catalyzed histone succinylation is highly enriched at gene promoters and is essential for the promoter association of Mediator complex. Furthermore, the family of NCOA HSTs is critically important for global transcriptional activity in both cancer and embryonic stem cells. Altogether, our study identifies NCOA1/2/3 as unique HSTs and establishes histone succinylation as a critical regulator of Mediator promoter association and global transcriptional activation.
中文摘要:组蛋白琥珀酰化是一种保守的赖氨酸酰基化修饰,但其作用机制及在转录中的功能重要性尚不明确。本研究鉴定出特征明确的核受体共激活因子NCOA1至NCO3(NCOA1/2/3)为哺乳动物细胞中负责大部分组蛋白琥珀酰化的组蛋白琥珀酰转移酶(HSTs)。与具有多种酰基转移酶活性的经典乙酰转移酶如CBP/p300不同,NCOA1/2/3仅表现出HST活性,并通过该活性驱动相分离凝聚体的形成。体外结合实验鉴定出Mediator复合物是琥珀酰化组蛋白尾肽及核小体的特异性「阅读器」。表观基因组谱系分析表明,由NCOA1/2/3催化的组蛋白琥珀酰化在基因启动子区域高度富集,且对Mediator复合物在启动子区域的结合至关重要。此外,NCOA HST家族对癌症细胞和胚胎干细胞中的全局转录活性具有关键重要性。综上所述,本研究将NCOA1/2/3鉴定为独特的HSTs,并确立组蛋白琥珀酰化为调节Mediator启动子结合及全局转录激活的关键因子。
Nature communications IF 18.1 2026-11-13 PMID: 43026291
Epithelial stratification, the transition from a monolayer to a multilayer structure, occurs across a wide range of phenomena. Recent studies have identified several cell behaviors as triggers, including junctional tension, cell density and geometry, and topological defects. However, how these factors drive stratification throughout the entire epithelium remains poorly understood. Here, we show that epithelial stratification proceeds through a nucleation-and-growth mechanism. Combining cell culture with three-dimensional vertex modeling, we demonstrate that multilayer origins emerge in a dispersed manner and expand across the epithelium through disordered intermediate states. This transition is induced by a mechanical instability inherent in the foam-like geometry of the epithelium. Moreover, the nucleation-growth concept applies to embryonic skin development and intestinal cancer transformation. These findings conceptualize epithelial stratification as a form of structural transition governed by foam mechanics, offering a physical perspective on various epithelial developments.
中文摘要:上皮分层即从单层向多层结构的转变,广泛发生于多种现象中。近期研究已识别出几种触发细胞行为,包括连接张力、细胞密度与几何形态以及拓扑缺陷。然而,这些因素如何驱动整个上皮的层化过程仍知之甚少。本研究显示上皮层化通过成核与生长机制进行。结合细胞培养与三维顶点模型,我们证明多层起源以分散方式出现,并通过无序中间状态在上皮中扩展。这种转变由上皮泡沫状几何结构中固有的机械不稳定性诱导。此外,成核-生长概念适用于胚胎皮肤发育和肠道癌变过程。这些发现将上皮层化概念化为受泡沫力学支配的结构转变形式,为各种上皮发育提供了物理视角。
Nature cell biology IF 22.7 2026-11-13 PMID: 43026276
Receptor tyrosine kinase (RTK) fusions are a large class of oncoproteins found in ~5% of cancers. Key questions remain, however, about how RTK fusions transmit oncogenic signals, including how these largely cytoplasmic proteins activate downstream pathways that originate at the plasma membrane. Fusions are often multimeric and can form mesoscale condensates in cancer cells, and condensation has been implicated as an essential mechanism to enable signal transmission from the cytoplasm. However, whether condensates play a causal role or whether smaller 'diffuse' assemblies are sufficient to transduce signals, has been challenging to establish. Here we apply advanced microscopy, single-cell analysis and synthetic fusions to determine the principles by which multimerization and condensation drive signalling from cytoplasmic RTK fusions. For EML4-ALK, a prominent fusion that forms condensates, we found poor correlation between condensation and signalling and abundant EML4-ALK activity in the diffuse phase. Synthetic RTK fusions showed that cytoplasmic dimers of ALK or RET domains-and even constitutively active monomers-were sufficient to induce strong Ras-Erk signalling despite the absence of condensates, and non-condensing fusions were sufficient to transform cells in vitro and in subcutaneous tumour models. A panel of various other cancer-driving RTK fusions showed that low-order multimerization was widespread across fusions, whereas mesoscale condensation was rare and did not correlate with signalling. Our results suggest that low-order multimerization is sufficient to drive fusion phosphorylation, which is necessary and sufficient to trigger downstream oncogenic signalling.
中文摘要:受体酪氨酸激酶融合蛋白是一类在约5%的癌症中发现的大型致癌蛋白。然而关于RTK融合蛋白如何传递致癌信号,包括这些主要位于细胞质的蛋白质如何激活起源于质膜的下游通路,仍存在关键问题。融合蛋白通常为多聚体,可在癌细胞中形成介观凝聚体,且凝聚被认为是一种使信号从细胞质传递的关键机制。然而,确定凝聚体是否起因果作用或较小的弥散组装体是否足以转导信号一直具有挑战性。本研究应用先进显微镜技术、单细胞分析和合成融合蛋白,以确定多聚化和凝聚如何驱动来自细胞质RTK融合蛋白的信号传导原则。对于形成凝聚体的显著融合蛋白EML4-ALK,我们发现凝聚与信号传导之间相关性较差,且在弥散相中存在丰富的EML4-ALK活性。合成RTK融合蛋白显示,尽管缺乏凝聚体,ALK或RET结构域的细胞质二聚体甚至组成型活性单体足以诱导强烈的Ras-Erk信号传导,且不形成凝聚体的融合蛋白在体外和皮下肿瘤模型中足以转化细胞。一系列其他驱动癌症的RTK融合蛋白面板显示,低阶多聚化在融合蛋白中广泛存在,而介观凝聚体罕见且与信号传导无相关性。我们的结果表明,低阶多聚化足以驱动融合蛋白磷酸化,这是触发下游致癌信号传导所必需且充分的条件。
Advanced healthcare materials IF 11.0 2026-11-13 PMID: 43026184
Organelle-level precision can advance cancer nanomedicine beyond nonspecific intracellular delivery toward spatially defined therapeutic action. DNA nanoframeworks, nanodevices, and nanomachines are promising because their sequence, geometry, valency, and dynamic states can be programmed to integrate molecular recognition with sensing, computation, structural reconfiguration, and cargo release. However, organelle targeting is often treated as a localization problem, whereas therapeutic function demands a sequence of biological and engineering steps: systemic stability, tumor-cell recognition, cellular uptake, endosomal escape, intracellular trafficking, organelle recognition, functional localization, stimulus processing, actuation, and measurable biological response. This review differentiates DNA nanoframeworks, nanodevices, and nanomachines and evaluates their progression from molecular design to intracellular action. We summarize DNA-containing systems targeting mitochondria, lysosomes, the nucleus, endoplasmic reticulum, and Golgi apparatus, focusing on targeting ligands, trafficking routes, stimulus-responsive mechanisms, actuation, reporting, and therapeutic function. Non-DNA systems are considered only as contextual comparators relevant to DNA-device engineering. Finally, we discuss artificial intelligence and self-driving laboratories as emerging tools for sequence and structure optimization, image analysis, and closed-loop experimentation, while separating demonstrated capabilities from the still prospective goal of autonomous intracellular navigation. We also identify design rules, evidence standards, and translational barriers guiding reproducible, mechanistically validated DNA nanodevices for precision intracellular therapy.
中文摘要:细胞器水平的精准递送能力可将癌症纳米医学从非特异性的胞内递送推进至空间定义的治疗作用。DNA纳米框架、纳米器件和纳米机器因其序列、几何形状、价态及动态状态可被编程,从而整合分子识别与传感、计算、结构重排及货物释放等功能而展现出巨大潜力。然而,细胞器靶向常被视为单纯的定位问题,而治疗功能则要求一系列生物学与工程化步骤:系统稳定性、肿瘤细胞识别、细胞摄取、内体逃逸、胞内运输、细胞器识别、功能定位、刺激处理、驱动动作及可测量的生物学响应。本综述区分了DNA纳米框架、纳米器件和纳米机器,并评估了其从分子设计到胞内作用的发展进程。我们总结了靶向线粒体、溶酶体、细胞核、内质网和高尔基体的含DNA系统,重点探讨其靶向配体、运输路径、刺激响应机制、驱动动作、报告系统及治疗功能。非DNA系统仅作为与DNA器件工程相关的背景比较对象被纳入讨论。最后,我们探讨了人工智能和自动驾驶实验室作为序列与结构优化、图像分析及闭环实验新兴工具的应用,同时区分了已证实的能力与自主胞内导航这一仍处于前景阶段的目标。我们还明确了设计规则、证据标准及转化障碍,旨在指导实现可重复且机制验证的DNA纳米器件以用于精准胞内治疗。